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A B S T R A C T
Background
Common fetal aneuploidies include Down syndrome (trisomy 21 or T21), Edward syndrome (trisomy 18 or T18), Patau syndrome
(trisomy 13 or T13), Turner syndrome (45,X), Klinefelter syndrome (47,XXY), Triple X syndrome (47,XXX) and 47,XYY syndrome
(47,XYY). Prenatal screening for fetal aneuploidies is standard care in many countries, but current biochemical and ultrasound tests
have high false negative and false positive rates. The discovery of fetal circulating cell-free DNA (ccfDNA) in maternal blood offers the
potential for genomics-based non-invasive prenatal testing (gNIPT) as a more accurate screening method. Two approaches used for
gNIPT are massively parallel shotgun sequencing (MPSS) and targeted massively parallel sequencing (TMPS).
Objectives
To evaluate and compare the diagnostic accuracy ofMPSS and TMPS for gNIPT as a first-tier test in unselected populations of pregnant
women undergoing aneuploidy screening or as a second-tier test in pregnant women considered to be high risk after first-tier screening
for common fetal aneuploidies. The gNIPT results were confirmed by a reference standard such as fetal karyotype or neonatal clinical
examination.
Search methods
We searched 13 databases (including MEDLINE, Embase and Web of Science) from 1 January 2007 to 12 July 2016 without any
language, search filter or publication type restrictions. We also screened reference lists of relevant full-text articles, websites of private
prenatal diagnosis companies and conference abstracts.
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Selection criteria
Studies could include pregnant women of any age, ethnicity and gestational age with singleton or multifetal pregnancy. The women
must have had a screening test for fetal aneuploidy by MPSS or TMPS and a reference standard such as fetal karyotype or medical
records from birth.
Data collection and analysis
Two review authors independently carried out study selection, data extraction and quality assessment (using the QUADAS-2 tool).
Where possible, hierarchical models or simpler alternatives were used for meta-analysis.
Main results
Sixty-five studies of 86,139 pregnant women (3141 aneuploids and 82,998 euploids) were included. No study was judged to be at
low risk of bias across the four domains of the QUADAS-2 tool but applicability concerns were generally low. Of the 65 studies, 42
enrolled pregnant women at high risk, five recruited an unselected population and 18 recruited cohorts with a mix of prior risk of fetal
aneuploidy. Among the 65 studies, 44 evaluated MPSS and 21 evaluated TMPS; of these, five studies also compared gNIPT with a
traditional screening test (biochemical, ultrasound or both). Forty-six out of 65 studies (71%) reported gNIPT assay failure rate, which
ranged between 0% and 25% for MPSS, and between 0.8% and 7.5% for TMPS.
In the population of unselected pregnant women, MPSS was evaluated by only one study; the study assessed T21, T18 and T13. TMPS
was assessed for T21 in four studies involving unselected cohorts; three of the studies also assessed T18 and 13. In pooled analyses (88
T21 cases, 22 T18 cases, eight T13 cases and 20,649 unaffected pregnancies (non T21, T18 and T13)), the clinical sensitivity (95%
confidence interval (CI)) of TMPS was 99.2% (78.2% to 100%), 90.9% (70.0% to 97.7%) and 65.1% (9.16% to 97.2%) for T21,
T18 and T13, respectively. The corresponding clinical specificity was above 99.9% for T21, T18 and T13.
In high-risk populations, MPSS was assessed for T21, T18, T13 and 45,X in 30, 28, 20 and 12 studies, respectively. In pooled analyses
(1048 T21 cases, 332 T18 cases, 128 T13 cases and 15,797 unaffected pregnancies), the clinical sensitivity (95% confidence interval
(CI)) of MPSS was 99.7% (98.0% to 100%), 97.8% (92.5% to 99.4%), 95.8% (86.1% to 98.9%) and 91.7% (78.3% to 97.1%)
for T21, T18, T13 and 45,X, respectively. The corresponding clinical specificities (95% CI) were 99.9% (99.8% to 100%), 99.9%
(99.8% to 100%), 99.8% (99.8% to 99.9%) and 99.6% (98.9% to 99.8%). In this risk group, TMPS was assessed for T21, T18,
T13 and 45,X in six, five, two and four studies. In pooled analyses (246 T21 cases, 112 T18 cases, 20 T13 cases and 4282 unaffected
pregnancies), the clinical sensitivity (95% CI) of TMPS was 99.2% (96.8% to 99.8%), 98.2% (93.1% to 99.6%), 100% (83.9% to
100%) and 92.4% (84.1% to 96.5%) for T21, T18, T13 and 45,X respectively. The clinical specificities were above 100% for T21,
T18 and T13 and 99.8% (98.3% to 100%) for 45,X. Indirect comparisons of MPSS and TMPS for T21, T18 and 45,X showed no
statistical difference in clinical sensitivity, clinical specificity or both. Due to limited data, comparative meta-analysis of MPSS and
TMPS was not possible for T13.
We were unable to perform meta-analyses of gNIPT for 47,XXX, 47,XXY and 47,XYY because there were very few or no studies in
one or more risk groups.
Authors’ conclusions
These results show that MPSS and TMPS perform similarly in terms of clinical sensitivity and specificity for the detection of fetal
T31, T18, T13 and sex chromosome aneuploidy (SCA). However, no study compared the two approaches head-to-head in the same
cohort of patients. The accuracy of gNIPT as a prenatal screening test has been mainly evaluated as a second-tier screening test to
identify pregnancies at very low risk of fetal aneuploidies (T21, T18 and T13), thus avoiding invasive procedures. Genomics-based
non-invasive prenatal testing methods appear to be sensitive and highly specific for detection of fetal trisomies 21, 18 and 13 in high-
risk populations. There is paucity of data on the accuracy of gNIPT as a first-tier aneuploidy screening test in a population of unselected
pregnant women. With respect to the replacement of invasive tests, the performance of gNIPT observed in this review is not sufficient
to replace current invasive diagnostic tests.
We conclude that given the current data on the performance of gNIPT, invasive fetal karyotyping is still the required diagnostic approach
to confirm the presence of a chromosomal abnormality prior to making irreversible decisions relative to the pregnancy outcome.
However, most of the gNIPT studies were prone to bias, especially in terms of the selection of participants.
P L A I N L A N G U A G E S U M M A R Y
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Accuracy of gNIPT for identifying genetic abnormalities in unborn babies
What is the issue?
How accurate is the new test (genomics-based non-invasive prenatal testing (gNIPT)) for detecting abnormal chromosome number in
an unborn baby’s genetic material (DNA) found in the mother’s blood? We assessed the accuracy for the screening of Down syndrome
(trisomy 21), Edward syndrome (trisomy 18), Patau syndrome (trisomy 13), Turner syndrome (45,X), Klinefelter syndrome (47,XXY),
Triple X syndrome (47,XXX) and 47,XYY syndrome. There are different methods in use for gNIPT. We assessed MPSS (massively
parallel shotgun sequencing) that tests whole DNA and TMPS (targeted massively parallel sequencing) that tests targeted DNA.
Background
There are 46 chromosomes (23 pairs) in humans. Abnormal numbers of chromosomes can cause genetic disorders for which there
are no cures. Having an extra chromosome is called trisomy and an excess (or less) of sexual chromosome is called sex chromosome
abnormality (SCA). The most common trisomy is Down syndrome which occurs in about one in 1000 babies. Children with Downs
have slow growth, characteristic facial features and mild to moderate intellectual disability, with some requiring specialist education
later in life. However, the symptoms vary from mild to severe so that some infants lead relatively normal lives. The other trisomy or
SCA conditions have varying degrees of disability but the chance of a baby being affected is much less.
Current screening tests for these conditions require confirmation if the baby has the condition or not and for this an invasive test like
amniocentesis is used. Amniocentesis is where fetal cells that float in the fluid surrounding the unborn baby are collected by putting a
fine needle through the mother’s abdomen and collecting the fluid. Alternatively, tissue can be collected from the placenta (chorionic
villus sampling (CVS)). With these invasive tests, pregnant women are exposed to a higher chance of losing their baby even if the baby
is unaffected by Down syndrome. So, this invasive test is only offered to women who are thought to have a higher chance of having an
affected unborn baby
What we did
We looked for studies that included women of any age, ethnicity and gestational age who were carrying either a single baby or more
than one. We searched for studies (up to July 2016) that assessed the accuracy of the new test.
What we found
We found 65 studies with a total of 86,139 pregnant women, including 3141 affected pregnancies. Forty-two studies (65%) enrolled
pregnant women with a high chance of having babies with abnormal chromosome number. Forty-eight (74%) studies included only
women with a singleton pregnancy. Forty-four studies (68%) used MPSS and 21 studies (32%) used TMPS.
gNIPT seems to be accurate for screening unborn babies (either singletons or twins), especially for detecting Down syndrome, trisomy
18 and trisomy 13. However, there were some problems with how the studies were conducted which makes us cautious about our
findings. This may result in gNIPT appearing to perform better than it really does.
Other important information to consider
gNIPT method appears to perform well in identifying unborn babies with abnormal number of chromosomes. However, when a
gNIPT detects an abnormal chromosome number, then a confirmation using invasive tests (like amniocentesis or CVS) is still needed
before pregnancy-related decisions can be made.
It is important that pregnant women are given full information on the possible health problems that might arise for babies affected
by an additional chromosome. For example, with Down syndrome though some children have considerable disability, others can lead
relatively normal lives. In addition, in this review most studies enrolled pregnant women with increased chance of having babies with
abnormal chromosome number, so our findings do not directly apply to general populations of pregnant women.
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B A C K G R O U N D
Aneuploidies[1] are chromosomal abnormalities characterised by
a different (additional or missing) number of chromosomes than
the 23 pairs normally present in humans. These chromosomal
anomalies are among the most common types of genetic disor-
ders and they represent a significant cause of both childhood and
adulthood morbidity or death. In addition, they may lead to peri-
natal complications (Wellesley 2012; Wu 2013a). The severity of
associated symptoms is often variable and typically less severe in
mosaic cases (not all cells affected) (Fishler 1991;Modi 2003; Zhu
2013). Although offering prenatal screening for fetal aneuploi-
dies such as Down syndrome is now considered standard of care
in routine antenatal care in most upper-middle and high-income
countries, prenatal screening methods and strategies are evolving.
Prenatal screening consists of blood-based biochemical testing or
ultrasound measurements or a combination of both, in addition to
maternal age (Alldred 2012). Because of the serious health conse-
quences of various aneuploidies and given their incurable nature,
prenatal screening is an option available to pregnant women. An
invasive diagnostic test (e.g. amniocentesis) is offered to pregnant
women found to be at high risk of fetal aneuploidy after prena-
tal screening, but there is a procedure-related risk of miscarriage.
The discovery of circulating cell-free DNA (ccfDNA) in maternal
blood has enabled the development of genomics-based non-inva-
sive prenatal testing (gNIPT) to analyse the fetal genome. Prenatal
screening, and ultimately prenatal diagnosis, provides couples with
the information necessary for taking informed decisions (the op-
timisation of medical intervention and psychological counselling
for managing the identified condition or pregnancy termination).
The decision to terminate pregnancy among women who received
a positive diagnosis of fetal aneuploidy during the prenatal period
varies between 86% and 97% (Choi 2012; Irving 2011). Many
factors, such as religion, maternal age, gestational age at the time
of diagnosis, number of existing children, past history of induced
abortion and psychosocial factors (perceived parenting burden/re-
ward, quality of life of a child with a chromosomal abnormality,
attitudes toward, and comfort with individuals with disabilities,
and support from others) influence women’s decision making fol-
lowing prenatal anomaly detection (Choi 2012).
In this systematic review, we assessed the accuracy of gNIPT for
the detection of common fetal aneuploidies in pregnant women
according to their prior risk of fetal aneuploidy. More specifically,
we evaluated and compared the diagnostic performance of two
new next-generation sequencing approaches (i.e. massively par-
allel shotgun sequencing (MPSS) and targeted massively parallel
sequencing (TMPS)) that have recently been proposed as meth-
ods of choice to detect fetal aneuploidies by analysing ccfDNA in
maternal plasma. We also made comparisons between MPSS and
TMPS or between gNIPT and their combination with other first-
tier screening approaches. gNIPT could be used as a first-tier test
in pregnant women without prior risk (i.e. in unselected pregnant
women or the general population) or as a second-tier test after a
positive result for traditional first-tier screening tests such as bio-
chemical, ultrasound or both markers (with maternal age included
in risk assessment) and previous maternal history when possible.
[1] For a glossary of terms, see Appendix 1. For a list of acronyms
and abbreviations, see Appendix 2.
Target condition being diagnosed
The target conditions are fetal chromosomal abnormalities diag-
nosed in pregnant women. The seven target conditions assessed
were Down syndrome (trisomy 21 or T21), Edward syndrome
(trisomy 18 or T18), Patau syndrome (trisomy 13 or T13), Turner
syndrome (45,X), Klinefelter syndrome (47,XXY), Triple X syn-
drome (47,XXX) and 47,XYY syndrome (47,XYY) (Table 1). The
majority of aneuploidies are associatedwith an extra copy (trisomy)
of one chromosome (e.g. three copies of chromosome 21 for T21
instead of two) or a loss of one chromosome (e.g. female 45,X).
Chromosomal abnormality is usually caused by a chromosome di-
vision failure or a chromosomal translocation. For example, most
cases (76.2%) of 45,X karyotype (all cells affected) are caused by
paternal chromosome division failure (Uematsu 2002). The most
common chromosomal abnormalities are T21 and 45,X, respec-
tively. For T21, the prevalences reported for pregnant women are
0.11% and 0.44% at 25 and 35 years old, respectively at diagnosis
procedure (Snijders 1999).
Clinical characteristics and spectrumof severity are variable among
aneuploidies. It has been reported that 50% of 45,X cases are mo-
saic (Sybert 2004). During the past few decades, caring for chil-
dren with T21 or sex chromosomal abnormalities and provision
of counselling to their family has changed fundamentally. These
changes, including medical and surgical advances, specific inter-
ventions in the classroom for those with learning disabilities, inter-
ventions and support for parents and familymembers, have helped
individuals with T21 live longer and enjoy an improved quality
of life (Van Riper 2001). Many health problems associated with
T21, 45,X, 47,XXY, 47,XXX and 47,XYY aneuploidies can be
treated but fetuses with T18 and T13 aremost affected and usually
die in utero. The age at diagnosis varies widely depending on the
condition. T21, T18 and T13 are generally detected during the
perinatal period, while detection of 45,X, 47,XXX and 47,XYY
is often delayed, sometimes up to 60 years old (Stochholm 2006;
Stochholm 2010a; Tartaglia 2010). Around 10% of fetuses with
47,XXY are diagnosed prenatally and the mean age at diagnosis is
in the mid-30s. Most 47,XXY cases are never diagnosed (Groth
2013; Tyler 2004). The incidence, clinical features and prognosis
of the target conditions are summarised in Table 1.
Index test(s)
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Genomics-based non-invasive prenatal tests are based on the find-
ing that placental cells continuously release detectable amounts of
fetal ccfDNA into maternal blood. This fetal ccfDNA originates
from normal placental cell death and consists mainly of relatively
short fragments of < 300 base pairs (Bianchi 2004; Fan 2010).
Proof-of-concept studies showed the feasibility of such tests to de-
tect fetal aneuploidy in 2008 (Chiu 2008; Fan 2008).
We assessed these two gNIPT approaches (Figure 1):
Figure 1. Difference between massively parallel shotgun sequencing (MPSS) and targeted massively parallel
sequencing (TMPS). Genomics-based non-invasive prenatal testing (gNIPT) aims to count the number of
copies of DNA fragments from the chromosomes of interest (chromosome 21 (Chrom. 21) in this example)
present in circulating cell-free DNA (ccfDNA) from a pregnant woman, relative to a reference set of
chromosomes (Ref. Chrom.). DNA fragments circulating in maternal blood in the case of a euploid (left) and
aneuploid (right) pregnancy are illustrated (top). MPSS produces a large number of sequence reads from all
chromosomes while TMPS generates a larger proportion of reads from the chromosomes of interest
(bottom). In both methods, sequence reads can be used to detect a slight excess of fetal genomic material
coming from the chromosome of interest. Figure was created by FR.
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• massively parallel shotgun sequencing (MPSS) which
randomly analyses all DNA fragments of a sample; and
• targeted massively parallel sequencing (TMPS) which
targets specific DNA fragments from the chromosomal regions
of interest.
The fraction of the total ccfDNA in maternal circulation that is
of fetal origin (the fetal fraction) is an important parameter for
correctly identifying an aneuploid fetus by gNIPT (Canick 2013).
Although the fetal ccfDNA fraction is a relatively small fraction
(about 2% to 20%) of all ccfDNA in maternal blood, it can be
detected from five weeks of gestation (Birch 2005; Canick 2013;
Lo 1997; Lun 2008). Invasive procedures such as amniocentesis,
may (Samura 2003) or may not be (Bussani 2011; Vora 2010)
associated with a statistically significant increase of ccfDNA in
maternal blood, which could affect fetal DNA concentration and
affect gNIPT results. Therefore, in the context of clinical studies,
maternal blood for gNIPT is usually collected either before or af-
ter waiting for a minimum of 24 hours following an invasive test.
Indeed, the half-life of ccfDNA has been estimated to be less than
one day (Lo 1999; Yu 2013). On average, euploid multifetal preg-
nancies have a higher fetal ccfDNA fraction than euploid singleton
pregnancies (Attilakos 2011; Canick 2012). There is no reported
difference in ccfDNA concentration between monochorionic and
dichorionic multifetal pregnancies (Attilakos 2011). However, di-
chorionic pregnancies complicate gNIPT analysis by the presence
of an additional genome (or more in the presence of more than
two fetuses) as opposed to the two genomes of mother and fetus
present in singleton or monochorionic twin pregnancies.
Next generation sequencing (NGS) applied on DNA extracted
from the plasmaof pregnantwomengeneratesmillions ofDNA se-
quences from both maternal and fetal genomes in relative propor-
tion to their original abundance (for technical details see Appendix
3). The data thus produced can be used to detect a slight excess
(or loss) of fetal genomic material associated with cases of fetal
aneuploidy (Papageorgiou 2012). These NGS technologies have
paved the way for the development of gNIPT by alleviating the
need for fetal-specific genetic markers and with potentially better
test accuracy than current fetal aneuploidy screening methods.
Currently, gNIPT for the detection of common aneuploidies has
been developed by companies in America, Asia and Europe and
are commercially available. As part of their marketing material,
these companies have published the diagnostic performance of
their respective tests on theirwebsites (Table 2). In addition, several
research and clinical laboratories have developed in-house gNIPT.
Before taking a personal decision to accept or decline gNIPT, preg-
nant women should be given information on the screening pro-
cess, which must include a discussion with a health professional
(Gagnon 2010; Legare 2010; Legare 2011; St-Jacques 2008). Fol-
lowing screening, the results should be explained in the context
of the harms and benefits of definitive diagnosis through non di-
rective counselling (Benn 2013b). In their recent guideline, the
American College of Obstetricians and Gynecologists (ACOG)
recommends that gNIPT should not be used to replace diagnos-
tic testing and that all pregnant women with a positive gNIPT
result should have a diagnostic procedure before undertaking any
irreversible action such as pregnancy termination. Guidelines also
recommend that pregnant women with an unreported, indeter-
minate or uninterpretable gNIPT result should receive further ge-
netic counselling and be offered comprehensive ultrasound evalu-
ation and diagnostic testing (ACOG #163 2016).
Clinical pathway
Prior test(s)
Prenatal screening for fetal aneuploidy (mostly T21) is part of
public health programs in most upper-middle and high-income
countries and is typically offered to all pregnant women (Benn
2013b; Chitayat 2011). Up to now, screening tests for aneuploi-
dies have relied on blood-based biochemical testing of placental
markers with or without ultrasound imaging to assess for nuchal
translucency thickness and othermarkers of fetal aneuploidy in the
first trimester. The age of the pregnant woman is combined with
levels of biomarkers and nuchal translucency as predictive mark-
ers for T21 in the first or second trimester (Benn 2011; Chitayat
2011; Summers 2007). Table 3 presents the various testing combi-
nations (e.g. sequential, integrated or contingent algorithms) that
have been described and are currently in use in prenatal clinics
(Alldred 2017b). The screening performance of these algorithms is
mostly related to the detection rates of different marker combina-
tions and the accepted level of false positive rates. A large prospec-
tive Canadian study of 32,227 pregnant women showed that the
detection rate of existing screening strategies for T21 can reach
about 88.4%, with a screen-positive rate of 3.3% when applying
the integrated prenatal screening procedure (Okun 2008).
A woman is classified as screen-positive if her risk is equal to or
exceeds a predetermined threshold following prenatal screening
result or due to some other factors such as personal or familial
history of aneuploidies or translocations. Although these factors
are considered to significantly increase the risk of fetal aneuploidy,
the indications for invasive testing may vary between countries.
To confirm the presence or absence of fetal aneuploidy in these
high-risk pregnant women, a diagnostic test involving karyotyp-
ing by an invasive procedure such as amniocentesis or chorionic
villi sampling (CVS) is offered (ACOG #88 2007; Benn 2011;
Chitayat 2011). Karyotyping by traditional banding techniques of
fetal cells obtained from amniotic fluid or placental tissue has been
considered the standard of care for prenatal diagnosis of aneuploi-
dies (ACOG #545 2012; Benn 2013a; ICFMM 2013). Fluores-
cence in situ hybridisation (FISH) and quantitative fluorescence
polymerase chain reaction (QF-PCR) are appropriate standards of
care for pregnant women at increased risk of common fetal aneu-
ploidies based on screening results (Duncan 2011; Langlois 2011;
South 2013). Microarray analysis by array comparative genomic
hybridisation (aCGH) is recommended in pregnancies with fe-
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tal anomalies and it is increasingly replacing karyotyping (ACOG
#682 2016).
Five reviews published in the Cochrane Library examined serum,
urine, ultrasound or a combination of these tests for T21 screen-
ing. For first-trimester serum tests (Alldred 2015a), the authors
concluded that two markers in combination with maternal age,
specifically pregnancy associated plasma protein A (PAPP-A) and
free human chorionic gonadotropin (hCG) are significantly bet-
ter than those involving single markers combined with or without
maternal age. For second-trimester serum tests (Alldred 2012), the
authors concluded that two or more markers, with or without in-
hibin A, in combination with maternal age are significantly more
sensitive than one marker alone. Their review also showed that
no test combination was superior to the others and therefore it
was not possible to recommend a specific test combination. For
first-trimester ultrasound tests alone of in combination with first-
trimester serum tests (Alldred 2017a), the authors concluded that
test strategies that combine ultrasound markers with serummark-
ers, especially PAPP-A and free ßhCG, and maternal age were
significantly better than those involving only ultrasound markers
(with or without maternal age) except nasal bone. For first- and
second-trimester serum tests with and without first-trimester ul-
trasound tests (Alldred 2017b), the authors concluded that tests in-
volving first-trimester ultrasound with first- and second-trimester
serum markers in combination with maternal age are significantly
better than those without ultrasound, or those evaluating first-
trimester ultrasound in combination with second-trimester serum
markers, without first-trimester serum markers. For first- and sec-
ond-trimester urine tests (Alldred 2015b), the authors concluded
that second-trimester ß-core fragment and oestriol with maternal
age are significantly more sensitive than the single marker second-
trimester ß-core fragment and maternal age. However, there were
few studies and the evidence does not support the use of urine
tests for T21 screening for the first 24 weeks of pregnancy.
Role of index test(s)
Genomics-based non-invasive prenatal testing such as MPSS or
TMPS could be offered to pregnant women after a first-tier screen-
ing and before a diagnostic test in order to better identify which
pregnant women at increased risk of fetal aneuploidy should be
offered further testing (triage) (Figure 2). The use of such NGS-
based approaches has also been suggested as a replacement for
current first-tier screening tests (biochemical, ultrasound or both)
or as potential diagnostic tests to replace current diagnostic test
(karyotyping of fetal cells from amniocentesis or CVS) (Bianchi
2012).
7Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Current clinical pathway and three proposed uses of genomics-based non-invasive prenatal testing
(gNIPT). Currently (on the left), pregnant women can have a prenatal screening test consisting of biomarkers
or ultrasound, or both. For high-risk pregnant women, an invasive diagnostic test (karyotyping) is offered. In
the present review, we propose 3 different clinical pathways. First, gNIPT could be used as a triage test, to
decide which pregnant women should receive further testing. Second, gNIPT could be used to replace current
prenatal screening tests. Finally, gNIPT could be used to replace current invasive diagnostic tests (if diagnostic
performance permits). At any point in a clinical pathway, a pregnant woman may decide not to proceed with
other tests (not shown in the figure). Figure was designed by CL, JB, MB and YT.
Rationale
Current screening tests (biochemical, ultrasound or both) have
relatively high false positive rates, which may result in undue anx-
iety for many pregnant women who will be offered an invasive di-
agnostic procedure. For example, at a prenatal screening risk cut-
off of 1:300, fetal aneuploidy is confirmed by karyotyping in only
about 1/34 to 1/14 (3% to 7%) screen-positive cases (Renshaw
2013; Wald 2005). As a result, many more women will undergo
invasive diagnostic testing following positive screening tests than
the number carrying a fetus with aneuploidy. In France, each year,
about 800,000 pregnant women opt for prenatal T21 biochemical
screening, ultrasound measurements or both, and about 24,000
of them (3%) will have karyotype testing (Basset 2013). Inva-
sive testing methods for prenatal diagnosis of aneuploidy identify
pregnancies with fetal chromosomal abnormalities, but contribute
to an additional procedure-related fetal loss rate (Wilson 2007).
A recent meta-analysis showed that weighted pooled procedure-
related risks of miscarriage of invasive testing methods before 24
weeks’ gestation were 0.11% for amniocentesis and 0.22% for
CVS (Akolekar 2015). The risk of miscarriage of normal fetuses
associated with such invasive procedures has fostered the develop-
ment of alternative screening and diagnostic approaches.
The discovery of fetal circulating cells and fetal ccfDNA in ma-
ternal blood during pregnancy has enabled the development of
non-invasive methods to analyse the fetal genome (Birch 2005;
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Lo 1997; Wright 2009). Fetal DNA offers advantages over circu-
lating fetal cells because it is more easily extracted from maternal
plasma samples and it disappears within hours after birth (unde-
tectable about one to two days postpartum), as compared to the
paucity and persistence of fetal cells in maternal blood over several
consecutive pregnancies (up to 27 years) (Wright 2009; Yu 2013).
At present, the analysis of ccfDNA by NGS technologies seems
to be the most promising alternative gNIPT approach for the de-
tection of fetal aneuploidies from maternal blood. This allows se-
quencing of tens of millions of these DNA fragments simultane-
ously, paving the way for the development of a non-invasive, less
psychologically stressful method potentially able of detecting fetal
aneuploidies earlier and with better accuracy than current screen-
ing programs. As such, NGS technologies have the potential to
radically change prenatal screening for fetal aneuploidy. Indeed,
a study exploring the impact of gNIPT on prenatal care showed
that more pregnant women with positive first-trimester screening
opt for further testing (from 47.2% to 78.8%) than before the in-
troduction of gNIPT, while the rate of invasive diagnostic testing
has decreased significantly (from 47.2% to 39.2%). Additionally,
fewer pregnant women declined follow-up testing when gNIPT
was an option (from 52.8% to 21.2%) (Chetty 2013). Another
study suggested that gNIPT could reduce procedure-related fetal
losses in high-risk women by up to 88% (O’Leary 2013).
For instance, the new gNIPT approach is reported to detect ane-
uploidy with high sensitivity to select a subset of pregnant women
for an invasive diagnostic procedure and could be performed in
high-risk pregnant women (as a second-tier test) following a posi-
tive screening result (Benn 2013a). The major expected advantage
of gNIPT byNGS over current (biochemical, ultrasound or both)
screening tests is the significant decrease in false positive results and
thus the reduction of invasive procedures and their associated nor-
mal fetus losses. Also, it was reported that a reduction of invasive
prenatal procedures with the introduction gNIPT has indeed been
documented (Chetty 2013; Larion 2014; Tiller 2014). Assessment
of how NGS should be used in clinical practice for aneuploidy
detection is currently being studied. NGS approaches could also
be performed in general obstetrical population (as first-tier test),
in place of current screening algorithms (biochemical, ultrasound
or both) (Figure 2). However, the field is moving rapidly. From
January to July 2014, around 60 NIPT studies were published in
PubMed compared to 70 studies in 2013 and 40 studies in 2012.
Up to now, no comprehensive systematic review including meta-
analyses has analysed and compared the diagnostic accuracy of
MPSS and TMPS methods for the detection of fetal aneuploidies,
either as a second-tier test (i.e. in women at increased risk of fetal
aneuploidy after current screening procedures) or as a first-tier test
(i.e. in all pregnant women). Benn 2013b published a review on
gNIPT focused on providing the information needed by clinicians
and public health providers before implementation of this tech-
nology in routine clinical practice. However, their review included
only T21 and T18. Mersy 2013 published a systematic review on
quality and outcome of diagnostic test accuracy studies on non-
invasive detection of fetal T21 only. One updated meta-analysis
(Gil 2015a) pooled all gNIPT methods but did not assess the rel-
ative performance of MPSS and TMPS technologies separately.
More recently, Taylor-Phillips 2016 published a meta-analysis on
gNIPT accuracy for major autosomal anomalies (T21, T18 and
T13) without sex chromosome aneuploidies (SCAs) assessment
and using restrictive inclusion criteria for included publications
(e.g. limited to the English language, cohorts ofmore than50 preg-
nant women) and including studies with incomplete follow-up
(pregnant women without reference standard). In the meta-analy-
sis of Mackie 2017, multifetal pregnancies and case-control study
design were excluded. In themeta-analysis published by theHaute
Autorité de Santé in France (HAS 2015), the accuracy of gNIPT
was evaluated for T21 only and included studies with pregnant
women selected at high risk of fetal aneuploidy as well as studies
with pregnant women unselected for their risk (general popula-
tion). Only studies published in English were included. The re-
view of Agarwal 2013 described the properties of commercial tests
available (e.g. type of gNIPTmethod, costs, turnaround times and
reimbursement), intellectual property, commercialisation, patent-
ing, patenting litigation and licensing landscape of technologies
underlying these tests.
Genomics-based non-invasive prenatal tests are already adver-
tised and marketed to North-American, European and Asian
healthcare providers. Leading companies are summarised in Table
2. Other entities are trying to make their way into the mar-
ket (Birmingham Women’s NHS; Counsyl; GENDIA; Genesis
Genetics; Integrated Genetics; NIPD Genetics; Progenity; Quest
Diagnostics; RAVGEN; Xcelom). Some of these assays have yet to
be approved by the US Food and Drug Administration. There is
significant pressure for increasing their use in clinical practice, but
comparative effectiveness and cost-effectiveness studies, as well as
studies of the ethical, legal and social issues are scarce. Further-
more, tools needed for their patient value-based implementation
are not available or have not been validated.
O B J E C T I V E S
To evaluate and compare the diagnostic accuracy of massively par-
allel shotgun sequencing (MPSS) and targeted massively parallel
sequencing (TMPS) using circulating cell-free DNA (ccfDNA) in
maternal blood for the detection of common fetal aneuploidies
(T21, T18, T13, 45,X, 47,XXY, 47,XXX and 47,XYY) according
to their prior risk of fetal aneuploidy. The genomics-based non-
invasive prenatal testing (gNIPT) results were confirmed by a ref-
erence standard such as fetal karyotype or neonatal clinical exam-
ination.
To evaluate the screening performance of MPSS and TMPS as
triage tests (a second-tier screening test) for identifyingwhich preg-
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nant women at increased risk of fetal aneuploidy should be offered
further testing, that is, after a first-tier screening, but before a di-
agnostic test.
To assess the screening performance ofMPSS and TMPS as a first-
tier test in pregnant women without prior risk (i.e. in unselected
pregnant women or general population) as a replacement for cur-
rent offered first-tier tests (biochemical, ultrasound or both).
To assess the diagnostic performance of MPSS and TMPS as a
second-tier test as potential diagnostic tests to replace current in-
vasive diagnostic tests.
Secondary objectives
To investigate potential sources of heterogeneity that may influ-
ence the diagnostic accuracy of MPSS and TMPS such as gesta-
tional age at the time of blood collection and type of reference
standard used.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included studies that met the following inclusion criteria:
• randomised studies where pregnant women were
randomised to receive one gNIPT (MPSS or TMPS) as well as
the reference standard;
• retrospective and prospective cohort studies where all
pregnant women were tested with one or more gNIPT methods
and the reference standard (including head-to-head studies); and
• retrospective and prospective case-control studies
comparing one or more of the gNIPT methods with the
reference standard.
Although studies with a retrospective or case-control design are
prone to biases, we included such studies because we anticipated
a paucity of other study designs. When data were sufficient, we
explored the effect of excluding case-control studies in sensitivity
analyses.
We excluded studies for which it was not possible to extract or
derive the number of true positives, false positives, false negatives
and true negatives.
Participants
We included women of any age, ethnicity and gestational age
with a singleton or multifetal (monochorionic and dichorionic)
pregnancy.
Index tests
Genomics-based non-invasive prenatal tests based on plasma
ccfDNA in maternal blood, analysis by either MPSS or TMPS
methods.
Target conditions
We considered seven fetal aneuploidies, namely T21, T18, T13,
45,X, 47,XXY, 47,XXX and 47,XYY.
Reference standards
We considered the following test as reference standard: fetal kary-
otyping performed on cells obtained from chorionic villi sampling
(CVS), amniotic fluid, placental tissue, a fetus lost by miscarriage
or other equivalent and recognised methods on the samematerials.
By “fetal karyotyping” we mean traditional banding techniques,
spectral karyotyping, fluorescence in situ hybridisation (FISH),
array comparative genomic hybridisation (aCGH) or quantitative
fluorescence polymerase chain reaction (QF-PCR). If fetal kary-
otyping was not performed, we used neonatal clinical examination
or medical records from birth as a secondary reference standard
for T21, T18 or T13. For sex chromosome aneuploidies (SCA),
only fetal karyotype was an appropriate reference standard because
newborns usually have a normal phenotype.
Search methods for identification of studies
Electronic searches
We used a sensitive search strategy that included the following
three sets of search terms and synonyms:
• index test (e.g. cell-free DNA, sequencing, non-invasive
and genetic diagnosis);
• participants’ description (e.g. pregnant women, fetus and
prenatal); and
• target condition (e.g. aneuploidy and chromosome
anomalies).
We combined free-text words and subject headings used within
each set with the Boolean operator OR and then combined the
three sets using AND.We reviewed publications from 1st January
2007 because MPSS and TMPS were introduced in the literature
in 2008 (Chiu 2008; Fan 2008). We did not limit our search
by language, search filter or publication type (e.g. journal article,
clinical trial, validation study, review and comment).
We applied a comparable search strategy (Appendix 4) with adap-
tations for each of the following databases:
• MEDLINE (Ovid) (January 2007 to July 2016);
• Embase (January 2007 to July 2016);
• Web of Science (ISI) (January 2007 to July 2016);
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• Cochrane Register of Diagnostic Test Accuracy Studies,
Cochrane Library (January 2007 to October 2016);
• ClinicalTrials.gov (January 2007 to September 2016);
• European Clinical Trials Register (January 2007 to
September 2016);
• WHO ICTRP (January 2007 to September 2016);
• The National Technical Information Service (NTIS)
(January 2007 to September 2016);
• OpenGrey (January 2007 to October 2016); and
• National Guideline Clearing House (January 2007 to
September 2016).
Searching other resources
We examined references cited in potentially relevant full-text pa-
pers and those cited in previous reviews by cross-checking bibli-
ographies. We examined grey literature by searching data available
on the websites of private prenatal diagnosis companies (Ariosa
Diagnostics 2016; BGI 2016; Berry Genomics 2016; Genoma
2016; Genome Care 2016; Illumina 2016; LabGenomics 2016;
LifeCodexx 2016; Natera 2016; Genesupport 2016; Premaitha
Health plc 2016; Sequenom 2016) using gNIPT technologies
(January 2007 to December 2016). We also searched for confer-
ence abstracts and theses in appropriate sources (e.g. TheseNet,
Theses Canada Portal) (January 2007 to October 2016).
Data collection and analysis
We used the methods suggested by the Cochrane Diagnostic Test
Accuracy Working Group (Deeks 2013). For selection of stud-
ies, data extraction and assessment of methodological quality, we
conducted a pilot using 20 randomly selected articles to trial our
forms in order to ensure criteria were applied consistently.
None of the review authors involved in conducting a gNIPT pri-
mary study (FL, FR, SL and YG) took part in the selection of
studies, nor in any decisions/analyses related to their own studies.
Furthermore, by the final date of data collection, these authors
had not published a primary gNIPT study.
Selection of studies
Two review authors (MB and CL) independently identified rel-
evant studies by screening the titles and abstracts of all studies
identified by the search strategy. We obtained the full-text version
of all potentially relevant studies and assessed them for inclusion
by using a study eligibility table based on prespecified inclusion
criteria. The data collection form (Excel® format) for classifying
studies during the full-text assessment is presented in Appendix
5. We considered all comments, statements or errata related to in-
cluded studies. We excluded studies that did not match the inclu-
sion criteria and we recorded the reason(s) for exclusion. If results
from the same study cohort were reported in multiple publica-
tions, we considered all the publications and included results from
the most relevant and comprehensive publications. We excluded
papers with preliminary results whose full published results were
available. We resolved any disagreement between assessors (MB
and CL) by iteration, discussion and consensus. If required, we
consulted a third review author (JB or LN).
Data extraction and management
Two review authors (MB and CL, JB or LN) independently ex-
tracted information and data from each included study by using
a data extraction form that we developed in Excel® format. We
included the following items:
• study characteristics (e.g. reference details allowing
identification of the publication, language and study design);
• population characteristics (e.g. gestational age, maternal
age, ethnicity, total number of pregnant women, number of
aneuploid cases, number of euploid cases, recruitment location
(country, geographic locations or regions), recruitment period
and other relevant tests carried out prior to index test (e.g.
ultrasonography, biochemical screening));
• features of the reference standard (e.g. fetal karyotyping,
chromosome analysis or clinical examination);
• features of the index test (e.g. technical details, commercial
or in-house gNIPT, cutpoint, failure rate, blood sample
collection time (before or after reference standard) and first-tier
test or second-tier test); and
• data for constructing two-by-two tables (number of true
positives, false positives, false negatives and true negatives) or
summary statistics from which the data were derived. In the two-
by-two tables, the true negative cases were patients with any
other aneuploidy than the one under analysis and all euploid
cases were considered unaffected. When data were presented in
three-by-two tables due to unclassified index test results (defined
as grey zone between positive and negative test results), we
constructed two-by-two tables by considering all unclassified
gNIPT results as test positives. This is because in practice such
results will lead to further testing and investigation to ensure a
case of fetal aneuploidy is not missed.
We cross-checked all extracted and recorded data and we resolved
any disagreement by iteration, discussion and consensus between
two review authors (MB and CL, JB or LN). If required, we con-
sulted a third author (JB, LNorCL).Wewrote to the study contact
author if information was missing or unclear or to clarify potential
overlap between publications based on the same dataset to avoid
including the same women more than once. If an article presented
results including other aneuploidies than the ones under review,
we considered only the subset of the cohort with the aneuploidies
of interest.
11Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Assessment of methodological quality
We used the revised QUality Assessment of Diagnostic Accuracy
Studies (QUADAS-2) tool for assessment of methodological qual-
ity of included studies (Whiting 2011).We tailored the tool to this
review question using the operational criteria detailed in Appendix
6 to answer signalling questions and make the overall judgment of
risk of bias and applicability concerns for each domain of the tool.
We answered each signalling question with a ‘yes’, ‘no’ or ‘unclear’
response for each included study and we recorded the reason for
the judgment made. If a study was recorded as ‘yes’ on all sig-
nalling questions related to risk of bias, then it was deemed appro-
priate to have an overall judgment of ‘low risk of bias’. If a study
is recorded ‘no’ or ‘unclear’ on one or more signalling questions
in a domain, then it was judged as having ‘high or unclear risk of
bias’. Judgments about applicability concern were rated as ‘low’,
‘high’ or ‘unclear’ in relation to our review question. ‘Unclear con-
cern’ was used only if insufficient information was available. Two
review authors (MB and CL, JB or LN) independently applied
the QUADAS-2 tool to each included study and we resolved any
disagreement by iteration, discussion and consensus. If required,
we consulted a third review author (JB, LN or CL).
Statistical analysis and data synthesis
The unit of analysis was the pregnant woman irrespective of the
type of pregnancy (multifetal or singleton pregnancy). We evalu-
ated the performance ofMPSS andTMPS for the detectionof each
type of aneuploidy under study both individually and globally for
any type of aneuploidy (all autosomal aneuploidies combined and
all sex chromosomal aneuploidies combined). We distinguished
between each of the following groups of pregnant women and
performed separate analyses for each subgroup:
• unselected pregnant women undergoing aneuploidy
screening (first-tier gNIPT, i.e. offered to all pregnant women)
and women selected at high risk of fetal aneuploidy (second-tier
gNIPT);
• women with singleton and multifetal pregnancy because
ccfDNA’s fetal fraction in multifetal pregnancy is higher than in
singleton pregnancy (Attilakos 2011; Canick 2012); and
• pregnant women who underwent gNIPT during the first
trimester (15 weeks or less), the first or second trimester (29
weeks or less) or at any time during pregnancy (42 weeks or less).
For each gNIPT method, we used Review Manager® to produce
coupled forest plots of sensitivity and specificity, together with
their 95% confidence intervals (CIs). We also plotted study-spe-
cific estimates of sensitivity and specificity in receiver operating
characteristic (ROC) space. All gNIPTs are laboratory-developed
tests based on differently calibrated assays with specific cutpoints
to classify samples as euploid or aneuploid. There is no consen-
sus on the cutpoints to use in practice. For this reason, we had
planned to use a modelling strategy that focuses on the estimation
of summary ROC curves (Macaskill 2010; Rutter 2001) and to
estimate summary points (summary sensitivity and specificity) if
a sufficient number of studies reported common cutpoints. How-
ever, given the qualitative nature of the cutpoints, which is highly
dependent on each laboratory’s developed gNIPT and study popu-
lations, it was not possible to identify a common cutpoint. There-
fore, we reasoned that this was a special case where we can assume
gNIPT results were binary (positive or negative). The rationale
was further strengthened by the lack of apparent threshold effect
when we examined the studies in ROC space. If a study reported
more than one cutpoint, we considered all cutpoints and chose
one cutpoint, the most commonly reported across all studies, such
that only one pair of sensitivity and specificity from a study was
included in meta-analysis.
Due to limited or absence of threshold effect, there was no require-
ment to account for correlation between sensitivity and specificity
across studies in meta-analysis. Therefore, we removed the correla-
tion parameter from the bivariate model (Chu 2006), thus simpli-
fying the model to two univariate random-effects logistic regres-
sion models for separate meta-analyses of sensitivities and speci-
ficities (Takwoingi 2015). In cases where there were few studies in
the meta-analysis or a random-effects analysis failed to converge,
we used fixed-effect logistic regressionmodels.Where all studies in
the meta-analysis reported 100% sensitivity or 100% specificity,
these fixed-effect models fail as the prediction is perfect. There-
fore, in such situations we used simple pooling by summing up the
numbers of true positives and total cases to compute sensitivity,
and the numbers of true negatives and unaffected pregnancies to
compute specificity. CIs were obtained using the Wilson method
(Newcombe 1998).
We compared the diagnostic accuracy ofMPSS and TMPS by first
using all available data (indirect comparison). If studies that com-
pared MPSS and TMPS in the same population (head-to-head or
direct comparison) were available, we had planned a second set of
analyses restricted to direct comparisons. Comparative meta-anal-
yses were done by adding a covariate for test type to random-effects
or fixed-effect models. We used likelihood ratio tests to assess the
statistical significance of differences between tests by comparing
models that included covariate terms for test type with models
that did not include the terms. If data were available, compar-
isons between gNIPTs and traditional screening approaches were
planned using a similar strategy to that described above. Meta-
analyses were performed using the xtmelogit and blogit functions
in the Stata software package (version 13; StataCorp, College Sta-
tion, Texas 77845, USA). When meta-analyses of direct compar-
isons were not possible, we examined individual study results. For
each comparative study, we computed differences in sensitivity
and specificity, and 95% CIs were calculated for the differences
using the Newcombe-Wilson method without continuity correc-
tion (Newcombe 1998).
Investigations of heterogeneity
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We examined forest plots of sensitivity and specificity and sum-
mary ROC plots for each gNIPT method to visually assess het-
erogeneity. If sufficient data were available for meta-regression (by
adding a covariate to a logistic regressionmodel to explore its effect
on sensitivity and specificity), we had planned to investigate the
effect of the following:
• study population (e.g. ethnicity, gestational age at blood
collection); and
• type of reference standard (i.e. karyotype or mixed reference
standard).
However, formal investigations using meta-regression were not
possible due to limited data and little or no heterogeneity in test
accuracy.
Sensitivity analyses
We performed sensitivity analyses to assess the effect of excluding
case-control studies and studies with a small number of cases of
aneuploidy (less than 10 cases) on the summary estimates of test
accuracy.
We had planned to also assess the effect of:
• studies where pregnant women received an invasive
diagnostic test less than one day before blood collection for
gNIPT;
• third trimester gestational age at the moment of blood
collection for gNIPT;
• studies available only as abstracts; and
• studies at ‘high or unclear risk of bias’ according to the
QUADAS-2 assessment tool.
However, due to lack of data or lack of variability in estimates of
sensitivity and specificity, only assessments of the impact of study
design and number of cases were performed.
R E S U L T S
Results of the search
We found a total of 11,912 articles through our electronic searches
from January 2007 to October 2016 (see PRISMA study flow dia-
gram inFigure 3). A total of 11,700 articleswere identified through
databases (941 throughMEDLINE, 8381 through Embase, 1986
through Web of Science, 18 through Cochrane Diagnostic Test
Accuracy register of studies, 245 through ClinicalTrial.gov, 43
through European Clinical Trials Register, 21 through WHO IC-
TRP, 34 through NTIS, 19 through OpenGrey and 12 through
the National Guideline Clearing House). We found 212 publica-
tions through other sources (two articles received from the author,
175 from gNIPT company’s website, 27 from TheseNet and eight
from These Canada Portal). After removing 2354 duplicates, two
review authors independently screened the titles and abstracts of
9558 publications. Of the 9558 publications, 9209 were deemed
irrelevant to our review question. We retrieved the full texts of
the remaining 349 articles to assess their eligibility. After resolving
disagreement between two or three review authors, 261 articles
were excluded (see Characteristics of excluded studies for details)
and 63 articles fulfilled our inclusion criteria (see Characteristics
of included studies for details). Among these 63 articles, 62 were
journal articles and one was a letter to the editor with sufficient
information to be included (Jackson 2014). From the 63 articles,
two articles presented two studies (two different cohort, two 2x2
tables). At all, we included 65 studies of 86,139 pregnant women
(3141 aneuploids and 82,998 euploids). No studies are awaiting
classification. We identified 25 ongoing trials through clinical tri-
als databases (see Characteristics of ongoing studies for details).
We will consider these trials in future updates.
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Figure 3. PRISMA flow diagram for selection of studies from January 2007 to October 2016.#: number,
DTA: diagnostic test accuracy, NTIS: The National Technical Information Service and WHO ICTRP: World
Health Organization International Clinical Trials Registry Platform.
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Basic features of the included studies
The clinical characteristics of pregnant women and sequencing
method were generally well described or referenced. Some studies
did not clearly report how patient selection was done and which
inclusion and exclusion criteria were applied. Patients’ enrolment
flow-charts, pregnancy outcome flow-chart and 2 x 2 tables were
unclear in many studies. We therefore contacted study authors to
clarify unclear information, to obtain missing data or to clarify
potential overlap of patients between publications.
We described the characteristics of included studies in
Characteristics of included studies table and provided a sum-
mary in Table 4. Forty-two studies (65%) enrolled pregnant
women selected at high risk of fetal aneuploidy (Alberti 2015;
Ashoor 2012; Benachi 2015; Bianchi 2012; Bianchi 2013; Bijok
2014; Canick 2012; Chen 2011; Ehrich 2011; Hall 2014; Hooks
2014; Hou 2012; Huang 2014; Jeon 2014; Jiang 2012; Johansen
2016; Ke 2015; Kim 2016; Lee 2015; Lefkowitz 2016; Liang
2013; Liu 2012; Mazloom 2013; Nicolaides 2013; Nicolaides
2014a; Norton 2012; Palomaki 2012; Papageorghiou 2016a;
Papageorghiou 2016b; Persico 2016; Poon 2016; Porreco 2014;
Sehnert 2011; Song 2015; Sparks 2012a; Stumm 2014; Sukhikh
2015; Sung-Hee 2015; Verweij 2013; Wang 2014; Wang 2015a;
Zhang 2016); five studies (8%) enrolled pregnant women with-
out prior risk of fetal aneuploidy (del Mar Gil 2014; Nicolaides
2012; Norton 2015; Quezada 2015; Song 2013); and 18 stud-
ies (28%) enrolled pregnant women from a mixed risk cohort of
fetal aneuploidy (Ashoor 2013; Bevilacqua 2015; Bianchi 2014a;
Chiu 2011; Comas 2015; Fiorentino 2016; Gil 2016; Jackson
2014; Korostelev 2014; Lau 2012; Ma 2016; Pergament 2014;
Samango-Sprouse 2013; Shaw 2014; Tynan 2016; Yao 2014;
Zhou 2014a; Zhou 2014b). Mixed-risk samples included a mix-
ture of selected pregnant women with low, high or no prior risk of
fetal aneuploidy. Such samples do not represent the real-life situa-
tion (i.e. using gNIPT as a first-tier screening test or as a second-
tier test) and so such studies were not used for addressing our re-
search objectives. Nevertheless, as we did not pre-specify exclusion
of such studies, we analysed the data and the results are presented
in Appendix 7.
The studies assessed MPSS and TMPS using various algorithms
and cutpoints. Table 4 describes the specific gNIPT assay used
in the included studies. Each assay was developed and validated
by the testing laboratory. Among the 65 studies, 44 studies
(68%) used a whole genome sequencing method (MPSS) (Alberti
2015; Benachi 2015; Bianchi 2012; Bianchi 2013; Bianchi 2014a;
Bijok 2014; Canick 2012; Chen 2011; Chiu 2011; Ehrich 2011;
Fiorentino 2016; Hou 2012; Huang 2014; Jeon 2014; Jiang
2012; Johansen 2016; Ke 2015; Kim 2016; Lau 2012; Lee 2015;
Lefkowitz 2016; Liang 2013; Liu 2012;Ma 2016;Mazloom 2013;
Palomaki 2012; Papageorghiou 2016a; Papageorghiou 2016b;
Poon 2016; Porreco 2014; Sehnert 2011; Shaw 2014; Song 2013;
Song 2015; Stumm 2014; Sukhikh 2015; Sung-Hee 2015; Tynan
2016; Wang 2014; Wang 2015a; Yao 2014; Zhang 2016; Zhou
2014a; Zhou 2014b), and 21 (32%) used a targeted method
(TMPS) (Ashoor 2012; Ashoor 2013; Bevilacqua 2015; Comas
2015; del Mar Gil 2014; Gil 2016; Hall 2014; Hooks 2014;
Jackson 2014; Korostelev 2014; Nicolaides 2012; Nicolaides
2013; Nicolaides 2014a; Norton 2012; Norton 2015; Pergament
2014; Persico 2016; Quezada 2015; Samango-Sprouse 2013;
Sparks 2012a; Verweij 2013). Of the 65 studies, five studies com-
pared gNIPT with traditional screening tests (Bianchi 2014a;
Nicolaides 2012; Norton 2015; Quezada 2015; Song 2013).
MPSS studies involved 50,864 pregnant women, TMPS studies
involved 35,275 pregnant women and traditional screening tests
involved 24,279 pregnant women. The most commonly (15 stud-
ies) used cutpoint for gNIPT assays was a chromosomal ratio Z
score of 3. Thirteen studies used the FORTE risk score, eight stud-
ies used a normalised chromosome value (NCV) and 13 studies
did not report their cutpoint. The remaining studies used other
cutpoints (Table 4). Timing of blood sampling for gNIPT was be-
fore invasive procedure in 55 studies, before ormore than 24 hours
after invasive sampling in four studies (Ashoor 2013; Lefkowitz
2016; Pergament 2014; Samango-Sprouse 2013), and was not re-
ported in six studies (Bevilacqua 2015; Jiang 2012; Song 2013;
Sparks 2012a; Wang 2014; Zhang 2016).
Among all aneuploidies considered, 36 studies (55%) reported
analyses only for autosomes, four (6%) for only sex chromosome
aneuploidies (SCA) and 25 studies (39%) for both autosomes
and SCA. Fifty-seven studies (82,620 pregnant women) evaluated
T21, 50 studies (79,322pregnantwomen) evaluatedT18, 39 stud-
ies (68,958 pregnant women) evaluated T13, 20 studies (10,081
pregnant women) evaluated 45,X, seven studies (6035 pregnant
women) evaluated 47,XXX, 12 studies (7609 pregnant women)
evaluated 47,XXY and 10 studies (6987 pregnant women) evalu-
ated 47,XYY (Table 4). Among all 65 included studies, there are a
total of 2004 T21 cases, 634 T18 cases, 215 T13 cases, 232 45,X
cases, 14 47,XXX cases, 25 47,XXY cases and 16 47,XYY cases. All
65 studies used an appropriate reference standard such as fetal or
neonatal karyotype, genetic testing, neonatal clinical examination
or medical records from birth. In 36 studies (55%), only one ref-
erence standard was used while 29 studies (45%) used more than
one reference standard (Table 4).
Among the 65 studies, 40 (62%) studies were prospective cohort
studies (Ashoor 2013; Bevilacqua 2015; Bianchi 2014a; Bijok
2014;Comas 2015; Fiorentino 2016;Gil 2016;Hou 2012;Huang
2014; Jackson 2014; Jeon 2014; Jiang 2012; Johansen 2016;
Ke 2015; Kim 2016; Korostelev 2014; Lau 2012; Lee 2015;
Liang 2013; Liu 2012; Mazloom 2013; Nicolaides 2013; Norton
2012;Norton2015; Pergament 2014; Persico 2016; Porreco2014;
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Quezada 2015; Samango-Sprouse 2013; Shaw 2014; Song 2013;
Song 2015; Stumm 2014; Sukhikh 2015; Verweij 2013; Wang
2014; Wang 2015a; Zhang 2016; Zhou 2014a; Zhou 2014b),
eight (12%) studies were retrospective cohort studies (Benachi
2015; Bianchi 2013; del Mar Gil 2014; Nicolaides 2012; Sehnert
2011; Sung-Hee 2015; Tynan 2016; Yao 2014), one (1%) study
was a prospective and retrospective cohort study (Ma 2016) and
16 (25%) studies used a case-control design (Alberti 2015; Ashoor
2012; Bianchi 2012;Canick 2012;Chen2011;Chiu 2011; Ehrich
2011;Hall 2014;Hooks 2014; Lefkowitz 2016;Nicolaides 2014a;
Palomaki 2012; Papageorghiou 2016a; Papageorghiou 2016b;
Poon 2016; Sparks 2012a) (Table 4).
Forty-eight (74%) studies included only singleton pregnancies,
while five (8%) studies included only multifetal pregnancies. Four
(6%) studies included women with either type of pregnancy and
eight (12%) studies did not report the type of pregnancy. Ten
(15%) studies included only pregnant women in the first trimester
(15 weeks or less), 21 (33%) studies included pregnant women
in the first two trimesters (29 weeks or less), 24 studies (37%)
included pregnant women in the three trimesters (42 weeks or
less) and 10 studies (15%) did not report gestational age. Eighteen
studies (28%) had more than 50% Caucasian women in their
cohort, 21 studies (32%) had more than 50% Asian women and
26 studies (40%) did not report ethnicity.
Thirty-seven studies (57%) were industry-funded or were written
by one or more author affiliated with a company who sells gNIPT
(Benachi 2015; Bianchi 2012; Bianchi 2013; Bianchi 2014a;
Canick 2012; Chen 2011; Chiu 2011; Ehrich 2011; Hall 2014;
Hooks 2014; Huang 2014; Jackson 2014; Jiang 2012; Kim 2016;
Lau 2012; Lee 2015; Lefkowitz 2016; Ma 2016; Mazloom 2013;
Nicolaides 2012; Nicolaides 2013; Norton 2012; Norton 2015;
Palomaki 2012; Papageorghiou 2016a; Papageorghiou 2016b;
Pergament 2014; Persico 2016; Porreco 2014; Samango-Sprouse
2013; Sehnert 2011; Shaw 2014; Sparks 2012a; Stumm 2014;
Tynan 2016; Verweij 2013; Yao 2014); 22 studies (34%) were not
reported to be funded by industry but samples were sequenced
and analysed by a commercial laboratory (Ashoor 2012; Ashoor
2013; Bevilacqua 2015; Bijok 2014; Comas 2015; del Mar Gil
2014; Fiorentino 2016;Gil 2016;Hou 2012; Jeon 2014; Ke 2015;
Korostelev 2014; Liang 2013; Poon 2016; Quezada 2015; Song
2013; Song 2015; Sung-Hee 2015; Wang 2014; Wang 2015a;
Zhou 2014a; Zhou 2014b); three studies (4.5%) had no link with
industry (Alberti 2015; Johansen 2016; Sukhikh 2015); and the
funding source was not reported for three studies (4.5%) (Liu
2012; Nicolaides 2014a; Zhang 2016). Table 5 describes the spe-
cific gNIPT assay used in the included studies. Of the 65 studies,
61 (94%) used a commercial gNIPT (15 from Ariosa Diagnos-
tics, Inc., 12 from Bejing Genomics Institute, four from Illumina
(or Verinata Health), six from Natera, nine from Sequenom and
15 from other companies) (Table 5). It appears that, for three of
the commercially available assays, there are nine studies or more
adding up to a large number of cases and unaffected cases analysed.
Further, only two assays (one TMPS and one MPSS) were used in
one of the five studies involving unselected pregnant women and
one assay (Ariosa’s Harmony™ test) was used in four of them.
Twelve studies (19%) included their entire cohort in the analyses,
36 studies (55%) included between 80% to 99.9%, and 17 studies
(26%) included less than 80%. We found 54 (83%) studies where
patient exclusions and failed samples were reported (Table 6; Table
7).
Summary of excluded studies
We described the excluded studies in the PRISMA flow diagram
(Figure 3) as well as in Characteristics of excluded studies. After
full-text assessment, we excluded 261 articles.
Of these 261:
• 93 (36%) studies were not diagnostic test accuracy studies
(e.g. implementation study, simulation model, method
development, proof-of-concept, method without sequencing
approach);
• 55 (21%) studies had overlapping samples and were
excluded to avoid double counting;
• 54 (21%) studies had incomplete 2 X 2 data or insufficient
information to derive a 2 X 2 table;
• 22 (8%) studies had either an inappropriate or no reference
standard;
• 8 (3%) studies were identified as reviews or Health
Technology Assessment reports;
• 11 (4%) studies had target conditions, methods or
sampling schemes other than those specified in our review; and
• 18 (7%) studies were news, letters, comments, notes, replies
or editorials without new data.
The 25 ongoing studies are described inCharacteristics of ongoing
studies.
Methodological quality of included studies
Figure 4 and Figure 5 show the risk of bias and applicability con-
cerns for each included study for MPSS and TMPS, respectively.
In Figure 6, the quality assessment results are summarised across
all studies.
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Figure 4. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each of the studies included for massively parallel shotgun sequencing (MPSS).
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Figure 5. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each study included for targeted massively parallel sequencing (TMPS).
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Figure 6. Risk of bias and applicability concerns (all tests included): review authors’ judgements about each
domains presented as percentages across included studies. MPSS: massively parallel shotgun sequencing,
TMPS: targeted massively parallel sequencing.
Risk of bias
No study was assessed as being at low risk of bias across all do-
mains (Figure 4). For the patient selection domain, the ’Risk of
bias’ judgement was influenced mainly by inappropriate exclu-
sions than the other signalling questions in this domain. Of the
61 studies judged to be at high risk of bias, 57 (93%) had inap-
propriate exclusions. The exclusions were mainly due to multi-
fetal pregnancy, gestational age limits, and the prior risk of fetal
aneuploidy. The remaining four (7%) studies were judged to be
at unclear risk of bias (Figure 6).
In the index test domain, the risk of bias was considered to be low
in 38 (58%) of the 44 MPSS studies and unclear in three (5%)
studies. The remaining three (5%)MPSS studies were judged to be
at high risk of bias because the index test was performed knowing
the results of the reference standard or the threshold was not pre-
specified. The risk of bias was low in 18 (27%) of the 21 TMPS
studies. The remaining three (5%) TMPS studies were judged to
be at unclear risk of bias. All five studies that assessed traditional
screening approaches were judged to be at low risk of bias for the
index test domain (Figure 6).
In the reference standard domain, all studies used a reference stan-
dard likely to correctly classify the target condition. We consid-
ered 50 (77%) studies to be at low risk of bias because the studies
stated that the reference standard results were interpreted without
knowledge of the results of the index test. Of the remaining 15
studies, two (3%) studies were at high risk of bias because the ref-
erence standard was performed knowing the results of the index
test while it was unclear what was done in the other 13 (20%)
studies (Figure 6).
For the flow and timing domain, 46 (71%) studies were considered
to be at high risk of bias because some pregnant women were ex-
cluded from 2 x 2 tables because gNIPT failed during the sequenc-
ing process. Fifteen (23%) studies were judged to be at low risk of
bias. For the remaining four (6%) studies, information about the
appropriate interval between the index test and reference standard
was not provided (Figure 6).
Applicability concerns
We judged all studies to be of low applicability concern in the index
test and reference standard domains because the studies matched
the review question (Figure 4; Figure 6). All studies used a gNIPT
method with ccfDNA in maternal blood and appropriate refer-
ence standard for the detection of common fetal aneuploidies. In
the patient selection domain, 47 (72%) studies included cohort
of pregnant women selected at high risk of fetal aneuploidy or co-
hort of unselected pregnant women and were judged to be of low
applicability concern. In the other 18 (28%) studies, the cohorts
comprised pregnant women with different prior risk of fetal ane-
uploidy (mixed risk cohorts). This population did not represent
the real-life situation and those cohorts were judged to be of high
applicability concern.
Findings
The characteristics of the studies are summarised in Table 4 and
Summary of findings 1. Results are presented separately for each of
themain fetal aneuploidies (T21,T18,T13 and45,X) and globally
for all autosomes or all sex chromosome aneuploidies (SCA) com-
bined (Summary of findings 2; Summary of findings 3; Summary
of findings 4; Summary of findings 5; Summary of findings 6;
Summary of findings 7). For each aneuploidy, results are presented
according to the prior risk of chromosomal abnormality as high
risk or unselected population and according to MPSS and TMPS
methods. Results from mixed-risk populations are summarised in
Appendix 7. No study directly compared the accuracy of MPSS
and TMPS. There were insufficient data to separately consider
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monochorionic and dichorionic pregnancies and four of the nine
studies did not report chorionicity.
1. Trisomy 21 (T21 or Down syndrome)
A total of 57 studies assessed gNIPT for T21 in 2004 affected and
80,616 non T21 pregnancies. Five studies enrolled an unselected
population of pregnant women undergoing aneuploidy screening,
36 studies enrolled pregnant women selected at high risk of fetal
aneuploidy and 16 studies enrolled pregnant women with various
prior risk and no a priori risk of fetal aneuploidy (mixed risk).
Of the 57 studies, 41 assessed MPSS and 16 assessed TMPS. The
results are summarised in Summary of findings 2.
a. Unselected population of pregnant women undergoing
aneuploidy screening
Five cohort studies evaluated gNIPT in an unselected population
of pregnant women undergoing aneuploidy screening. The studies
included 22,412 non T21 pregnancies and 96 (0.43%) T21 cases.
MPSS was assessed in one study and TMPS was assessed in four
studies (Figure 7).
Figure 7. Forest plot of MPSS and TMPS for T21 in unselected pregnant women undergoing aneuploidy
screening. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS: targeted
massively parallel sequencing, TN: true negative and TP: true positive.
i. MPSS
One prospective cohort study included eight T21 cases and 1733
non T21 pregnancies (Song 2013). The sensitivity (95% confi-
dence interval (CI)) of MPSS was 100% (67.6% to 100%) and
the specificity (95% CI) was 100% (99.8% to 100%).
20Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
ii. TMPS
TMPS was evaluated in four studies comprising 20,679 non T21
pregnancies and 88 T21 cases (delMarGil 2014;Nicolaides 2012;
Norton 2015; Quezada 2015). The summary sensitivity (95%CI)
was 99.2% (78.2% to 100%) and the summary specificity (95%
CI) was 100% (> 99.9% to 100%).
iii. Comparative accuracy of MPSS and TMPS
It was not possible to compare the accuracy of MPSS and TMPS
in a meta-analysis because of limited data.
b. Selected population of pregnant women at high risk of
fetal aneuploidy
Overall, 36 studies included pregnant women selected at high risk
of fetal aneuploidy involving 20,317 non T21 pregnancies and
1294 (6.37%) T21 cases. MPSS was assessed in 30 studies and
TMPS in six studies (Figure 8).
Figure 8. Forest plot of MPSS and TMPS for T21 in pregnant women selected at high risk of fetal
aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS:
targeted massively parallel sequencing, TN: true negative and TP: true positive.
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i. MPSS
The 30 MPSS studies included 15,937 non T21 pregnancies
and 1048 T21 cases (Alberti 2015; Benachi 2015; Bianchi 2012;
Bianchi 2013; Canick 2012; Ehrich 2011; Hou 2012; Huang
2014; Jeon 2014; Jiang 2012; Johansen 2016; Ke 2015; Kim2016;
Lee 2015; Lefkowitz 2016; Liang 2013; Liu 2012; Palomaki 2012;
Papageorghiou 2016a; Papageorghiou 2016b; Poon 2016; Porreco
2014; Sehnert 2011; Song 2015; Stumm 2014; Sukhikh 2015;
Sung-Hee 2015; Wang 2014; Wang 2015a; Zhang 2016). The
summary sensitivity (95% CI) was 99.7% (98.0% to 100%) and
the summary specificity (95% CI) was 99.9% (99.8% to 100%).
ii. TMPS
Six studies evaluated TMPS in 4380 non T21 pregnancies and
246 T21 cases (Ashoor 2012; Nicolaides 2013; Norton 2012;
Persico 2016; Sparks 2012a; Verweij 2013). The summary sensi-
tivity (95% CI) was 99.2% (96.8% to 99.8%) and the summary
specificity (95% CI) was 100% (99.8% to 100%).
iii. Comparative accuracy of MPSS and TMPS
An indirect comparison of the 30 MPSS and six TMPS studies
showed no statistical evidence of a difference in sensitivity or speci-
ficity or both (P value = 0.52). The differences in sensitivity and
specificity were negligible (Summary of findings 2).
2. Trisomy 18 (T18)
Fifty studies assessed T18 in 634 cases and 78,688 non T18
pregnancies. Four studies enrolled unselected population of preg-
nantwomenundergoing aneuploidy screening, 33 studies enrolled
pregnant women selected at high risk of fetal aneuploidy and 13
studies enrolled a cohort with mixed prior risk. Of the 50 stud-
ies, 38 evaluated MPSS and 12 evaluated TMPS. The results are
summarised in Summary of findings 3.
a. Unselected population of pregnant women undergoing
aneuploidy screening
Four studies, comprising 22,292 non T18 pregnancies and 24
(0.11%) T18 cases, assessed gNIPT for fetal aneuploidy in un-
selected pregnant women. One study assessed MPSS and three
studies assessed TMPS (Figure 7).
i. MPSS
One MPSS study evaluated two T18 cases and 1739 non T18
pregnancies (Song 2013). The sensitivity (95% CI) was 100%
(34.3% to 100%) and the specificity (95%CI) was 99.9% (99.7%
to 100%).
ii. TMPS
Three studies evaluated TMPS in 20,553 non T18 pregnancies
and22T18 cases (Nicolaides 2012;Norton2015;Quezada 2015).
The summary sensitivity (95% CI) was 90.9% (70.0% to 97.7%)
and the summary specificity (95% CI) was 100% (99.9% to
100%).
iii. Comparative accuracy of MPSS and TMPS
It was not possible to compare the accuracy of MPSS and TMPS
in a meta-analysis because data were sparse.
b. Selected population of pregnant women at high risk of
fetal aneuploidy
A total of 33 studies included pregnant women selected at high risk
of fetal aneuploidy involving 444 (2.20%) T18 cases and 20,190
non T18 pregnancies. Of these, 28 studies assessedMPSS and five
studies assessed TMPS (Figure 9).
22Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 9. Forest plot of MPSS and TMPS for T18 in pregnant women selected at high risk of fetal
aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS:
targeted massively parallel sequencing, TN: true negative and TP: true positive.
i. MPSS
Twenty-eight studies evaluated MPSS in 16,180 non T18 preg-
nancies and 332 T18 cases (Benachi 2015; Bianchi 2012; Bianchi
2013; Bijok 2014; Chen 2011; Hou 2012; Huang 2014; Jeon
2014; Jiang 2012; Johansen 2016; Ke 2015; Lee 2015; Lefkowitz
2016; Liang 2013; Liu 2012; Palomaki 2012; Papageorghiou
2016a; Papageorghiou 2016b; Poon 2016; Porreco 2014; Sehnert
2011; Song 2015; Stumm 2014; Sukhikh 2015; Sung-Hee 2015;
Wang 2014;Wang 2015a; Zhang 2016). The summary sensitivity
(95% CI) was 97.8% (92.5% to 99.4%) and the summary speci-
ficity (95% CI) was 99.9% (99.8% to 100%).
ii. TMPS
Five studies evaluated TMPS in 4010 non T18 pregnancies and
112 T18 cases (Ashoor 2012; Nicolaides 2013; Norton 2012;
Persico 2016; Sparks 2012a). The summary sensitivity (95% CI)
was 98.2% (93.1% to 99.6%) and the summary specificity (95%
CI) was 100% (99.8% to 100%).
iii. Comparative accuracy of MPSS and TMPS
An indirect comparison of the 28 MPSS and five TMPS studies
showed no statistical evidence of a difference in sensitivity, speci-
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ficity or both (P value = 0.47). The differences in sensitivity and
specificity were negligible (Summary of findings 3).
3. Trisomy 13 (T13)
T13was assessed in 39 studies comprising 215 affected and 68,743
non T13 pregnancies. Four studies evaluated unselected popula-
tion of pregnant women undergoing fetal aneuploidy screening,
while 22 studies evaluated women at high risk of fetal aneuploidy
and 13 studies evaluated mixed prior risk cohorts. Of the 39 stud-
ies, 29 assessedMPSS and 10 assessed TMPS. The results are sum-
marised in Summary of findings 4.
a. Unselected population of pregnant women undergoing
aneuploidy screening
Four studies assessed gNIPT for T13 in unselected pregnant
women. The studies included 15,894 non T13 pregnancies and
nine (0.06%) T13 cases. Three studies evaluated TMPS and one
study evaluated MPSS (Figure 7).
i. MPSS
One study evaluated MPSS in one T13 case and 1740 non T13
pregnancies (Song 2013). The sensitivity (95% CI) was 100%
(20.7% to 100%) and the specificity (95% CI) was 100% (99.8%
to 100%).
ii. TMPS
Three studies evaluated TMPS in 14,154 non T13 pregnancies
and eight T13 cases (del Mar Gil 2014; Norton 2015; Quezada
2015). The summary sensitivity (95% CI) was 65.1% (9.2% to
97.2%) and the summary specificity (95% CI) was 100% (99.9%
to 100%).
iii. Comparative accuracy of MPSS and TMPS
It was not possible to compare the accuracy of MPSS and TMPS
in a meta-analysis because data were sparse.
b. Selected population of pregnant women at high risk of
fetal aneuploidy
A total of 22 studies evaluated pregnant women selected at high
risk of fetal aneuploidy. The studies included 14,103 non T13
pregnancies and 148 (1.05%) T13 cases. Twenty studies assessed
MPSS and two studies assessed TMPS (Figure 10).
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Figure 10. Forest plot of MPSS and TMPS for T13 in pregnant women selected at high risk of fetal
aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS:
targeted massively parallel sequencing, TN: true negative and TP: true positive.
i. MPSS
Twenty studies evaluated MPSS in 13,810 non T13 pregnancies
and 128 T13 cases (Benachi 2015; Bianchi 2012; Bianchi 2013;
Canick 2012; Chen 2011; Jiang 2012; Johansen 2016; Ke 2015;
Lee 2015; Lefkowitz 2016; Liang 2013; Liu 2012; Palomaki 2012;
Papageorghiou 2016a; Poon 2016; Porreco 2014; Sehnert 2011;
Song 2015; Stumm 2014; Sukhikh 2015). The summary sensi-
tivity (95% CI) was 95.8% (86.1% to 98.9%) and the summary
specificity (95% CI) was 99.8% (99.8% to 99.9%).
ii. TMPS
Two studies evaluated TMPS in 293 non T13 pregnancies and
20 T13 cases (Hall 2014; Persico 2016). The summary sensitivity
(95% CI) was 100% (83.9% to 100%) and the summary speci-
ficity (95% CI) was 100% (98.7% to 100%).
iii. Comparative accuracy of MPSS and TMPS
It was not possible to compare the accuracy of MPSS and TMPS
in a meta-analysis because data were sparse.
4. Turner syndrome (45,X)
Turner syndrome (45,X) was assessed in 20 studies, comprising
232 affected and 9849 non 45,X pregnancies. Among these stud-
ies, 16 enrolled pregnant women selected at high risk of fetal aneu-
ploidy and four enrolled a cohort of pregnant women with mixed
prior risk. Of the 20 studies, 14 evaluatedMPSS and six evaluated
TMPS. The results are summarised in Summary of findings 5.
a. Unselected population of pregnant women undergoing
aneuploidy screening
No study assessed 45,X in this population.
b. Selected population of pregnant women at high risk of
fetal aneuploidy
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Sixteen studies included 198 (2.35%) affected and 8421 non 45,X
pregnancies. MPSS and TMPS were assessed by 12 and four stud-
ies respectively (Figure 11).
Figure 11. Forest plot of MPSS and TMPS for 45,X in pregnant women selected at high risk of fetal
aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS:
targeted massively parallel sequencing, TN: true negative and TP: true positive.
i. MPSS
Twelve studies evaluated MPSS in 119 affected and 7440 non
45,X pregnancies (Bianchi 2012; Bianchi 2013; Hou 2012; Jiang
2012; Lefkowitz 2016; Liang 2013; Liu 2012; Mazloom 2013;
Porreco 2014; Sehnert 2011; Song 2015; Sukhikh 2015). The
summary sensitivity (95% CI) was 91.7% (78.3% to 97.1%) and
the summary specificity (95% CI) was 99.6% (98.9% to 99.8%).
ii. TMPS
Four studies evaluated TMPS in 79 affected and 985 non 45,X
pregnancies (Hooks 2014; Nicolaides 2013; Nicolaides 2014a;
Persico 2016). The summary sensitivity (95% CI) was 92.4%
(84.1% to 96.5%) and the summary specificity (95% CI) was
99.8% (98.3% to 100%).
iii. Comparative accuracy of MPSS and TMPS
An indirect comparison of the 12 MPSS and four TMPS studies
showed no statistical evidence of a difference in sensitivity, speci-
ficity or both (P value = 0.40). The differences in sensitivity and
specificity were negligible (Summary of findings 5).
5. Triple X syndrome (47,XXX)
Seven studies assessed 47,XXX, comprising 14 (0.23%) affected
and6021non47,XXXpregnancies (Hooks 2014; Lefkowitz 2016;
Liang 2013; Mazloom 2013; Nicolaides 2014a; Porreco 2014;
Song 2015). The studies enrolled pregnant women selected at
high risk of fetal aneuploidy. Five studies evaluatedMPSS and two
studies evaluated TMPS. (Figure 12; Table 8).We did not perform
a separate meta-analysis for 47,XXX due to sparse data (very few
cases or studies, or one or more subgroups had no study).
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Figure 12. Forest plot of MPSS and TMPS for 47,XXX, 47,XXY and 47,XYY in pregnant women selected at
high risk of fetal aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel shotgun
sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.
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6. Klinefelter syndrome (47,XXY)
Twelve studies assessed 47,XXY in 25 (0.33%) affected and
7584 non 47,XXY pregnancies (Hooks 2014; Hou 2012; Jiang
2012; Lau 2012; Lefkowitz 2016; Liang 2013; Mazloom 2013;
Nicolaides 2014a; Persico 2016; Porreco 2014; Samango-Sprouse
2013; Song 2015). Ten studies enrolled pregnant women selected
at high risk of fetal aneuploidy (Figure 12; Table 8) and two stud-
ies enrolled pregnant women with mixed risk (See Finding section
11). No study assessed 47,XXY in an unselected population of
pregnant women undergoing aneuploidy screening. Eight studies
assessed MPSS and four studies assessed TMPS. We did not per-
form a separate meta-analysis for 47,XXY due to sparse data (very
few cases or studies, or one or more subgroups had no study).
7. 47,XYY
Ten studies assessed 47,XYY in 16 (0.23%) affected and 6971
non 47,XYYpregnancies (Hou 2012; Jiang 2012; Lefkowitz 2016;
Liang 2013; Liu 2012;Mazloom 2013; Nicolaides 2014a; Porreco
2014; Samango-Sprouse 2013; Shaw2014). Eight studies enrolled
pregnant women selected at high risk of fetal aneuploidy (Figure
12; Table 8) and two studies enrolled pregnant women with mixed
risk (See Finding section 11). Eight studies used MPSS and two
studies used TMPS. We did not perform a separate meta-analysis
for 47,XXX due to sparse data (very few cases or studies, or one
or more subgroups had no study).
8. All autosomes combined
Autosomal aneuploidies were assessed in 61 studies. The studies
included 84,954 pregnant women of which 2853 were T21, T18
or T13 pregnancies and 82,073 were unaffected. Among these
61 studies, 43 assessed MPSS and 18 assessed TMPS. Of the
61 studies, five enrolled unselected pregnant women, 39 enrolled
high-risk pregnant women and 17 enrolled a cohort of mixed prior
risk. The results are summarised in Summary of findings 6. The
results for mixed risk cohorts are summarised in Appendix 7.
a. Unselected population of pregnant women undergoing
aneuploidy screening
Five studies assessed 129 (0.58%) affected and 22,379 unaffected
(non T21, T18 and T13) pregnancies. Of the five studies, one
study assessed MPSS and four studies assessed TMPS (Figure 13).
Figure 13. Forest plot of MPSS and TMPS for autosomes (T21, T18 and T13 combined) in unselected
pregnant women undergoing aneuploidy screening. FN: false negative, FP: false positive, MPSS: massively
parallel shotgun sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true
positive.
i. MPSS
Only one study assessed MPSS (Song 2013). The study evaluated
1730 unaffected (non T21, T18 and T13) pregnancies and 11
cases in women with singleton pregnancy. The sensitivity (95%
CI) was 100% (74.1% to 100%) and the specificity (95% CI) was
99.9% (99.7% to 100%).
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ii. TMPS
Four studies assessed TMPS in 20,649 unaffected (non T21, T18
andT13) pregnancies and 118 cases (del MarGil 2014;Nicolaides
2012; Norton 2015; Quezada 2015). Of the four studies, three
studies included only women with singleton pregnancy and the
remaining study included only women with multifetal pregnancy
(Table 9). Based on the four studies, the summary sensitivity (95%
CI) was 94.9% (89.1% to 97.7%) and the summary specificity
(95% CI) was 99.9% (99.8% to 99.9%).
iii. Comparative accuracy of MPSS and TMPS
It was not possible to compare the accuracy of MPSS and TMPS
in a meta-analysis due to limited data.
b. Selected population of pregnant women at high risk of
fetal aneuploidy
A total of 39 studies included 1886 (9.39%) affected and 20,079
unaffected (non T21, T18 and T13) pregnancies. Of the 39 stud-
ies, 32 assessed MPSS and seven assessed TMPS (Figure 14).
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Figure 14. Forest plot of MPSS and TMPS for autosomes (T21, T18 and T13) in pregnant women selected
at high risk of fetal aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel shotgun
sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.
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i. MPSS
Thirty-two MPSS studies evaluated 15,797 unaffected (non
T21, T18 and T13) pregnancies and 1508 cases (Alberti 2015;
Benachi 2015; Bianchi 2012; Bianchi 2013; Bijok 2014; Canick
2012; Chen 2011; Ehrich 2011; Hou 2012; Huang 2014; Jeon
2014; Jiang 2012; Johansen 2016; Ke 2015; Kim 2016; Lee
2015; Lefkowitz 2016; Liang 2013; Liu 2012; Palomaki 2012;
Papageorghiou 2016a; Papageorghiou 2016b; Poon 2016; Porreco
2014; Sehnert 2011; Song 2015; Stumm 2014; Sukhikh 2015;
Sung-Hee 2015; Wang 2014; Wang 2015a; Zhang 2016). Of the
32 studies, 19 evaluated only singleton pregnancies, three eval-
uated only multifetal pregnancies, three evaluated singleton and
multifetal pregnancies, and the remaining seven studies did not
report type of pregnancy. Based on the 32 studies, the summary
sensitivity (95% CI) was 98.8% (97.2% to 99.5%) and the sum-
mary specificity (95% CI) was 99.9% (99.7% to 100%). Results
are presented separately for singleton and multifetal pregnancy
studies in Table 9. The sensitivity tends to be lower in multifetal
pregnancies but there are no enough studies in this subgroup to
compare MPSS performance according to pregnancy type.
ii. TMPS
Seven TMPS studies evaluated 378 cases and 4282 unaffected
(non T21, T18 and T13) pregnancies in women with singleton
pregnancy (Ashoor 2012; Hall 2014; Nicolaides 2013; Norton
2012; Persico 2016; Sparks 2012a; Verweij 2013). The summary
sensitivity (95%CI)was 98.9 (97.2% to 99.6%) and the summary
specificity (95% CI) was 99.9% (99.8% to 100%) (Table 9).
iii. Comparative accuracy of MPSS and TMPS
An indirect comparison of the 32 MPSS and seven TMPS studies
showed no statistical evidence of a difference in sensitivity, speci-
ficity or both (P value = 0.11). The differences in sensitivity and
specificity were negligible (Summary of findings 6).
9. All sex chromosome aneuploidies (SCA) combined
The sex chromosome aneuploidies (45,X, 47,XXX, 47,XXY and
47,XYY) were considered together as one target condition. SCA
was assessed in 20 studies, comprising 286 affected cases and 9839
non SCA pregnancies. MPSS and TMPS were assessed by 14 and
six studies, respectively. Among the 20 studies, 16 enrolled preg-
nant women selected at high risk of fetal aneuploidy and four en-
rolled a cohort of pregnant women with mixed prior risk. The
results are summarised in Summary of findings 7. The results for
mixed risk cohorts are summarised in Appendix 7.
a. Unselected population of pregnant women undergoing
aneuploidy screening
No study assessed SCA in an unselected population of pregnant
women.
b. Selected population of pregnant women at high risk of
fetal aneuploidy
Sixteen studies involving 247 (2.93%) affected and 8420 non SCA
pregnancies were included. MPSS and TMPS were assessed by 12
and four studies respectively (Figure 15).
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Figure 15. Forest plot of MPSS and TMPS for SCA (45,X, 47,XXX, 47,XXY and 47,XYY combined) in
pregnant women selected at high risk of fetal aneuploidy. FN: false negative, FP: false positive, MPSS:
massively parallel shotgun sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and
TP: true positive.
i. MPSS
Twelve MPSS studies evaluated 151 affected and 7452 non SCA
pregnancies (Bianchi 2012; Bianchi 2013; Hou 2012; Jiang 2012;
Lefkowitz 2016; Liang 2013; Liu 2012; Mazloom 2013; Porreco
2014; Sehnert 2011; Song 2015; Sukhikh 2015). Of the 12 stud-
ies, seven included only women with singleton pregnancy, one
evaluated singleton and multifetal pregnancies, and the remaining
four studies did not report type of pregnancy. Results are presented
separately for singleton and multifetal pregnancy studies in Table
9. Based on all 12 studies, the summary sensitivity (95% CI) was
91.9% (73.8% to 97.9%) and the summary specificity (95% CI)
was 99.5% (98.8% to 99.8%).
ii. TMPS
Four TMPS studies evaluated 96 affected and 968 non SCA
pregnancies in women with singleton pregnancy (Hooks 2014;
Nicolaides 2013; Nicolaides 2014a; Persico 2016). The summary
sensitivity (95% CI) was 93.8% (86.8% to 97.2%) and the sum-
mary specificity (95% CI) was 99.6% (98.1% to 99.9%).
iii. Comparative accuracy of MPSS and TMPS
An indirect comparison of the 12 MPSS and four TMPS studies
showed no statistical evidence of a difference in sensitivity, speci-
ficity or both (P value = 0.41). The differences in sensitivity and
specificity were negligible (Summary of findings 7).
10. gNIPT approach (MPSS or TMPS) against
traditional screening tests
Five studies directly compared a gNIPT approach (MPSS or
TMPS) and traditional screening tests for autosomal aneuploidies
by using cohorts of pregnant women who were tested by both
methods. Three studies compared TMPS and traditional screen-
ing tests, and two studies compared MPSS and traditional screen-
ing tests. The results are summarised in Summary of findings 2,
Summary of findings 3, Summary of findings 4 and Summary of
findings 6.
a. Unselected population of pregnant women undergoing
aneuploidy screening
Only one study that compared TMPS and a traditional screening
test evaluated T21, T18 and T13 individually in an unselected
population of pregnant women undergoing aneuploidy screening
32Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Norton 2015). This study evaluated 38, 10 and two cases of T21,
T18 and T13, respectively and 15,803, 15,831 and 11,183 non
T21, T18 and T13, respectively (Figure 16). Direct comparisons
between gNIPT and traditional screening tests were not possible
because there was only one study but authors observed eight, two
and one cases of T21, T18 and T13 respectively missed by tradi-
tional screening test and only one T18 case missed by TMPS.
Figure 16. Forest plot of traditional screening tests for T21, T18 and T13 in unselected pregnant women
undergoing aneuploidy screening. FN: false negative, FP: false positive, MPSS: massively parallel shotgun
sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.
Four studies compared a gNIPT approach with a traditional
screening test for autosomal aneuploidies (T21, T18 and T13
combined) in 22,367 unselected pregnant women (Figure 17).
Three studies (Nicolaides 2012; Norton 2015; Quezada 2015)
compared TMPS and first-trimester combined test (Figure 18),
and one study (Song 2013) compared MPSS and a second-
trimester triple test. The three TMPS studies had similar char-
acteristics. Meta-analyses of direct comparisons between gNIPT
and traditional screening tests were not possible because tradi-
tional screening tests used different cutpoints and there were very
few studies to enable estimation of summary sensitivity and speci-
ficity at specific cutpoints. Individual study results are presented
in Table 10. Overall, 16 aneuploid cases were missed by tradi-
tional screening test and only five cases were missed by gNIPT ap-
proach. While specificity was consistently higher for TMPS than
traditional screening tests, sensitivity was not consistently higher
as shown in Figure 18.
Figure 17. Forest plot of traditional screening tests for autosomes (T21, T18 and T13 combined) in
unselected pregnant women undergoing aneuploidy screening. FN: false negative, FP: false positive, TN: true
negative and TP: true positive.
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Figure 18. Forest plot of comparative studies of TMPS and traditional screening tests for autosomes (T21,
T18 and T13 combined) in unselected pregnant women undergoing aneuploidy screening. FN: false negative,
FP: false positive, TN: true negative and TP: true positive.
b. Mixed-risk cohort of fetal aneuploidy
One study compared MPSS and traditional screening test for au-
tosomal aneuploidies (T21, T18 and T13 combined) in a co-
hort with mixed prior risk of fetal aneuploidy including 1908
non T21, T18 and T31 pregnancies and four cases of autosomal
aneuploidy (Bianchi 2014a). Traditional screening tests included
first-trimester combined test or a second-trimester result (quadru-
ple, serum integrated, fully integrated or sequential) (Figure 19).
Overall, 80 unaffected pregnancies were detected as affected by
traditional screening test against 12 for TMPS.
Figure 19. Forest plot of traditional screening tests for autosomes (T21, T18 and T13 combined) in pregnant
women with mixed prior risk of fetal aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel
shotgun sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.
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11. Pregnant women with mixed prior risk of fetal
aneuploidy
Summary sensitivities and specificities for cohorts of pregnant
women with mixed prior risk of fetal aneuploidy are presented
in Appendix 7. For autosomal aneuploidies, 17 studies included
838 cases and 39,615 unaffected (non T21, T18 and T13) preg-
nancies. Of the 17 studies, 10 assessed MPSS and seven assessed
TMPS (Figure 20). For T21, 16 studies included 614 cases (1.6%)
and 37,887 non T21 pregnancies. Of the 16 studies, 10 assessed
MPSS and six assessed TMPS. For T18, 13 studies included 166
cases (0.5%) and 36,206 non T18 pregnancies. Of the 13 studies,
nine assessed MPSS and four assessed TMPS. For T13, 13 stud-
ies included 58 cases (0.1%) and 38,746 non T13 pregnancies.
Eight of the 13 studies assessed MPSS and the other five assessed
TMPS (Figure 21). For SCA, four studies included 39 cases and
1419 non SCA pregnancies; two of the studies assessed MPSS and
the other two assessed TMPS (Figure 22). For 45,X, four stud-
ies included 34 cases (2.4%) and 1424 non 45,X pregnancies. Of
the four studies, two studies assessed MPSS and two studies as-
sessed TMPS. For 47,XXY, two studies (one of MPSS and one of
TMPS) included three cases (1%) and 291 non 47,XXY pregnan-
cies. For 47,XYY, two studies included two cases (0.5%) and 384
non 47,XYY pregnancies; one study assessed MPSS and the other
study assessed TMPS. No study assessed gNIPT for 47,XXX in
cohorts of pregnant women with mixed prior risk of fetal aneu-
ploidy (Figure 23).
Figure 20. Forest plot of MPSS and TMPS for autosomes (T21, T18 and T13 combined) in pregnant women
with mixed prior risk of fetal aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel
shotgun sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.
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Figure 21. Forest plot of MPSS and TMPS for T21, T18 or T13 in pregnant women with mixed prior risk of
fetal aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel shotgun sequencing, TMPS:
targeted massively parallel sequencing, TN: true negative and TP: true positive.
36Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 22. Forest plot of MPSS and TMPS for SCA (45,X, 47,XXX, 47,XXY and 47,XYY combined) in
pregnant women with mixed prior risk of fetal aneuploidy. FN: false negative, FP: false positive, MPSS:
massively parallel shotgun sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and
TP: true positive.
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Figure 23. Forest plot of MPSS and TMPS for 45,X, 47,XXY or 47,XYY in pregnant women with mixed
prior risk of fetal aneuploidy. FN: false negative, FP: false positive, MPSS: massively parallel shotgun
sequencing, TMPS: targeted massively parallel sequencing, TN: true negative and TP: true positive.
12. Failure rates
Table 7 shows the non-negligible failure rate of gNIPT reported
in the studies. gNIPT assay failure rate was reported in 46 out of
65 (71%) studies. The largest failure rate (25%) was observed in a
study that used its own developedMPSS assay (Alberti 2015). The
main reasons for assay failure included low amount of ccfDNA,
low fetal fraction DNA and failure of sample to pass quality con-
trol. The failure rate ranged between 0% and 25% for MPSS and
between 0.8% and 7.5% for TMPS. The number of aneuploid
and euploid cases in failed samples was reported in 23 of 46 (50%)
studies. Among these 23 studies, there were 1064 euploid cases and
79 aneuploid cases among 1143 failed samples. The failure rate
among aneuploid cases, ranged between 0% and 50% for MPSS
and between 0% and 23% for TMPS. The failure rate among eu-
ploid cases ranged between 0% and 6.7% for MPSS and between
1% and 7.6% for TMPS.
Investigation of heterogeneity
We planned to evaluate the effect of potential sources of hetero-
geneity such as type of reference standard and ethnicity. However,
formal investigations using meta-regression were not possible due
to limited data and little or no heterogeneity in the sensitivities
and specificities. Most studies (55%) used karyotyping while the
remaining 29 studies (45%) used multiple reference standards.
Ethnicity was not reported by 26 (40%) studies while the popu-
lation in 21 (32%) studies was more than 50% Asian and in 18
(28%) studies the population was more than 50% Caucasian. In
Appendix 8, the number of studies, affected and unaffected preg-
nancies are shown according to the gNIPT approach and prior risk
of fetal aneuploidy. We also planned to assess gNIPT performance
according to gestational age and gNIPT approach for autosomes
and SCA aneuploidies. The accuracy of gNIPT appears to be high
in all gestational age groups.
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Sensitivity analyses
We did not perform sensitivity analyses to assess the effect of the
interval between blood collection for gNIPT and fluid collection
for reference standard because most studies had an acceptable in-
terval between sample collection for index test and reference stan-
dard. Due to lack of data or lack of variability in estimates of
sensitivity and specificity, analyses of the effect of high or unclear
risk of bias according to the QUADAS-2 domains were not done.
We performed sensitivity analyses using data from all autosomes
combined and all SCA combined in order to have enough studies
to assess the impact of study design and number of cases. The
results are presented in Table 11. Excluding case-control studies
or studies with less than 10 aneuploid cases had little or no impact
on our findings.
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Summary of findings
Summary characteristics of included studies
Review question What is the diagnost ic accuracy of massively parallel shotgun sequencing
(MPSS) and targeted massively parallel sequencing (TMPS) using circulat ing
cell-f ree DNA (ccfDNA) in maternal blood for the detect ion of common fetal
aneuploidies (T21, T18, T13, 45,X, 47,XXY, 47,XXX and 47,XYY) in pregnant
women according to their prior risk of fetal aneuploidy?
Importance (rationale) These new genomics-based non-invasive prenatal test ing (gNIPT) approach
report higher sensit ivity and lower false posit ive rate than tradit ional screen-
ing tests. gNIPT is already advert ised and marketed. How gNIPT should be
used in clinical pract ice should be assessed in order to provide a f ramework
for its use
Study design There were 40 prospect ive cohort studies, 8 retrospect ive cohort studies, 16
case-control studies and 1 prospect ive and retrospect ive cohort study
Population Pregnant women of any age, ethnicity and gestat ional age, with singleton
or mult if etal pregnancy who had a screening test for fetal aneuploidy using
gNIPT and received a reference standard. 42 studies enrolled pregnant
women selected at high risk of fetal aneuploidy, 5 enrolled unselected
pregnant women undergoing aneuploidy screening and 18 enrolled pregnant
women f rom a mixed-risk populat ion of fetal aneuploidy. 48 studies included
only women with singleton pregnancy, 5 included only mult if etal pregnancies,
4 included either type of pregnancy and 8 did not report type of pregnancy.
10 studies included only women in the f irst trimester (15 weeks or less)
, 21 studies included women in the f irst 2 trimesters (29 weeks or less),
24 studies included women in the 3 trimesters (42 weeks or less) and 10
studies (15%) did not report gestat ional age
Index tests gNIPT by MPSS (44 studies) or TMPS (21 studies), including 5 studies that
compared a gNIPT with a tradit ional screening test. 37 studies were industry-
funded or were writ ten by 1 or more authors af f iliated with a company
who sells gNIPT. 22 studies were not reported to be funded by industry
but samples were sequenced and analysed by a commercial laboratory. 3
studies had no links with industry
Target conditions 36 studies reported results for only autosomes (T21, T18, T13), 4 for only
SCA (45,X, 47,XXY, 47,XXX and 47,XYY), and 25 for both autosomes and SCA
Reference standard Fetal karyotyping performed on cells obtained f rom chorionic villi sampling,
amniot ic f luid, placental t issue, a fetus lost by miscarriage or other equivalent
and recognised methods on the same materials for autosomes and SCA. If
fetal karyotyping was not performed, we used neonatal clinical examinat ion
or medical records f rom birth (for autosomes only). Only 1 reference
standard was used for all pregnant women included in 36 studies while
mult iple reference standards were used in 29 studies
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Risk of bias The QUality Assessment of Diagnost ic Accuracy Studies (QUADAS-2) tool
was used to assess the methodological quality of included studies
No study was assessed as being at low risk of bias across all domains. For
the pat ient select ion domain, no study was assessed as being at low risk of
bias. For the index test, reference standard and f low and tim ing domains,
the risk of bias was low for 94%, 77% and 23% of studies, respect ively
Applicability concerns Applicability was of low concern for all studies in the index test and reference
standard domains because the studies matched the review quest ion. In
the pat ient select ion domain, 47 (71%) studies were judged to be of low
applicability concern because they included pregnant women matching the
review quest ion
45,X: Turner syndrome, 47,XXX: triple X syndrome, 47,XXY: Klinefelter syndrome,MPSS: massively parallel shotgun sequencing,
TMPS: targeted massively parallel sequencing, T21: trisomy 21, T18: trisomy 18, T13: trisomy 13.
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Performance of gNIPT for detection of T21
Test strategy Number of
studies
Number of affected
pregnancies (Num-
ber of
unaffected preg-
nancies)a
Sensitivity
% (95% CI)
Specificity
% (95% CI)
Median
prevalenceb
% (range)
M issed
cases
(FN)c
False
positives
(FP)d
Unselected pregnant women
MPSS 1 8 (1733) 100 (67.6 to 100) 100 (99.8 to 100) 0.46
(0.24 to 5.21)
0 0
TMPS 4 88 (20,679) 99.2 (78.2 to 100) 100 (> 99.9 to 100) 4 0
Tradit ional screen-
ing teste
1 38 (15,803) 78.9 (63.7 to 88.9) 94.6 (94.2 to 94.9) 97 5375
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Implicat ions • 460 of 100,000 pregnancies expected to be af fected by T21;
• MPSS will detect all cases and no pregnant woman will undergo an unnecessary invasive test;
• with TMPS, 4 cases will be missed and no pregnant woman will undergo unnecessary invasive test; and
• with tradit ional screening tests, 363 cases will be detected and 5375 unaf fected pregnant women will undergo unnecessary invasive test.
Selected high- risk pregnant women
MPSS 30 1048 (15,937) 99.7 (98.0 to 100) 99.9 (99.8 to 100) 4.95
(0.44 to 27.66)
15 95
TMPS 6 246 (4380) 99.2 (96.8 to 99.8) 100 (99.8 to 100) 40 0
Dif ference between MPSS and TMPS 0.53 (-0.73 to 1.78) -0.03 (-0.11 to 0.04) NA
Implicat ions • 4950 of 100,000 pregnancies expected to be af fected by T21;
• 4936 and 4911 cases will be detected while 15 and 40 cases will be missed by MPSS and TMPS, respect ively; and
• of 95,050 expected pregnancies unaf fected by T21, 95 and 0 pregnant women will undergo unnecessary invasive tests with MPSS and TMPS,
respect ively.
MPSS: massively parallel shotgun sequencing, NA; not applicable, TMPS: targeted massively parallel sequencing, T21: trisomy
21.
aUnaf fected pregnancies: we included pat ients with any other aneuploidy than the one under analysis with all euploid cases
as ‘‘unaf fected’’ pregnancies.
bThe median prevalence and range were calculated by using all prospect ive or retrospect ive studies for each category
considered.
cMissed cases per 100,000 tested. FN: false negat ives.
dFalse posit ives per 100,000 tested. A false posit ive result may lead to unnecessary invasive tests depending on choices by
the pregnant woman.
eTradit ional screening tests are f irst-trimester combined test, second-trimester quadruple test, second-trimester fully
integrated test, second-trimester sequent ial test or second-trimester triple test.
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Performance of gNIPT for detection of T18
Test strategy Number of
studies
Number of affected
pregnancies (Num-
ber of
unaffected preg-
nancies)a
Sensitivity
% (95% CI)
Specificity
% (95% CI)
Median
prevalenceb
% (range)
M issed
cases
(FN)c
False
positives
(FP)d
Unselected pregnant women
MPSS 1 2 (1739) 100 (34.3 to 100) 99.9 (99.7 to 100) 0.11
(0.06 to 0.36)
0 100
TMPS 3 22 (20,553) 90.9 (70.0 to 97.7) 100 (99.9 to 100) 10 0
Tradit ional screen-
ing teste
1 10 (15,831) 80.0 (49.0 to 94.3) 99.7 (99.6 to 99.8) 22 300
Implicat ions • 109 of 100,000 pregnancies expected to be af fected by T18;
• MPSS will detect all cases and 100 unaf fected pregnant women will undergo an unnecessary invasive test;
• with TMPS, 10 cases will be missed and no unaf fected pregnant woman will undergo unnecessary invasive test; and
• with tradit ional screening tests, 87 cases will be detected, 22 will be missed and 300 unaf fected pregnant women will undergo unnecessary
invasive test.
Selected high- risk pregnant women
MPSS 28 332 (16,180) 97.8 (92.5 to 99.4) 99.9 (99.8 to 100) 1.46
(0.22 to 17.02)
32 99
TMPS 5 112 (4010) 98.2 (93.1 to 99.6) 100 (99.8 to 100) 26 0
Dif ference between
MPSS and TMPS
-0.41 (-4.11 to 3.28) -0.06 (-0.14 to 0.03) NA
Implicat ions • 1463 of 100,000 pregnancies expected to be af fected by T18;
• 1431 and 1437 cases will be detected while 32 and 26 cases will be missed by MPSS and TMPS, respect ively; and
• of 98,537 expected unaf fected by T18, 99 and 0 pregnant women will undergo unnecessary invasive test with MPSS and TMPS, respect ively.
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MPSS: massively parallel shotgun sequencing, NA: not applicable, TMPS: targeted massively parallel sequencing, T18: trisomy
18.
aUnaf fected pregnancies: we included pat ients with any other aneuploidy than the one under analysis with all euploid cases
as ‘‘unaf fected’’ pregnancies.
bThe median prevalence and range were calculated by using all prospect ive or retrospect ive studies for each category
considered.
cMissed cases per 100,000 tested. FN: false negat ives.
dFalse posit ives per 100,000 tested. A false posit ive result may lead to unnecessary invasive tests depending on choices by
the pregnant woman.
eTradit ional screening tests are f irst-trimester combined test, second-trimester quadruple test, second-trimester fully
integrated test, second-trimester sequent ial test or second-trimester triple test.
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Performance of gNIPT for detection of T13
Test strategy Number of
studies
Number of affected
pregnancies (Num-
ber of
unaffected preg-
nancies)a
Sensitivity %
(95% CI)
Specificity %
(95% CI)
Median
prevalenceb
% (range)
M issed
cases
(FN)c
False
positives
(FP)d
Unselected pregnant women
MPSS 1 1 (1740) 100 (20.7 to 100) 100 (99.8 to 100) 0. 12
(0.01 to 0.52)
0 0
TMPS 3 8 (14,154) 65.1 (9.16 to 97.2) 100 (99.9 to 100) 41 0
Tradit ional screen-
ing teste
1 2 (11,183) 50.0 (9.45 to 90.5) 99.7 (99.6 to 99.8) 59 300
Implicat ions • 118 of 100,000 pregnancies expected to be af fected by T13;
• MPSS will detect all cases and no unaf fected pregnant woman will undergo an unnecessary invasive test;
• with TMPS, 41 cases will be missed and no unaf fected pregnant woman will undergo unnecessary invasive test; and
• with tradit ional screening tests, 59 cases will be missed and 300 unaf fected pregnant women will undergo unnecessary invasive test.
Selected high- risk pregnant women
MPSS 20 128 (13,810) 95.8 (86.1 to 98.9) 99.8 (99.8 to 99.9) 1.09
(0.04 to 3.54)
46 198
TMPS 2 20 (293) 100 (83.9 to 100)f 100 (98.7 to 100)f 0 0
Implicat ions • 1087 of 100,000 pregnancies expected to be af fected by T13;
• 1041 and 1087 cases will be detected while 46 and 0 cases will be missed by MPSS and TMPS, respect ively; and
• of 98,913 expected unaf fected by T13, 198 and 0 pregnant women will undergo unnecessary invasive test with MPSS and TMPS, respect ively.
MPSS: massively parallel shotgun sequencing, NA: not applicable, TMPS: targeted massively parallel sequencing, T13: trisomy
13.
aUnaf fected pregnancies: we included pat ients with any other aneuploidy than the one under analysis with all euploid cases
as ‘‘unaf fected’’ pregnancies.
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bThe median prevalence and range were calculated by using all prospect ive or retrospect ive studies for each category
considered.
cMissed cases per 100,000 tested. FN: false negat ives.
dFalse posit ives per 100,000 tested. A false posit ive result may lead to unnecessary invasive tests depending on choices by
the pregnant woman.
eTradit ional screening tests are f irst-trimester combined test, second-trimester quadruple test, second-trimester fully
integrated test, second-trimester sequent ial test or second-trimester triple test.
f Simple pooling used to obtain summary est imates of sensit ivity, specif icity or both.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Performance of gNIPT for detection of 45,X
Test strategy Number of
studies
Number of affected
pregnancies (Num-
ber of
unaffected preg-
nancies)a
Sensitivity
% (95% CI)
Specificity
% (95% CI)
Median
prevalenceb
% (range)
M issed
cases
(FN)c
False
positives
(FP)d
Selected high- risk pregnant women
MPSS 12 119 (7440) 91.7 (78.3 to 97.1) 99.6 (98.9 to 99.8) 1.04
(0.27 to 18.58)
86 396
TMPS 4 79 (985) 92.4 (84.1 to 96.5) 99.8 (98.3 to 100) 79 198
Dif ference between MPSS and TMPS -0.74 (-11.1 to 9.60) -0.23 (-0.82 to 0.36) NA
Implicat ions • 1039 of 100,000 pregnancies expected to be af fected by 45X;
• 953 and 960 cases will be detected while 86 and 79 cases will be missed by MPSS and TMPS, respect ively; and
• of 98,961 expected unaf fected by 45X, 396 and 198 pregnant women will undergo unnecessary invasive test with MPSS and TMPS, respect ively.
45,X: Turner syndrome, MPSS: massively parallel shotgun sequencing, NA: not applicable, TMPS: targeted massively parallel
sequencing.
aUnaf fected pregnancies: we included pat ients with any other aneuploidy than the one under analysis with all euploid cases
as ‘‘unaf fected’’ pregnancies.
bThe median prevalence and range were calculated by using all prospect ive or retrospect ive studies for each category
considered.
cMissed cases per 100,000 tested. FN: false negat ives.
dFalse posit ives per 100,000 tested. A false posit ive result may lead to unnecessary invasive tests depending on choices by
the pregnant woman.
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Performance of gNIPT for detection of autosomes aneuploidies (T21, T18 and T13 combined)
Test strategy Number of
studies
Number of affected
pregnancies (Num-
ber of
unaffected preg-
nancies)a
Sensitivity
% (95% CI)
Specificity
% (95% CI)
Median
prevalenceb
% (range)
M issed
cases
(FN)c
False
positives
(FP)d
Unselected pregnant women
MPSS 1 11 (1730) 100 (74.1 to 100) 99.9 (99.7 to 100) 0,63
(0.32 to 5.73)
0 99
TMPS 4 118 (20,649) 94.9 (89.1 to 97.7) 99.9 (99.8 to 99.9) 32 99
Tradit ional screen-
ing teste
4 120 (22,247) NDf ND
Implicat ions • 632 of 100,000 pregnancies expected to be af fected by T21, T18 or T13;
• 632 and 600 cases will be detected whereas 0 and 32 cases will be missed by MPSS and TMPS, respect ively; and
• of 99,368 unaf fected, 99 pregnant women will undergo unnecessary invasive test with MPSS or TMPS.
Selected high- risk pregnant women
MPSS 32 1508 (15,797) 98.8 (97.2 to 99.5) 99.9 (99.7 to 100) 5.85
(0.67 to 46.81)
70 94
TMPS 7 378 (4282) 98.9 (97.2 to 99.6) 99.9 (99.8 to 100) 64 94
Dif ference between MPSS and TMPS -0.11
(-1.58 to 1.35)
-0.08
(-0.22 to 0.07)
NA
Implicat ions • 5851 of 100,000 pregnancies expected to be af fected by T21, T18 or T3;
• 5781 and 5787 cases will be detected, whereas 70 and 64 cases will be missed by MPSS and TMPS, respect ively; and
• of 94,149 unaf fected, 94 pregnant women will undergo unnecessary invasive test with MPSS or TMPS.
MPSS: massively parallel shotgun sequencing, NA: not applicable, ND: no data available, TMPS: targeted massively parallel
sequencing, T13: trisomy 13, T18: trisomy 18, T21: trisomy 21.
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aUnaf fected pregnancies: we included pat ients with any other aneuploidy than the one under analysis with all euploid cases
as ‘‘unaf fected’’ pregnancies.
bThe median prevalence and range were calculated by using all prospect ive or retrospect ive studies for each category
considered.
cMissed cases per 100,000 tested. FN: false negat ives.
dFalse posit ives per 100,000 tested. A false posit ive result may lead to unnecessary invasive tests depending on choices by
the pregnant woman.
eTradit ional screening tests are f irst-trimester combined test, second-trimester quadruple test, second-trimester fully
integrated test, second-trimester sequent ial test or second-trimester triple test.
f Summary sensit ivity and specif icity were not obtained for tradit ional screening tests because the four studies used dif ferent
cut-of f s to determ ine test posit ivity. Three of the four studies compared TMPS and tradit ional screening tests in the same
populat ion (direct comparison).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Performance of gNIPT for detection of sex chromosome aneuploidies (45,X, 47,XXX, 47,XXY and 47,XYY combined)
Test strategy Number of
studies
Number of affected
pregnancies (Num-
ber of
unaffected preg-
nancies)b
Sensitivity
% (95% CI)
Specificity
% (95% CI)
Median
prevalencec
% (range)
M issed
cases
(FN)d
False
positives
(FP)e
Selected high- risk pregnant women
MPSS 12 151 (7452) 91.9 (73.8 to 97.9) 99.5 (98.8 to 99.8) 1.53
(0.45 to 18.58)
124 492
TMPS 4 96 (968) 93.8 (86.8 to 97.2) 99.6 (98.1 to 99.9) 95 394
Dif ference between MPSS and TMPS -1.85 (-13.3 to 9.60) -0.06 (-0.82 to 0.71) NA
Implicat ions • 1535 of 100,000 pregnancies expected to be af fected by SCA;
• 1411 and 1440 cases will be detected while 124 and 95 cases will be missed by MPSS and TMPS, respect ively;
• of 98,465 unaf fected by SCA, 492 and 394 pregnant women will undergo unnecessary invasive test with MPSS and TMPS, respect ively.
45,X: Turner syndrome, 47,XXX: triple X syndrome, 47,XXY: Klinefelter syndrome,MPSS: massively parallel shotgun sequencing,
NA: not applicable, ND: no data available, TMPS: targeted massively parallel sequencing
aWe did not assess the accuracy of gNIPT individually for 47,XXX, 47,XXY and 47,XYY due to paucity data.
bUnaf fected pregnancies: we included pat ients with any other aneuploidy than the one under analysis with all euploid cases
as ‘‘unaf fected’’ pregnancies.
cThe median prevalence and range were calculated by using all prospect ive or retrospect ive studies for each category
considered.
dMissed cases per 100,000 tested. FN: false negat ives.
eFalse posit ives per 100,000 tested. A false posit ive result may lead to unnecessary invasive tests depending on choices by
the pregnant woman.
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D I S C U S S I O N
Summary of main results
This review included data from 65 studies of 86,139 pregnant
women (including 3141 aneuploids) tested by genomics-based
non-invasive prenatal testing (gNIPT) and a reference standard.
The gNIPT method used circulating cell-free DNA (ccfDNA) in
maternal blood for the detection of common fetal aneuploidies
(T21, T18, T13, 45,X, 47,XXY, 47,XXX and 47,XYY). The num-
ber of gNIPT studies in unselected populations was limited (five
studies), but 42 studies in high-risk cohorts provided data for var-
ious meta-analyses. Few (14%) studies included more than 100
aneuploid cases. Importantly, in almost all studies, the risk of bias
was generally high with respect to patient selection as well as flow
and timing. Some women can spontaneously lose their pregnancy
after enrolment into a study.However, none of the studies reported
such events. Since women with spontaneous abortions are likely
to be lost to follow-up, we believe that any risk of bias has been
captured in the quality assessment of studies. Blood samples for
gNIPT were mainly taken just before the invasive test (reference
standard) and so pregnancies were unlikely to terminate naturally
between the gNIPT and the reference standard. Across all stud-
ies, applicability concerns were low in the index test and reference
standard domains.
These results show that massively parallel shotgun sequencing
(MPSS) and targeted massively parallel sequencing (TMPS) per-
form similarly in terms of clinical sensitivity and specificity for the
detection of fetal T21, T18, T13 and sex chromosome aneuploidy
(SCA). However, no study compared the two approaches head-to-
head in the same cohort of patients.
In high-risk pregnancies, gNIPT methods (MPSS and TMPS)
were highly accurate for detection of any of the three major tri-
somies (T21, T18 and T13) with sensitivities from 95.8% to
99.7% depending on specific trisomies and specificities above
99%. There were no statistically significant differences in accuracy
between MPSS and TMPS.
In unselected cohorts of pregnant women, only one study eval-
uated MPSS. Based on meta-analytic findings for each trisomy,
TMPS appeared to be accurate for the detection of T21, with
lower accuracy for T18 and T13. When compared to traditional
prenatal screening tests, only four studies were identified (three for
TMPS and one for MPSS). Genomics-based non-invasive prena-
tal testing showed greater specificity for T21 and T18 than tradi-
tional screening tests, while inconsistent results were observed for
sensitivity. The inconsistency may be due to different cutpoints
for traditional screening tests though one would expect that to
also affect specificity. Given the small number of studies, the dif-
ferences may be due to chance or there may be other differences
between the studies that were not apparent.
With respect to the replacement of invasive tests, the performance
of gNIPTobserved in this review is not sufficient to replace current
invasive diagnostic tests.
We also compared the diagnostic test accuracy ofMPSS andTMPS
for all three autosomes combinedbecause gNIPT is being clinically
proposed as one test during prenatal follow-up to detect any of
the three conditions. Under this scenario, in high-risk pregnancies
of fetal aneuploidy, there was no statistically significant difference
in diagnostic accuracy between MPSS and TMPS. In unselected
cohorts of pregnant women, a test comparison was not possible
due to limited data.
There was paucity of data for each SCA. In high-risk cohorts, all
SCAs combined gave a pooled sensitivity (95% CI) and speci-
ficity (95% CI) of 91.9% (73.8% to 97.9%) and 99.5% (98.8%
to 99.8%) from 12 MPSS studies. The pooled sensitivity (95%
CI) and specificity (95% CI) were 93.8% (86.8% to 97.2%) and
99.6% (98.1% to 99.9%) from four TMPS studies. SCAs are con-
sidered “incidental” findings of current aneuploidy screening pro-
grams. It should be noted that SCAs are not of interest for prenatal
screening since they do not lead to any intervention prior to birth.
The failure rate associated with gNIPT, which is higher than the
current failure rate of traditional screening tests which is close
to zero, is worrying and may be a source of bias. Futhermore,
the large heterogeneity between laboratory-developed assays in
their protocol details and observed failure rates highlight the fact
that each laboratory providing gNIPT services should determine
its own failure rate and inform healthcare professionals ordering
the test about this important test characteristic. Failed samples
were excluded from the analyses in the studies. This systematic
review found a slightly larger failure rate for TMPS than theMPSS
approach. This was also reported by Yaron 2016. We also found
that the proportion of failed samples for aneuploid samples was
higher than the proportion of failed samples for euploid samples.
If these failed samples were included in the summary statistics, the
diagnostic performance of gNIPT would be lower.
Comparison with other systematic reviews with meta
analysis
At the time of writing, there are four published systematic reviews
with meta-analyses of gNIPT (Gil 2015a; HAS 2015; Mackie
2017; Taylor-Phillips 2016). Although these meta-analyses had
different criteria for including studies and analyses, they reported
similar sensitivities and specificities to our findings.
As reported by Gil 2015a, the detection rate of gNIPT for auto-
somes was between 91.0% to 99.2% and specificity above 99.9%
in singleton pregnancies. The detection rate for 45,X and SCA
other than 45,X was 90.3% and 93.0%, respectively with speci-
ficity above 99.8% in singleton pregnancies. The results fromHAS
2015 group for T21 were respectively 98.0% and 99.9% for sen-
sitivity and specificity. Regarding Mackie 2017, the sensitivity was
between 90.6% to 99.4% and specificity above 99.9% for auto-
somes. For 45,X, the sensitivity and specificity was 92.9% and
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99.9%, respectively. They also pointed out that failed results were
poorly reported across studies. Finally, Taylor-Phillips 2016 re-
ported sensitivity between 97.4% to 99.3% for autosomes and
specificity of 99.9%.
This is the first Cochrane diagnostic test accuracy (DTA) review on
gNIPT. There are five published Cochrane DTA reviews on pre-
natal screening tests (Alldred 2012; Alldred 2015; Alldred 2015a;
Alldred 2017a; Alldred 2017b). The suite of reviews addressed
traditional biochemical, ultrasound and urine markers for Down
syndrome screening (Alldred 2010) and none of the other fetal
aneuploidies considered in this review were evaluated in this suite.
In the first of the three reviews, Alldred and colleagues evaluated
second-trimester serum markers and found that double and triple
test combinations (involving alpha-fetoprotein, human chorionic
gonadotropin (hCG) (free and total) or unconjugated estriol) sig-
nificantly outperformed individual markers, detecting six to seven
out of every 10 Down syndrome pregnancies at a 5% false positive
rate (Alldred 2012). The second review evaluated first-trimester
serum markers and found that a test strategy involving maternal
age, PAPP-A and free ßhCG significantly outperformed individ-
ual markers, detecting about seven out of every 10 Down’s syn-
drome pregnancies at a 5% false positive rate (Alldred 2015a). The
third review evaluated urine markers and concluded there was a
paucity of evidence to support the use of urine testing for Down
syndrome screening (Alldred 2015b). The fourth review evaluated
first-trimester ultrasound tests alone or in combination with first-
trimester serum tests and found that a combination of ultrasound
and serum markers (especially PAPP-A and free ßhCG) and ma-
ternal age can detect about nine of 10 T21 affected pregnancies
for a fixed 5% false positive rate (Alldred 2017a). The fifth review
evaluated first- and second-trimester serum tests with and without
first-trimester ultrasound tests and found that a combination of
first-trimester ultrasound with first- and second-trimester serum
markers with maternal age are significantly better than those with-
out ultrasound or those evaluating first-trimester ultrasound in
combination with second-trimester serum markers, without first-
trimester serum markers (the authors cannot make recommenda-
tions about a specific strategy) (Alldred 2017b).
Strengths and weaknesses of the review
Strengths
The review methodology was transparent with the full protocol
published in the Cochrane Library (1 July 2015) and in PROS-
PERO (11 November 2015). The review evaluated the screening
and diagnostic accuracy of gNIPT by MPSS and TMPS for seven
common aneuploidies with no restriction imposed on population
characteristics such as maternal age, gestational age, aneuploidy
risk, number of fetuses and ethnicity.We performed a comprehen-
sive search with no language restriction and we included studies in
the languages used by various authors in the field, including Chi-
nese, Bulgarian, Russian, Polish, Korean and Spanish. Study selec-
tion, data extraction and quality assessment were independently
performed by two review authors. We contacted authors to clarify
data and to avoid duplication of data as a result of overlapping
populations.
We evaluated the performance of the two major gNIPT meth-
ods (MPSS and TMPS which included digital analysis of selected
regions (DANSR) and single nucleotide polymorphism (SNP)-
based method) and included data on traditional screening tests
when compared to gNIPT.
We collected and reported data on excluded and failed samples and
presented the failure rate at first attempt, the number of repeated
tests and the final failure rate for each study. When it was possible,
we also reported separate failure rates among aneuploid and eu-
ploid cases. Where possible, we performed subgroups analyses to
investigate heterogeneity, and also performed sensitivity analyses
to assess the robustness of these findings.
Weaknesses
Fetal karyotyping is the reference standard for establishing a diag-
nosis of fetal aneuploidy. This is an invasive procedure with some
risk for the fetus and the pregnant woman.Many pregnant women
included in the studies, especially those involving unselected co-
horts, were not tested by karyotyping. Rather, clinical examina-
tion of the newborn or medical records from birth were used as a
secondary reference standard. We are aware that these secondary
reference standards are not as accurate as fetal karyotype and some
cases may have been missed.
Studies rarely reported the qualification of the person conducting
the neonatal clinical examination at birth. Such examination is
expected to be more reliable if it was made by a paediatrician or a
geneticist. Ideally, this examination should be done a few months
after birth because the phenotypic characteristics of aneuploidies
are more apparent than at birth (Devlin 2004).
Genomics-based non-invasive prenatal testing assays are labora-
tory-developed tests that are not standardised in their methods, se-
quencing platforms, sequencing datamanipulation,measures used
or cut-offs for interpretation. Each assay was developed and vali-
dated by the testing laboratory and each laboratory has a different
method. Usually detailed information about the assays were not
available. As shown in Table 5, 15, different gNIPT assays were
used in the studies included in this review. Thus, theymay differ in
various aspects and show different analytical and clinical validity.
We have grouped them accordingly to the type of assay used (tar-
geted versus shotgun), but there are also differences within each
of these two subgroups that we were not able to account for, given
the small number of studies published on most of these different
assays. Thirteen of the assays were used only in studies of high-
risk pregnancies or mixed cohorts. Only a few gNIPT assays were
used in a significant number of studies. Thus, caution should be
used before generalising the diagnostic accuracy observed in this
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category of patients to all gNIPT assays. This limits the generalis-
ability of these findings and we cannot infer that all gNIPT assays
will show the same performance.
Applicability of findings to the review question
These findings suggest that gNIPT has high sensitivity and speci-
ficity for detection of fetal aneuploidies in high-risk pregnancies.
Performance varied depending on the type of aneuploidy. There
was limited evidence of the performance of gNIPT in unselected
cohorts of pregnant women.Most studies involved either high-risk
pregnancies or mixed populations where it was not possible to dif-
ferentiate between high-risk pregnancies and unselected pregnant
women. Thus, more studies are needed in the general population
of pregnant women before firm conclusions can be made about
the sensitivity of gNIPT as a first-tier screening test. The two ma-
jor types of gNIPT method (MPSS and TMPS) appear to have
comparable performance, but there are many different gNIPT as-
says for each approach. For many of these assays, very little data
have been published about their diagnostic accuracy. Additionally,
performance in the cohorts studied may not reflect performance
in other populations owing to differences in fetal fraction distri-
bution because of, for example, differences in mean body mass
index or gestational age. Importantly, summary sensitivities and
specificities derived from cohort data can be very different from
the probability associated with any particular patient sample to be
positive or negative depending on the sample’s specific fetal frac-
tion. Thus, summary sensitivity, specificity and associated predic-
tive values of an assay cannot be used as a straightforward measure
of the probability of a specific patient’s sample to be affected given
a positive or negative result. This underscores the importance, be-
fore clinically offering a laboratory developed gNIPT assay, that
it is fully validated according to recognised best practice clinical
laboratory molecular diagnostics guidelines. Finally, the method-
ological quality of studies was generally poor with high risk of bias,
especially in terms of patient selection and flow and timing.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Genomics-based non-invasive prenatal testing (gNIPT) appears
to be an accurate prenatal screening test, its accuracy having been
evaluated as a second-tier screening test to identify pregnancies at
very low risk of fetal aneuploidies (T21, T18 and T13) and thus to
decrease the false positive rate of traditional screening approaches
and avoid invasive procedures in those pregnant women. As a first-
tier aneuploidy screening test, based on limited data from compar-
ative studies, gNIPT appears to have significantly better specificity
than current screening approaches usingmaternal serumbiochem-
ical markers, ultrasound or both, but evidence about sensitivity is
inconsistent. At current gNIPT pricing levels, gNIPT as a second-
tier screening test provides the best value for money, especially for
publicly-funded screening programs while gNIPT as a first-tier
screening test was found not to be cost-effective (Nshimyumukiza
2017). The failure rate of gNIPT is a concern as it is substantially
larger than the current failure rate of traditional prenatal screening
approaches.
It is worth noting that gNIPT shows good performance for the
detection of sex chromosome aneuploidies though data are sparse.
The number of studies for sex chromosome aneuploidy (SCA)
was small and confidence intervals on sensitivity and specificity
estimates are therefore wide. Thus, sex chromosome aneuploidies
appear to be more difficult to detect since performances of gNIPT
are not as good as for detecting autosomal aneuploidies. SCAs are
considered “incidental” findings of current aneuploidy screening
programs and they do not lead to any intervention prior to birth.
Maternal serum screening, ultrasound fetal examination, gNIPT
and invasive diagnostic tests are thus complementary approaches
because in its current state, gNIPT cannot detect all chromosomal
abnormalities or adverse obstetrical outcomes. About 44% to 64%
of all chromosomal abnormalities found during prenatal diagnos-
tic are common aneuploidies which gNIPT can detect (Kazerouni
2011; Shani 2016). Counselling expectantmothers and their part-
ners is essential for explaining the advantages, limitations and risks
of these procedures.
We conclude that given the current data on the performance of
gNIPT, invasive fetal karyotyping is still the required diagnostic
approach to confirm the presence of a chromosomal abnormality
prior to making irreversible decisions relative to the pregnancy
outcome.
Implications for research
This systematic reviewhas highlighted the fact thatmost published
studies on gNIPT have high risk of bias in the patient selection
and flow and timing domains. Many different gNIPT assays are
in use and for the majority of them, there is insufficient published
data to individually assess their clinical performance. Therefore,
the results in this systematic review may not be generalisable to all
gNIPT assays. Studies are needed that directly compare the accu-
racy of gNIPT with that of current traditional prenatal screening
methods for fetal aneuploidy, especially in unselected populations
of pregnant women. Such studies can provide valid evidence of
the incremental accuracy of gNIPT if gNIPT is being considered
as a first-tier test. Particular attention should be paid to study de-
sign in order to minimise patient selection biases as well as biases
in flow and timing domain. Further well-designed, independent
large-scale studies on real life gNIPT’s implementation into prena-
tal care should be performed. Large scale randomised clinical trials
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of tests and patient outcomes are needed to validate the clinical
utility of gNIPT in the various clinical settings. Given the rapid
evolution of gNIPT and its capacity to detect other fetal chromo-
somal anomalies (Benn 2016), future systematic reviews may have
to widen the scope of target conditions.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alberti 2015
Study characteristics
Patient sampling Study design: case-control study (1:2) from a prospective cohort.
Participants: pregnant women selected from a high-risk population of fetal aneuploidy.
Inclusion criteria: pregnant women who had a risk of fetal trisomy 21 (> 1 in 250), based on the
combination of maternal age with ultrasound and maternal serummarkers during the first or second
trimester and prior invasive testing.
Exclusion criteria: multifetal pregnancies, absence of medical coverage by the National Health
System and women declining an invasive procedure
Patient characteristics and set-
ting
Number enrolled: 976 pregnant women.
Number available for 2 x 2 table: 183 pregnant women (subgroup of 19%). 23 euploid samples
were used as reference set and 8 samples randomly chosen for pretesting phase.
Setting: 3 centres in France.
Recruitment period: March 2010 to April 2013.
Ethnicity: not reported.
Mean gestational age (± SD): 14 (± 2) weeks.
Mean maternal age (± SD): 35.2 (± 6.7) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina HiSeq 2000 without multiplexing. Each library was sequenced using
50 bases-length reads chemistry in a single end-flow cell
Mean fetal fraction DNA: (male only) euploid: 20.11% and T21: 16.86%.
Blood samples for gNIPT were collected before reference standard.
Cutpoint: positive if Z score > 3.
In-house gNIPT.
Target condition and reference
standard(s)
Target condition: T21.
Reference standard: fetal karyotype of chorionic villi or amniotic fluid
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a second-tier test.
701/976 samples were not selected for the case-control study
50/275 samples were excluded during DNA extraction (47 for low amount of DNA and 3 for
haemolysis) (no gNIPT results)
31/225 samples were excluded from analysis (8 for pretesting phase and 23 for reference set)
11/194 samples were excluded from analysis for insufficient fetal fraction DNA (no gNIPT results)
No repeated test reported.
Comparative
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Alberti 2015 (Continued)
Aim to study To evaluate the implementation of gNIPT for trisomy 21 into a cytogenetics laboratory in a uni-
versity teaching hospital as well as validate gNIPT’s clinical use on samples collected prospectively
Funding source or sponsor of
the study
Study not funded by industry.
Informations about the authors
contacted
Authors were contacted on: 23 March and 4 May 2016.
Last reply received on: 16 May 2016.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
Yes
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Alberti 2015 (Continued)
of the results of the index tests?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Ashoor 2012
Study characteristics
Patient sampling Study design: nested case-control study (1:3) from a prospective cohort.
Participants: pregnant women selected from a high-risk population (archived maternal plasma sam-
ples) of fetal aneuploidy
Inclusion criteria: singleton pregnancies between 11 to 13 weeks’ gestation.
Exclusion criteria: pregnancies that were conceived by in vitro fertilization
Patient characteristics and set-
ting
Number enrolled: 400 pregnant women.
Number available for 2 x 2 table: 397 archived plasma samples (subgroup of 99%).
Setting: 1 centre. Tertiary Referral Centre, King’s College Hospital, London, United Kingdom.
Recruitment period: March 2006 to August 2011.
Ethnicity: Caucasian (88.5%), Afro-Caribbean (5%), South Asian (4%), East Asian (2%) and
multiracial (0.5%).
Mean gestational age (range): 13.3 (12.1 to 13.7) weeks.
Mean maternal age (range): 36.2 (29.9 to 41.2) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening.
Language of the study: English.
Index tests gNIPT by TMPS (DANSR assay) on Illumina HiSeq 2000 in 96-plex
Fetal fraction DNA: not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint: not reported. Usually, Harmony™ prenatal test uses FORTE algorithm; positive if
FORTE risk score ≥ 1%.
Commercial test: Harmony™ prenatal test by Ariosa Diagnostics, Inc
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Ashoor 2012 (Continued)
Target condition and reference
standard(s)
Target conditions: T21 and T18.
Reference standard: fetal karyotype of chorionic villi.
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a second-tier test.
3/400 samples failed amplification and sequencing (no gNIPT result)
25 samples did not meet Ariosa Diagnostics, Inc acceptance criteria but they were replaced with the
next available cases
No repeated test reported.
Comparative
Aim to study To assess the prenatal detection rate of T21 and T18 and the false-positive rate by chromosome-
selective sequencing of maternal plasma ccfDNA
Funding source or sponsor of
the study
Study not funded by industry but samples were analysed at Ariosa Diagnostics, Inc
Informations about the authors
contacted
No need for further contact.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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Ashoor 2012 (Continued)
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Ashoor 2013
Study characteristics
Patient sampling Study design: blinded prospective cohort (second phase). First phase (case-control study) not shown
in the present review.
Participants: euploid pregnancies underwent routine first-trimester combined screening and con-
firmed T13 cases were selected.
Inclusion criteria: singleton pregnancies.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 2167 pregnant women.
Number available for 2 x 2 table: 1949 pregnant women (subgroup of 90%).
Setting: several centres. Euploid pregnancies were from King’s College Hospital, London, UK and
T13 cases were from the USA.
Recruitment period: October 2010 to January 2011 for euploid pregnancies. Not reported for T13
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Ashoor 2013 (Continued)
cases.
Ethnicity: Caucasian (70.8%), African (20%), Asian (6.8%), mixed (2.6%).
Mean gestational age (± SD; range): 12.7 (± 0.62; 13 to 26) weeks.
Mean maternal age (± SD): 31.8 (± 5.6) years.
Relevant tests carried out prior to index test: not reported.
Language of the study: English.
Index tests gNIPT by TMPS (DANSR assay) on Illumina HiSeq 2000 in 96-plex
Median fetal fraction DNA (range): euploids: 10.0% (4.1% to 31.0%) and T21: 14.0% (6.1% to
24.0%).
Blood samples for gNIPT were collected before reference standard for euploid pregnancies. T13
samples were collected post-confirmation of trisomy by karyotyping (reference standard).
Cutpoint: positive if FORTE algorithm risk score ≥ 1%.
Commercial test: Harmony™ Prenatal Test by Ariosa Diagnostics, Inc
Target condition and reference
standard(s)
Target condition: T13.
Reference standards: fetal karyotype of chorionic villi or amniotic fluid or neonatal clinical exami-
nation
Flow and timing Blood samples were obtained at the time of screening for euploid pregnancies (before reference
standard)
Blood samples were obtained after T13 confirmation following invasive procedure (reference stan-
dard)
gNIPT was a first- or a second-tier test.
165/2167 samples were excluded because they were used in the first phase
53/2002 samples failed during amplification or sequencing (no gNIPT result)
No repeated test reported.
Comparative
Aim to study To assess the performance of chromosome-selective sequencing of maternal plasma cell-free DNA
(cfDNA) in non-invasive prenatal testing for trisomy 13
Funding source or sponsor of
the study
Study not funded by industry but samples were analysed at Ariosa Diagnostics, Inc
Informations about the authors
contacted
No need for further contact.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
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Ashoor 2013 (Continued)
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
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Benachi 2015
Study characteristics
Patient sampling Study design: blinded, retrospective analysis from a prospective cohort.
Participants: all pregnant women considered at high risk of fetal aneuploidies who were willing to
undergo invasive procedure.
Inclusion criteria: at least 18 years old, more than 10 weeks of gestation and singleton or twin
pregnancies.
Exclusion criteria: vanishing twin or < 18 years old.
Patient characteristics and set-
ting
Number enrolled: 900 pregnant women.
Number available for 2 x 2 table: 886 pregnant women (subgroup of 98%).
Setting: 29 centres. French Fetal Medicine Centres in France.
Recruitment period: December 2012 to October 2013.
Ethnicity: Caucasian (84.2%), Black or Caribbean (4.6%), Asian (2.0%), mixed (5.7%) and un-
known (3.5%).
Median gestational age (range): 15.1 (10.2 to 34.6) weeks.
Median maternal age (range): 35 (30 to 39) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening.
Language of the study: English.
Index tests gNIPT by MPSS with Illumina v3 flow-cell on a HiSeq 1500 sequencer in 12-plex
Mean fetal fraction DNA: group 1 (patients without abnormal fetal ultrasound findings, but at high
risk of fetal aneuploidy): 10.9% and group 2 (high risk of fetal aneuploidy after ultrasound finding)
: 11.2%.
Blood samples for gNIPT were collected just before reference standard.
Cutpoint: positive if Z score > 3 (T21) or > 3.95 (T18 and T13).
Commercial test: Laboratoire CERBA’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21, T18 and T13.
Reference standards: fetal karyotype of chorionic villi or amniotic fluid or neonatal clinical exami-
nation
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a second-tier test.
8/900 samples without karyotype result were excluded.
42 samples failed the initial MPSS testing for technical issues
42/42 repeated tests using a second aliquot and 36/42 samples obtained gNIPT results
6/892 samples failed during gNIPT process (low fetal fraction DNA or result appeared atypical)
(no gNIPT result)
Comparative
Aim to study To evaluate the performance of the gNIPT (using fetal ccfDNA) for detection of the 3 main au-
tosomal fetal trisomies in a very high-risk population of patients whose fetuses display ultrasono-
graphically identified anomalies by comparing the results with those obtained by conventional fetal
karyotyping
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Benachi 2015 (Continued)
Funding source or sponsor of
the study
Funding source not reported. 1 author is an employee of Laboratoire CERBA and also a shareholder
Informations about the authors
contacted
Authors were contacted on: 25 May 2016.
Reply received on: 26 May 2016.
Notes Authors are from de Collaborative SEquençage a Haut Debit et Aneuploidies (SEHDA) Study
Group
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
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Benachi 2015 (Continued)
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Bevilacqua 2015
Study characteristics
Patient sampling Study design: prospective cohort study.
Participants: pregnant women between 10 to 28 weeks’ gestation selected at high risk of fetal trisomy
orwomenwhowanted to have the new test as a primarymethod of screening (unselected population)
.
Inclusion criteria: singleton (not reported in the present review) or twin pregnancies between 10 to
28 weeks’ gestation.
Exclusion criteria: not reported.
Patient characteristics and set-
ting
Number enrolled: 2362 pregnant women including 1847 singleton pregnancies (data not reported
in the present review) and 515 twin pregnancies.
Number available for 2 x 2 table: 340 twin pregnancies (subgroup of 66%).
Setting: multicentre.
Recruitment period: May 2013 to September 2014 (twin).
Ethnicity: not reported.
Median gestational age (range): 13.0 (10 to 28) weeks.
Median maternal age (range): 36.8 (19 to 50.3) years.
Chorionicity (368/515): 13% monochorionic and 58.4% dichorionic.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening for some women.
Language of the study: English.
Index tests gNIPT by TMPS (DANSR assay) on Illumina HiSeq 2000 in 96-plex
Mean fetal fraction DNA (range): twins: 8.7% (4.1% to 30.0%) and singleton: 11.7% (4.0% to
38.9%).
Blood samples for gNIPT were collected before reference standard.
Cutpoint: not reported. Usually, Harmony™ prenatal test uses FORTE algorithm; positive if
FORTE risk score ≥ 1%.
Commercial test: Harmony™ Prenatal Test by Ariosa Diagnostics, Inc
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Bevilacqua 2015 (Continued)
Target condition and reference
standard(s)
Target conditions: T21, T18 and T13.
Reference standards: fetal karyotype of chorionic villi or amniotic fluid or neonatal karyotype
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a first- or second-tier test.
164/515 samples without follow-up were excluded including138 lost to follow-up, 19 still pregnant
and 7 miscarriages or stillbirths without karyotype of fetal tissue
29/515 samples failed the initial TMPS testing.
26/29 samples resequenced with a second aliquot of the first sampling and 13/26 samples obtained
a gNIPT result
16/515 samples failed during sequencing process (no gNIPT result)
Comparative
Aim to study To report the clinical implementation of cfDNA analysis of maternal blood in screening for T21,
T18 and T13 in a large series of twin pregnancies and examine variables that could influence the
failure rate of the test
Funding source or sponsor of
the study
Study not funded by industry but Ariosa Diagnostics, Inc made blinded sequencing and analysis
Informations about the authors
contacted
Author was contacted on: 1 June and 27 September 2016.
No replies received from the author.
Notes gNIPT results from singleton pregnancies were not reported in the present review for incomplete 2
x 2 tables
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Yes
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Bevilacqua 2015 (Continued)
dard?
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Bianchi 2012
Study characteristics
Patient sampling Study design: nested case-control (1:4) study from the MELISSA prospective cohort.
Participants: pregnant women randomly selected from a high-risk population (archived maternal
plasma samples).
Inclusion criteria: singleton pregnancies at high risk of fetal aneuploidy between 8 and 22 weeks of
gestation.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 2882 pregnant women.
Number available for 2 x 2 table: 503 pregnant women for T21, 502 for T18, 501 for T13 and 489
for 45,X (subgroup of 17%).
Setting: 60 centres. Medical centre in 25 states in USA. Samples from 53 centres were analysed.
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Bianchi 2012 (Continued)
Recruitment period: June 2010 to August 2011.
Ethnicity: Caucasian (72.7%), Afro American (10.9%), Asian (9.9%), Native American or Alaska
Native (0.9%) and multiracial (5.6%).
Mean gestational age (± SD; range): 15.1 (± 3.16; 10 to 23) weeks.
Mean maternal age (± SD; range): 35.2 (± 6.40; 18 to 46) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina HiSeq 2000 sequencer in 6-plex.
Fetal fraction DNA: amount measured but not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint:
1) for T21, T18, and T13: positive if NCV > 4 (aneuploidy suspected if NCV is between 2.5 and
4)
2) for 45,X: positive if NCV for Chrom. X < -4 and NCV for Chrom. Y < 2.5
3) for 47,XXX: positive if NCV for Chrom. X > 4 and NCV for Chrom. Y < 2.5
4) for 47,XXY: positive if NCV for Chrom. X between -2.5 and 2.5 and NCV for Chrom. Y > 33
5) for 47,XYY: positive if NCV for Chrom. X < -4 and NCV for Chrom. Y > 4 with NCV for
Chrom. Y is 2 times greater than expected NCV Chrom. X.
Commercial test: Verinata’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21, T18, T13, 45,X, 47,XXX, 47,XXY and 47,XYY.
Reference standard: fetal karyotype of chorionic villi (42.7%), amniotic fluid (56.4%) or products
of conception (0.9%)
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a second-tier test.
257/2882 samples were excluded (127 were ineligibles, 45 without karyotype and 85 for multifetal
pregnancies)
2091/2625 samples were not selected for this case-control study
2/534 samples were excluded for tracking issue.
16/532 samples without fetal DNA detected were excluded during process (no gNIPT result)
13/516 samples were excluded of T21 2 x 2 table for censored complex karyotype
14/516 samples were excluded of T18 2 x 2 table for censored complex karyotype
15/516 samples were excluded of T13 2 x 2 table for censored complex karyotype
27/516 samples were excluded of 45,X 2 x 2 table for censored complex karyotype
No repeated test reported.
Comparative
Aim to study To prospectively determine the diagnostic accuracy of massively parallel sequencing to detect whole
chromosome fetal aneuploidy from maternal plasma
Funding source or sponsor of
the study
Study funded by Verinata Health, Inc. (a wholly owned subsidiary of Illumina, Inc.)
Informations about the authors
contacted
Authors were contacted on: 1 March and 30 November 2016.
Replies received on: 1 March and 8 December 2016.
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Notes This study is a clinical trial. MELISSA study. Clinicaltrials.gov NCT01122524
Data for 47,XXY, 47,XYY and 47,XXX were incomplete in the publication (data not shown in the
present review)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
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Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Bianchi 2013
Study characteristics
Patient sampling Study design: retrospective study (archived maternal plasma samples) from a prospective cohort.
Participants: pregnant women selected from a high-risk population (archived maternal plasma sam-
ples).
Inclusion criteria: eligible blood samples, singleton pregnancies with karyotype result and nuchal
cystic hygroma on fetal ultrasound.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 2882 pregnant women.
Number available for 2 x 2 table: 113 pregnant women (subgroup of 4%).
Setting: 60 centres in USA.
Recruitment period: June 2010 to August 2011.
Ethnicity: Caucasian (73%), Afro-American (10%), Asian (9%) and multiracial (8%).
Mean gestational age (± SD): 13.2 (± 2.0) weeks.
Median gestational age (range): 12.6 (10 to 21) weeks.
Mean maternal age (± SD): 32.2 (± 5.8) years.
Median maternal age (range): 32.9 (18 to 44) years.
Relevant test carried out prior to index test: ultrasonography (nuchal translucency measurement).
Language of the study: English.
Index tests gNIPT by MPSS with the sequencing chemistry Illumina TrueSeq 3.0
Fetal fraction DNA: not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint:
1) for T21, T18 and T13: positive if NCV > 4 (aneuploidy suspected zone between 3 and 4)
2) for 45,X: positive if NCV Chrom. X < -3 and NCV Chrom. Y < 3.
Commercial test: Verinata’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21, T18, T13 and 45,X.
Reference standard: fetal karyotype of chorionic villi (78%), amniotic fluid (20%) or products of
conception (2%)
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Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a second-tier test.
2769/2882 samples were not selected for this study.
No failed sample reported.
No repeated test reported.
Comparative
Aim to study To estimate the accuracy and potential clinical effect of using massively parallel sequencing of
maternal plasma DNA to detect fetal aneuploidy in a population of pregnant women carrying
fetuses with nuchal cystic hygroma
Funding source or sponsor of
the study
Study funded by Verinata Health, Inc. (a wholly owned subsidiary of Illumina, Inc.)
Informations about the authors
contacted
No need for further contact.
Notes 74/113 samples were previously sequenced during theMELISSA trial. In this study, all 113 samples
were newly resequenced (no overlap) with MELISSA study
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Bianchi 2014a
Study characteristics
Patient sampling Study design: blinded, prospective cohort study.
Participants: pregnant women who planned to undergo (without prior risk) or had completed (high-
or low-risk) standard prenatal serum screening for fetal aneuploidy.
Inclusion criteria: pregnant women of 18 years or older, gestational age ≥ 8 weeks, able to provide
consent and pregnancy records accessible and available for data collection.
Exclusion criteria: invasive procedure (amniocentesis or CVS) performed within 2 weeks prior
enrolment or prenatal screening determination by nuchal translucency measurement only
Patient characteristics and set-
ting
Number enrolled: 2052 pregnant women.
Number available for 2 x 2 table: 1952 for T21 and T18 (subgroup of 95%) and 1914 for T13
(subgroup of 93%).
Setting: 21 centres. In 14 states (USA).
Recruitment period: 2 July 2012 to 4 January 2013.
Ethnicity: Caucasian (65.4%), Afro-American (22.3%), Asian (7.3%) and other (5%).
Mean gestational age (± SD; range): 20.3 (± 8.6; 8 to 39.4) weeks
Mean maternal age (± SD; range): 29.6 (± 5.54; 18 to 48.6) years.
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Bianchi 2014a (Continued)
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina HiSeq 2000 in 8-plex.
Mean fetal fraction DNA: more than 35 years old: 11.3%, less than 35 years old: 11.6%, and at
third trimester only: 24.6%.
Blood samples for gNIPT were collected before or after reference standard.
Cutpoint: positive if NCV ≥ 4. Resequenced if NCV is between 3 and 4.
Commercial test: verifi® prenatal test by Verinata Health.
The traditional screening tests (first-trimester combined test or a second-trimester result (quadruple,
serum integrated, fully integrated or sequential)) were also assessed. Mixed cutpoints used
Target condition and reference
standard(s)
Target conditions: T21, T18 and T13.
Reference standards: fetal karyotype of chorionic villi, amniotic fluid or products of conception,
neonatal clinical examination or medical record from birth
Flow and timing Blood samples were obtained prior or after the invasive procedure (reference standard)
gNIPT was a first- or second-tier test.
10/2052 samples failed blood quality control before sequencing process
72/2042 samples without clinical outcome.
38/2042 samples without standard screening result.
17/2042 samples without gNIPT result.
1/2042 samples without standard screening result and without gNIPT result
12 resequenced sampleswere in the grey zone (between affected andunaffected) andwere successfully
resequenced in uniplex
Comparative
Aim to study To compare the results of gNIPT with ccfDNA for fetal autosomal aneuploidy with the results
of conventional screening for T21 and T18 in a general obstetrical population. To compare false
positive rates with the use of each method. To compare false positive rates for T13 in a subset of
pregnant women in whom standard screening results included a risk assessment for trisomy 13. To
compare fetal ccfDNA fractions in low-risk patients and those in high-risk patients in the CARE
study population to assess the potential effects of demographic differences on test performance
Funding source or sponsor of
the study
Study funded by Illumina, Inc.
Informations about the authors
contacted
Author was contacted on: 10 February, 1 June and 28 June 2016.
No replies received from the author.
Notes This study is a clinical trial (Comparison of Aneuploidy Risk Evaluations; CARE study). Clinical-
Trials.gov number: NCT0166335
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 2: Index Test Traditional screening tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
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DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Bijok 2014
Study characteristics
Patient sampling Study design: prospective cohort study.
Participants: pregnant women selected at high risk of fetal aneuploidy.
Inclusion criteria: pregnant women at high risk of fetal aneuploidy with invasive test result.
Exclusion criteria: not reported.
Patient characteristics and set-
ting
Number enrolled: 10 pregnant women.
Number available for 2 x 2 table: 9 pregnant women (subgroup of 90%).
Setting: obstetric and gynaecology clinic in Warsaw, Poland.
Recruitment period: not reported.
Ethnicity: not reported.
Median gestational age (range): 16 (13 to 23) weeks.
Median maternal age (range): 31 (26 to 36) years.
Relevant test carried out prior to index test: ultrasonography (nuchal translucency measurement).
Language of the study: Polish.
Index tests gNIPT by MPSS on Illumina Genome Analyzer IIx or HiSeq 2000 sequencer in multiplex with
BGI’s algorithm
Fetal fraction DNA: amount measured but not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint: not reported.
Commercial test: NIFTY™ test by Bejing Genomics Institute.
Target condition and reference
standard(s)
Target conditions: T21, T18, and T13.
Reference standard: fetal karyotype of chorionic villi (30%) or amniotic fluid (70%)
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a second-tier test.
1/10 sample failed during sequencing process (no gNIPT result) for low fetal fraction DNA
No repeated test reported.
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Comparative
Aim to study To present initial results of non-invasive prenatal diagnosis of common aneuploidies (T21, T18,
and T13) based on ccfDNA in maternal plasma in high-risk pregnant women, and to compare the
results with routine karyotyping
Funding source or sponsor of
the study
Study not funded by industry but NIFTY™ tests were provided by Beijing Genomics Institute,
Shenzen, China
Informations about the authors
contacted
Authors were contacted on: 2 May and 4 July 2016.
Replies received on: 4 and 16 May 2016.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Canick 2012
Study characteristics
Patient sampling Study design: case-control study.
Participants: all multifetal pregnant women with T21, T18 or T13 fetus were selected along with
all euploid triplet pregnancies and a random selection of euploid twin pregnancies.
Inclusion criteria: multifetal pregnant women, at least 18 years old, between about 10 weeks and
21 weeks 6 days of gestation, at high risk of aneuploidies and who undergo an invasive procedure.
Exclusion criteria: singleton pregnancies or low risk of aneuploidy
Patient characteristics and set-
ting
Number enrolled: 4664 pregnant women.
Number available for 2 x 2 table: 27 multifetal pregnancies (25 twin and 2 triplet pregnancies)
(subgroup of 0.6%).
Setting: 27 centres. Prenatal diagnostic centres (Canada, Italy, Spain, Czech Republic, Argentina,
Ireland, Hungary, USA, Israel and Australia).
Recruitment period: April 2009 to February 2011.
Ethnicity: not reported.
Mean gestational age (range): 15.0 (10.9 to 19) years.
Maternal age: not reported.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina HiSeq 2000 sequencer in 4-plex.
Fetal fraction DNA range: 7% to 55%.
Blood samples for gNIPT were collected before reference standard.
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Cutpoint: positive if Z score ≥ 3.
Commercial test: Sequenom’s test.
Target condition and reference
standard(s)
Target conditions: T21 and T13. T18 was also assessed but no case was found.
Reference standard: fetal karyotype of chorionic villi or amniotic fluid
Flow and timing Blood samples were obtained immediately prior the invasive procedure (reference standard)
gNIPT was a second-tier test.
4637/4664 samples were not selected for this case-control study
No failed sample was reported in multifetal pregnancies.
No repeated test reported.
Comparative
Aim to study To study prenatal testing for T21, T18, and T13 by MPSS of fetal ccfDNA in high-risk multifetal
pregnant women
Funding source or sponsor of
the study
Study funded by Sequenom, Inc. Some authors are employees and shareholders of Sequenom, Inc.
or of Sequenom Center for Molecular Medicine
Informations about the authors
contacted
Author was contacted on: 10 March 2016.
Reply received on: 16 March 2016.
Notes This study is a clinical trial “A New Prenatal Blood Test for Down Syndrome” ClinicalTrials.gov
number: NCT00877292
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Chen 2011
Study characteristics
Patient sampling Study design: nested case-control study from a prospective cohort and archived plasma
Participants: pregnant women with clinical indications of fetal aneuploidy (high risk of fetal aneu-
ploidy) for invasive procedure
Inclusion criteria: singleton pregnancies with and without trisomy 13, 18 or 21, matched for
gestational ages
Exclusion criteria: twin pregnancies.
Patient characteristics and set-
ting
Number enrolled: 392 pregnant women (252 from the prospective cohort and 140 were archived
plasma)
Number available for 2 x 2 table: 289 pregnant women (subgroup of 74%)
Setting: 10 centres in Hong Kong, the Netherlands, and UK.
Recruitment period for the prospective cohort: October 2008 to May 2009
Recruitment period for the archived plasma samples collection: October 2003 to September 2008
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Ethnicity: not reported.
Gestational age: not reported.
Maternal age: not reported.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening
Language of the study: English.
Index tests gNIPT by MPSS on Illumina Genome Analyzer IIx in 2-plex.
Feta fraction DNA: not reported.
Blood samples for gNIPT were collected before reference standard
Cutpoint: positive if Z score > 3.
Commercial test: Sequenom’s test.
Target condition and reference
standard(s)
Target conditions: T18 and T13.
Reference standard: fetal karyotype of chorionic villi or amniotic fluid
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a second-tier test.
103/392 samples were selected as reference control.
No failed sample reported.
No repeated test reported.
Comparative
Aim to study To assess the prenatal diagnostic performance by MPSS of maternal plasma DNA on a cohort of
pregnant women with T13 and T18 fetuses
Funding source or sponsor of
the study
Study co-sponsored by Sequenom, Inc and Life Technologies. Some authors have filed patent on
gNIPT (part of this patent has been licensed to Sequenom, Inc)
Informations about the authors
contacted
Author was contacted on: 14 December 2015 and 10 May 2016.
Reply received on: 12 May 2016.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
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High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Chiu 2011
Study characteristics
Patient sampling Study design: blinded, case-control study (1:5) from a prospective cohort and archived plasma
Participants: pregnant women with clinical indications for invasive procedure, mixed risk (mostly
high risk (> 1/300 at traditional screening test), intermediate risk (between 1/300 and 1/1000) or
other risk factors)
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T21 and non T21 pregnancies matched for gestational ages.
Inclusion criteria: singleton pregnancies.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 824 pregnant women.
Number available for 2 x 2 table: 753 (8-plex) (subgroup of 91%)
Setting: 10 centres in Hong Kong, the Netherlands, and UK.
Recruitment period for the prospective cohort: October 2008 to May 2009
Recruitment period for the archived plasma samples collection: October 2003 to September 2008
Ethnicity: not reported.
Median gestational age: 13.1 weeks.
Median maternal age: 35.4 years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening
Language of the study: English.
Index tests gNIPT byMPSS on Illumina Genome Analyzer II in 8-plex and 2-plex (not reported in the present
review)
Median fetal fraction DNA (interquartile 1 and 3): male euploid: 15.2% (10.6% and 19.1%),
archived samples: 14.7%, and prospective samples: 15.4%
Blood samples for gNIPT were collected before reference standard
Cutpoint: positive if Z score > 3.
Commercial test: Sequenom’s test.
Target condition and reference
standard(s)
Target condition: T21.
Reference standard: fetal karyotype of chorionic villi or amniotic fluid
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a second-tier test.
60/824 samples were excluded before sequencing process (2 twin pregnancies, 12 without karyotype
and 46 failed quality control for blood sampling)
11/764 samples failed quality control during sequencing process (no gNIPT result)
96/753 samples were also used for reference controls (8-plex)
No repeated test reported.
Comparative
Aim to study To validate the diagnostic performance and practical feasibility of massively parallel genomic se-
quencing for the non-invasive prenatal assessment of trisomy 21 in pregnant women who had un-
dergone conventional screening and were clinically indicated for definitive testing
Funding source or sponsor of
the study
Study sponsored by Sequenom, Inc. Some authors have filed patent applications on gNIPT (part
of this patent has been licensed to Sequenom, Inc)
Informations about the authors
contacted
No need for further contact.
Notes Data from 2-plex sequencing were excluded from the present review to avoid double counting. We
kept data from 8-plex because it is the method most likely to be used for routine testing
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Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Comas 2015
Study characteristics
Patient sampling Study design: blinded, observational prospective cohort study.
Participants: all pregnant women who underwent conventional first-trimester combined screening
for fetal aneuploidies (without prior risk of fetal aneuploidy). Some pregnant women were referred
after their combined test (high risk of fetal aneuploidy).
Inclusion criteria: singleton pregnancies.
Exclusion criteria: multifetal pregnancies, cases of ultrasound anomalies, nuchal translucency > 99
centile, combined risk at first-trimester screening > 1/10, or women at high risk of other genetic
conditions
Patient characteristics and set-
ting
Number enrolled: 333 pregnant women (85.5% without prior risk and 16.5% were at high risk of
fetal aneuploidy).
Number available for 2 x 2 table: 312 pregnant women (subgroup of 95%).
Setting: 1 private prenatal diagnostics centre in Barcelona, Spain (Hospital Universitari Quiron
Dexeus).
Recruitment period: January to December 2013.
Ethnicity: not reported.
Mean gestational age (range): 14.6 (9.5 to 23.5) weeks.
Mean maternal age (range): 37 (21 to 46) years.
Relevant test carried out prior to index test: biochemical screening for a part of the cohort.
Language of the study: English
Index tests gNIPT by TMPS (DANSR assay or SNP-based method).
Mean fetal fraction DNA (range): 12.7% (4.2% to 27.9%), Harmony™ prenatal test: 13.1%, and
Panorama™ prenatal test: 12.7%.
Blood samples for gNIPT were collected before reference standard.
DANSR assay cutpoint: not reported. Usually, Harmony™ prenatal test uses FORTE algorithm;
positive if FORTE risk score ≥ 1%
SNP-based method cutpoint: not reported.
Commercial test: Panorama™ prenatal test by Natera, Inc. or Harmony™ prenatal test by Ariosa
Diagnostics, Inc
Target condition and reference
standard(s)
Target conditions: T21, T18, T13, 45,X, 47,XXX, 47, XXY, 47,XYY. SCA data were not reported
in the present review. T18 and T13 were also assessed but no case was found
Reference standards: fetal karyotype of chorionic villi or amniotic fluid or neonatal clinical exami-
nation
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Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a first- or second-tier test.
17/333 samples excluded because still pregnant at the time of publication (no follow-up)
9/333 samples failed the initial TMPS testing.
6/9 repeated sampling was performed and results were obtained in 5/6
3/333 samples without gNIPT result were excluded (unrepeated samples)
1/333 samples without gNIPT result and follow-up were excluded (still pregnant)
Comparative
Aim to study To evaluate gNIPT of ccfDNA as a screening method for major chromosomal anomalies in a clinical
setting
Funding source or sponsor of
the study
Study not funded by industry but Ariosa Diagnostics, Inc and Natera, Inc. made sequencing and
analysis
Informations about the authors
contacted
Author was contacted on: 27 May 2016 and 31 May 2016.
Reply received on: 31 May 2016.
Notes gNIPT is offered to pregnant women at their own cost. 45,X, 47,XXY, 47,XYY and 47,XXX were
also screened but inappropriate reference standard for the present review was used. gNIPT data
from SCA were not shown in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
del Mar Gil 2014
Study characteristics
Patient sampling Study design: retrospective cohort study. Data from prospective cohort were not shown in the
present review.
Participants: pregnant women without a priori risk who undergo first-trimester screening for tri-
somies (archived maternal plasma samples).
Inclusion criteria: multifetal pregnancies between 11 to 13 weeks’ gestation.
Exclusion criteria: singleton pregnancies.
Patient characteristics and set-
ting
Number enrolled: 207 pregnant women from the retrospective cohort.
Number available for 2 x 2 table: 192 pregnant women (subgroup of 93%)
Setting: 1 centre at Kings’ College Hospital in London, UK.
Recruitment period: not reported.
Ethnicity: not reported.
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Median gestational age (range): 13.0 (12.4 to 13.9) weeks.
Median maternal age (range): 33.7 (26.7 to 37.9) years.
Chorionicity: 41% of pregnancies were monochorionic (85/207) and 59% of pregnancies were
dichorionic (122/207)
Relevant tests carried out prior to index test: none.
Language of the study: English.
Index tests gNIPT by TMPS (DANSR assay) on Illumina HiSeq 2000 in 96-plex
Mean fetal fraction DNA (range): euploids: 9.8% (7.4% to 12.1%), T21: 10.8% (6.8% to 12.1%)
, and T13: 7%.
Blood samples for gNIPT were collected before reference standard.
Cutpoint: not reported. Usually, Harmony™ prenatal test uses FORTE algorithm; positive if
FORTE risk score ≥ 1%.
Commercial test: Harmony™ prenatal test by Ariosa Diagnostics, Inc
Target condition and reference
standard(s)
Target conditions: T21 and T13. T18 was also assessed but no case was found.
Reference standard: fetal karyotype of chorionic villi or amniotic fluid
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a first-tier test.
15/207 samples failed during sequencing process (11 for low fetal fractionDNA and 4 for laboratory
processing failures) (no gNIPT result)
No repeated test reported.
Comparative
Aim to study To examine the clinical implementation of TMPS of ccfDNA in maternal blood and an algorithm
that relies on the lower fetal fraction DNA contribution of the 2 fetuses in the assessment of risk
for trisomies in twin pregnancies
Funding source or sponsor of
the study
Study not funded by industry but Ariosa Diagnostics, Inc have performed gNIPT at their own
expense. Study funded by a grant from The Fetal Medicine Foundation, UK
Informations about the authors
contacted
Author was contacted on: 27 May and 27 September 2016.
No reply received from the author.
Notes Data from prospective cohort study were not shown in the present review because patients with
gNIPT negative result were without follow-up to confirm gNIPT result
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
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Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Low
DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
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Ehrich 2011
Study characteristics
Patient sampling Study design: blinded, case-control study (1:11) from a prospective cohort.
Participants: pregnant women selected from a high-risk population.
Inclusion criteria: not reported.
Exclusion criteria: not reported.
Patient characteristics and set-
ting
Number enrolled: 480 pregnant women.
Number available for 2 x 2 table: 449 pregnant women (subgroup of 94%).
Setting: in clinical practice and pregnancy termination centres.
Recruitment period: May 2009 to unknown date.
Ethnicity: not reported.
Median gestational age (range): 16 (8 to 36) weeks.
Mean maternal age (range): 37 (18 to 47) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina Genome Analyzer IIx in 4-plex.
Minimum fetal fraction DNA as estimated with the fetal quantifier assay: 3.9%.
Blood samples for gNIPT were collected before reference standard.
Cutpoint: positive if Z score > 2.5.
Commercial test: Sequenom’s test.
Target condition and reference
standard(s)
Target condition: T21.
Reference standard: fetal karyotype of chorionic villi (19%) or amniotic fluid (81%)
Flow and timing Blood samples were obtained prior or after the invasive procedure (reference standard)
gNIPT was a second-tier test.
13/480 samples excluded before sequencing process (9 for plasma volume < 3.5 mL and 4 for
processing errors)
20/467 samples failed the initial MPSS testing.
20/20 samples were resequenced using the same library (10 samples in 4-plex and 10 in monoplex)
and 2/20 samples obtained a gNIPT results
18/467 samples failed quality control during sequencing process, including 7 samples for low fetal
fraction DNA (no gNIPT result)
Comparative
Aim to study To evaluate a multiplexed massively parallel shotgun sequencing assay for noninvasive trisomy 21
detection using circulating cell-free fetal DNA
Funding source or sponsor of
the study
Study funded by Sequenom, Inc.
Informations about the authors
contacted
Author was been contacted on: 5 May and 28 September 2016.
No reply received from the author.
Notes
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Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
Unclear
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Fiorentino 2016
Study characteristics
Patient sampling Study design: blinded, prospective cohort study. Retrospective cohort (training set) not reported in
the present review.
Participants: mostly pregnant women selected from a high-risk population and pregnant women
without prior risk (14%).
Inclusion criteria: singleton pregnancies.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 7103 pregnant women.
Number available for 2 x 2 table: 7082 pregnant women (subgroup of 99.7%).
Setting: in Italy.
Recruitment period: September to December 2014.
Ethnicity: not reported.
Mean gestational age (± SD; range): 12.8 (± 2.3; 10 to 30) weeks.
Mean maternal age (± SD; range): 36.4 (± 4.7; 24 to 54) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina HiSeq 2500 sequencer in 15-plex with SAFeR™ algorithm
Fetal fraction DNA: the limit of detection (the lowest fetal fraction DNA with a detectable aneu-
ploidy) for T21 was determined at 2% fetal fraction level.
Blood samples for gNIPT were collected before reference standard.
Cutpoint: positive if NCV > 4 (aneuploidy suspected if NCV was between 3 and 4).
Commercial test: Genoma’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21, T18 and T13.
Reference standards: fetal karyotype of chorionic villi or amniotic fluid or neonatal clinical exami-
nation
Flow and timing Blood samples for gNIPT were obtained prior to the invasive procedure (reference standard).
gNIPT was a first- or a second-tier test.
100/7103 samples failed the initial MPSS testing.
79/100 repeated samples with a second blood draw and all obtained a gNIPT result
21/100 unrepeated samples failed quality control metrics (no gNIPT result)
Comparative
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Fiorentino 2016 (Continued)
Aim to study To determine the limit of detection of a gNIPT method, in order to define the actual lower fetal
fraction DNA required to detect common fetal autosomal trisomies, using a model system to
simulate samples at different proportions of fetal ccfDNA. Secondly, to assess the impact of low
fetal fraction DNA on the performance of ccfDNA-based maternal plasma testing for aneuploidies
Funding source or sponsor of
the study
Study not funded by industry but the samples were analysed in the GENOMA laboratory (Rome,
Italy)
Informations about the authors
contacted
Authors were contacted on: 30 August and 6 September 2016.
Reply received on: 6 September.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Gil 2016
Study characteristics
Patient sampling Study design: prospective cohort study.
Participants: pregnant women with a first-trimester combined test selected for their risk of fetal
aneuploidy (cut-off of 1 in 100 for high risk and 1 in 101 to 1 in 2500 for intermediate risk).
Inclusion criteria: singleton pregnancies.
Exclusion criteria: multifetal pregnancies, terminations of pregnancy, miscarriages or stillbirths
without follow-up
Patient characteristics and set-
ting
Number enrolled: 11,692 pregnant women.
Number available for 2 x 2 table: 3633 pregnant women (subgroup of 31%).
Setting: 2 centres. King’s College Hospital, London, and Medway Maritime Hospital, Gillingham,
Kent in UK.
Recruitment period: October 2013 to February 2015.
Ethnicity: Caucasian (70%), Afro-Carabbean (20%), Asian (7%) and mixed (3%)
Gestational age: not reported.
Median maternal age (range): 31.6 (25.8 to 39.5) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by TMPS (DANSR assay).
Fetal fraction DNA: not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint: not reported. Usually, Harmony™ prenatal test uses FORTE algorithm; positive if
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FORTE risk score ≥ 1%.
Commercial test: Harmony™ prenatal test by Ariosa Diagnostics, Inc
Traditional screening test was also assessed but 2 x 2 tables were incomplete
Target condition and reference
standard(s)
Target conditions: T21, T18 and T13.
Reference standards: fetal karyotype of chorionic villi, postnatal karyotype or neonatal clinical
examination
Flow and timing Blood samples for gNIPT were obtained prior to the invasive procedure (reference standard).
gNIPT was a second-tier test.
7994/11,692 samples did not undergo a gNIPT (no gNIPT result)
99/3698 samples failed the initial TMPS testing.
54/99 repeated sampling were processed and 34/54 gNIPT results were obtained
65/3698 samples without gNIPT result.
Comparative
Aim to study To report the feasibility of implementing gNIPT. To examine the factors affecting patient decisions
concerning their options for screening and decisions on the management of affected pregnancies.
To report the prenatal diagnosis of fetal trisomies and outcome of affected pregnancies following
the introduction of contingent screening
Funding source or sponsor of
the study
Study not funded by industry but the cost of collection and analysis of the blood samples for the
cell-free DNA test was covered by Ariosa Diagnostics, Inc. These organisations had no role in study
design, data collection, data analysis, data interpretation or writing of the report. Study was funded
by a grant from The Fetal Medicine Foundation, UK
Informations about the authors
contacted
No need for further contact.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
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DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
No
High Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Hall 2014
Study characteristics
Patient sampling Study design: case-control study (1:3), age-matched randomly selected from a larger cohort.
Participants: pregnant women with an affected fetus or considered to be at high risk of fetal aneu-
ploidy were recruited
Inclusion criteria: pregnant women at least 18 years of age who had signed an informed consent,
and with singleton pregnancy.
117Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hall 2014 (Continued)
Exclusion criteria: fetal mosaicism.
Patient characteristics and set-
ting
Number enrolled: more than 1000 pregnant women.
Number available for 2 x 2 table: 64 pregnant women (subgroup of 6%).
Setting: 6 centres. Western Institutional (WA, USA), Einstein Institutional (CA and MO, USA),
PolishMother’sMemorial Hospital Institutional (Polish), BioMedical Research Institute of America
(CA, USA), and the Mt. Sinai School of Medicine (NY, USA).
Recruitment period: March to December of 2012.
Ethnicity: not reported.
Median gestational age (range): 16.0 (12.1 to 22.7) weeks.
Maternal age: not reported.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening.
Language of the study: English.
Index tests gNIPT by TMPS (SNP-based method) on Illumina Genome Analyzer IIx or HiSeq sequencer.
Sampleswere amplifiedusing 11,000-plex or 19,488-plex targeted polymerase chain reaction (targets
included SNPs from chromosomes 13, 18, 21, X, and Y)
Mean fetal fraction DNA (median; range): 12.1% (11.1%; 2.2% to 30.4%).
Blood samples for gNIPT were collected before reference standard.
Cutpoint: not reported.
Commercial test: Natera’s prenatal test.
Target condition and reference
standard(s)
Target condition: T13.
Reference standards: fetal karyotype of chorionic villi or amniotic fluid or genetic testing of the cord
blood, buccal, saliva or products of conception
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a second-tier test.
About 932 samples were not selected for this case-control study.
4/68 samples failed DNA quality threshold for low fetal fraction DNA (no gNIPT result)
No repeated test reported.
Comparative
Aim to study To determine how a single nucleotide polymorphism (SNP)- and informatics-based non-invasive
prenatal aneuploidy test performs in detecting trisomy 13
Funding source or sponsor of
the study
Study funded by Natera, Inc. (involved in study design, data collection and analysis, decision to
publish, and preparation of the manuscript)
Informations about the authors
contacted
Authors were contacted on: 21 April 2016, and 27 May 2016.
No reply received from the authors.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
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High
Hooks 2014
Study characteristics
Patient sampling Study design: case-control study from archived plasma samples from a prospective cohort.
Participants: pregnant women selected at high risk of fetal aneuploidy presenting for invasive testing.
Inclusion criteria: pregnant women 18 years and older, with a singleton pregnancy at gestational
age 10 weeks or greater, and who were planning to undergo invasive prenatal diagnosis.
Exclusion criteria: multifetal pregnancies, pregnant women with a known maternal aneuploidy,
active malignancy or a history of metastatic cancer, or those who had already undergone chorionic
villus sampling or amniocentesis during the current pregnancy
Patient characteristics and set-
ting
Number enrolled: not reported. 432 maternal plasma samples were retrieved from the prospective
cohort.
Number available for 2 x 2 table: 414 samples (subgroup of 96%).
Setting: 16 centres. Selected prenatal care centres in the USA, the Netherlands and Sweden.
Recruitment period: not reported.
Ethnicity: not reported.
Mean gestational age (± SD; range): 15.4 (± 3.7; 10 to 34.1) weeks.
Mean maternal age (± SD; range): 35.6 (± 5.7; 18.5 to 45.5) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by TMPS (DANSR assay) on Illumina HiSeq 2000 in 96-plex
Fetal fraction DNA: amount measured but not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint: not reported. Usually, Harmony™ prenatal test uses FORTE algorithm; positive if
FORTE risk score ≥ 1%.
Commercial test: Harmony™ Prenatal Test by Ariosa Diagnostics, Inc
Target condition and reference
standard(s)
Target conditions: 45,X, 47,XXY and 47,XXX. 47,XYY was also assessed but no case was found.
Reference standard: fetal karyotype of chorionic villi or amniotic fluid
Flow and timing Blood samples were obtained prior the invasive procedure (reference standard)
gNIPT was a second-tier test.
18/432 samples failed during sequencing process (no gNIPT result) for low fetal fraction DNA,
unusually high variation in ccfDNA counts or failure to pass the quality control measures of the
DANSR assay
No repeated test reported.
Comparative
Aim to study To assess the performance of a directed chromosomal analysis approach in the prenatal evaluation
of fetal sex chromosome aneuploidy
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Funding source or sponsor of
the study
Study funded by Ariosa Diagnostics, Inc.
Informations about the authors
contacted
BGI-Shenzhen were contacted on: 19 May 2016.
Author was contacted on: 16 June 2016.
No reply received from the author.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
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Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Hou 2012
Study characteristics
Patient sampling Study design: prospective cohort study.
Participants: pregnant women selected at high risk of fetal aneuploidy presenting for invasive testing.
Inclusion criteria: singleton pregnancies.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 308 pregnant women.
Number available for 2 x 2 table: 205 pregnant women (subgroup of 67%).
Setting: 1 centre. Henan Province People’s Hospital in China.
Recruitment period: October 2010 to January 2012.
Ethnicity: Asian.
Gestational age range: 14 to 24 weeks.
Mean maternal age (range): 31 (21 to 44) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: Chinese.
Index tests gNIPT by MPSS on IIIumina HiSeq 2000 sequencer with BGI’s algorithm
Fetal fraction DNA: not reported.
Blood samples for gNIPT were collected just before reference standard.
Cutpoint: not reported.
Commercial test: BGI-Shenzhen’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21, T18, 45,X, 47,XXY and 47,XYY. T13 and 47,XXX were also assessed but
no cases were found.
Reference standard: fetal karyotype of amniotic fluid.
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Flow and timing Blood samples were obtained just prior the invasive procedure (reference standard)
gNIPT was a second-tier test.
103/308 patients did not undergo gNIPT (no gNIPT result).
No failed sample reported.
No repeated test reported.
Comparative
Aim to study To investigate the clinical value of gNIPT using ccfDNA in maternal blood
Funding source or sponsor of
the study
Study not funded by industry but BGI-Shenzhen provided the test
Informations about the authors
contacted
Author was contacted on: 11 April 2016 (author) and 19 May 2016 (BGI’s contact).
No reply received from the author.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Huang 2014
Study characteristics
Patient sampling Study design: blinded, prospective cohort study.
Participants: pregnant women selected at high risk of fetal aneuploidy (as real clinical samples).
Inclusion criteria: twin pregnancies with live fetuses and karyotype result.
Exclusion criteria: singleton pregnancies, twins with intrauterine fetal demise at the time of sampling
or without fetal karyotype result
Patient characteristics and set-
ting
Number enrolled: 189 pregnant women.
Number available for 2 x 2 table: 189 pregnant women (whole cohort included in analyses).
Setting: 7 centres. Hospitals in China.
Recruitment period: April 2012 to April 2013.
Ethnicity: most Asian.
Median gestational age (range): 19 (11 to 39) weeks.
Median maternal age (range): 31 (22 to 44) years.
Chorionicity: 17% monochorionics (33/189), 80% dichorionics (152/189) and 2% unknown (4/
189)
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening.
Language of the study: English.
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Index tests gNIPT by MPSS on Illumina Genome Analyzer IIx or HiSeq 2000 platform
Fetal fraction DNA: not reported.
Blood samples for gNIPT were collected 30 minutes before reference standard.
Cutpoint: positive if t score > 2.5 and L score risk > 1 (warning zone if t score > 2.5 or L score > 1).
Commercial test: BGI’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21 and T18.
Reference standard: fetal karyotype of chorionic villi (2.1%), amniotic fluid (94.2%) or cord blood
(3.7%)
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a second-tier test.
No failed sample reported.
No repeated test reported.
Comparative
Aim to study To assess the performance of noninvasive prenatal testing for trisomies 21 and 18 on the basis of
MPSS of ccfDNA from maternal plasma in twin pregnancies
Funding source or sponsor of
the study
Funded by the Shenzhen Engineering Laboratory for Clinical Molecular Diagnostic, the China
National GeneBank-Shenzhen, the Medical Centre for Critical Pregnant Women in Guangzhou
and Prenatal monitoring, In utero therapy and Follow-up after birth in the complexity of Twin
Pregnancy. Some authors worked for BGI-Shenzhen
Informations about the authors
contacted
Author was contacted on: 10 February 2016.
BGI-Shenzhen were contacted on: 19 May 2016.
No reply received from author.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
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DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Jackson 2014
Study characteristics
Patient sampling Study design: prospective cohort study.
Participants: pregnant women selected at high risk and low risk of fetal aneuploidy presenting for
screening.
Inclusion criteria: not reported.
Exclusion criteria: not reported.
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Patient characteristics and set-
ting
Number enrolled: 1228 pregnant women screened at first-trimester, including 1184 pregnant
women with normal first-trimester ultrasound and 44 with abnormal ultrasound.
Number available for 2 x 2 table: 1161 pregnant women (subgroup of 95%).
Setting: 1 centre. South Shore Hospital in USA.
Recruitment period: June 2012 to January 2013.
Ethnicity: not reported.
Gestational age: not reported.
Median maternal age: 31.5 years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by TMPS (DANSR assay).
Fetal fraction DNA: not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint: not reported. Usually, Harmony™ prenatal test uses FORTE algorithm; positive if
FORTE risk score ≥ 1%.
Commercial test: Harmony™ Prenatal Test.
Target condition and reference
standard(s)
Target conditions: T21, T18 and T13.
Reference standards: fetal karyotype of chorionic villi or amniotic fluid, or medical record from
birth
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a second-tier test.
67/1228 samples excluded of 2 x 2 tables, including 7 women with other abnormal ultrasound, 14
women opted for CVS only without gNIPT, 32 women declined all testing and 14 samples failed
after 2 attempts during sequencing process (no gNIPT result)
Comparative
Aim to study To assess the performance of nuchal translucency measurement followed by gNIPT in the first-
trimester to screen for aneuploidy in a community-based average-risk population
Funding source or sponsor of
the study
Funding source not reported but 1 author is employed by Ariosa Diagnostics, Inc
Informations about the authors
contacted
Author was contacted on: 22 February 2016 and 15 March 2016.
No reply received from the author.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear High
DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
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Jeon 2014
Study characteristics
Patient sampling Study design: prospective cohort study.
Participants: pregnant women selected at high risk of fetal aneuploidy presenting for invasive testing.
Inclusion criteria: women who gave written informed consent participated in the study if they were
≥ 19 years old and had a singleton pregnancy with a gestational age of at least 12 weeks.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 155 pregnant women.
Number available for 2 x 2 table: 155 pregnant women (whole cohort included in analyses).
Setting: 1 centre. Xiamen Maternal & Child Health Care Hospital, Xiamen, Fujian, China.
Recruitment period: March 2012 to October 2013.
Ethnicity: Asian.
Gestational age ranges: 12 to 16 weeks (18.1%), 17 to 21 weeks (55.5%), ≥ 22 weeks (26.5%). All
between 12 to 24 weeks.
Mean maternal age (± SD; range): 30.73 (± 4.99; 19 to 43) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by MPSS on Ion Torrent PGM sequencer with 10 samples per chip
Fetal fraction DNA: not reported.
Blood samples for gNIPT were collected just before reference standard.
Cutpoint: positive if Z score > 2.566 (T21) or > 2.459 (T18).
Commercial test: Genome Care’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21 and T18.
Reference standard: fetal karyotype of amniotic fluid.
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a second-tier test.
No failed sample reported.
No repeated test reported.
Comparative
Aim to study To investigated whether fetal T18 and T21 were sensitively and specifically detectable by semicon-
ductor sequencer: Ion Proton™
Funding source or sponsor of
the study
Study funded by the Industrial Strategic Technology Development Program, “Bioinformatics plat-
form development for next generation bioinformation analysis” funded by the Ministry of Knowl-
edge Economy (MKE, Korea)
Informations about the authors
contacted
Author was contacted on: 6 and 11 April 2016.
Reply received on: 11 April 2016.
Notes
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
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Were all patients included in the
analysis?
Yes
Low
Jiang 2012
Study characteristics
Patient sampling Study design: prospective cohort study.
Participants: pregnant women at high risk of fetal aneuploidy presenting for invasive testing selected
from the cohort.
Inclusion criteria: not reported.
Exclusion criteria: not reported.
Patient characteristics and set-
ting
Number enrolled: 903 pregnant women.
Number available for 2 x 2 table: 903 pregnant women (whole cohort included in analyses).
Setting: 3 centres in Shenzen, China.
Recruitment period: June 2009 to August 2010.
Ethnicity: Asian.
Gestational age range: 10 to 39 weeks.
Maternal age range: 20 to 45 years.
Relevant tests carried out prior to index test: not reported.
Language of the study: English.
Index tests gNIPT byMPSS on platforms Illumina Genome Analyzer IIx or Illumina HiSeq 2000 by multiplex
sequencing
Fetal fraction DNA (range): quality control criteria > 3.5% (1% to 33%).
It is not reported if the blood samples for gNIPT were collected before or after reference standard.
Cutpoint:
1) Positive if binary hypothesis t score (first hypothesis) > 3 and t score (second hypothesis) < 3 and
if logarithmic LR > 1 (autosomal aneuploidy)
2) Positive if t score < -2.5 (45,X and 47,XXX) without Chrom. Y representation
3) Positive if t score > 2.5 combined with estimation of fetal ccfDNA concentration by Chrom. X
and Y independently (47,XXY and 47,XYY) for male fetus.
Commercial test: NIFTY™ prenatal test by Bejing Genomics Institute (BGI)
Target condition and reference
standard(s)
Target conditions: T21, T18, T13, 45,X, 47,XXY, 47,XYY and 47,XXX.
Reference standard: fetal karyotype of amniotic fluid.
Flow and timing It is not reported if the blood samples were obtained prior or after the invasive procedure (reference
standard)
gNIPT was a second-tier test.
No failed sample reported.
No repeated test reported.
Comparative
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Jiang 2012 (Continued)
Aim to study To develop an advanced gNIPT method based on MPSS.
Funding source or sponsor of
the study
Study funded by industry. BGI was involved in the study design, conduct of the study, analysis and
interpretation of results
Informations about the authors
contacted
Author was contacted on: 19 May 2016.
No reply received from the author.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
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Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Johansen 2016
Study characteristics
Patient sampling Study design: prospective cohort study.
Participants: pregnant women selected at high risk of fetal aneuploidy presenting for invasive testing.
Inclusion criteria: singleton pregnancies.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 375 pregnant women (184 for the validation set).
Number available for 2 x 2 table: 173 pregnant women (subgroup of 94%).
Setting: Danish public health setting.
Recruitment period: not reported.
Ethnicity: not reported.
Median gestational age (range): 13.4 (10.6 to 31) weeks.
Maternal age: not reported.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by MPSS on Ion Proton™ sequencer in 5-plex.
Fetal fraction DNA: amount measured but not reported.
Blood samples for gNIPT were collected just before reference standard.
Cutpoint: positive if Z score ≥ 4 and WISECONDOR ≥ 1% (unclassified if Z score between 3
and 4).
In-house test.
Target condition and reference
standard(s)
Target conditions: T21, T18 and T13.
Reference standard: fetal karyotype of chorionic villi or amniotic fluid
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Johansen 2016 (Continued)
Flow and timing Blood samples for gNIPT were obtained just prior the invasive procedure (reference standard).
gNIPT was a second-tier test.
191/375 not selected, samples for the validation set were excluded.
11/184 samples failed during sequencing process for low fetal fraction DNA (no gNIPT result)
2/173 samples were resequenced because gNIPT results were in the inconclusive zone and 2 results
were obtained
Comparative
Aim to study To introduce gNIPT for fetal autosomal trisomies and gender in a Danish public health setting,
using semi-conductor sequencing and published open source scripts for analysis
Funding source or sponsor of
the study
No funding source was reported.
Informations about the authors
contacted
No need for further contact.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
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DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Ke 2015
Study characteristics
Patient sampling Study design: prospective cohort study.
Participants: pregnant women considered at high risk of fetal aneuploidy.
Inclusion criteria: singleton pregnancies. Pregnant women at high risk of fetal aneuploidy describe as
follows: over age 35, the histories of abnormal pregnancy including children with T21 and repeated
spontaneous abortion, stillbirth in pregnancy periods, abnormal serological screening for T21 at
early and mid pregnancy, abnormal screening for fetal nuchal translucency using colour duplex
ultrasonography between 11-14 weeks of gestation.
Exclusion criteria: not reported.
Patient characteristics and set-
ting
Number enrolled: 2340 pregnant women.
Number available for 2 x 2 table: 2340 pregnant women (whole cohort included in analyses).
Setting: 1 centre. Clinical setting at Shenzhen Second People’s Hospital in China.
Recruitment period: March 2012 to May 2013.
Ethnicity: Asian.
Gestational age: positive cases were between 16 to 24 weeks. All cohort: 95% were between 15 to
20 weeks, 3% were between 12 to 14 weeks and 0.9% were ≥ 24 weeks.
Maternal age: 88% were less than 35 years old and 12% were 35 years old or more.
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Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by MPSS.
Fetal fraction DNA: not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint: positive if t score > 3.
Commercial test: BGI-Shenzhen’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21, T18, and T13.
Reference standards: fetal karyotype or newborn outcome.
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a second-tier test.
No failed sample reported.
No repeated test reported.
Comparative
Aim to study To validate the efficacy of detection of fetal cell-free DNA in maternal plasma of trisomy 21, 18
and 13 in a clinical setting
Funding source or sponsor of
the study
Study not funded by industry but patients had obtained insurance plans on behalf of Shenzhen
Huada Genomics Institute
Informations about the authors
contacted
Author was contacted on: 22 April 2016.
No reply received from the author.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Kim 2016
Study characteristics
Patient sampling Study design: blinded, prospective cohort study.
Participants: pregnant women selected at high risk of fetal aneuploidy presenting for invasive testing.
Inclusion criteria: not reported.
Exclusion criteria: not reported.
Patient characteristics and set-
ting
Number enrolled: 101 pregnant women.
Number available for 2 x 2 table: 101 pregnant women (whole cohort included in analyses).
Setting: 3 centres (Mirae & Heemang, Namujungwon and GN hospitals) in Korea.
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Recruitment period: December 2014 to April 2015.
Ethnicity: Asian.
Gestational age range: 11 to 18 weeks.
Mean maternal age (± SD; range): 35.45 (± 3.64; 25 to 42) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening (quadruple test screening).
Language of the study: English.
Index tests gNIPT by MPSS on Ion Torrent PGM (data not shown in the present review) and Ion Proton™
sequencer in multiplex
Fetal fraction DNA: not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint: positive if Z score > 2.10 for Ion Proton™.
Commercial test: Genome Care’s prenatal test.
Target condition and reference
standard(s)
Target condition: T21.
Reference standard: fetal karyotype of amniotic fluid.
Flow and timing Blood samples for gNIPT were obtained prior to the invasive procedure (reference standard).
gNIPT was a second-tier test.
No failed sample reported.
No repeated test reported.
Comparative
Aim to study To compare the Ion Torrent PGM and Ion Proton™ platforms for gNIPT for fetal T21 directly
using PGM and Ion Proton™ simultaneously for the same set of samples
Funding source or sponsor of
the study
Study funded by Genome Care internal research funding. The first author is employee of Genome
Care
Informations about the authors
contacted
No need for further contact.
Notes Data from PGM sequencer are not shown in the present review to avoid patients overlap
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
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Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Korostelev 2014
Study characteristics
Patient sampling Study design: prospective cohort study.
Participants: pregnant women selected from a population at high risk or without prior risk of fetal
aneuploidy.
Inclusion criteria: women who had a singleton pregnancy and more than 9 weeks of gestation.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 1968 pregnant women.
Number available for 2 x 2 table: 685 pregnant women (subgroup of 35%).
Setting: private clinics in Moscow, Russia.
Recruitment period: 2012 to 2014.
Ethnicity: not reported.
Median gestational age (range): 14 (9 to 33) weeks.
Mean maternal age (range): 34.4 (26 to 45) years.
Relevant tests carried out prior to index test: biochemical screening or ultrasonography (nuchal
translucency measurement) or both.
Language of the study: English.
Index tests gNIPT by TMPS (SNP-based method) on Illumina Genome Analyzer IIx or HiSeq sequencers
with NATUS algorithm
Fetal fraction DNA: not reported (usually NATERA used quality control criteria > 4%).
Blood samples for gNIPT were collected before reference standard.
Cutpoint: not reported.
Commercial test: Natera’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21, T18 and T13. 45,X, 47,XXY, 47,XYY and 47,XXX were also screened but
inappropriate reference standard for the present review was used (data not shown in this review).
Reference standards: fetal karyotype of chorionic villi or amniotic fluid or medical record from birth
Flow and timing Blood samples for gNIPT were obtained prior to the invasive procedure (reference standard).
gNIPT was a second-tier test.
240/1968 samples did not undergo gNIPT (no gNIPT result).
1043/1728 samples without follow-up were excluded.
No repeated test reported.
Comparative
Aim to study To examine possibility to use combination of gNIPT and chromosomal microarray analysis for
prenatal diagnostics and their advantages between combined first-trimester screenwith confirmation
by karyotyping of CVS or amniocytes
Funding source or sponsor of
the study
Study not funded by industry but gNIPT was carried out by Natera, Inc
Informations about the authors
contacted
Author was contacted on: 21 June 2016.
No reply received from the author.
Notes
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Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Lau 2012
Study characteristics
Patient sampling Study design: blinded, prospective cohort study.
Participants: pregnant women mostly at high risk of fetal aneuploidy presenting for invasive testing
Inclusion criteria: not reported.
Exclusion criteria: not reported.
Patient characteristics and set-
ting
Number enrolled: 108 pregnant women.
Number available for 2 x 2 table: 108 pregnant women (whole cohort included in analyses)
Setting: 1 centre in Japan.
Recruitment period: not reported.
Ethnicity: Asian.
Median gestational age (range): 12.7 (11.6 to 28) weeks, 89.8% < 14 weeks
Mean maternal age (± SD): 37 (± 4.3) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening
Language of the study: English.
Index tests gNIPT by MPSS on Illumina HiSeq 2000 sequencer in 12-plex.
Fetal fraction DNA: not reported.
Blood samples for gNIPT were collected immediately before reference standard
Cutpoint:
1) positive if Z score ≥ 3 (T21, T18 and T13).
2) for female fetus, positive if Chrom. X Z score ≤ -3 (45,X)
3) for female fetus, positive if Chrom. X Z score ≥ 3 (47,XXX)
4) for male fetus, positive if Chrom. Y Z score ≥ 3 (47,XXY)
Commercial test: NIFTY™ prenatal test by BGI-Shenzhen.
Target condition and reference
standard(s)
Target conditions: T21, T18, T13, 45,X and 47,XXY. 47,XYY and 47,XXX were also assessed but
no case was found
Reference standard: fetal karyotype of chorionic villi or amniotic fluid
Flow and timing Blood samples for gNIPT were collected immediately before invasive procedure (reference standard)
gNIPT was a second-tier test.
No failed sample reported.
No repeated test reported.
Comparative
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Aim to study To investigate the inclusion of an internal reference in the noninvasive prenatal identification of
common fetal aneuploidies using massively parallel sequencing on maternal plasma
Funding source or sponsor of
the study
Study funded by BGI-Shenzhen.
Informations about the authors
contacted
BGI-Shenzhen contacted on: 19 May 2016.
No reply received from the author.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
High High
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
Yes
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of the results of the index tests?
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Lee 2015
Study characteristics
Patient sampling Study design: blinded, prospective cohort study.
Participants: pregnant women selected at high risk of fetal aneuploidy presenting for invasive testing.
Inclusion criteria: pregnant women who were > 18 years old and gestational age > 8 weeks, multifetal
and singleton pregnancies.
Exclusion criteria: not reported.
Patient characteristics and set-
ting
Number enrolled: 93 pregnant women.
Number available for 2 x 2 table: 92 pregnant women (subgroup of 99%).
Setting: 1 centre at Asan Medical Centre, Seoul, Korea.
Recruitment period: August 2014 to February 2015.
Ethnicity: Asian.
Median gestational age (range): 21.1 (8.2 to 31.1) weeks.
Median maternal age (range): 32 (21 to 43) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina MiSeq sequencer in 12-plex or on NextSeq 500 sequencer in 96-plex
Median fetal fraction DNA (range): male fetus only: 10.2% (3.85% to 25.0%).
Blood samples for gNIPT were collected before reference standard.
Cutpoint:
1) positive if Z score > 4 (intermediate risk if Z score between 2.5 and 4) for T21 and T18
2) positive if Z score > 2.8 (intermediate risk if Z score between 1.9 and 2.8) for T13.
Commercial test: MomGuard™ by LabGenomics.
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Target condition and reference
standard(s)
Target conditions: T21, T18 and T13. SCA were also assessed but no case was found.
Reference standards: fetal karyotype of chorionic villi, amniotic fluid, cord blood or products of
conception or neonatal karyotype from peripheral blood
Flow and timing Blood samples for gNIPT were obtained just prior to the invasive procedure (reference standard).
gNIPT was a second-tier test.
1/93 samples failed during sequencing process for low fetal fraction DNA (no gNIPT result)
No repeated test reported.
Comparative
Aim to study To evaluate the performance of MomGuard™, a gNIPT, for detecting T21, T18, T13, and SCA
abnormalities recently developed in Korea
Funding source or sponsor of
the study
Study funded by a grant from the LabGenomics Clinical Research Institute
Informations about the authors
contacted
No need for further contact.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Lefkowitz 2016
Study characteristics
Patient sampling Study design: Retrospective cohort, blinded case-control study.
Participants: pregnant women selected at high risk of fetal aneuploidy from 4 cohorts (archived
maternal plasma samples).
Inclusion criteria: not reported.
Exclusion criteria: cases of fetal mosaicism or incomplete karyotype or microarray information
Patient characteristics and set-
ting
Number enrolled: 5321 pregnant women in all 4 cohorts. 1222 pregnant women selected for this
study.
Number available for 2 x 2 table: 1166 pregnant women (subgroup of 95%) for autosomes and
1144 pregnant women (subgroup of 94%) for SCA.
Setting: multicentre.
Recruitment period: not reported.
Ethnicity: not reported.
Median gestational age (range): 17 (8 to 38) weeks.
Median maternal age (range): 36.0 (17.8 to 47) years.
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Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina HiSeq 2000 in 6-plex or uniplex.
Fetal fraction DNA: amount measured but not reported.
Blood samples for gNIPTwere collected before (for 1189 pregnant women) or after (for 24 pregnant
women) reference standard.
Cutpoint:
1) positive for T21 if Z score ≥ 3.
2) positive for T18 or T13 if Z score ≥ 3.95.
3) positive for 45,X if Z score < -3.5 (non-reportable regions between -2.5 and -3.5)
4) positive for 47,XXX if Z score > 3.5 (non-reportable regions between 2.5 and 3.5)
5) positive for 47,XYY if Z score < -3.5 with Chrom. Y representation
6) positive for 47,XXY if Z score is between -3.5 and 3.5 with Chrom. Y representation
Commercial test: Sequenom’s test.
Target condition and reference
standard(s)
Target conditions: T21, T18, T13, 45,X, 47,XXY, 47,XYY and 47,XXX. copy number variants ≥
7 Mb were also assessed but data not shown in the present review.
Reference standard: fetal karyotype of chorionic villi or amniotic fluid
Flow and timing Blood samples for gNIPT were obtained prior or after the invasive procedure (reference standard).
gNIPT was a second-tier test.
4099/5321 samples not selected for this study.
14/1222 samples were excluded before sequencing process (11/14 samples excluded for incomplete
diagnostic information and 3/14 samples excluded for confirmed mosaicism)
42/1208 samples failed during autosome sequencing process (no gNIPT result) including 11/42
failed samples for low fetal fraction DNA, 29/42 failed samples for technical reasons and 2/42 failed
samples for other biological reasons (maternal event)
22/1166 samples failed SCA sequencing process (no gNIPT result)
No repeated test reported.
Comparative
Aim to study To provide a clinical validation of the sensitivity and specificity of a novel NIPT for detection of
genome wide abnormalities
Funding source or sponsor of
the study
Study funded by Sequenom, Inc.
Informations about the authors
contacted
No need for further contact.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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Lefkowitz 2016 (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
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High
Liang 2013
Study characteristics
Patient sampling Study design: blinded, prospective cohort study.
Participants: pregnant women considered at high risk for fetal T21.
Inclusion criteria: singleton and twin pregnancies underwent conventional serum screening and
ultrasound scanning, and who invasive prenatal diagnostics were offered.
Exclusion criteria: not reported.
Patient characteristics and set-
ting
Number enrolled: 435 pregnant women.
Number available for 2 x 2 table: 412 pregnant women (subgroup of 94.7%).
Setting: 3 hospitals in China.
Recruitment period: March 2009 to June 2011.
Ethnicity: Asian.
Median gestational age (range): 21.4 (11.4 to 39.4) weeks.Most pregnant women (60%) are between
21 to 40 weeks. Only 1 case is in the first trimester (0.23%).
Mean maternal age (± SD): 31 (± 5.9) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or multiple screening tests.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina HiSeq 2000 in 8-plex or 12-plex.
Fetal fraction DNA: for a Z score cutoff value of 3 for chromosome 21, fetal DNA was estimated
to 5.52%.
Blood samples for gNIPT were collected before reference standard.
Cutpoint:
1) positive if Z score > 3 (T21).
2) positive if Z score > 5.91 (T18).
3) positive if Z score > 5.72 (T13).
4) positive if Z score Chrom. X < -2.91 and Z score Chrom. Y < 3 (45,X)
5) positive if Z score Chrom. X range from -2.91 to +2.91 and Z score Chrom. Y > 3 (47,XXY)
6) positive if Z score Chrom. X > 2.91 and Z score Chrom. Y < 3 (47,XXX)
7) positive if Z score Chrom. X < -2.91 and Z score Chrom. Y > 3 (47,XYY).
Commercial test: Berry Genomics’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21, T18, T13, 45,X, 47,XXY, 47,XYY, and 47,XXX.
Reference standard: fetal karyotype of chorionic villi (1%) or amniotic fluid (77%) or cord blood
(22%)
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a second-tier test.
12/435 samples failed sequencing process quality control (no gNIPT result)
11/423 samples without karyotype were excluded (no reference standard result)
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Comparative
Aim to study To determine whether gNIPT by maternal plasma DNA sequencing can uncover all fetal chromo-
some aneuploidies in 1 simple sequencing event
Funding source or sponsor of
the study
Study not funded by industry but Berry Genomics Co. Ltd performed the sequencing analysis
for free. This study was supported by the grants from the National High Technology Research
and Development Program of China (863 Program) (No.2011AA02A112), the National Key Basic
Research Program of China (2012CB944600) and the National Key Technology R&D Program of
China (2012BAI09B05)
Informations about the authors
contacted
No need for further contact.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
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Liang 2013 (Continued)
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Liu 2012
Study characteristics
Patient sampling Study design: prospective cohort study.
Participants: pregnant women selected at high risk of fetal aneuploidy presenting for invasive testing.
Inclusion criteria: women who planned an invasive testing for 1 or more of the following reasons:
abnormality in plasma test, older than 35 years old, infant deformity (ultrasound), taken drugs
(teratogen) during early pregnancy or history of malformation caused by virus infection, history
of birth defect caused by abnormal chromosome, history of fetus stopping growth or repeated
spontaneous abortion or dead fetus or dead birth for unknown reason, history of chromosome
abnormality in family or either of the couple, too much or little amniotic fluid.
Exclusion criteria: not reported.
Patient characteristics and set-
ting
Number enrolled: 153 pregnant women.
Number available for 2 x 2 table: 153 pregnant women (whole cohort included in analyses)
Setting: Henan Province People Hospital Medical.
Recruitment period: October to November 2011.
Ethnicity: Asian.
Gestational age: more than 14 weeks.
Mean maternal age (± SD; range): 32.3 (± 1.2; 20 to 44) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
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Language of the study: Chinese.
Index tests gNIPT by MPSS on Illumina HiSeq sequencer in multiplex.
Fetal fraction DNA: not reported.
Blood samples for gNIPT were collected 30 minutes before reference standard.
Cutpoint: positive if Z score ≥ 3.
It is not reported if gNIPT was a commercial or an in-house test
Target condition and reference
standard(s)
Target conditions: T21, T18, T13, 45,X and 47,XYY. 47,XXY and 47,XXX were also assess but no
case were found.
Reference standard: fetal karyotype of amniotic fluid.
Flow and timing Blood samples for gNIPT were obtained 30 minutes prior to the invasive procedure (reference
standard).
gNIPT was a second-tier test.
No failed sample reported.
No repeated test reported.
Comparative
Aim to study To determine the feasibility and accuracy of detecting numerical chromosomal abnormalities by
high-flux sequencing analysis of ccfDNA from maternal plasma
Funding source or sponsor of
the study
Study funded by by the Nalional Natural Science Foundation of China and a Medical Science and
Technology Research Project of Henan Province
Informations about the authors
contacted
Author was contacted on 11 April 2016 but contact author’s email is no longer valid
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Unclear
Unclear Low
DOMAIN 2: Index Test MPSS
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Ma 2016
Study characteristics
Patient sampling Study design: blinded, prospective and retrospective cohort study.
Participants: pregnant women selected from a high-risk population presenting for invasive testing
(prospective cohort) and archived maternal plasma from mixed-risk (high and low risk of fetal
aneuploidy) pregnant women (retrospective cohort).
Inclusion criteria: singleton pregnancies with gestational age of 12 weeks or above at the time of
sampling.
Exclusion criteria: women with twin pregnancy or organ donation history or maternal chromosome
abnormality
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Patient characteristics and set-
ting
Number enrolled: 10,598 pregnant women. 2439 from prospective cohort and 8159 from retro-
spective cohort.
Number available for 2 x 2 table: 10,579 pregnant women (subgroup of 99.8%).
Setting: 20 centres. Prenatal diagnosis clinics in China.
Recruitment period: January 2012 to January 2014 (retrospective) and February to May 2014
(prospective).
Ethnicity: Asian.
Median gestational age: 19 weeks.
Median maternal age (range): 32 (16 to 53) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by MPSS on BGISEQ-1000 platform in 16 or 24-plex.
Fetal fraction DNA: not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint: positive if Z score > 3.
Commercial test: BGI-Shenzhen’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21, T18 and T13.
Reference standards: fetal karyotype of chorionic villi, amniotic fluid or cord blood, or postnatal
follow-up
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a second- or a first-tier test.
19/10,598 samples were excluded from the analysis including 5 from retrospective cohort (4 samples
had incomplete clinical information and 1 sample failed quality control during sequencing) and
14 from prospective cohort (10 samples had incomplete clinical information and 4 samples failed
quality control during sequencing)
No repeated test reported.
Comparative
Aim to study To report the established gNIPT screening system and the clinical performance of a new ultrahigh
throughout gNIPT method based on combinatorial probe-anchor ligation sequencing (cPAL) of
ccfDNA in detecting T21, T18 and T13 in the multicentre network using a centralised testing
mode
Funding source or sponsor of
the study
Some authors are employees of BGI-Shenzhen, BGI-Manufacture or BGI-DX. Study funded by
ShenzhenBirthDefect Screening Project Lab, Key Laboratory of Cooperation Project inGuangdong
Province, Shenzhen Municipal Government of China, Pilot projects of regional strategic emerging
industry cluster development byHubei provincial development andReformCommission andAction
plan for the development of high-tech industry in biotechnology and new medicine in 2012 by
Wuhan Science and Technology Bureau
Informations about the authors
contacted
No need for further contact.
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Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Mazloom 2013
Study characteristics
Patient sampling Study design: blinded, prospective cohort study (validation set).
Participants: pregnant women selected at high risk of fetal aneuploidy.
Inclusion criteria:≥ 18 years old and singleton pregnancies between 10.5 and 20 weeks of gestation.
Exclusion criteria: multifetal pregnancies, mosaic cases for sex chromosomes, or samples without
documented karyotype report available
Patient characteristics and set-
ting
Number enrolled: 1975 pregnant women including 1564 in the training set (data not shown in the
present review) and 411 in the validation set.
Number available for 2 x 2 table: 411 pregnant women (subgroup of 95% of validation set).
Setting: not reported.
Recruitment period: not reported.
Ethnicity: Caucasian (58.4%), Asian (18.5%), Afro-American (7.5%), other and not specified (15.
6%).
Median gestational age (range): 17 (8 to 29) weeks.
Median maternal age (range): 36 (19 to 47) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina v3 flow cells on HiSeq 2000 sequencer in 12-plex
Fetal fraction DNA: amount measured but not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint:
1) positive for 45,X if Z score < -3.5 (non-reportable regions between -2.5 and -3.5)
2) positive for 47,XXX if Z score > 3.5 (non-reportable regions between 2.5 and 3.5)
3) positive for 47,XYY if Z score < -3.5 with Chrom. Y representation
4) positive for 47,XXY if Z score is between -3.5 and 3.5 with Chrom. Y representation
Commercial test: Sequenom’s prenatal test.
Target condition and reference
standard(s)
Target conditions: 45,X, 47,XXY, 47,XYY and 47,XXX.
Reference standard: fetal karyotype of chorionic villi or amniotic fluid
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a second-tier test.
1564/1975 excluded samples were used for the training set.
21/411 failed samples were in the non reportable region and were considered positive gNIPT result
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by authors
No repeated test reported.
Comparative
Aim to study To extend the detection of autosomal aneuploidies by MPSS of ccfDNA from maternal plasma to
include common sex chromosome aneuploidies
Funding source or sponsor of
the study
Study funded by Sequenom, Inc. and Sequenom Center for Molecular Medicine (SCMM)
Informations about the authors
contacted
Author was contacted on: 26 May 2016.
No reply received from the author.
Notes Data from the training set were not shown in the present review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Nicolaides 2012
Study characteristics
Patient sampling Study design: retrospective study from a prospective cohort.
Participants: selected archived plasma samples from pregnant women without prior risk of fetal
aneuploidy (general population) attending for their routine first-trimester combined screening for
aneuploidies.
Inclusion criteria: singleton pregnancies between 11 to 13.9 weeks’ gestation. Archived samples of
at least 2 mL.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 2230 pregnant women.
Number available for 2 x 2 table: 1949 pregnant women (subgroup of 87%).
Setting: not reported.
Recruitment period: October 2010 to January 2011.
Ethnicity: Caucasian (69.8%), African (20.6%), South Asian (4%), East Asian (2.8%) and mixed
(2.8%).
Gestational age range: 11 to 13.9 weeks.
Median maternal age (range): 31.8 (27.7 to 35.4) years.
Relevant tests carried out prior to index test: none.
Language of the study: English.
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Index tests gNIPT by TMPS (DANSR assay).
Median fetal fraction DNA (interquartile range): euploids: 10.0% (7.8% to 13.0%), T21: 12.5%
(9.2% to 21.3%), and T18: 9.3% (5.6% to 13.0%).
Blood samples for gNIPT were collected before reference standard.
Cutpoint: positive if FORTE algorithm risk score ≥ 1%.
Commercial test: Harmony™ Prenatal test by Ariosa Diagnostics, Inc
The traditional screening test (combined test at the first trimester) was also assessed
Cutpoint of combined test: 1 in 150.
Target condition and reference
standard(s)
Target conditions: T21 and T18.
Reference standards: fetal karyotype of chorionic villi or amniotic fluid or neonatal clinical exami-
nation
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a first-tier test.
181/2230 samples were ineligible (no fetal karyotype or follow-up, miscarriage, stillbirth, termina-
tion of pregnancy or other abnormalities)
100/2049 samples failed during sequencing process including 46 for low fetal DNA and 54 had
assay failures (no gNIPT result)
No repeated test reported.
Comparative
Aim to study To assess performance of noninvasive prenatal testing for fetal trisomy in a routinely screened first-
trimester pregnancy population
Funding source or sponsor of
the study
The studywas supported by a grant from the FetalMedicine Foundation (UK). The cost of collection
and analysis of the samples was covered by Ariosa Diagnostics, Inc
Informations about the authors
contacted
No need for further contact.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
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High Low
DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 2: Index Test Traditional screening tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
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Were all patients included in the
analysis?
No
High
Nicolaides 2013
Study characteristics
Patient sampling Study design: blinded, prospective cohort study.
Participants: pregnant women selected at high risk of fetal aneuploidy presenting for invasive testing.
Inclusion criteria: singleton pregnancies at high risk of fetal aneuploidy between 11 to 13 weeks’
gestation.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 242 pregnant women.
Number available for 2 x 2 table: 229 pregnant women (subgroup of 95%).
Setting: 1 centre. Fetal Medicine Centre, in UK.
Recruitment period: not reported.
Ethnicity: not reported.
Median gestational age (range): 13.1 (11.3 to 13.9) weeks.
Median maternal age (range): 35.7 (18.5 to 46.5) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening.
Language of the study: English.
Index tests gNIPT by TMPS (SNP-based method) on Illumina Genome Analyzer IIx or HiSeq sequencers
with NATUS algorithm
Fetal fraction DNA: the lowest fetal fraction DNA on a case that returned a result was 3.95%.
Blood samples for gNIPT were collected immediately before reference standard.
Cutpoint: not reported.
Commercial test: Natera’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21, T18, 45,X. 47,XXY, 47,XYY and 47,XXX were also assessed but no case
was found. T13 was also assessed but the only 1 case presented in this publication was published
thereafter in Hall 2014. T13 case was excluded to avoid double counting.
Reference standard: fetal karyotype of chorionic villi.
Flow and timing Blood samples were obtained just before the invasive procedure (reference standard)
gNIPT was a second-tier test.
13/242 samples failed sequencing process quality control (no gNIPT result)
No repeated test reported.
1 T13 cases was excluded to avoid double counting because it was published thereafter in Hall 2014.
Comparative
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Aim to study To assess the performance of ccfDNA testing in maternal blood for detection of fetal aneuploidy of
chromosomes 13, 18, 21, X, and Y using TMPS of single-nucleotide polymorphisms
Funding source or sponsor of
the study
Study funded by a grant from the Fetal Medicine Foundation (UK Charity No: 1037116). Analysis
of samples was performed at their own expense by Natera, Inc
Informations about the authors
contacted
No need for further contact.
Notes T13 cases data are not shown in the present review. They were excluded to avoid double counting
because they are also published in Hall 2014.
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Nicolaides 2014a
Study characteristics
Patient sampling Study design: case-control study.
Participants: pregnant women selected from a high-risk population (archived maternal plasma sam-
ples)
Inclusion criteria: singleton pregnancies.
Exclusion criteria: cases of fetal mosaicism and multifetal pregnancies
Patient characteristics and set-
ting
Recruited participants: 177 archived maternal plasma.
Number available for 2 x 2 table: 172 samples (subgroup of 97%)
Setting: recruitment in London, UK.
Ethnicity: Caucasian (90%), Afro-Caribbean (4%), Asian (5%) and other (1%)
Gestational age range: 11.2 to 14.1 weeks.
Maternal age range: 17.3 to 47.8 years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening
Language of the study: English.
Index tests gNIPT by TMPS (DANSR assay) on Illumina HiSeq 2000 in 96-plex
Median fetal fraction DNA (range): euploids: 13.0% (4.8% to 32.0%), 45,X: 10.0% (6.3% to 18.
0%), and 47,XXX, 47,XXY, and 47,XYY: 12.0% (6.4% to 16.0%)
Blood samples for gNIPT were collected just before reference standard
Cutpoint: positive if FORTE algorithm risk score ≥ 1%.
Commercial test: Harmony™ Prenatal Test by Ariosa Diagnostics, Inc
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Target condition and reference
standard(s)
Target conditions: 45,X, 47,XXX, 47,XXY, and 47,XYY.
Reference standard: fetal karyotype of chorionic villi or amniotic fluid
Flow and timing Blood samples for gNIPT were collected just before invasive procedure (reference standard)
gNIPT was a second-tier test.
5/177 samples failed during sequencing process (no gNIPT result), including 1 sample failed labo-
ratory quality control metrics and 4 samples failed for an insufficient fetal ccfDNA fraction
No repeated test reported.
Comparative
Aim to study To report the clinical performance of chromosome-selective sequencing of cfDNA inmaternal blood
and the FORTE algorithm for the assessment of fetal sex chromosome aneuploidies
Funding source or sponsor of
the study
No funding source was reported.
Informations about the authors
contacted
Author was contacted on: 10 February 2016.
No reply received from the author.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Norton 2012
Study characteristics
Patient sampling Study design: blinded, prospective cohort study.
Participants: pregnant women selected at high risk of fetal aneuploidy presenting for invasive testing.
Inclusion criteria: pregnant women aged ≥ 18 years, at gestational age ≥ 10 weeks, with a singleton
pregnancy, who were planning to undergo invasive prenatal diagnosis for any indication.
Exclusion criteria: multifetal pregnancies, women with know aneuploidy, had active malignancy or
a history of metastatic cancer, or had already undergone CVS or amniocentesis during the current
pregnancy
Patient characteristics and set-
ting
Number enrolled: 4002 pregnant women.
Number available for 2 x 2 table: 3080 pregnant women (subgroup of 77%).
Setting: 48 centres. Selected prenatal care Centres in USA, the Netherlands and Sweden.
Recruitment period: not reported.
Ethnicity: Caucasian (49.6%), Afro-American (6.4%), Asian (13.4%), Hispanic (22.7%) and other
(7.9%).
Mean gestational age (± SD; range): 16.9 (± 4.1; 10 to 38.7) weeks.
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Mean maternal age (± SD; range): 34.3 (± 6.4; 18 to 50) years.
Relevant test carried out prior to index test: not reported.
Language of the study: English.
Index tests gNIPT by TMPS (DANSR assay) on Illumina HiSeq 2000 in 96-plex
Mean fetal fraction DNA (± SD; range): euploids: 11% (± 4.5%; 4.2% to 51.3%), T21: 11.6% (±
4.2%; 5.1% to 23.3%), and T18: 10% (± 3.8%; 4.9% to 20.8%).
Blood samples for gNIPT were collected before reference standard.
Cutpoint: positive if FORTE algorithm risk score ≥ 1%.
Commercial test: Ariosa Diagnostics, Inc’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21 and T18.
Reference standard: fetal karyotype of chorionic villi (74.7%) or amniotic fluid (25.3%)
Flow and timing Blood samples for gNIPT were obtained prior to the invasive procedure (reference standard).
gNIPT was a second-tier test.
774/4002 samples excluded for ineligible criteria.
148/3228 samples failed during sequencing process (no gNIPT result), including 57 samples failed
for low fetal fraction DNA and 91 samples failed sequencing process
No repeated test reported.
Comparative
Aim to study To evaluate performance of a gNIPT of fetal T21 and T18.
Funding source or sponsor of
the study
Study funded by Ariosa Diagnostics, Inc.
Informations about the authors
contacted
No need for further contact.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
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Norton 2012 (Continued)
DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Norton 2015
Study characteristics
Patient sampling Study design: blinded, prospective cohort study.
Participants: unselected population of pregnant women undergoing aneuploidy screening (without
prior risk of fetal aneuploidy)
Inclusion criteria: singleton pregnancies, at least 18 years of age, and between 10 to 14 weeks of
gestation
Exclusion criteria: womenwhohad amiscarriage, chose to terminate the pregnancy or had a stillbirth
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without confirmatory genetic testing
Patient characteristics and set-
ting
Number enrolled: 18,955 pregnant women.
Number available for 2 x 2 table: 15,841 pregnant women (subgroup of 84%)
Setting: 35 centres in USA States, Canada, Sweden, the Netherlands, Belgium, and Italy
Recruitment period: March 2012 to April 2013.
Ethnicity: Caucasian (70.9%), Afro-American (8.2%), Asian (10.5%), Native American (0.6%),
multiracial (2.7%), other (6.7%) and missing data (0.5%)
Mean gestational age (range): 12.5 (10.0 to 14.3) weeks.
Mean maternal age (range): 31 (18 to 48) years whose 76% of pregnant women analysed had < 35
years old
Relevant tests carried out prior to index test: none.
Language of the study: English.
Index tests gNIPT by TMPS (DANSR assay) on Illumina HiSeq 2000 sequencer in 96-plex
Fetal fraction DNA: amount measured but not reported.
Blood samples for gNIPT were collected before reference standard
Cutpoint: not reported. Usually, Harmony™ prenatal test uses FORTE algorithm; positive if
FORTE risk score ≥ 1%
Commercial test: Harmony™ Prenatal Test by Ariosa Diagnostics, Inc
The traditional screening tests (combined test at the first trimester) were also assessed
Cutpoint of combined test: 1 in 270 for T21 or 1 in 150 for T18 and T13
Target condition and reference
standard(s)
Target conditions: T21, T18 and T13.
Reference standards: fetal karyotype of chorionic villi, amniotic fluid or products of conception or
neonatal karyotype, neonatal clinical examination or medical record from birth
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a first-tier test.
3114/18,955 samples excluded of analysis including 229 samples did not meet inclusion criteria
or meet exclusion criteria, 31 had twins, 121 had unknown ovum-donor status, 64 withdrew or
were withdrawn by investigator, 384 had sample-handling errors, 308 without standard screening
test result, 488 failed sequencing and have no gNIPT result (192 for low fetal fraction DNA, 83
for non fetal fraction DNA and 213 for high assay variance or assay failures) and 1489 were lost to
follow-up
Comparative
Aim to study To test the hypothesis that gNIPT has better performance than standard first-trimester screening
(with measurement of nuchal translucency and biochemical analytes) in risk assessment for trisomy
21 in a large, unselected population of women presenting for aneuploidy screening
To also evaluate the performance of gNIPT and standard screening in the assessment of risk for
trisomies 18 and 13
Funding source or sponsor of
the study
Study funded by Ariosa Diagnostics, Inc and Perinatal Quality Foundation
Informations about the authors
contacted
Author was contacted on: 10 February 2016.
Reply received on: 11 February 2016.
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Notes This study is a clinical trial (Noninvasive Examination of Trisomy (NEXT) ClinicalTrials.gov num-
ber, NCT01511458)
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 2: Index Test Traditional screening tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
No
Were all patients included in the
analysis?
No
High
Palomaki 2012
Study characteristics
Patient sampling Study design: nested case-control (1:3) study.
Participants: pregnant women at high risk of fetal aneuploidy presenting for invasive testing were
selected.
Inclusion criteria:≥ 18 years old, between about 10 weeks and 21 weeks 6 days of gestation, at high
risk of aneuploidies and who underwent a diagnostic procedure.
Exclusion criteria: multifetal pregnancies or low risk of fetal aneuploidy
Patient characteristics and set-
ting
Number enrolled: 4664 pregnant women. 1776 pregnant women selected for this study and 212
reanalysed samples from Palomaki 2011.
Number available for 2 x 2 table: 1971 pregnant women (1759 from this study + 212 fromPalomaki
2011) (subgroup of 42%).
Setting: 27 centres. Prenatal diagnostic centres (Canada, Italy, Spain, Czech Republic, Argentina,
Ireland, Hungary, USA, Israel and Australia).
Recruitment period: April 2009 to February 2011.
Ethnicity (only for 293 pregnant women): Caucasian (84.9%), Afro-american (4.1%), Asian (5.
5%) and unknown (5.5%).
Mean gestational age (range): 14.7 (9 to 22) weeks.
Mean maternal age (± SD): 37.2 (± 5) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
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Index tests gNIPT by MPSS on Illumina HiSeq 2000 sequencer in 4-plex.
Mean (geometric) fetal fraction DNA (range): 13.4% (4% to 50%).
Blood samples for gNIPT were collected before reference standard.
Cutpoint: positive if Z score > 3 (T21), > 3.88 (T18) or > 7.17 (T13).
Commercial test: Sequenom’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21, T18 and T13.
Reference standard: fetal karyotype of chorionic villi, amniotic fluid or products of conception
Flow and timing Blood samples were obtained immediately prior the invasive procedure (reference standard)
gNIPT was a second-tier test.
2888/4664 samples were not selected for this study.
110/1776 samples failed the initial MPSS testing.
105/110 samples required repeat testing using a second aliquot and 5/110 samples were resequenced
with the same library. 93/110 samples obtained a gNIPT results
17/1776 samples failed during sequencing process, most for low fetal fraction DNA (no gNIPT
result)
Comparative
Aim to study To determine whether maternal plasma ccfDNA sequencing can identify T18 and T13 as well as
T21
Funding source or sponsor of
the study
Study fully funded by Sequenom, Inc.
Informations about the authors
contacted
No need for further contact.
Notes This study is a clinical trial “A New Prenatal Blood Test for Down Syndrome” ClinicalTrials.gov
number: NCT00877292
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
High Low
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DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Papageorghiou 2016a
Study characteristics
Patient sampling Study design: blinded, case-control study (1:9).
Participants: pregnant women selected at high risk of fetal aneuploidy presenting for invasive testing.
Inclusion criteria: at least 18 years of age, singleton or twin pregnancies of at least 10 weeks’ gestation
and a clinical indication for an invasive procedure.
Exclusion criteria: higher-order multiple pregnancies (triplets or more), known mosaicism, partial
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trisomy or translocations, fetal demise, disappearing twin, malignancy or known aneuploidy in the
pregnancy
Patient characteristics and set-
ting
Number enrolled: 442 pregnant women.
Number available for 2 x 2 table: 426 singleton pregnancies (subgroup of 96%).
Setting: 6 hospital centres in England, UK.
Recruitment period: April 2008 to November 2014.
Ethnicity: not reported.
Median gestational age (range): 15.4 (11 to 36.6) weeks.
Median maternal age (range): 35 (18 to 55) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by MPSS on Ion Proton™ sequencer in 8-plex.
Fetal fraction DNA: amount measured but not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint: positive if likelihood ratio > 1 and maternal age-adjusted probability risk score.
Commercial test: IONA® test by Premaitha Health (public limited company)
Target condition and reference
standard(s)
Target conditions: T21, T18 and T13.
Reference standards: fetal karyotype of chorionic villi or amniotic fluid or medical record from birth
Flow and timing Blood samples for gNIPT were obtained prior to the invasive procedure (reference standard).
gNIPT was a second-tier test.
5/442 samples failed during sequencing process including 3 samples for low fetal fraction DNA and
2 samples did not have sufficient DNA fragment counts (no gNIPT result)
11/437 twin pregnancies were not selected.
No repeated test reported.
Comparative
Aim to study To investigate the accuracy of the IONA® test in the discrimination between euploid pregnancies
and those affected by fetal trisomies 21, 18 and 13
Funding source or sponsor of
the study
Study funded by Premaitha Health (public limited company). Some authors are employees of
Premaitha Health plc
Informations about the authors
contacted
Author was contacted on: 19 September 2016.
Reply received on: 20 September 2016.
Notes Data from singleton pregnancies only reported here. See Papageorghiou 2016b for data on twin
pregnancies.
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
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Papageorghiou 2016a (Continued)
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
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High
Papageorghiou 2016b
Study characteristics
Patient sampling Study design: blinded, case-control study (1:9).
Participants: pregnant women selected at high risk of fetal aneuploidy presenting for invasive testing.
Inclusion criteria: at least 18 years of age, a singleton or twin pregnancies of at least 10 weeks’
gestation and a clinical indication for an invasive procedure.
Exclusion criteria: higher-order multiple pregnancies (triplets or more), known mosaicism, partial
trisomy or translocations, fetal demise, disappearing twin, malignancy or known aneuploidy in the
pregnancy
Patient characteristics and set-
ting
Number enrolled: 442 pregnant women.
Number available for 2 x 2 table: 11 twin pregnancies (subgroup of 2%).
Setting: 6 hospital centres in England, UK.
Recruitment period: April 2008 to November 2014.
Ethnicity: not reported.
Median gestational age (range): 15.4 (11 to 36.6) weeks.
Median maternal age (range): 35 (18 to 55) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by MPSS on Ion Proton™ sequencer in 8-plex.
Fetal fraction DNA: amount measured but not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint: positive if likelihood ratio > 1 and maternal age-adjusted probability risk score.
Commercial test: IONA® test by Premaitha Health (public limited company)
Target condition and reference
standard(s)
Target conditions: T21, T18 and T13.
Reference standards: fetal karyotype of chorionic villi or amniotic fluid or medical record from birth
Flow and timing Blood samples for gNIPT were obtained prior to the invasive procedure (reference standard).
gNIPT was a second-tier test.
5/442 samples failed during sequencing process including 3 samples for low fetal fraction DNA and
2 samples did not have sufficient DNA fragment counts (no gNIPT result)
426/437 singleton pregnancies were not selected.
No repeated test reported.
Comparative
Aim to study To investigate the accuracy of the IONA® test in the discrimination between euploid pregnancies
and those affected by fetal trisomies 21, 18 and 13
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Papageorghiou 2016b (Continued)
Funding source or sponsor of
the study
Study funded by Premaitha Health (public limited company). Some authors are employees of
Premaitha Health plc
Informations about the authors
contacted
Author was contacted on: 19 September 2016.
Reply received on: 20 September 2016.
Notes Data from twin pregnancies only reported here. Data from singleton pregnancies reported in
Papageorghiou 2016a.
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
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Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Pergament 2014
Study characteristics
Patient sampling Study design: blinded, prospective cohort study.
Participants: pregnant women from a population with mixed risk of fetal aneuploidy presenting for
aneuploidy screening (51% high risk and 49% low risk).
Inclusion criteria: women were 18 years of age or older with a singleton pregnancy of at least 7
weeks of gestation and signed an informed consent.
Exclusion criteria: women with confirmed sex chromosome abnormality (47,XXX, XXY, XYY),
confirmed triploidy, confirmed fetal mosaicism or multifetal pregnancy or egg donor
Patient characteristics and set-
ting
Number enrolled: 1064 pregnant women.
Number available for 2 x 2 table: 963 pregnant women for T21, 964 for T18 and 45,X and 965
for T13 (subgroup of 91%).
Setting: 35 centres. Prenatal care centres worldwide in Czech Republic, Japan, USA, Ireland and
Spain.
Recruitment period: not reported.
Ethnicity: not reported.
Mean gestational age (± SD; range): 17.0 (± 4.1; 7.6 to 40.6) weeks.
Median gestational age: 14.3 weeks.
Mean maternal age (± SD; range): 30.3 (± 7.4; 18 to 47) years.
Median maternal age: 30.0 years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by TMPS (SNP-based method) on Illumina Genome Analyzer IIx or HiSeq sequencers, 19,
488-plex targeted PCR with NATUS algorithm
Range fetal fraction DNA: 2% to 50%.
Blood samples for gNIPT were collected before (93%) or 4 days or later after (7%) reference
standard.
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Cutpoint: not reported.
Commercial test: Natera’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21, T18, T13 and 45,X.
Reference standards: fetal karyotype with confirmatory fluorescence in situ hybridisation or cyto-
genetic karyotype analysis or by genetic testing of cord blood, buccal sample, saliva, or products of
conception, post-natal or post-live birth follow-up
Flow and timing Blood samples for gNIPT were obtained prior (93%) or after (7%) to the invasive procedure
(reference standard).
gNIPT was a second-tier test.
13/1064 samples excluded for other aneuploidies, including 6 cases with triploidy, 3 fetal mosaics,
2 cases with 47,XXY, 1 case with 47,XXX and 1 case with 47,XYY
85/1051 samples failed quality control (no gNIPT result) including 64 low fetal fraction DNA, 12
low DNA, 6 contaminations, 2 loss of heterozygosity and 1 poor model fit
Between 1 to 3 samples did not passed quality control for all 5 chromosomes
No repeated test reported.
Comparative
Aim to study To estimate performance of a single nucleotide polymorphism-based gNIPT (TMPS) for fetal
aneuploidy in high-risk and low-risk populations on single venipuncture
Funding source or sponsor of
the study
Study funded by Natera, Inc. and a grant from the National Institute of Health, National Institute
of Child Health and Human Development (4R44HD062114-02). The majority of the authors are
employees of Natera, Inc. and hold stock or options to hold stock in the company
Informations about the authors
contacted
Author was contacted on: 22 June 2016.
No reply received from the author.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
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DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Persico 2016
Study characteristics
Patient sampling Study design: blinded, prospective cohort study.
Participants: pregnant women selected from a high-risk population.
Inclusion criteria: singleton pregnancies.
Exclusion criteria: multifetal pregnancies.
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Patient characteristics and set-
ting
Number enrolled: 259 pregnant women.
Number available for 2 x 2 table: 249 pregnant women (subgroup of 96%).
Setting: 4 fetal medicine centres in Italy.
Recruitment period: March to December 2014.
Ethnicity: not reported.
Gestational age: not reported.
Median maternal age (range): 36 (20 to 46) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by TMPS (SNP-based method) on Illumina Genome Analyzer IIx or HiSeq sequencers, 19,
488-plex targeted PCR with NATUS algorithm
Fetal fraction DNA: amount measured but not reported (usually NATERA used quality control
criteria > 4%).
Blood samples for gNIPT were collected just before reference standard.
Cut-off value: positive if risk score > 1%.
Commercial test: Natera’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21, T18, T13, 45,X, 47,XXY and 47,XXX. 47,XYY was also assessed but no
case was found.
Reference standard: fetal karyotype of chorionic villi or amniotic fluid
Flow and timing Blood samples for gNIPT were obtained prior to the invasive procedure (reference standard).
gNIPT was a second-tier test.
10/259 samples failed during sequencing process (no gNIPT result) including 2 samples failed
internal quality control and 8 samples had low fetal fraction DNA
No repeated test reported.
Comparative
Aim to study To investigate a strategy for clinical implementation of ccfDNA testing in high-risk pregnancies
after first-trimester combined screening
Funding source or sponsor of
the study
Study not funded by industry but the cost of ccfDNA testing were covered by Natera, Inc
Informations about the authors
contacted
No need for further contact.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
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Study characteristics
Patient sampling Study design: retrospective cohort, blinded nested case-control study.
Participants: archivedmaternal plasma frompregnantwomen selected at high risk of fetal aneuploidy
presenting for invasive testing (CVS).
Inclusion criteria: singleton pregnancies.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 242 pregnant women.
Number available for 2 x 2 table: 241 pregnant women (subgroup of 99.6%).
Setting: 1 centre at King’s College Hospital, London, UK.
Recruitment period: April 2007 to June 2012.
Ethnicity: Caucasian (75%), Afro-Caribbean (17%), Asian (5%) and mixed (3%).
Median gestational age (range): 12.7 (11.4 to 13.6) weeks.
Median maternal age (range): 33.7 (29.2 to 40.5) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by MPSS on Ion Proton™ sequencer.
Fetal fraction DNA: amount measured but not reported.
Blood samples for gNIPT were collected just before reference standard.
Cutpoint: not reported but authors used the same prenatal test than Papageorghiou 2016a (cutpoint:
positive if likelihood ratio > 1 and maternal age-adjusted probability risk score)
Commercial test: IONA® test by Premaitha Health (public limited company)
Target condition and reference
standard(s)
Target conditions: T21, T18 and T13.
Reference standard: fetal karyotype of chorionic villi.
Flow and timing Blood samples for gNIPT were obtained just before the invasive procedure (reference standard).
gNIPT was a second-tier test.
1/242 samples failed for low fetal fraction DNA (no gNIPT result)
No repeated test reported.
Comparative
Aim to study To assess the potential performance of screening for fetal T21, T18 and T13 by ccfDNA analysis
of maternal blood using the IONA® test
Funding source or sponsor of
the study
Study not funded by industry but the IONA® test was provided by Premaitha Health plc, Manch-
ester, UK. Study supported by a grant from The Fetal Medicine Foundation
Informations about the authors
contacted
Author was contacted on: 19 September 2016.
No reply received from the author.
Notes
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
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Were all patients included in the
analysis?
No
High
Porreco 2014
Study characteristics
Patient sampling Study design: blinded, prospective cohort, observational study.
Participants: pregnant women selected at high risk of fetal aneuploidy presenting for invasive testing
when research personnel have been available.
Inclusion criteria: singleton pregnancy in a patient 18 years of age or older who had provided written
informed consent and who had made the decision to pursue invasive prenatal diagnosis by CVS or
amniocentesis.
Exclusion criteria: inability to give written informed consent, multifetal pregnancies, or fetal demise
of an additional embryo during the current pregnancy at 8 weeks or more of gestation
Patient characteristics and set-
ting
Number enrolled: 4170 pregnant women.
Number available for 2 x 2 table: 3322 for autosomes (subgroup of 80%), 3278 for 45,X and 47,
XXX (subgroup of 79%) and 3201 for 47,XXY and 47,XYY (subgroup of 77%).
Setting: 31 centres in USA.
Recruitment period: September 2009 to April 2011.
Ethnicity: Caucasian (60,1%), Asian (18,7%), Afro-American (4,5%) and other (16.7%).
Mean gestational age (± SD; range): 16.3 (± 3.5; 9.0 to 37.0).
Mean maternal age (± SD; range): 35.1 (± 5.6; 18.0 to 50.0).
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina HiSeq 2000 in 12-plex.
Range fetal fraction DNA: 4% to 50%.
Blood samples for gNIPT were collected before reference standard.
Cutpoint:
1) for T21, positive if Z score ≥ 3.
2) for T18 and T13, positive if Z score ≥ 3.95.
3) positive for 45,X if Z score < -3.5 (non-reportable regions between -2.5 and -3.5)
4) positive for 47,XXX if Z score > 3.5 (non-reportable regions between 2.5 and 3.5)
5) positive for 47,XYY if Z score risk < -3.5 with Chrom. Y representation
6) positive for 47,XXY if Z score risk is between -3.5 and 3.5 with Chrom. Y representation
Commercial test: Sequenom’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21, T18, T13, 45,X, 47,XXX, 47,XXY and 47,XYY.
Reference standards: fetal karyotype of chorionic villi or amniotic fluid, or medical record from
birth
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Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a second-tier test.
740/4170 samples excluded before sequencing process including 320 samples for insufficient sam-
ple volume,120 samples processed outside of the 6 hours laboratory process window, 270 failed
laboratory quality control set, 24 for incomplete case report form and 6 without invasive procedure
performed)
For autosomes: 54/3430 autosomes samples excluded for quality control deviation (low fetal DNA
fraction, library concentration, total counts, and amplification bias)
For autosomes: 54/3376 samples excluded for complex autosome karyotypes (mosaic, triploidies,
unbalanced rearrangements with missing or duplicated genetic material)
For 45,X and 47,XXX: 102/3430 samples excluded for low fetal fraction DNA or copy number
variation of the Chrom. X is confounded by maternal component and cannot be determined
For 45,X and 47,XXX: 50/3328 samples excluded for complex SCA karyotype
For 47,XXY and 47,XYY: 182/3430 samples excluded for low fetal fraction DNA or copy number
variation of the Chrom. X is confounded by maternal component and cannot be determined
For 47,XXY and 47,XYY: 47/3248 samples excluded for complex SCA karyotype
No repeated test reported.
Comparative
Aim to study To validate the clinical performance of MPSS of ccfDNA contained in specimens from pregnant
women at high risk of fetal aneuploidy to test fetuses for T21, T18, T13, 45,X, 47,XXX, 47,XXY
and 47,XYY
Funding source or sponsor of
the study
Study funded by Sequenom, Inc.
Informations about the authors
contacted
Author was contacted on: 30 May 2016.
Reply received on: 31 May 2016.
Notes This study is a clinical trial (Non-Invasive Screening for Fetal Aneuploidy) ClinicalTrials.gov num-
ber, NCT00847990
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
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High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Quezada 2015
Study characteristics
Patient sampling Study design: prospective cohort study.
Participants: self-selected pregnant women from the general population presenting for aneuploidy
screening (without prior risk of fetal aneuploidy).
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Inclusion criteria: pregnant women between 10 to 11 weeks’ gestation with singleton pregnancy
who underwent the combined test.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 2905 pregnant women.
Number available for 2 x 2 table: 2785 pregnant women (subgroup of 96%).
Setting: 1 centre. Fetal Medicine Centre in London, UK.
Recruitment period: October 2012 to January 2014.
Ethnicity: Caucasian (88.5%), South Asian (6.0%), East Asian (3.3%), Afro-Caribbean (0.7%) and
mixed (1.5%).
Median gestational age (range): 10.6 (10 to 11.9) weeks.
Median maternal age (range): 36.9 (20.4 to 51.9) years.
Relevant tests carried out prior to index test: none.
Language of the study: English.
Index tests gNIPT by TMPS (DANSR assay).
Median fetal fraction DNA (range): 11% (4% to 40%).
Blood samples for gNIPT were collected before reference standard.
Cutpoint: not reported. Usually, Harmony™ prenatal test uses FORTE algorithm; positive if
FORTE risk score ≥ 1%.
Commercial test: Harmony™ Prenatal test by Ariosa Diagnostics, Inc
The traditional screening tests (combined test at the first trimester) was also assessed
Cutpoint of combined test: 1 in 100 for T21.
Target condition and reference
standard(s)
Target conditions: T21, T18 and T13.
Reference standards: fetal karyotype of chorionic villi, amniotic fluid or products of conception,
neonatal karyotype, neonatal clinical examination or medical record from birth
Flow and timing Blood samples were obtained prior to invasive procedure (reference standard)
gNIPT was a first-tier test.
122/2905 failed the initial TMPS testing (122 = 123 - 1 sample lost in mail)
66/2851 samples without follow-up were excluded.
110/122 required repeat testing using a second blood sample and results were obtained in 69/110
samples
53/2905 samples failed during sequencing process (41 samples failed second sequencing and 12
unrepeated tests) (no gNIPT result)
Comparative
Aim to study To examine, in a general population (pregnant women without prior risk of fetal aneuploidy), the
performance of ccfDNA testing for T21, T18 and T13 at 10 to 11 weeks’ gestation and compare
it to that of the combined test at 11 to 13 weeks’ gestation
Funding source or sponsor of
the study
Study not funded by industry but Ariosa Diagnostics, Inc made sequencing and analyses
Informations about the authors
contacted
Author was contacted on: 21 April 2016 and 30 May 2016.
No reply received from the author.
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Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 2: Index Test Traditional screening tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Samango-Sprouse 2013
Study characteristics
Patient sampling Study design: blinded, prospective cohort study.
Participants: pregnant women at high or low risk of fetal aneuploidy (known sex chromosome
aneuploidy and euploid pregnancies).
Inclusion criteria: women were at least 18 years of age, had singleton pregnancy, or with known sex
chromosome aneuploidy.
Exclusion criteria: pregnant women with known mosaicism, autosomal trisomy, or triploidy
Patient characteristics and set-
ting
Number enrolled: 201 pregnant women.
Number available for 2 x 2 table: 186 pregnant women (subgroup of 93%).
Setting: 8 prenatal care centres in UK, USA, Poland, and Czech Republic.
Recruitment period: not reported.
Ethnicity: not reported.
Mean gestational age: euploid pregnancies 13.2 weeks, and aneuploid pregnancies 15.3 weeks
Gestational age range: overall 9.4 to 36.4 weeks.
Maternal age: not reported.
Relevant test carried out prior to index test: not reported.
Language of the study: English.
Index tests gNIPT by TMPS (SNP-based method) on Illumina HiSeq 2000 sequencer with NATUS algorithm
Mean fetal fraction DNA: euploids: 10.9% and aneuploids: 12.1%. Overall range: 2.9% to 37.7%.
Blood samples for gNIPT were collected just before or at least 4 days after reference standard.
Cutpoint: not reported.
Commercial test: Natera’s prenatal test.
189Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Samango-Sprouse 2013 (Continued)
Target condition and reference
standard(s)
Target conditions: 45,X, 47,XXX, 47,XXY, and 47,XYY.
Reference standards: fetal karyotype of chorionic villi or amniotic fluid or genetic testing of cord
blood, buccal sample, saliva, or products of conception
Flow and timing Blood sampleswere collected just before or at least 4 days after invasive procedure (reference standard)
.
gNIPT was a first- or second-tier test.
14/201 samples failed sequencing process quality control (no gNIPT result) including 12 for low
fetal fraction or poor DNA quality and 2 samples did not return a result for SCA
1/187 sample excluded for conflicting algorithm metrics (no meaningful gNIPT result)
No repeated test reported.
Comparative
Aim to study To develop a SNP-based and informatics-based gNIPT that detects sex chromosome aneuploidies
early in pregnancy
Funding source or sponsor of
the study
It is unclear if the study was funded by industry but all authors are employees of Natera, Inc. except
the first author (Carole Samango-Sprouse). This study was supported in part by a grant from the
National Institute of Health, National Institute of Child Health and Human Development
Informations about the authors
contacted
Author was contacted on: 22 April, 4 July and 29 September 2016
Replies received on: 29 and 30 September 2016.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
Yes
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dard?
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Sehnert 2011
Study characteristics
Patient sampling Study design: blinded retrospective study (archived maternal plasma samples).
Participants: pregnant women selected from a high risk of fetal aneuploidy population.
Inclusion criteria: pregnant women age 18 years or older with singleton or multifetal pregnancy.
Exclusion criteria: not reported.
Patient characteristics and set-
ting
Number enrolled: overall: 1014 pregnant women including 71 women selected on 435 for the
training set (not shown in the present review) and 48 women selected on 575 for the test set.
Number available for 2 x 2 table: 47 (subgroup of 8%).
Setting: 13 centres in USA.
Recruitment period: January 2010 to June 2010.
Ethnicity: Caucasian (62.7%), Hispanic (16.5%), Asian (6.2%), multiethnic (5.2%), Afro-Ameri-
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can (4.0%), Native American (0.9 %) and other or not specified (1.8%).
Mean gestational age (range): 15.4 (10.6 to 28.4) weeks.
Mean maternal age (± SD; range): 34.2 (± 8.22; 18 to 46) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina Genome Analyzer IIx sequencer in uniplex
Fetal fraction DNA: not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint prespecified with the training set:
1) positive if NCV > 4 for autosomes. There is a “no call zone” between 2.5 and 4 considering as
gNIPT positive result for the present review
2) positive if NCV for Chrom. Y < -2.0 SDs from the mean of male samples and if NCV for Chrom.
X < -3.0 SDs from the mean of female samples for 45,X.
Commercial test: Verinata’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21, T18, T13 and 45,X.
Reference standard: fetal karyotype of chorionic villi (58,3%) or amniotic fluid (41.7%)
Flow and timing Blood samples for gNIPT were obtained prior to the invasive procedure (reference standard).
gNIPT was a second-tier test.
895/1014 samples were not selected for sequencing.
71/119 samples were selected for the training set (not shown in the present review)
1/48 sample from twin gestation in the test set was removed from the final analysis
No repeated test reported.
Comparative
Aim to study To develop and test an optimised algorithm from MPSS data and demonstrated the potential
universality of the sequence tag mapping and chromosome quantification method for the detection
of multiple chromosomal abnormalities
Funding source or sponsor of
the study
Study funded by Illumina (formerly Verinata Health). The funding organizations played a direct
role in the design of the study, the choice of enrolled patients, the review and interpretation of data,
and the preparation and final approval of the manuscript
Informations about the authors
contacted
No need for further contact.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Shaw 2014
Study characteristics
Patient sampling Study design: prospective cohort study.
Participants: consecutive pregnant women were selected from a mixed-risk population. They were
classified in extremely high-risk group for T21 with a screening T21 risk > 1:30 or nuchal translu-
cency > 3.0 mm and low-risk group with a screening T21 risk < 1:1500.
Inclusion criteria: pregnant women at > 12 weeks’ gestation, singleton or multifetal pregnancies.
Exclusion criteria: not reported.
Patient characteristics and set-
ting
Number enrolled: 201 pregnant women.
Number available for 2 x 2 table: 200 pregnant women (subgroup of 99.5%).
Setting: 11 medical centres in Taiwan.
Recruitment period: June to December 2012.
Ethnicity: Asian.
Mean gestational age (± SD): high-risk pregnant women 17.3 (± 2.1) weeks, and low-risk pregnant
women 16.1 (± 3.0) weeks
Gestional age range: overall 12 to 20 weeks.
Mean maternal age (± SD): high-risk pregnant women 35.1 (± 3.2) years, and low-risk pregnant
women 34.6 (± 2.6) years.
Chorionicity: all dichorionic (4/4).
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina v2 HiSeq 2000 sequencer in 12-plex
Fetal fraction DNA: not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint:
1) positive if Z score > 3 (T21, T18, and T13).
2) positive if Z score Chrom. X < -3 and Z score Chrom. Y < 3 (45,X)
3) positive if Z score Chrom. X < -3 and Z score Chrom. Y > 3 (47,XYY).
Commercial test: Berry Genomics’ prenatal test.
The traditional screening test (combined test at the first trimester) was also assessed but complete
data for 2 x 2 tables were unavailable
Target condition and reference
standard(s)
Target conditions: T21, T18, T13, 45,X, and 47,XYY. 47,XXX and 47,XXY were also screened but
no case was found.
Reference standards: fetal karyotype of amniotic fluid or medical record from birth
Flow and timing Blood samples for gNIPT were obtained prior to the invasive procedure (reference standard).
gNIPT was a second-tier test.
1 sample excluded for early gestational age (< 12 weeks).
No repeated test reported.
Comparative
Aim to study To evaluate the performance of gNIPT for all fetal chromosomal aneuploidies in an extremely high-
risk group undergoing first-trimester combined T21 screening
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Funding source or sponsor of
the study
Funding sources were not reported but 2 authors are affiliated to Berry Genomics Co. Ltd., Beijing,
PR China
Informations about the authors
contacted
Author was contacted on: 10 February and 23 June 2016.
No reply received from the author.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
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DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Song 2013
Study characteristics
Patient sampling Study design: blinded, prospective cohort study.
Participants: pregnant women without a priori risk of fetal aneuploidy who undergo routine prenatal
screening.
Inclusion criteria: singleton pregnancies and pregnant women younger than 35 years old.
Exclusion criteria: not reported.
Patient characteristics and set-
ting
Number enrolled: 1916 pregnant women.
Number available for 2 x 2 table: 1741 pregnant women (subgroup of 91%).
Setting: 2 clinical centres in Beijing, China.
Recruitment period: April 2011 to December 2011.
Ethnicity: Asian.
Mean gestational age (± SD; range): 16.57 (± 1.56; 11 to 21.9) weeks.
Mean maternal age (± SD; range): 29.03 (± 2.70; 20 to 34) years.
Relevant tests carried out prior to index test: none.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina v2 HiSeq 2000 sequencer in 12-plex
Fetal fraction DNA: not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint: positive if Z score ≥ 3.
Commercial test: Berry Genomics’ prenatal test.
The traditional screening test (second-trimester triple test) was also assessed
Cutpoint of triple test: 1 in 270 for T21 and T18.
Target condition and reference
standard(s)
Target conditions: T21, T18 and T13. 45,X, 47,XXX, 47, XXY, 47,XYY were also screened but
inappropriate reference standard for the present review was used.
Reference standards: fetal karyotype of chorionic villi, amniotic fluid or cord blood or medical
record from birth
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Flow and timing It is not reported if the blood samples were collected before or after invasive procedure (reference
standard).
It is not reported if the gNIPT was a first- or second-tier test.
64/1916 samples failed sequencingprocess (failedDNAquality control criteria or sequencingquality
control) (no gNIPT result)
102/1916 samples without follow-up were excluded.
9/1916 samples were without follow-up and failed sequencing process (no gNIPT result)
No repeated test reported.
Comparative
Aim to study To evaluate the performance of gNIPT for detection of fetal aneuploidies in a Chinese cohort of
women younger than 35 years old in a prospective clinical setting. Also, to compare the performance
of gNIPT with the routine prenatal screening (second-trimester combined test)
Funding source or sponsor of
the study
Study not funded by industry. This study was supported by a grant (2006BAI05A10) from the
National Key Technology Research and Development Program of China during the ‘11th Five-Year
Plan’
Informations about the authors
contacted
No need for further contact.
Notes SCAwere also screened but inappropriate reference standard for the present review was used. gNIPT
data from SCA were not shown in this review
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 2: Index Test Traditional screening tests
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all analysed patients receive
the reference standard?
No
Were all patients included in the
analysis?
No
High
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Study characteristics
Patient sampling Study design: blinded, prospective cohort study.
Participants: pregnant women selected arbitrarily at high risk of fetal aneuploid presenting for
aneuploidy screening by gNIPT.
Inclusion criteria: advanced maternal age (≥ 35 years) and singleton pregnancies.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 213 pregnant women.
Number available for 2 x 2 table: 204 pregnant women (subgroup of 96%).
Setting: 1 centre. Peking Union Medical College Hospital (PUMCH), Beijing, China.
Recruitment period: May 2012 to August 2013.
Ethnicity: Asian.
Median gestational age (range): 9.9 (8 to 12.9) weeks.
Mean maternal age (range): 37.25 (35 to 45) years.
Relevant tests carried out prior to index test: none.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina v2 HiSeq 2000 sequencer in 12-plex
Median fetal fraction DNA (range): only male fetus: 8.54% (2.69% to 18.75%).
Blood samples for gNIPT were collected before reference standard.
Cutpoint: positive if Z score ≥ 3.
Commercial test: Berry Genomics’ prenatal test.
Target condition and reference
standard(s)
Target conditions: T21, T18, T13, 45,X, 47,XXY and 47,XXX. 47,XYY were also assessed but no
case was found.
Reference standards: fetal karyotype of chorionic villi or amniotic fluid for all analysed women (178/
178) and neonatal clinical examination (198/212)
Flow and timing Blood samples for gNIPT were obtained prior the invasive procedure (reference standard).
gNIPT was a first-tier test.
1/213 sample failed quality control (haemolysis).
8/212 samples without reference standard were excluded including 5 miscarriages, 2 intrauterine
fetal deaths and 1 termination of pregnancy
No repeated test reported.
Comparative
Aim to study To evaluate the feasibility of gNIPT of maternal plasma samples collected from pregnant Chinese
women in early gestation, between 8 and 12.9 weeks’ gestation
Funding source or sponsor of
the study
Study not funded by industry but gNIPTs were done and analysed at Berry Genomics Co. Ltd.
Study funded by a grant from the National Natural Science Foundation of China
Informations about the authors
contacted
No need for further contact.
Notes
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Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
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Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Sparks 2012a
Study characteristics
Patient sampling Study design: case-control study from a prospective cohort.
Participants: pregnant women selected from a high risk of fetal aneuploidy population.
Inclusion criteria: women at least 18 years of age, at least 10 weeks’ gestation and have singleton
pregnancy.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: not reported. A subset of 338 pregnant women including 171 women in the
training set (data not shown in the present review) and 167 women in the validation set were selected
for this study.
Number available for 2 x 2 table: 167 pregnant women (subgroup of 49%).
Setting: not reported.
Recruitment period: not reported.
Ethnicity: not reported.
Mean gestational age (± SD; range): 18.6 (± 4.0; 11 to 36.1) weeks.
Mean maternal age (± SD; range): 33.5 (± 7.1; 18 to 51) years.
Relevant tests carried out prior to index test: not reported.
Language of the study: English.
Index tests gNIPT by TMPS (DANSR assay) on Illumina HiSeq 2000 sequencer in multiplex with FORTE
algorithm
Range fetal fraction DNA: 3% to 33%.
It is not reported if the blood samples for gNIPT were collected before or after reference standard.
Cutpoint: not reported.
Commercial test: Ariosa Diagnostics, Inc’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21 and T18.
Reference standards: fetal karyotype or chromosome analysis by FISH or both
Flow and timing It is not reported if the blood samples were collected before or after invasive procedure (reference
standard).
gNIPT was a second-tier test.
171/338 samples were excluded for the training set.
No failed sample reported in the validation set.
No repeated test reported.
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Comparative
Aim to study To develop a novel biochemical assay and algorithm for the prenatal evaluation of risk for fetal T21
and T18 using ccfDNA obtained from maternal blood
Funding source or sponsor of
the study
Study funded by Ariosa Diagnostics, Inc. All authors are employees of Aria Dx Inc. (now Ariosa
Diagnostics). K Sparks is a member of the board of the company
Informations about the authors
contacted
Author was contacted on: 23 June 2016.
No reply received from the author.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
No
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Unclear
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
Yes
Unclear
Stumm 2014
Study characteristics
Patient sampling Study design: prospective cohort study. Blinded for T21 and unblinded for T18 and T13.
Participants: all consecutively enrolled pregnant women selected at high risk of fetal aneuploidy.
Inclusion criteria: pregnant women at least 18 years old, at high risk for chromosomal aberrations,
signed informed consent, planned a conventional karyotyping procedure (invasive diagnostic), had
singleton pregnancy and blood drawn before the invasive procedure.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 522 pregnant women.
Number available for 2 x 2 table: 472 pregnant women (subgroup of 90%).
Setting: 5 clinical centres in Germany and Switzerland.
Recruitment period: not reported.
Ethnicity: not reported.
Mean gestational age (range): 15.6 (11.0 to 32.1) weeks.
Mean maternal age (range): 36.0 (19 to 47) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina HiSeq 2000 sequencer in 12-plex with DAP.21 algorithm without
CG correction
Mean fetal fraction DNA (range): male fetus only: 12.3% (3.7% to 36.8%).
Blood samples for gNIPT were collected just before reference standard.
Cutpoint:
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1) positive if MAD-based Z -score ≥ 3 for T21.
2) positive if MAD-based Z score ≥ 3.2 for T18.
3) positive if MAD-based Z score ≥ 3.9 for T13.
Commercial test: LifeCodexx’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21, T18 and T13.
Reference standard: fetal karyotype of chorionic villi (30.3%), amniotic fluid (69.1%) or cord blood
(0.6%)
Flow and timing Blood samples for gNIPT were obtained just prior the invasive procedure (reference standard).
gNIPT was a second-tier test.
18/522 samples excluded, including 8 without reference standard result, 9 without consent and 1
was previously analysed
32/504 samples failed during sequencing process (no gNIPT result), including 14 samples failed
sequencing quality criteria and 18 samples failed libraries
No repeated test reported.
Comparative
Aim to study To validate the diagnostic accuracy of a gNIPT for detecting T21, T18 and T13 for a population
in Germany and Switzerland
Funding source or sponsor of
the study
Study funded by LifeCodexx AG and GATC Biotech AG.
Informations about the authors
contacted
Author was contacted on: 22 February 2016, 24 February and 19 May 2016.
Reply received on: 24 February 2016.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
No
If a threshold was used, was it
pre-specified?
No
High Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Sukhikh 2015
Study characteristics
Patient sampling Study design: prospective cohort study.
Participants: pregnant women selected at high risk of fetal aneuploidy presenting for invasive testing.
Inclusion criteria: not reported.
Exclusion criteria: not reported.
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Patient characteristics and set-
ting
Number enrolled: 200 pregnant women.
Number available for 2 x 2 table: 200 pregnant women (whole cohort included in analyses).
Setting: not reported.
Recruitment period: not reported.
Ethnicity: not reported.
Median gestational age (range): 14 (10 to 20) weeks.
Maternal age: not reported.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: Russian.
Index tests gNIPT by MPSS on Ion Proton™ sequencer.
Fetal fraction DNA: not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint:
1) Positive for T21 and T18 if T score > 5.
2) Positive for T13 if T score > 4.
3) Positive for 45,X if T score for chrom. X > 0.04 and for chrom. Y < 0.04
In-house test.
Target condition and reference
standard(s)
Target conditions: T21, T18, T13 and 45,X.
Reference standard: fetal karyotype of chorionic villi, amniotic fluid or placenta
Flow and timing Blood samples for gNIPT were obtained prior to the invasive procedure (reference standard).
gNIPT was a second-tier test.
No failed sample reported.
No repeated test reported.
Comparative
Aim to study To estimate the feasibility of using a next-generation sequencing technique for the noninvasive
prenatal diagnosis of fetal aneuploidies
Funding source or sponsor of
the study
Funding source not reported.
Informations about the authors
contacted
Author was contacted on: 9 September and 4 October 2016.
No reply received from the author.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
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Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
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Sung-Hee 2015
Study characteristics
Patient sampling Study design: retrospective study from a prospective cohort.
Participants: pregnant women selected from a high risk of fetal aneuploidy population.
Inclusion criteria: singleton pregnancies.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 918 pregnant women.
Number available for 2 x 2 table: 901 pregnant women (subgroup of 99%).
Setting: various medical sites in Korea.
Recruitment period: May 2012 to December 2013.
Ethnicity: Asian.
Mean gestational age (± SD; range): 16.6 (± 2.2; 11 to 25) weeks.
Mean maternal age (± SD; range): 35.3 (± 4.1; 22 to 46) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening (59%) or both.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina Genome Analyzer IIx or HiSeq 2000 sequencer in 12-plex
Fetal fraction DNA: amount measured but not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint: positive if L score > 1 and t score > 2.5 (warning zone if t score risk > 2.5 or L score risk
> 1).
Commercial test: BGI-Shenzhen’s test.
Biochemical serum-screening results were reported in the study but 2 x 2 tables could not be derived
Target condition and reference
standard(s)
Target conditions: T21 and T18. T13 were also assessed but the only case found was without follow-
up. SCA were also screened but inappropriate reference standard for the present review was used.
Reference standards: fetal karyotype for gNIPT positive cases and medical record from birth for
gNIPT negative cases
Flow and timing Blood samples for gNIPT were obtained prior to the invasive procedure (reference standard).
gNIPT was a first- or a second-tier test.
8/918 samples were ineligible.
9/910 samples without follow-up were excluded (all samples had positive gNIPT result). 2/9 women
had abortion and 7/9 women declined invasive testing
21/910 samples failed to give a risk score for gNIPTof the first blood samples including 1haemolysed
sample, 8 samples thawing due to transport delay, 3 due to cell-free DNA extraction failures and 9
samples had low fetal fraction
16/21 samples were repeated with new sampling. 14/16 samples obtained a gNIPT results and 2/
16 samples failed to provide informative results and were classified as test failures
7/910 samples failed during sequencing process (no gNIPT result). 5/7 samples failed the initial
MPSS testing and were not resequenced and 2/7 samples failed the second MPSS testing
Comparative
Aim to study To report the initial clinical performance of gNIPT in detecting fetal chromosomal aneuploidies,
especially T21, T18 and T13, in singleton pregnancies in Korea
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Sung-Hee 2015 (Continued)
Funding source or sponsor of
the study
Study not funded by industry but BGI performed sequencing and analysis. Study funded by Seoul
Clinical Laboratories Research Grant (2015, President: Kyoung-Ryul Lee)
Informations about the authors
contacted
Author was contacted on: 13, 19 and 26 September 2016.
Replies received on: 19 and 25 September and 11 October 2016
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
No
High Low
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DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Tynan 2016
Study characteristics
Patient sampling Study design: blinded, retrospective clinical evaluation study.
Participants: pregnant women selected from 3 internal clinical studies (archived maternal plasma
samples). 84.5% without prior risk and 15.8% had high risk of fetal aneuploidy.
Inclusion criteria: singleton pregnancies.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 1100 pregnant women.
Number available for 2 x 2 table: 1048 pregnant women (subgroup of 95%).
Setting: multicentre.
Recruitment period: beginning in November 2009.
Ethnicity: not reported.
Gestational age (range): 9 to 38.1 weeks.
Maternal age (range): 18 to 45 years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina HiSeq 2000 or HiSeq 2500 sequencer in multiplex
Mean fetal fraction DNA (± SD): low-risk group: 10% (± 3.1%), high-risk group (< 35years): 11.
9% (± 4.8%), and high-risk group (≥ 35years): 11.1% (± 3.4%)
Median fetal fraction DNA (range): low-risk group: 10.7% (3.1% to 22.9%), high-risk group (<
35years): 10.7% (4.9% to 28.3%), and high-risk group (≥ 35years): 11% (3.1% to 25.5%).
Blood samples for gNIPTwere collected before reference standard.
Cutpoint: positive if risk score ≥ 1%.
Commercial test: VisibiliT™ test by Sequenom, Inc.
Target condition and reference
standard(s)
Target conditions: T21, T18 and T13.
Reference standards: fetal karyotype of chorionic villi or amniotic fluid or medical record from birth
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Flow and timing Blood samples for gNIPT were obtained prior to the invasive procedure (reference standard).
gNIPT was a first- or second-tier test.
52/1100 samples failed during sequencing process (no gNIPT result) including 28 for technical
failures (library preparation or low aligned reads counts) and 24 for discretionary non-reporting
because of factors such as sequencing bias
No repeated test reported.
Comparative
Aim to study To demonstrate the clinical performance of a simplified, low coverage, low cost MPSS assay (Visi-
biliT™) that combines a maternal age-based risk for T21, T18, and T13, the fractional concentra-
tion of fetal DNA, and the representation of chromosomes 21, 18, and 13 in the sample to provide
a risk score for T21, T18 and T13, with classification of fetal sex result
Funding source or sponsor of
the study
Study funded by Sequenom, Inc.
Informations about the authors
contacted
No need for further contact.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Verweij 2013
Study characteristics
Patient sampling Study design: blinded, prospective cohort study.
Participants: consecutive pregnant women selected at high risk of fetal aneuploidy presenting for
invasive testing.
Inclusion criteria: women who sign informed consent, ≥ 18 years old and carrying a singleton
pregnancy with a gestational age of at least 10 weeks.
Exclusion criteria: multifetal pregnancies, an invasive procedure performed prior to the blood sam-
pling, history or active significant malignancy requiring major surgery or systemic chemotherapy,
or language restriction with failure to understand the study information
Patient characteristics and set-
ting
Number enrolled: 595 pregnant women.
Number available for 2 x 2 table: 504 pregnant women (subgroup of 85%).
Setting: multicentres in the Netherlands and Sweden.
Recruitment period: May 2011 to March 2012.
Ethnicity: Caucasian (84.8%), Mediterranean (6%), Asian (3.3%), Afro-European (1.3%), and
other (4.6%).
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Mean gestational age (± SD; range): 14.0 (± 2.1; 10 to 28) weeks.
Mean maternal age (± SD; range): 36.4 (± 4.6; 20 to 47) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by TMPS (DANSR assay) on Illumina HiSeq 2000 in 96-plex with FORTE algorithm
Mean fetal fraction DNA (± SD; range): 11.1% (± 4.1%; 4% to 30%).
Blood samples for gNIPT were collected just before reference standard.
Cutpoint: positive if FORTE risk score ≥ 1%.
Commercial test: Ariosa Diagnostics, Inc’s test.
Target condition and reference
standard(s)
Target condition: T21.
Reference standard: fetal karyotype of chorionic villi (54%) or amniotic fluid (46%)
Flow and timing Blood samples for gNIPT were obtained just prior the invasive procedure (reference standard).
gNIPT was a second-tier test.
75/595 samples were ineligible.
51/520 samples failed the initial TMPS testing.
51/51 samples were repeated with a second aliquot of the first sampling and 35/51 samples obtained
a gNIPT results
16/520 samples failed during sequencing process (no gNIPT result), including 7 samples with low
fetal DNA fraction and 9 samples failed laboratory processing or specimen issues
Comparative
Aim to study To evaluate the performance of a directed gNIPT method of ccfDNA analysis for fetal T21 by
shipping the whole blood samples from Europe to a laboratory in the USA
Funding source or sponsor of
the study
Study funded by Ariosa Diagnostics, Inc. 2 authors are paid employees of Ariosa Daignostics. 1
author is a board member of Ariosa Diagnostics
Informations about the authors
contacted
Author was contacted on: 22 April 2016.
Reply received on: 25 April 2016.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
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Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test TMPS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
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Wang 2014
Study characteristics
Patient sampling Study design: prospective cohort study.
Participants: pregnant women in the first trimester of pregnancy with advanced maternal ages or
ultrasound abnormality (high risk of fetal aneuploidy).
Inclusion criteria: singleton pregnancies between 11 to 14 weeks’ gestation.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 136 pregnant women.
Number available for 2 x 2 table: 136 pregnant women (whole cohort included in analyses).
Setting: 1 centre. General Hospital of PLA, Beijing, China.
Recruitment period: March 2011 to August 2013.
Ethnicity: Asian.
Gestational age range: 11 to 13.9 weeks.
Maternal age range: 35 to 44 years.
Relevant test carried out prior to index test: ultrasonography for some women.
Language of the study: Chinese.
Index tests gNIPT by MPSS on Illumina HiSeq 2000 sequencer with NIFTY™ algorithm
Fetal fraction DNA: not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint: not reported.
Commercial test: BGI-Shenzhen’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21 and T18. T13 was also assessed but no case was found. 45,X was also
screened but inappropriate reference standard for the present review was used for pregnant women
with gNIPT negative result. gNIPT data from 45,X were not shown in this review.
Reference standards: fetal karyotype of amniotic fluid or cord blood or neonatal clinical examination
at 42 days after birth or both
Flow and timing Blood samples for gNIPT were obtained prior to the invasive procedure (reference standard).
gNIPT was a first- or second-tier test.
No failed sample reported.
No repeated test reported.
Comparative
Aim to study To investigate the value of maternal plasma ccfDNA examination in detection of fetal chromosomal
aneuploidy in pregnant women at advanced maternal age during the first trimester of pregnancy
Funding source or sponsor of
the study
Study not funded by industry. Study funded by National Science & Technology Pillar Program
during the Twelfth Five-year Plan Period (2012BA131B06)
Informations about the authors
contacted
Author was contacted on: 19 May and 27 June 2016.
No replies received from the author.
Notes
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all analysed patients receive
the reference standard?
Yes
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Were all patients included in the
analysis?
Yes
Unclear
Wang 2015a
Study characteristics
Patient sampling Study design: prospective cohort study.
Participants: pregnant women selected from a high risk of fetal aneuploidy population.
Inclusion criteria: pregnant women at high risk of fetal aneuploidy between 14 and 26 weeks of
gestation.
Exclusion criteria: not reported.
Patient characteristics and set-
ting
Number enrolled: 917 pregnant women.
Number available for 2 x 2 table: 917 pregnant women (whole cohort included in analyses).
Setting: 1 centre at prenatal clinic, Lianyungang Maternal and ChildHealthHospital, Lianyungang,
Jiangsu 222001, China.
Recruitment period: January 2012 to December 2013.
Ethnicity: Asian.
Gestational age range: 14 to 26 weeks.
Maternal age range: 18 to 46 years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina v2 HiSeq 2000 flow cell on a HiSeq sequencer
Fetal fraction DNA: not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint:
1) for T21, T18 and T13, positive if Z score > 3.
2) for 47,XXY and 47,XYY, positive if Z score Chrom. X > -3 and Z score Chrom. Y < 3
3) for 45,X and 47,XXX, positive if Z score Chrom. X between -3 and 3 without Chrom. Y
representation.
Commercial test: Berry Genomics’ prenatal test.
Target condition and reference
standard(s)
Target conditions: T21 and T18. T13 was also assessed but no case was found. SCAwas also assessed
but inappropriate reference standard for the present review was used.
Reference standards: fetal karyotype of amniotic fluid or clinical follow-up (once per month) from
birth to 6 months
Flow and timing Blood samples for gNIPT were obtained prior to the invasive procedure (reference standard).
gNIPT was a second-tier test.
No failed sample reported.
No repeated test reported.
Comparative
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Aim to study To investigate the clinical efficiency of gNIPT identifying fetal chromosomal aneuploidies
Funding source or sponsor of
the study
Study not funded by industry but Berry Genomics Co. Ltd give technical support. Study funded by
the Community Development Fund, granted by the Department of Family Planning and Health-
care, Jiangsu Province, China
Informations about the authors
contacted
No need for further contact.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
Unclear
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of the results of the index tests?
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
Yes
Low
Yao 2014
Study characteristics
Patient sampling Study design: retrospective study.
Participants: pregnant women presenting with low-, high- or without prior risk factors of fetal
aneuploidy (gNIPT was offered routinely as a prenatal screening test).
Inclusion criteria: singleton pregnancies.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 5950 pregnant women.
Number available for 2 x 2 table: 5530 pregnant women (subgroup of 93%).
Setting: 1 centre. The Prenatal Diagnosis Centre, Southwest Hospital, Chongqing, China.
Recruitment period: June 2011 to December 2012.
Ethnicity: Asian.
Mean gestational age (range): 19.6 weeks (65% of the cohort were between 16 to 20.9 weeks).
Mean maternal age (± SD): 30 (± 5) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both for some women.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina Genome Analyzer IIx or HiSeq 2000 sequencer in 12-plex with
NIFTY™ algorithm
Fetal fraction DNA: amount measured but not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint:
1) positive if t score ≥ 2.5 for autosomes.
2) positive if t score for Chrom. X < -2.5 for female fetuses for 45,X
3) positive if t score for Chrom. X > 2.5 for female fetuses for 47,XXX
4) positive if t score for Chrom. X > 2.5 combined with estimation of fetal ccfDNA concentration
by Chrom. X (expected value of zero) for 47,XXY
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5) positive if t score for Chrom. X > 2.5 and R-value (the ratio of the fetal DNA fraction estimated
by chromosome Y to that estimated by chromosome X) between 1.8 and 2.2 for 47,XYY
Commercial test: BGI-Shenzhen’s prenatal test.
Target condition and reference
standard(s)
Target conditions: T21, T18, T13. 45,X, 47,XXY, 47,XYY and 47,XXX were also screened but
inappropriate reference standard for the present review was used. gNIPT data from SCA were not
shown in this review.
Reference standards: fetal karyotype of chorionic villi or amniotic fluid or follow-up by telephone
interview with the clinician after the expected delivery date
Flow and timing Blood samples for gNIPT were obtained prior to the invasive procedure (reference standard).
gNIPT was a first- or second-tier test.
420/5950 samples without follow-up were excluded.
No failed sample reported.
No repeated test reported.
Comparative
Aim to study To evaluate the performance of a MPSS in detecting fetal sex chromosome aneuploidy (SCA) and
to present a comprehensive clinical counselling protocol for SCA-positive patients. Author also
assessed autosomes aneuploidies
Funding source or sponsor of
the study
Funding source not reported but many authors are employees of the Clinical Laboratory of BGI
Health, BGI-Shenzen or of the Shenzen Birth Defect Screening Projet Lab
Informations about the authors
contacted
No need for further contact.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test MPSS
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Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Zhang 2016
Study characteristics
Patient sampling Study design: blinded, prospective cohort study.
Participants: pregnant women selected from a high risk of fetal aneuploidy population.
Inclusion criteria: women aged ≥ 35 years at the time of delivery, single birth, high risk of T21 or
single abnormal multiple of the median, elevated fetal nuchal translucency in the early pregnancy, a
soft marker in the genetic scan, or cardiac structural abnormalities in the second trimester genetic
sonography, not suitable for invasive prenatal diagnosis, such as those with human immunodefi-
ciency virus infection, placenta previa, low set placenta, oligohydramnios, Rh-negative blood type,
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a history of abortion, threatened abortion or precious pregnancy.
Exclusion criteria: multifetal pregnancies, maternal with chromosomal diseases, or received allo-
geneic blood transfusion, organ transplantation, stem cell therapy, or with a gestational age of < 12
weeks
Patient characteristics and set-
ting
Number enrolled: 87 pregnant women.
Number available for 2 x 2 table: 87 pregnant women (whole cohort included in analyses).
Setting: 1 centre at the Obstetrics and Gynecology Hospital of Fudan University (Shanghai, China)
.
Recruitment period: January 2012 to December 2013.
Ethnicity: Asian.
Median gestational age (range): 19 (12.4 to 32.5) weeks.
Mean maternal age (± SD): 37.48 (± 2.17) years.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
or biochemical screening or both.
Language of the study: English.
Index tests gNIPT by MPSS on Illummina Hiseq 2000 sequencer in 12-plex.
Fetal fraction DNA: not reported.
It is not reported if the blood samples for gNIPT were collected before or after reference standard.
Cutpoint for T21: positive if Z score ≥ 3.
No other cutpoint reported.
Commercial test: Berry Genomics’ prenatal test.
Target condition and reference
standard(s)
Target conditions: T21, T18. 45,X and 47,XXX were also screened but inappropriate reference
standard for the present review was used.
Reference standards: fetal karyotype of amniotic fluid or cord blood or neonatal clinical examination
by neonatologists
Flow and timing It is not reported if the blood samples were collected before or after invasive procedure (reference
standard).
gNIPT was a second-tier test.
No failed sample reported.
No repeated test reported.
Comparative
Aim to study To evaluate the efficacy of using gNIPT technology in screening T21 among women of advanced
maternal age and to provide evidence for prenatal screening of T21
Funding source or sponsor of
the study
Funding source not reported.
Informations about the authors
contacted
Author was contacted on: 7 September 2016.
No reply received from the author.
Notes
Methodological quality
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Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High Low
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Yes
Low Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Unclear
Did all analysed patients receive
the reference standard?
Yes
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Were all patients included in the
analysis?
Yes
Unclear
Zhou 2014a
Study characteristics
Patient sampling Study design: blinded, prospective cohort study.
Participants: pregnant women selected at high risk for T21 (51.3%), low risk for T21 (2.6%) or
without a priori risk (46.1%). gNIPT was integrated in clinical workflow.
Inclusion criteria: singleton pregnancies.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 306 pregnant women.
Number available for 2 x 2 tables: 301 pregnant women in the pilot validation set (subgroup of
98%). See Zhou 2014b for the integration set.
Setting: 1 centre. Women’s Hospital, Zhejiang University School of Medicine, Hangzhouin, China.
Recruitment period: September 2011 to October 2011.
Ethnicity: Asian.
Gestational age range: 12 to 24 weeks.
Maternal age: not reported.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening for a part of this cohort.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina Genome Analyzer IIx or HiSeq 2000 sequencer in 12-plex
Fetal fraction DNA: amount measured but not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint: positive if T score > 2.5 and L score > 1 (warning zone if t score > 2.5 or L score > 1).
Commercial test: NIFTY™ prenatal test by BGI-Shenzhen.
Target condition and reference
standard(s)
Target conditions: T21, T18 and T13.
Reference standards: fetal karyotype of amniotic fluid or neonatal karyotype or birth outcome
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a first- or second-tier test.
For the pilot validation set: 5/306 samples without follow-up were excluded
No failed sample reported.
No repeated test reported.
Comparative
Aim to study To report the clinical application of gNIPT to detect chromosomal aneuploidies, especially T21,
T18 and T13 in Chinese singleton pregnancies
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Funding source or sponsor of
the study
Study not funded by industry but BGI-Shenzhen made sequencing and analysis. Some authors are
employees of BGI-Shenzhen
Informations about the authors
contacted
Author was contacted on: 31 May 2016.
No reply received from author.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
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DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
Zhou 2014b
Study characteristics
Patient sampling Study design: blinded, prospective cohort study.
Participants: pregnant women selected at high risk, low risk for T21 or without a priori risk. gNIPT
was integrated in clinical workflow.
Inclusion criteria: singleton pregnancies.
Exclusion criteria: multifetal pregnancies.
Patient characteristics and set-
ting
Number enrolled: 7705 pregnant women.
Number available for 2 x 2 tables: 3950 pregnant women in the integration set (subgroup of 51%).
Setting: 1 centre. Women’s Hospital, Zhejiang University School of Medicine, Hangzhouin, China.
Recruitment period: September 2011 to July 2013.
Ethnicity: Asian.
Gestational age range: 12 to 24 weeks.
Maternal age: not reported.
Relevant tests carried out prior to index test: ultrasonography (nuchal translucency measurement)
and biochemical screening for a part of this cohort.
Language of the study: English.
Index tests gNIPT by MPSS on Illumina Genome Analyzer IIx or HiSeq 2000 sequencer in 12-plex
Fetal fraction DNA: amount measured but not reported.
Blood samples for gNIPT were collected before reference standard.
Cutpoint: positive if T score > 2.5 and L score > 1 (warning zone if t score > 2.5 or L score > 1).
Commercial test: NIFTY™ prenatal test by BGI-Shenzhen.
Target condition and reference
standard(s)
Target conditions: T21, T18 and T13.
Reference standards: fetal karyotype of amniotic fluid or neonatal karyotype or birth outcome
Flow and timing Blood samples were obtained prior to the invasive procedure (reference standard)
gNIPT was a first- or second-tier test.
141/7705 samples failed the initial MPSS testing. 141/141 samples were repeated with a new
sampling and 137/141 samples obtained a gNIPT results
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4/7705 samples failed the second MPSS testing for low fetal fraction DNA (no gNIPT result)
3751/7701 samples without birth outcome were excluded (no reference standard)
Comparative
Aim to study To report the clinical application of gNIPT to detect chromosomal aneuploidies, especially T21,
T18 and T13 in Chinese singleton pregnancies
Funding source or sponsor of
the study
Study not funded by industry but BGI-Shenzhen made sequencing and analysis. Some authors are
employees of BGI-Shenzhen
Informations about the authors
contacted
Author was contacted on: 31 May 2016.
No reply received from the author.
Notes
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
No
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
No
High High
DOMAIN 2: Index Test MPSS
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Unclear
If a threshold was used, was it
pre-specified?
Yes
Unclear Low
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all analysed patients receive
the reference standard?
Yes
Were all patients included in the
analysis?
No
High
CVS: chorionic villi sampling
DANSR: digital analysis of selected regions
FISH: fluorescence in situ hybridisation
gNIPT: genomics-based non-invasive prenatal testing
MAD: Median absolute deviation
MPSS: massively parallel shotgun sequencing
NCV: normalised chromosome value
SD: standard deviation
SNP: single nucleotide polymorphism
TMPS: targeted massively parallel sequencing
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anderson 2015 Not a diagnostic test accuracy study. Poster abstract.
Anselem 2016 Decision making study. Observational study. Not a diagnostic test accuracy study
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Bayindir 2015 Samples overlap with Brady 2016. Most gNIPT results unconfirmed by a reference stan-
dard test. Insufficient information to derive 2 x 2 tables
Beamon 2013 Poster abstract of the 33rd Annual Meeting of the Society for Maternal-Fetal Medicine:
The PregnancyMeeting. Observational study with incomplete follow-up. Samples overlap
with Beamon 2014.
Beamon 2014 Observational study with incomplete follow-up. Not a diagnostic test accuracy study.
Some gNIPT results unconfirmed by a reference standard test
Belloin 2016 Most women (95%) completed a questionnaire to report their birth outcome (inappro-
priate reference standard for this review)
Benachi 2015b Tribune. Not a diagnostic test accuracy study.
Benachi 2016 All samples overlap with Benachi 2015.
Benn 2015 Letter to the editor on Zhang 2015 without data. Not a diagnostic test accuracy study.
Bhatt 2014 Poster abstract of the 18th International Conference on Prenatal Diagnosis and Therapy,
ISPD 2014. Patients with gNIPT negative result were without follow-up (no reference
standard). Incomplete 2 x 2 tables
Bianchi 2012a Samples overlap with Bianchi 2012. Data excluded to avoid double counting.
Bianchi 2014b Editorial. Not a diagnostic test accuracy study.
Bianchi 2014c Data excluded to avoid double counting. Samples overlap with Bianchi 2015b.
Bianchi 2015a Not a diagnostic test accuracy study. Author presented some false positive cases in women
with malignancy
Bianchi 2015b Incomplete 2 x 2 table. In this observational study, most women (98.9%) had no follow-
up (no reference standard)
Bianchi 2015c Not a diagnostic test accuracy study. Author presented some false positive cases in women
with malignancy. Samples overlap with Bianchi 2015a.
Bianchi 2015d Poster abstract. Not a diagnostic test accuracy study. Author presented some false positive
cases in women with malignancy. Samples overlap with Bianchi 2015a.
BlueCross BlueShield Asssociation 2014 Technology Evaluation Center Assessment. Review.
Brady 2016 Review with new data but most gNIPT results unconfirmed by a reference standard test.
Insufficient information to derive 2 x 2 tables
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Chen 2013 Poster abstract of the ISPD 17th International Conference on Prenatal Diagnosis and
Therapy. Samples overlap with Huang 2014.
Chen 2014 Poster abstract. Samples overlap with Yeang 2014.
Cherry 2014 Poster abstract. Samples overlap with Meck 2015.
Cheung 2015 Incomplete 2 x 2 table. This letter presentedwomenwhohadpositive results after screening
and were referred for invasive procedure to confirm the presence of fetal aneuploidy. Only,
the true positive and false positive gNIPT results were reported
Chiu 2008 Proof-of-concept. Not a diagnostic test accuracy study.
Chiu 2010 Proof-of-concept. Not a diagnostic test accuracy study.
Christina 2012 Proof-of-concept. Not a diagnostic test accuracy study.
Cinnioglu 2012 Poster abstract. Samples overlap with Rabinowitz 2012a.
Cirigliano 2013 Full poster from the 17th International Conference on Prenatal Diagnosis and Therapy,
ISPD 2013 received. Samples overlap with Cirigliano 2014 and Ordoñez 2015. Insuffi-
cient information to derive 2 x 2 tables.
Cirigliano 2014 Full poster from the 18th International Conference on Prenatal Diagnosis and Therapy,
ISPD 2014 received. Samples overlap with Cirigliano 2013 and Ordoñez 2015. Insuffi-
cient information to derive 2 x 2 tables.
Cuckle 2015 Review with simulation model for gNIPT.
Curnow 2014 Poster abstract of the 18th International Conference on Prenatal Diagnosis and Therapy,
ISPD 2014. Samples overlap with Dar 2014.
Dan 2012 Incomplete 2 x 2 table. Women with gNIPT negative results completed a questionnaire
to report their birth outcome (inappropriate reference standard for this review)
Dar 2014 Implementation study. Incomplete 2 x 2 table. Most patients with gNIPT negative result
were without follow-up (no reference standard). Some women had follow-up by telephone
(inappropriate reference standard for this review)
De Ligt 2013 Case report (deletion).
Denona 2016 Poster abstract. Retrospective observational study. Insufficient information to derive 2 x
2 tables
Discenza 2015 Poster abstract. Some gNIPT results unconfirmed by a reference standard test. Insufficient
information to derive 2 x 2 tables
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Dobson 2015 Poster abstract. Insufficient information to derive 2 x 2 tables (gNIPT positive results
only). Decision making. Samples overlap with Dobson 2016.
Dobson 2016 Insufficient information to derive 2 x 2 tables (gNIPT positive results only). Decision
making
Dong 2016 Sequencing not based on maternal plasma ccfDNA.
Duenwald 2016 Method development. Analytical accuracy. Not a diagnostic test accuracy study
Ehrich 2011a Editorial comment without new data.
Eiben 2014 Review. Not a diagnostic test accuracy study.
Ellison 2015 Poster abstract. All gNIPT results (TMPS) were confirmed with a previous gNIPT result
(MPSS) (inappropriate reference standard for this review). Insufficient information to
derive 2 x 2 tables
Faas 2011 Poster abstract of the 8th European Cytogenetics Conference. Samples overlap with Faas
2012.
Faas 2012 Proof-of-concept. Not a diagnostic test accuracy study.
Fairbrother 2013a Observational study. Incomplete 2 x 2 data. Most patients were without follow-up (no
reference standard)
Fairbrother 2013b Conference abstract of the 17th International Conference on Prenatal Diagnosis and
Therapy, ISPD 2013. Samples overlap with Fairbrother 2013a.
Fan 2008 Proof-of-concept. Not a diagnostic test accuracy study.
Fang 2015 Insufficient information to derive 2 x 2 tables.
Ferres 2013 Not a diagnostic test accuracy study (implementation study).
Fiorentino 2015 Poster abstract. All samples overlap with Fiorentino 2016.
Fosler 2015 Poster abstract of the 35th Annual Meeting of the Society for Maternal-Fetal Medicine:
The Pregnancy Meeting. Observational study. Incomplete 2 x 2 table. Most patients with
gNIPT negative result were without follow-up (no reference standard)
Futch 2013 Observational study with incomplete follow-up. Incomplete 2 x 2 table. Many gNIPT
results unconfirmed by a reference standard test
Gabriel 2014 Conference abstract. Proof-of-concept.
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Galea 2014 Full poster from the 18th International Conference on Prenatal Diagnosis and Therapy,
ISPD 2014. Incomplete 2 x 2 table. Most patients with gNIPT negative result were
without follow-up (no reference standard)
Gao 2014 News, comment on Liao 2014 and Yuan 2013 without new data.
Gao 2015 Poster abstract. Insufficient information to derive 2 x 2 tables
Geifman-Holtzman 2013 Poster abstract of the 33rd Annual Meeting of the Society for Maternal-Fetal Medicine:
The Pregnancy Meeting. Samples overlap with Xiong 2015.
Geifman-Holtzman 2014 Poster abstract of the 34th Annual Meeting of the Society for Maternal-Fetal Medicine:
The Pregnancy Meeting. Samples overlap with Xiong 2015.
Gerundino 2017 Women were asked to complete a questionnaire to report their birth outcome (inappro-
priate reference standard for this review). Insufficient information to derive 2 x 2 tables
Gil 2013 Most patients with gNITP negative result were without follow-up (no reference standard)
because 962 women had not yet delivered at the time of writing the publication. Insuffi-
cient information to derive 2 x 2 tables. Some patients overlap with del Mar Gil 2014.
Gil 2015 Decision making including gNIPT accuracy data. All samples overlap with Gil 2016.
Gnetetskaya 2015 Poster abstract. Samples overlap with Kurtser 2015.
Grati 2014 Not a diagnostic test accuracy study. No sequencing data.
Gray 2013 Observational study. Not a diagnostic test accuracy study. Full poster received from the
authors. Poster of the 17th International Conference on Prenatal Diagnosis and Therapy,
ISPD 2013
Gromminger 2014 Data excluded to avoid double counting. BlindedDNA sequencing libraries were provided
by Sequenom from their clinical trial cohort (NCT00877292) and were resequenced by
LifeCodexx.
Guex 2013 Research letter. Samples overlap with Pescia 2017.
Halks-Miller 2015 In reply to Bianchi 2015a. Not a diagnostic test accuracy study.
Harasim 2016 Poster abstract. Insufficient information to derive 2 x 2 tables
Hernandez-Gomez 2015 Implementation study. Not a diagnostic test accuracy study.
Hofmann 2013 Poster abstract. Samples overlap with Stumm 2014.
Hofmann 2014 Conference abstract. Insufficient information to derive 2 x 2 tables
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Hofmann 2015 Method development. Data were reanalysed by a new algorithmic approach of PraenaT-
est®. Not a diagnostic test accuracy study
Hu 2014 Not a next generation sequencing publication. NIPT was ultrasound and serum biomark-
ers
Hu 2015 Incomplete 2 x 2 tables. Only gNIPT positive results presented
Hui 2015a Poster abstract. All samples overlap with Hui 2015b.
Hui 2015b Implementation study. Incomplete 2 x 2 table. Most patients with gNIPT negative result
were without follow-up (no reference standard)
Jackson 2013 Poster abstract. All samples overlap with Jackson 2014.
Jensen 2013 Proof-of-concept. Not a diagnostic test accuracy study. Samples overlap with Palomaki
2012.
Jensen 2015 Proof-of-concept study with unblinded samples. Not a diagnostic test accuracy study
Jin 2014 Incomplete 2 x 2 table. Women with gNIPT negative results were followed-up by tele-
phone (inappropriate reference standard for this review)
Johnson 2013 Not a next generation sequencing method.
Juneau 2014 Method development. Incomplete 2 x 2 table. Most patients were without follow-up (no
reference standard)
Kagan 2015 Not a diagnostic test accuracy study. Simulation model.
Kalantar 2014 Not next generation sequencing method.
Karlsson 2015 Methodological publication. Not a diagnostic test accuracy study
Kershberg 2015 Poster abstract. Some gNIPT results unconfirmed by a reference standard test. Insufficient
information to derive 2 x 2 tables
Kinde 2012 Methodological publication. Not a diagnostic test accuracy study
Korabecna 2012 Bioinformatic simulation with Palomaki 2011 data.
Koumbaris 2016 Method development (proof-of-concept study). Development of an advanced fetal frac-
tion estimation method and aneuploidy determination algorithm. Not a diagnostic test
accuracy study
Kurtser 2015 Most patients with gNIPT negative result were without follow-up (no reference standard)
. Incomplete 2 x 2 tables
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Lambert-Messerlian 2014 Samples overlap with Palomaki 2011 and Palomaki 2012. Data excluded to avoid double
counting.
Larion 2015 Poster abstract. Implementation study.
Lau 2012a Incomplete 2 x 2 table.Womenwith gNIPTnegative resultswere followedup by telephone
or by email (inappropriate reference standard for this review). All samples overlap with
Lau 2014.
Lau 2013 Sample overlap with Lau 2014.
Lau 2014 Incomplete 2 x 2 table.Womenwith gNIPTnegative resultswere followedup by telephone
or by email (inappropriate reference standard for this review)
Lebo 2015 Incomplete 2 x 2 table.
Leung 2013 Proof-of-concept. Not a diagnostic test accuracy study.
Levandoski 2015 Poster abstract. Observational study about discordant gNIPT results. Insufficient infor-
mation to derive 2 x 2 tables
Levy 2013 Poster abstract. Incomplete 2 x 2 table.
Levy 2013a Poster abstract. Incomplete 2 x 2 table.
Levy 2013b Proof-of-concept. Not a diagnostic test accuracy study. Samples overlap with
Zimmermann 2013.
Li 2012 Methodological publication about relation between fetal fraction and multiple clinical
factors
Li 2015 Observational study. Unavailable information about gNIPT approach used. It is unclear
if patients with gNIPT negative result were followed up (no reference standard)
Liao 2011 Not a diagnostic test accuracy study. No aneuploid case.
Liao 2012 Proof-of-concept. Not a diagnostic test accuracy study.
Liao 2013 This is a poster abstract. The full publication was also excluded. See Liao 2014 for reasons
of exclusion.
Liao 2014 Incomplete 2 x 2 table for the retrospective and the prospective cohort. In prospective
cohort, most patients were without follow-up (no reference standard). For the retrospec-
tive cohort, number of gNIPT results was not reported. Sensitivity and specificity were
presented for the retrospective cohort but 2 x 2 tables could not be derived
Liao 2014a Letter to the editor about Bianchi 2014b without new data.
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Liu 2015 Incomplete 2 x 2 table.Womenwith gNIPTnegative resultswere followedup by telephone
(inappropriate reference standard for this review)
Lo 2014 Bioinformatic development. Comparison of sensitivity and specificity using 3 different
count normalisation methods
Lo 2014a Poster abstract. Bioinformatic development. Comparison of sensitivity and specificity
using 3 different count normalisation methods. Samples overlap with Lo 2014.
Loucký 2013 Samples overlap with Palomaki 2012. Data excluded to avoid double counting.
Louis-Jacques 2014 Full poster. Observational study. Not a diagnostic test accuracy study
Ma 2015 Samples overlap with Ma 2016.
Ma 2015a Poster abstract. All samples overlap with Ma 2016.
Manotaya 2016 Insufficient information to derive 2 x 2 tables. Women without invasive testing results
were encouraged to report birth outcomes through the insurance policy reimbursed (in-
appropriate reference standard for this review)
Marchili 2015 Poster abstract. Implementation study. Not a diagnostic test accuracy study. Insufficient
information to derive 2 x 2 tables
Mayen 2015 Observational study. Not a diagnostic test accuracy study.
Mazloom 2013a Poster abstract. Samples overlap with Mazloom 2013.
McCullough 2014 Incomplete 2 x 2 table. The clinician of women who passed gNIPT was encouraged to
send ad hoc feedback to the lab (inappropriate reference standard for this review)
McCullough 2014a Poster abstract. Incomplete 2 x 2 table. Samples overlap with McCullough 2014.
McCullough 2015 Full poster of the 19th International Conference on Prenatal Diagnosis and Therapy,
ISPD 2015. Most gNIPT results unconfirmed by a reference standard test. Insufficient
information to derive 2 × 2 tables. Some patients overlap with McCullough 2014.
McLennan 2016 Most patients with gNIPT negative result were without follow-up (no reference standard)
. Insufficient information to derive 2 x 2 tables
Meck 2014 Poster abstract. Samples overlap with Meck 2015.
Meck 2015 Not a diagnostic test accuracy study. Observational study.
Meck 2015a Poster abstract. Samples overlap with Meck 2015.
Mennuti 2015 Review without original data.
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Minarik 2015 gNIPT negative results unconfirmed by a reference standard test. Not a diagnostic test
accuracy study
Miron 2011 Not a diagnostic test accuracy study. This these explore traditional screening tests
Mundy 2008 Health Technology Assessment. Not a diagnostic test accuracy study
Mundy 2009 Health Technology Assessment. Not a diagnostic test accuracy study
Musci 2014 Poster abstract. Samples overlap with Norton 2015.
Musci 2014a Poster abstract. Samples overlap with Hooks 2014 and Nicolaides 2014a.
NCT00770458 Not a gNIPT method (other method).
NCT00877292 Not with ccfDNA (other sampling).
NCT00891852 Not a gNIPT method (other method).
NCT00971334 Completed clinical trial but no published data.
NCT01052688 Incomplete 2 x 2 data (ongoing study with cases only).
NCT01256606 Not a gNIPT method (other method).
NCT01451671 Incomplete 2 x 2 data (ongoing study with cases only).
NCT01451684 Observational study on gNIPT without fetal karyotype.
NCT01555346 Completed clinical trial but no published data.
NCT01574781 Completed clinical trial but no published data.
NCT01597063 Completed clinical trial but no published data.
NCT01661010 Not a diagnostic test accuracy study.
NCT01663675 Adult with T21. Not with pregnant women (other population).
NCT01668251 Not a diagnostic test accuracy study.
NCT01725438 Not with ccfDNA (other sampling).
NCT01837979 Incomplete 2 x 2 data.
NCT01966991 Completed clinical trial but no published data.
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NCT02127515 Not a diagnostic test accuracy study. Pregnant women with gNIPT have not a reference
standard
NCT02226315 Inappropriate reference standard for this review (pregnancy outcome data obtained from
the patient)
NCT02872948 Not a gNIPT method (other method).
Neufeld-Kaiser 2015 Observational study. Not a diagnostic test accuracy study. Incomplete 2 x 2 tables. Most
gNIPT results unconfirmed by a reference standard test
Neveling 2015 Method validation for the NextSeq 500 platform. Not a diagnostic test accuracy study
Nickolich 2016 Not a diagnostic test accuracy study.
Nicolaides 2013a Poster abstract. All samples overlap with Nicolaides 2012.
Nicolaides 2014 Simulation model on gNIPT implantation in first- or second-tier test
Nicolaides 2014b Note on Nicolaides 2014a without new data.
Nicolaides 2014c Target condition presented in this publication is not the focus of this review. Publication
of next generation sequencing with ccfDNA for fetal triploidy
Norem 2015 Full poster received from authors. Most patients were without follow-up (no reference
standard). Incomplete 2 x 2 tables
Norton 2014 Bioinformatic simulation.
Norton 2014a Poster abstract. Samples overlap with Norton 2015.
Norton 2015a Bioinformatic simulation.
Norton 2015b Editorial on Norton 2015 without new data.
Norton 2015c Author reply to comments from Sentilhes 2015 and Smith-Bindman 2015 about Norton
2015 without new data.
Norton 2016 Simulation model to compare sequential and ccfDNA screening with data published in
the literature. Not a diagnostic test accuracy study
O’Leary 2014 Bioinformatic simulation.
Oepkes 2015 Most patients were without follow-up (no reference standard). Insufficient information
to derive 2 x 2 tables
Oneda 2016 Poster abstract. Insufficient information to derive 2 x 2 tables
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Ordoñez 2015 Full poster received. Some gNIPT results unconfirmed by a reference standard test. In-
sufficient information to derive 2 x 2 tables
Palomaki 2011 Samples overlap with Palomaki 2012 (samples in Palomaki 2011 have been reanalysed in
Palomaki 2012). Study excluded to avoid double counting.
Palomaki 2012a Samples overlap with Palomaki 2012. Conference abstract about Palomaki 2012 data.
Palomaki 2012b Editorial on Palomaki 2011 without new data.
Palomaki 2015 Not a diagnostic test accuracy study.
Palomaki 2015a Note about Palomaki 2015. Not a diagnostic test accuracy study.
Perez-Pedregosa 2015 Incomplete 2 x 2 tables. Some women with gNIPT negative results were followed up by
telephone (inappropriate reference standard for this review)
Pescia 2017 Follow-up for gNIPT negative results was ensured by an inquiry of two sets of randomly
selected samples (inappropriate reference standard for this review)
Petersen 2014 Not a next generation sequencing publication. NIPT was ultrasound measurement and
serum biomarkers
Pettit 2014 Most patients with gNIPT negative result were without follow-up (no reference standard)
. Insufficient information to derive 2 x 2 tables
Porreco 2014a Reply to Grati 2014 without sequencing data.
Rabinowitz 2012 Poster abstract. Proof-of-concept. Not a diagnostic test accuracy study
Rabinowitz 2012a Poster abstract with incomplete 2 x 2 tables.
Rabinowitz 2012b Poster abstract. Samples overlap with Rabinowitz 2012a.
Rabinowitz 2013 Poster abstract. Samples overlap with Pergament 2014.
Rabinowitz 2014 Poster abstract. Sample overlap with Pergament 2014.
Rad 2014 Implementation study without sequencing data presented.
Radoi 2015 Incomplete 2 x 2 tables. Most patients were without follow-up (no reference standard)
Rava 2012 Poster abstract. Samples overlap with Bianchi 2012.
Rava 2014 Methodological publication about fetal DNA fraction with MELISSA samples
Reiff 2015 Insufficient information to derive 2 x 2 tables.
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Reiff 2016 Insufficient information to derive 2 x 2 tables.
Reimers 2015 Conference abstract from the 19th International Conference on Prenatal Diagnosis and
Theraphy, ISPD 2015. Simulation model. Not a diagnostic test accuracy study
Revello 2016 Not a diagnostic test accuracy study. All samples overlap with Gil 2016 and Quezada
2015.
Ryan 2016 Method development of version 2 to SNP-based gNIPT. Not a diagnostic test accuracy
study
Sachse 2015 Proof-of-concept of fetal fraction quantification by qPCR.
Samura 2015 Most patients were without follow-up (no reference standard). Insufficient information
to derive 2 x 2 tables. Samples overlap with Sago 2015.
Sarno 2016 Some women reported their birth outcome (inappropriate reference standard for this
review). Information about false positive results were insufficient to derive all 2 x 2 tables
Schöck 2015 Poster abstract. Bioinformatics development with unblinded samples
Sehnert 2013 Poster abstract. Incomplete 2 x 2 table.
Sehnert 2014 Poster abstract. Samples overlap with Bianchi 2014b.
Sentilhes 2015 Comment about Norton 2015 without new data.
Seo 2015 Women with gNIPT result were without follow-up at birth.
Settler 2015 Full poster received. Insufficient information to derive 2 x 2 tables. Some gNIPT results
unconfirmed by a reference standard test
Shani 2016 Simulation model. Not a diagnostic test accuracy study.
Shaohua 2012 Poster abstract. Full poster not received. Incomplete 2 x 2 table
Sharma 2015 Poster abstract about patient perceptions of gNIPT from the multi-centered Canadian
PEGASUS trial. gNIPT results comparedwith first trimester combined test (inappropriate
reference standard for this review)
Shaw 2013 Poster abstract. Samples overlap with Shaw 2014.
Shen 2016 Method development. Not a diagnostic test accuracy study.
Shi 2015 Incomplete 2 x 2 table. gNIPT negative result unconfirmed by a reference standard test
Shulman 2014 Poster abstract. Incomplete 2 x 2 table. Most patients with gNIPT negative result were
without a reference standard test
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Sistermans 2015a Letter to the editor on Bianchi 2015a without data.
Smith-Bindman 2015 Comment about Norton 2015 without new data.
Song 2012 Poster abstract. Some samples overlap with Sparks 2012a.
Sparks 2012 Method development (all unblinded samples). Incomplete 2 x 2 table. Most patients with
gNIPT negative result were unconfirmed by a reference standard test
Srinivasan 2013 Poster abstract. Samples from MELISSA study (potentially overlap)
Stokowski 2015 Not a next generation sequencing method.
Strah 2015 Women were followed up by telephone interview to find out their birth outcome (inap-
propriate reference standard for this review)
Straver 2014 Proof-of-concept.
Strom 2015 Incomplete 2 x 2 table. Only women with gNIPT positive result were reported
Stumm 2011 Proof-of-concept. Not a diagnostic test accuracy study.
Stumm 2012 Proof-of-concept. Not a diagnostic test accuracy study.
Stumm 2012a Poster abstract. Samples overlap with Stumm 2014.
Stumm 2013 Poster abstract. Samples overlap with Stumm 2014.
Stumm 2016 Not a diagnostic test accuracy study.
Swanson 2012 Publication about Bianchi 2012 without new data.
Syngelaki 2014 Not a diagnostic test accuracy study. Simulation model.
Tan 2016 Women with gNIPT negative results were followed up by telephone interview (inappro-
priate reference standard for this review). Insufficient information to derive 2 x 2 tables
Taneja 2016 Incomplete follow-up. Incomplete 2 x 2 table. Many gNIPT results unconfirmed by a
reference standard test
Taneja 2017 Most patients with gNIPT negative result were without reference standard test. Providers
were encouraged to report discordant clinical outcomes. Insufficient information to derive
2 x 2 tables
Tarrier 2015 gNIPT results unconfirmed by a reference standard test. Their referencemethod is verifi®
results (inappropriate reference standard for this review)
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Taylor 2014 Not a diagnostic test accuracy study. Observational study and decision making about
gNIPT uptake in their center
Togneri 2016 Full poster received. Internal verification set and implantation in their centre. Not a
diagnostic test accuracy study
Tong 2016 Not a next-generation sequencing method with ccfDNA.
Valderramos 2016a Poster abstract. Insufficient information to derive 2 x 2 tables
Valderramos 2016b Poster abstract. Samples overlap with Valderramos 2016c.
Valderramos 2016c Insufficient information to derive 2 x 2 tables. Retrospective cohort of patients with gNIPT
positive results
van den Oever 2012a Proof-of-concept. Not a diagnostic test accuracy study.
van den Oever 2012b Proof-of-concept. Not a diagnostic test accuracy study.
van den Oever 2013 Proof-of-concept. Not a diagnostic test accuracy study.
Van Opstal 2016 Simulation model. Not a diagnostic test accuracy study.
Verweij 2013a Poster abstract. All samples overlap with Verweij 2013.
Wald 2015a Not a diagnostic test accuracy study. Prenatal screening workflow proposed
Wald 2015b Not a diagnostic test accuracy study. Prenatal screening workflow proposed
Wang 2012 Incomplete 2 x 2 table.Womenwith gNIPTnegative resultswere followedup by telephone
(inappropriate reference standard for this review)
Wang 2015b Not a diagnostic test accuracy study.
Wang 2015c Proof-of-concept. Not a diagnostic test accuracy study.
Wang 2015d Editorial on Wang 2015b without new data.
Wang 2015e Not a diagnostic test accuracy study.
Xiong 2015 Full poster received. Observational study and incomplete follow-up
Yankova 2015 Simulation model for gNIPT implantation. Not a diagnostic test accuracy study
Yaron 2015 Commentary about gNIPT for microdeletion syndromes and rare autosomal trisomies.
Not a diagnostic test accuracy study
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Yeang 2014 Proof-of-concept. Not a diagnostic test accuracy study.
Yu 2014 Proof-of-concept. Not a diagnostic test accuracy study.
Yuan 2013 Proof-of-concept. Not a diagnostic test accuracy study.
Zhang 2015 Incomplete 2 x 2 table. Women with gNIPT negative results were followed-up by tele-
phone (inappropriate reference standard for this review)
Zhou 2013 Poster abstract. Incomplete 2 x 2 table.
Zimmermann 2012 Proof-of-concept. Not a diagnostic test accuracy study.
Zimmermann 2013 Proof-of-concept. Not a diagnostic test accuracy study.
Zwiefelhofer 2013 Implementation assessment of 2 sequencing platforms for gNIPT in a routine clinical
environment. Not a diagnostic test accuracy study
ccfDNA: circulating cell-free DNA
gNIPT: genomics-based non-invasive prenatal testing
MPSS: massively parallel shotgun sequencing
TMPS: targeted massively parallel sequencing
Characteristics of ongoing studies [author-defined order]
Basaran 2015
Trial name or title Publication’s title: False positive and false negative results of cell free DNA testing
Target condition and reference standard(s) Target conditions: T21, T18, T13, 45,X, 47,XXY, 47,XYY and 47,XXX.
Reference standard: fetal karyotype of chorionic villi or amniotic fluid
Index and comparator tests gNIPTbyTMPS orMPSS by commercial company providing gNIPT inTurkey (Ariosa
Diagnostics, Inc., BGI-Shenzhen, Illumina, Inc, Natera, Inc. and Sequenom, Inc).
Blood samples for gNIPT were collected before reference standard
Starting date Not reported.
Contact information Dr Seher Basaran
Department of Medical Genetics
Istanbul University, Istanbul Medical Faculty
TURKEY
90 (212) 4142000
basarabs@istanbul.edu.tr
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Basaran 2015 (Continued)
Aim to study To demonstrate the importance of confirmation of fetus genotype by invasive testing
after gNIPT
Funding source or sponsor of the study The genetic centre is not affiliated with any commercial company providing gNIPT
Information about the authors contacted Author was contacted on: 12, 14 and 18 January 2016.
Last reply received on: 19 January 2016.
Notes At the time of this writing, the authors plan to publish a full publication soon
Buresch 2016
Trial name or title Poster’s title: Actual rates of recommended diagnostic testing after first-trimester screen-
ing vs same-day screening by cell free DNA
Target condition and reference standard(s) Target conditions: T21, T18, T13, 45,X, 47,XXY, 47,XYY and 47,XXX.
Reference standard: not reported.
Index and comparator tests MPS.
Starting date January to June 2015.
Contact information Susan Klugman
Department of Obstetrics and Gynecology and Women’s Health,
Albert Einstein College of Medicine,
Montefiore Medical Center 1695 Eastchester Road,
Bronx, NY 10461, United States.
sklugman@montefiore.org
Aim to study To compare actual patient referrals for post-screen diagnostic tests following first-
trimester screening vs same day ccfDNA
Funding source or sponsor of the study Not reported.
Information about the authors contacted Author was contacted on: 1 and 23 September 2016.
Reply received on: 23 September 2016.
Notes Authors are working on data at the time of writing and they plan to submit for publi-
cation
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Chen 2011a
Trial name or title Oral presentation’s title: Noninvasive prenatal diagnosis of fetal aneuploidy by massively
parallel sequencing of maternal plasma DNA
Target condition and reference standard(s) Target conditions: T21, T18, T13 and SCA.
Reference standard: fetal karyotype.
Index and comparator tests gNIPT by MPSS on Illumina GAIIx/HiSeq 2000 sequencer.
Cutpoint: positive if t score < -4.
Commercial test: BGI’s test.
Starting date Not reported.
Contact information Fang Chen, Beijing Genomics Institute, Shenzhen, China
Aim to study To assess gNIPT with ccfDNA performance on fetal aneuploidies
Funding source or sponsor of the study Not reported.
Information about the authors contacted BGI was contacted on: 19 May 2016.
No reply received from the author.
Notes Cohort of 5268 pregnant women. They successfully identified 62 cases of T21, 40 cases
of T18, 3 cases of T13, 13 cases of SCA. In a cohort of karyotyping cases, the sensitivity
and specificity of the aneuploidy fetus detection was 100% and 100%, respectively
Da Fonseca 2015
Trial name or title Abstract’s title: Non-Invasive prenatal testing for the most common aneuploidies (tri-
somies 21, 18, and 13) using a semiconductor-sequencing platform: a French multi-
center pilot study
Target condition and reference standard(s) Target conditions: T21, T18 and T13.
Reference standard: fetal karyotype.
Index and comparator tests gNIPT on semiconductor sequencing platform (MPSS).
Blood sample collection not reported.
Cutpoint: not reported.
Starting date Not reported.
Contact information J.P. Da Fonseca, Inserm U1016 Plateforme Génomique, Paris, France
Aim to study To validate a common protocol and to evaluate the efficiency and reliability of gNIPT
of the most common chromosomal aneuploidies using a semiconductor sequencing
platform
Funding source or sponsor of the study Not reported.
244Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Da Fonseca 2015 (Continued)
Information about the authors contacted Author was contacted on: 19 January 2016 and 23 March 2016.
Reply received on: 16 February 2016.
Notes Conference Abstract of the 10th European Cytogenetics Conference of the European
Cytogenetics Association, ECA 2015. Prospective study of 500 pregnant women at high
risk of fetal aneuploidy who undergo fetal karyotyping. The NIPT results matched the
fetal karyotyping results in all of the cases: all trisomies were detected
ISRCTN11174071
Trial name or title Comparison of false positive rates in prenatal combined screening and cell free DNA
screening for trisomy 21 (ReFaPo study)
Target condition and reference standard(s) Target condition: T21.
Reference standard: prenatal or postnatal karyotype.
Index and comparator tests gNIPT.
Starting date July 2016.
Contact information Karl Oliver Kagan
University of Tuebingen
Department of Obstetrics and Gynaecology
Calwerstrasse 7
Tuebingen
72076
Germany
Aim to study To compare the false positive rate of cell-free DNA and traditional screening methods
in a randomised controlled trial in a cohort without prior risk of fetal aneuploidy
Funding source or sponsor of the study Study funded by CENATA GmbH who does the analysis.
Information about the authors contacted No need for further contact.
Notes Target number of participants: 1400.
Recruitment end date: March 2017.
Intention to publish date: October 2018.
DOI 10.1186/ISRCTN11174071
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Lin 2014
Trial name or title Clinical implementation of noninvasive prenatal testing in twin pregnancies with as-
sisted reproductive technique treatment
Target condition and reference standard(s) Target conditions: T21, T18 and T13.
Reference standards: fetal karyotype or clinical outcomes.
Index and comparator tests gNIPT by MPSS.
Commercial test: BGI Shenzhen’s prenatal test.
Starting date Not reported.
Contact information BGI-Shenzhen
Shenzhen, China
Aim to study To assess the clinical implementation of MPS-based NIPT in twin pregnancies with
assisted reproductive technique treatment
Funding source or sponsor of the study Not reported but BGI-Shenzhen made sequencing and analyses.
Information about the authors contacted No need for further contact.
Notes Some women were still pregnant at the time of writing this poster abstract
Mu 2014
Trial name or title Maternal non-invasive fetal DNA test used in prenatal diagnosis
Target condition and reference standard(s) Target conditions: T21, T18, T13 and 45,X.
Reference standard: fetal karyotype of amniotic fluid.
Index and comparator tests gNIPT by MPSS.
NIFTY™ prenatal test by BGI-Shenzhen.
Starting date In 2012.
Contact information Mu Y.
Beijing United Family Hospital
Beijing, China.
Aim to study Not reported.
Funding source or sponsor of the study Not reported.
Information about the authors contacted Author was contacted on: 19 April and 19 May 2016.
No reply received from the author.
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Mu 2014 (Continued)
Notes Poster abstract. Some women were still pregnant at the time of writing this poster
abstract
NCT01429389
Trial name or title Specimen collection from pregnant women at increased risk for fetal aneuploidy
Target condition and reference standard(s) Target condition: T21.
Reference standard: fetal karyotype.
Index and comparator tests gNIPT.
Starting date May 2011.
Contact information Sequenom, Inc.
Aim to study To develop a prenatal aneuploidy test using ccfDNA from blood samples from preg-
nant women who have an increased risk indicator/s for fetal chromosomal aneuploidy
detection (T21)
Funding source or sponsor of the study Study funded by Sequenom, Inc.
Information about the authors contacted No need for further contact.
Notes
NCT01472523
Trial name or title A safer pre-natal diagnosis using free DNA in maternal blood (IONA®).
Target condition and reference standard(s) Target conditions: T21, T18, T13 and other chromosomal abnormalities yet to be
determined
Reference standards: prenatal karyotype and follow-up for 1 year
Index and comparator tests gNIPT by TMPS (selective amplification of fetal DNA) by Premaitha Health
Starting date April 2007.
Contact information Brenda Kelly
National Health Service, United Kingdom
Aim to study To validate a novel gNIPT method that could increase the titre of fetal DNA within a
given sample
Funding source or sponsor of the study Study funded by Premaitha Health.
Information about the authors contacted No need for further contact.
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Notes
NCT01545674
Trial name or title Prenatal Non-invasive Aneuploidy Test Utilizing SNPs trial (PreNATUS)
Target condition and reference standard(s) Target conditions: aneuploidy in a fetus at chromosomes 13, 18, 21, X and Y
Reference standard: fetal karyotype.
Index and comparator tests gNIPT by TMPS (SNP based technology by Natera, Inc.).
Starting date January 2012.
Contact information Ronald Wapner, MD, Columbia University
Aim to study To assess the diagnostic capability of an informatics enhanced SNP based technology
(Parental Support) to identify pregnant women who are carrying a fetus with an aneu-
ploidy from free floating DNA in the maternal blood
Funding source or sponsor of the study Study funded by Natera, Inc.
Information about the authors contacted No need for further contact.
Notes
NCT01925742
Trial name or title Study of the efficacy of new non-invasive prenatal tests for screening for fetal trisomies
using maternal blood (PEGASUS)
Target condition and reference standard(s) Target conditions: T21, T18 and T13.
Reference standards: prenatal or neonatal karyotype or medical record from birth
Index and comparator tests gNIPT by Semiconductor MPSS (Ion Torrent Proton™) or optical-based MPSS (Illu-
mina) or by TMPS with Harmony™ prenatal test by Ariosa Diagnostics, Inc
Starting date August 2013.
Contact information François Rousseau
CHU de Québec
Québec, Canada
Aim to study To perform a pan-Canadian large-scale validation study comparing the relative effec-
tiveness and clinical performances of 2 index gNIPT methods using fetal ccfDNA in
maternal blood in Canadian clinical laboratories between themselves and with that of
fetal karyotype for detecting fetal aneuploidy of chromosomes 13, 18 and 21 and to
compare the accuracy of this new gNIPT method with traditional prenatal screening
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methods
Funding source or sponsor of the study Study funded by Centre Hospitalier Universitaire deQuébec, Laval University, Genome
Canada,GenomeQuebec,GenomeBritishColumbia andCanadian Institutes ofHealth
Research (CIHR)
Information about the authors contacted No need for further contact.
Notes Recruitment of patients completed (near 5000 pregnant women enrolled). at the time of
writing, they are sequencing 3600 pregnant women with the 2 gNIPTMPSS platforms.
A subsample of about 2300 blood samples was analysed by Ariosa Diagnostics, Inc
(TMPS)
Estimated study completion date: June 2017.
NCT02201862
Trial name or title Non-invasive Chromosomal Evaluation of Trisomy study (NICHE)
Target condition and reference standard(s) Target conditions: T21, T18 and T13.
Reference standard: fetal karyotype.
Index and comparator tests gNIPT by TMPS by Ariosa Diagnostics, Inc.
Starting date April 2014.
Contact information Romielle Aquino
408-209-9098
raquino@ariosadx.com
Or
Thomas Musci
408-229-7500
tmusci@ariosadx.com
Aim to study To provide clinically annotated samples to support continued improvements in the
Ariosa Diagnostics, Inc Test content, methodology, specimen processing and quality
control
Funding source or sponsor of the study Study funded by Ariosa Diagnostics, Inc.
Information about the authors contacted No need for further contact.
Notes
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NCT02278536
Trial name or title Multiple gestation study.
Target condition and reference standard(s) Target conditions: T21, T18, T13 and SCA.
Reference standards: fetal karyotype (amniocentesis or CVS) or genetic testing from
cheek swab or saliva from live-born children
Index and comparator tests gNIPT by TMPS by Natera, Inc.
Starting date March 2013.
Contact information Brian Kirshon
Houston Perinatal Associates
Or
Zach Demko
Natera, Inc.
Aim to study To demonstrate the accuracy of our new NATUS diagnostic method to determine
the genetic health of the developing fetuses in a multiple gestation pregnancy from a
maternal blood sample
Funding source or sponsor of the study Study funded by Natera, Inc.
Information about the authors contacted No need for further contact.
Notes
NCT02278874
Trial name or title High risk multiple gestation study.
Target condition and reference standard(s) Target conditions: T21, T18, T13 and SCA.
Reference standards: fetal karyotype (amniocentesis or CVS) or genetic testing from
cheek swab or saliva from live-born children
Index and comparator tests gNIPT by TMPS by Natera, Inc.
Starting date August 2014.
Contact information Joanne Stone
Mt. Sinai Hospital, New York
Aim to study To demonstrate the accuracy of our proprietary algorithm method to determine the ge-
netic health of the developing fetuses in a multiple gestation pregnancy from a maternal
blood sample
Funding source or sponsor of the study Study funded by Natera, Inc., Mount Sinai Hospital New York, Montefiore Medical
Center, Long Island Jewish Medical Center and Tufts Medical Center
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NCT02278874 (Continued)
Information about the authors contacted No need for further contact.
Notes
NCT02317965
Trial name or title Non-invasive screening for fetal aneuploidy.
Target condition and reference standard(s) Target conditions: T21 and T18.
Reference standard: fetal karyotype.
Index and comparator tests gNIPT by MPSS by Progenity, Inc.
Starting date March 2015.
Contact information Richard Porreco
Obstetrix Medical Group of Colorado
Aim to study To detect whole chromosome abnormalities on all chromosomes 13, 16, 18, 21, X and
Y, in the fetus through analysis of ccfDNA and compound sample DNA in maternal
blood
Funding source or sponsor of the study Study funded by Progenity, Inc.
Information about the authors contacted No need for further contact.
Notes
NCT02424474
Trial name or title T21,18 and 13 screening by cell free fetal DNA in low risk patients (DEPOSA)
Target condition and reference standard(s) Target conditions: T21, T18 and T13.
Reference standard: fetal karyotype.
Index and comparator tests gNIPT by MPSS.
Starting date June 2015.
Contact information Alexandra Benachi
Antoine Béclère Hospital
Aim to study To evaluate the performance of gNIPT in a population of pregnant women with and
without in vitro fertilisation (IVF) concomitantly to regular first-trimester trisomy 21
(T21) screening using maternal age, nuchal fold measurement and serum screening
Funding source or sponsor of the study Study funded by Assistance Publique - Hôpitaux de Paris.
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Information about the authors contacted No need for further contact.
Notes Recruitment of patients completed (933 pregnant women enrolled)
NCT02787486
Trial name or title Expanded Noninvasive Genomic Medical Assessment: the Enigma study
Target condition and reference standard(s) Target conditions: T21, T18, T13, microdeletion syndromes, sex chromosome abnor-
malities, infectious and other diseases, and blood group typing
Reference standard: fetal karyotype or medical records.
Index and comparator tests gNIPT by MPSS provided by Progenity, Inc.
Starting date October 2015.
Contact information Paul Bien
760-494-1743
paul.bien@progenity.com
Aim to study To evaluate the relative clinical sensitivity, specificity, and performance of the laboratory-
developed test as a screening test for fetal chromosomal aneuploidy, infectious and other
diseases, and RhD genotyping in the general population of pregnant women
Funding source or sponsor of the study Study funded by Progenity, Inc.
Information about the authors contacted No need for further contact.
Notes
Sago 2015
Trial name or title Nationwide demonstration project of next-generation sequencing of cell-free DNA in
maternal plasma in Japan: 1-year experience
Target condition and reference standard(s) Target conditions: T21, T18 and T13.
Reference standards: fetal karyotype of chorionic villi or amniotic fluid or tissues of the
miscarriage or medical record from birth
Index and comparator tests gNIPT by MPSS.
Blood samples were collected before invasive procedure.
Commercial test: MaterniT21™ prenatal test from Sequenom, Inc
Starting date 15 November 2012. Recruitment period between April 2013 to March 2014
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Sago 2015 (Continued)
Contact information Haruhiko Sago
National center for Child-health and development
Perinatal Center
2-10-1Ookura, Setagaya-ku, Tokyo
03-3416-0181
sagou-h@ncchd.go.jp
Aim to study To evaluate the quality of the genetic counselling in Japan. Sago 2015 reported the
1-year experience of a nationwide demonstration project to introduce gNIPT of fetal
aneuploidy from maternal plasma and discuss how to implement this program in Japan
Funding source or sponsor of the study Study supported by theGrant of theNationalCenter forChildHealth andDevelopment
24-3, Japan. Sequenom, Inc made gNIPT
Information about the authors contacted Author was contacted on: 6 April and 14 June 2016.
No reply received from the author.
Notes Authors continue collecting follow-up data in the study population
Sanchez-Usabiaga 2015
Trial name or title Clinical implementation of non-invasive prenatal study for detecting aneuploidies by
fetal DNA based on single nucleotide polymorphisms: 2 years in Mexico
Target condition and reference standard(s) Target conditions: T21, T18, T13, 45,X, 47,XXY, 47,XYY and 47,XXX
Reference standards: fetal karyotype of chorionic villi or amniotic fluid ormedical record
from birth
Index and comparator tests gNIPT by TPMS.
Commercial test: Natera’s prenatal test.
Starting date Recruitment period: March 2013 to February 2015.
Contact information Dr. Rafael Sánchez Usabiaga
rsanchez@medicafertil.com.mx
Aim to study To describe our experience of 2 years integrating gNIPT by ccfDNA in its variant of
single nucleotide polymorphism (SNPs) as a screening method for the detection of
common aneuploidies, since 9 weeks of gestation
Funding source or sponsor of the study Not reported but Natera, Inc. made gNIPT sequencing and analyses
Information about the authors contacted No need for further contact.
Notes There are 270 pregnant women included in this study.
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Sistermans 2015
Trial name or title TRIDENT: or monitored NIPT implementation in the Netherlands
Target condition and reference standard(s) Target conditions: T21, T18 and T13.
Reference standard: fetal karyotype of chorionic villi or amniotic fluid is recommended
in case of abnormal gNIPT test results. Neonatal clinical examination not mentioned
Index and comparator tests gNIPT by MPSS.
Starting date 01 April 2014.
Contact information Dr. Erik Sistermans.
VU University Medical Center
Dept. of Clinical and Human Genetics
Van der Boechorststraat 7
1081 BT Amsterdam
NETHERLANDS
+31-20-020-4448346
Email: e.sistermans@vumc.nl
Aim to study To investigate and evaluate all relevant aspects of the introduction of NIPT in theDutch
prenatal screening program
Funding source or sponsor of the study The TRIDENT study was designed and proposed by the national multidisciplinary
NIPT consortium
Information about the authors contacted Author have been contacted on: 9 December 2015 and 15 March 2016.
Reply received on: 16 March 2016.
Notes Conference abstract presented at the Annual conference of the European Society of
Human Genetics at Glasgow, Scotland, UK. http://www.emgo.nl/research/quality-of-
care/research-projects/1451/trident-study-trial-by-dutch-laboratories-for-evaluation-
of-non-invasive-prenatal-testing-nipt/background/
The authors plan to publish a full publication soon.
Torres 2015
Trial name or title Genetic non invasive prenatal testing: A clinical and technical experience of 3000 cases
with follow-up
Target condition and reference standard(s) Target conditions: T21, T18, T13, 45,X, 47,XXY, 47,XYY and 47,XXX.
Reference standard: fetal karyotype of amniotic fluid.
Index and comparator tests gNIPT by MPSS.
Commercial test: TrisoNIM® prenatal test by NIMGenetics Genomics
Starting date Not reported.
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Torres 2015 (Continued)
Contact information Juan C Cigudosa
NIMGenetics Genomics
Madrid, Spain.
Aim to study To show a NIPT protocol, called TrisoNIM®, which has been partially performed in
our laboratory, based in massive parallel sequencing
Funding source or sponsor of the study Not reported.
Information about the authors contacted Author were contacted on: 29 February, 22 March, 15 and 27 June 2016.
Reply received on: 20 June 2016.
Notes Full poster received from the authors.
Van Wymersch 2015
Trial name or title Introduction of noninvasive prenatal testing for fetal trisomies: preliminary results and
consequences on invasive samplings
Target condition and reference standard(s) Target conditions: T21, T18, T13, 45,X, 47,XXY, 47,XYY and 47,XXX. Microdeletion
syndromes can also be detected.
Reference standards: fetal karyotype of chorionic villi or amniotic fluid ormedical record
from birth
Index and comparator tests gNIPT by MPSS.
Blood samples were collected before invasive procedure.
Cutpoint: not reported.
Commercial test: NIFTY™ test (Bejing Genomics Institute, Hong-Kong, China)
Starting date December 2013.
Contact information Dr Van Wymersch Didier,
Service de Gynécologie Obstétrique,
Centre Hospitalier de Luxembourg, 4 Rue Barblé, L-1210 Luxembourg
E-mail: vanwymersch.didier@chl.lu
Aim to study To analyse a year of gNIPT implantation in our institute and to analyse gNIPT impli-
cation in chromosomal abnormalities screening politic
Funding source or sponsor of the study No reported. Samples analysed at BGI.
Information about the authors contacted Author was contacted on: 12 September 2016.
Reply received on: 29 September 2016.
Notes This publication showed the first 683 samples. At the time of writing, authors have a
much larger population of 2132 pregnant women. No false negative results have been
observed to date for all the pregnancies that have already come to term
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Willems 2014
Trial name or title The first 3000 Non-Invasive Prenatal Tests (NIPT) with the Harmony test in Belgium
and the Netherlands
Target condition and reference standard(s) Target conditions: T21, T18 and T13.
Reference standard: fetal karyotype of chorionic villi or amniotic fluid
Index and comparator tests gNIPT by TMPS.
Commercial test: Harmony™ prenatal test by Ariosa Diagnostics, Inc
Starting date Recruitment period: March 2013 to December 2013.
Contact information Patrick Willems
patrick.willems@genetic-diagnostic.net
Aim to study To report the results of the first 3000 consecutive gNIPT tests performed in pregnant
women from Belgium and the Netherlands
Funding source or sponsor of the study Not reported. Ariosa Diagnostics, Inc made sequencing and analysis
Information about the authors contacted No need for further contact.
Notes
Yu 2014a
Trial name or title Maternal non-invasive fetal DNA test used in prenatal diagnosis
Target condition and reference standard(s) Target conditions: T21, T18, T13 and 45,X.
Reference standards: cytogenetic tests and postnatal follow-up
Index and comparator tests gNIPT by MPSS by BGI-Shenzhen.
Starting date Patients recruited in 2012.
Contact information Yu M or Fei S.
Beijing United Family Hospital.
Aim to study To determine gNIPT accuracy in Chinese population.
Funding source or sponsor of the study Not reported.
Information about the authors contacted Author was contacted on: 15 May 2016.
BGI was contacted on: 19 May 2016.
No reply received from the author or BGI.
Notes Conference abstract. Some women were still pregnant at the time of writing their
conference abstract
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Zwiefelhofer 2014
Trial name or title Prenatal detection of fetal aneuploidy on the Ion Torrent Proton™ platform
Target condition and reference standard(s) Target condition: T21.
Reference standard: fetal karyotype.
Index and comparator tests gNIPT by MPSS on the Proton™ platform.
Starting date Not reported.
Contact information Sequenom, Inc.
Aim to study To examine the performance of a gNIPT for fetal aneuploidy on the Ion Torrent Pro-
ton™ platform
Funding source or sponsor of the study Study funded by Sequenom, Inc.
Information about the authors contacted Author was contacted on: 19 April and 15 June 2016.
Reply received on: 22 June 2016.
Notes Full poster received from authors. This study includes 156 samples including 16 women
carrying a T21 fetus. All patient samples were correctly identified according to their
karyotype results
CVS: chorionic villi sampling
gNIPT: genomics-based non-invasive prenatal testing
MPSS: massively parallel shotgun sequencing
TMPS: targeted massively parallel sequencing
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 MPSS T21 41 50133
2 MPSS T18 38 49003
3 MPSS T13 29 46090
4 MPSS 45,X 14 7867
5 MPSS 47, XXX 5 5449
6 MPSS 47,XXY 8 6588
7 MPSS 47,XYY 8 6629
8 MPSS all 7 aneuploidies 44 50864
9 MPSS, autosomes 43 50453
10 MPSS, SCA 14 7911
11 TMPS T21 16 32487
12 TMPS T18 12 30319
13 TMPS T13 10 22868
14 TMPS 45,X 6 2214
15 TMPS 47,XXX 2 586
16 TMPS 47,XXY 4 1021
17 TMPS 47,XYY 2 358
18 TMPS all 7 aneuploidies 21 35275
19 TMPS, autosomes 18 34473
20 TMPS, SCA 6 2214
21 Traditional screening tests,
autosomes
5 24279
22 Traditional screening tests T21 2 17753
23 Traditional screening tests T18 2 17747
24 Traditional screening tests T13 1 11185
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Test 1. MPSS T21.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 1 MPSS T21
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Alberti 2015 47 0 0 136 1.00 [ 0.92, 1.00 ] 1.00 [ 0.97, 1.00 ]
Benachi 2015 76 1 0 809 1.00 [ 0.95, 1.00 ] 1.00 [ 0.99, 1.00 ]
Bianchi 2012 93 6 0 404 1.00 [ 0.96, 1.00 ] 0.99 [ 0.97, 0.99 ]
Bianchi 2013 30 1 0 82 1.00 [ 0.88, 1.00 ] 0.99 [ 0.93, 1.00 ]
Bianchi 2014a 5 6 0 1941 1.00 [ 0.48, 1.00 ] 1.00 [ 0.99, 1.00 ]
Canick 2012 7 0 0 20 1.00 [ 0.59, 1.00 ] 1.00 [ 0.83, 1.00 ]
Chiu 2011 68 6 18 565 0.79 [ 0.69, 0.87 ] 0.99 [ 0.98, 1.00 ]
Ehrich 2011 39 1 0 409 1.00 [ 0.91, 1.00 ] 1.00 [ 0.99, 1.00 ]
Fiorentino 2016 76 1 0 7005 1.00 [ 0.95, 1.00 ] 1.00 [ 1.00, 1.00 ]
Hou 2012 2 0 0 203 1.00 [ 0.16, 1.00 ] 1.00 [ 0.98, 1.00 ]
Huang 2014 9 0 0 180 1.00 [ 0.66, 1.00 ] 1.00 [ 0.98, 1.00 ]
Jeon 2014 11 0 0 144 1.00 [ 0.72, 1.00 ] 1.00 [ 0.97, 1.00 ]
Jiang 2012 16 0 0 887 1.00 [ 0.79, 1.00 ] 1.00 [ 1.00, 1.00 ]
Johansen 2016 27 1 1 144 0.96 [ 0.82, 1.00 ] 0.99 [ 0.96, 1.00 ]
Ke 2015 17 0 0 2323 1.00 [ 0.80, 1.00 ] 1.00 [ 1.00, 1.00 ]
Kim 2016 5 0 0 96 1.00 [ 0.48, 1.00 ] 1.00 [ 0.96, 1.00 ]
Lau 2012 11 0 0 97 1.00 [ 0.72, 1.00 ] 1.00 [ 0.96, 1.00 ]
Lee 2015 5 0 0 87 1.00 [ 0.48, 1.00 ] 1.00 [ 0.96, 1.00 ]
Lefkowitz 2016 84 1 0 1081 1.00 [ 0.96, 1.00 ] 1.00 [ 0.99, 1.00 ]
Liang 2013 40 0 0 372 1.00 [ 0.91, 1.00 ] 1.00 [ 0.99, 1.00 ]
Liu 2012 1 1 0 151 1.00 [ 0.03, 1.00 ] 0.99 [ 0.96, 1.00 ]
Ma 2016 162 2 0 10415 1.00 [ 0.98, 1.00 ] 1.00 [ 1.00, 1.00 ]
Palomaki 2012 210 1 2 1758 0.99 [ 0.97, 1.00 ] 1.00 [ 1.00, 1.00 ]
Papageorghiou 2016a 42 0 0 384 1.00 [ 0.92, 1.00 ] 1.00 [ 0.99, 1.00 ]
Papageorghiou 2016b 1 0 0 10 1.00 [ 0.03, 1.00 ] 1.00 [ 0.69, 1.00 ]
Poon 2016 35 0 0 206 1.00 [ 0.90, 1.00 ] 1.00 [ 0.98, 1.00 ]
Porreco 2014 137 3 0 3182 1.00 [ 0.97, 1.00 ] 1.00 [ 1.00, 1.00 ]
Sehnert 2011 13 0 0 34 1.00 [ 0.75, 1.00 ] 1.00 [ 0.90, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Shaw 2014 11 0 0 189 1.00 [ 0.72, 1.00 ] 1.00 [ 0.98, 1.00 ]
Song 2013 8 0 0 1733 1.00 [ 0.63, 1.00 ] 1.00 [ 1.00, 1.00 ]
Song 2015 2 0 0 202 1.00 [ 0.16, 1.00 ] 1.00 [ 0.98, 1.00 ]
Stumm 2014 40 0 2 430 0.95 [ 0.84, 0.99 ] 1.00 [ 0.99, 1.00 ]
Sukhikh 2015 17 0 2 181 0.89 [ 0.67, 0.99 ] 1.00 [ 0.98, 1.00 ]
Sung-Hee 2015 4 0 0 897 1.00 [ 0.40, 1.00 ] 1.00 [ 1.00, 1.00 ]
Tynan 2016 21 0 0 1027 1.00 [ 0.84, 1.00 ] 1.00 [ 1.00, 1.00 ]
Wang 2014 3 0 0 133 1.00 [ 0.29, 1.00 ] 1.00 [ 0.97, 1.00 ]
Wang 2015a 25 0 0 892 1.00 [ 0.86, 1.00 ] 1.00 [ 1.00, 1.00 ]
Yao 2014 31 0 0 5499 1.00 [ 0.89, 1.00 ] 1.00 [ 1.00, 1.00 ]
Zhang 2016 3 0 0 84 1.00 [ 0.29, 1.00 ] 1.00 [ 0.96, 1.00 ]
Zhou 2014a 4 0 0 297 1.00 [ 0.40, 1.00 ] 1.00 [ 0.99, 1.00 ]
Zhou 2014b 38 2 0 3910 1.00 [ 0.91, 1.00 ] 1.00 [ 1.00, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 2. MPSS T18.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 2 MPSS T18
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benachi 2015 22 1 3 860 0.88 [ 0.69, 0.97 ] 1.00 [ 0.99, 1.00 ]
Bianchi 2012 38 3 1 460 0.97 [ 0.87, 1.00 ] 0.99 [ 0.98, 1.00 ]
Bianchi 2013 10 0 0 103 1.00 [ 0.69, 1.00 ] 1.00 [ 0.96, 1.00 ]
Bianchi 2014a 2 3 0 1947 1.00 [ 0.16, 1.00 ] 1.00 [ 1.00, 1.00 ]
Bijok 2014 1 0 0 8 1.00 [ 0.03, 1.00 ] 1.00 [ 0.63, 1.00 ]
Chen 2011 34 5 3 247 0.92 [ 0.78, 0.98 ] 0.98 [ 0.95, 0.99 ]
Fiorentino 2016 20 1 0 7061 1.00 [ 0.83, 1.00 ] 1.00 [ 1.00, 1.00 ]
Hou 2012 3 0 0 202 1.00 [ 0.29, 1.00 ] 1.00 [ 0.98, 1.00 ]
Huang 2014 1 0 1 187 0.50 [ 0.01, 0.99 ] 1.00 [ 0.98, 1.00 ]
Jeon 2014 5 0 0 150 1.00 [ 0.48, 1.00 ] 1.00 [ 0.98, 1.00 ]
Jiang 2012 12 1 0 890 1.00 [ 0.74, 1.00 ] 1.00 [ 0.99, 1.00 ]
Johansen 2016 4 0 0 169 1.00 [ 0.40, 1.00 ] 1.00 [ 0.98, 1.00 ]
Ke 2015 6 0 0 2324 1.00 [ 0.54, 1.00 ] 1.00 [ 1.00, 1.00 ]
Lau 2012 10 0 0 98 1.00 [ 0.69, 1.00 ] 1.00 [ 0.96, 1.00 ]
Lee 2015 2 0 0 90 1.00 [ 0.16, 1.00 ] 1.00 [ 0.96, 1.00 ]
Lefkowitz 2016 27 0 0 1139 1.00 [ 0.87, 1.00 ] 1.00 [ 1.00, 1.00 ]
Liang 2013 14 0 0 398 1.00 [ 0.77, 1.00 ] 1.00 [ 0.99, 1.00 ]
Liu 2012 1 0 0 152 1.00 [ 0.03, 1.00 ] 1.00 [ 0.98, 1.00 ]
Ma 2016 46 2 0 10531 1.00 [ 0.92, 1.00 ] 1.00 [ 1.00, 1.00 ]
Palomaki 2012 59 5 0 1907 1.00 [ 0.94, 1.00 ] 1.00 [ 0.99, 1.00 ]
Papageorghiou 2016a 9 0 0 417 1.00 [ 0.66, 1.00 ] 1.00 [ 0.99, 1.00 ]
Papageorghiou 2016b 1 0 0 10 1.00 [ 0.03, 1.00 ] 1.00 [ 0.69, 1.00 ]
Poon 2016 4 0 0 237 1.00 [ 0.40, 1.00 ] 1.00 [ 0.98, 1.00 ]
Porreco 2014 36 0 3 3283 0.92 [ 0.79, 0.98 ] 1.00 [ 1.00, 1.00 ]
Sehnert 2011 8 0 0 39 1.00 [ 0.63, 1.00 ] 1.00 [ 0.91, 1.00 ]
Shaw 2014 8 0 0 192 1.00 [ 0.63, 1.00 ] 1.00 [ 0.98, 1.00 ]
Song 2013 2 1 0 1738 1.00 [ 0.16, 1.00 ] 1.00 [ 1.00, 1.00 ]
Song 2015 1 0 0 203 1.00 [ 0.03, 1.00 ] 1.00 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Stumm 2014 8 1 0 463 1.00 [ 0.63, 1.00 ] 1.00 [ 0.99, 1.00 ]
Sukhikh 2015 8 0 0 192 1.00 [ 0.63, 1.00 ] 1.00 [ 0.98, 1.00 ]
Sung-Hee 2015 2 0 0 899 1.00 [ 0.16, 1.00 ] 1.00 [ 1.00, 1.00 ]
Tynan 2016 10 0 0 1038 1.00 [ 0.69, 1.00 ] 1.00 [ 1.00, 1.00 ]
Wang 2014 1 0 0 135 1.00 [ 0.03, 1.00 ] 1.00 [ 0.97, 1.00 ]
Wang 2015a 3 1 0 913 1.00 [ 0.29, 1.00 ] 1.00 [ 0.99, 1.00 ]
Yao 2014 6 1 0 5523 1.00 [ 0.54, 1.00 ] 1.00 [ 1.00, 1.00 ]
Zhang 2016 1 0 0 86 1.00 [ 0.03, 1.00 ] 1.00 [ 0.96, 1.00 ]
Zhou 2014a 1 0 0 300 1.00 [ 0.03, 1.00 ] 1.00 [ 0.99, 1.00 ]
Zhou 2014b 10 2 0 3938 1.00 [ 0.69, 1.00 ] 1.00 [ 1.00, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 3. MPSS T13.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 3 MPSS T13
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Benachi 2015 12 1 0 873 1.00 [ 0.74, 1.00 ] 1.00 [ 0.99, 1.00 ]
Bianchi 2012 13 0 3 485 0.81 [ 0.54, 0.96 ] 1.00 [ 0.99, 1.00 ]
Bianchi 2013 3 0 1 109 0.75 [ 0.19, 0.99 ] 1.00 [ 0.97, 1.00 ]
Bianchi 2014a 1 3 0 1910 1.00 [ 0.03, 1.00 ] 1.00 [ 1.00, 1.00 ]
Canick 2012 1 0 0 26 1.00 [ 0.03, 1.00 ] 1.00 [ 0.87, 1.00 ]
Chen 2011 25 3 0 261 1.00 [ 0.86, 1.00 ] 0.99 [ 0.97, 1.00 ]
Fiorentino 2016 9 0 0 7073 1.00 [ 0.66, 1.00 ] 1.00 [ 1.00, 1.00 ]
Jiang 2012 2 0 0 901 1.00 [ 0.16, 1.00 ] 1.00 [ 1.00, 1.00 ]
Johansen 2016 3 0 0 170 1.00 [ 0.29, 1.00 ] 1.00 [ 0.98, 1.00 ]
Ke 2015 1 0 0 2339 1.00 [ 0.03, 1.00 ] 1.00 [ 1.00, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lau 2012 2 0 0 106 1.00 [ 0.16, 1.00 ] 1.00 [ 0.97, 1.00 ]
Lee 2015 1 0 0 91 1.00 [ 0.03, 1.00 ] 1.00 [ 0.96, 1.00 ]
Lefkowitz 2016 15 0 0 1151 1.00 [ 0.78, 1.00 ] 1.00 [ 1.00, 1.00 ]
Liang 2013 4 1 0 407 1.00 [ 0.40, 1.00 ] 1.00 [ 0.99, 1.00 ]
Liu 2012 1 0 0 152 1.00 [ 0.03, 1.00 ] 1.00 [ 0.98, 1.00 ]
Ma 2016 3 0 0 10576 1.00 [ 0.29, 1.00 ] 1.00 [ 1.00, 1.00 ]
Palomaki 2012 11 16 1 1943 0.92 [ 0.62, 1.00 ] 0.99 [ 0.99, 1.00 ]
Papageorghiou 2016a 5 0 0 421 1.00 [ 0.48, 1.00 ] 1.00 [ 0.99, 1.00 ]
Poon 2016 2 0 0 239 1.00 [ 0.16, 1.00 ] 1.00 [ 0.98, 1.00 ]
Porreco 2014 14 0 2 3306 0.88 [ 0.62, 0.98 ] 1.00 [ 1.00, 1.00 ]
Sehnert 2011 1 0 0 46 1.00 [ 0.03, 1.00 ] 1.00 [ 0.92, 1.00 ]
Shaw 2014 3 0 0 197 1.00 [ 0.29, 1.00 ] 1.00 [ 0.98, 1.00 ]
Song 2013 1 0 0 1740 1.00 [ 0.03, 1.00 ] 1.00 [ 1.00, 1.00 ]
Song 2015 1 0 0 203 1.00 [ 0.03, 1.00 ] 1.00 [ 0.98, 1.00 ]
Stumm 2014 5 0 0 467 1.00 [ 0.48, 1.00 ] 1.00 [ 0.99, 1.00 ]
Sukhikh 2015 1 1 0 198 1.00 [ 0.03, 1.00 ] 0.99 [ 0.97, 1.00 ]
Tynan 2016 6 0 0 1042 1.00 [ 0.54, 1.00 ] 1.00 [ 1.00, 1.00 ]
Yao 2014 1 1 0 5528 1.00 [ 0.03, 1.00 ] 1.00 [ 1.00, 1.00 ]
Zhou 2014b 2 2 0 3946 1.00 [ 0.16, 1.00 ] 1.00 [ 1.00, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 4. MPSS 45,X.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 4 MPSS 45,X
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bianchi 2012 21 46 6 416 0.78 [ 0.58, 0.91 ] 0.90 [ 0.87, 0.93 ]
Bianchi 2013 20 0 1 92 0.95 [ 0.76, 1.00 ] 1.00 [ 0.96, 1.00 ]
Hou 2012 1 1 0 203 1.00 [ 0.03, 1.00 ] 1.00 [ 0.97, 1.00 ]
Jiang 2012 3 1 1 898 0.75 [ 0.19, 0.99 ] 1.00 [ 0.99, 1.00 ]
Lau 2012 8 0 0 100 1.00 [ 0.63, 1.00 ] 1.00 [ 0.96, 1.00 ]
Lefkowitz 2016 19 7 0 1118 1.00 [ 0.82, 1.00 ] 0.99 [ 0.99, 1.00 ]
Liang 2013 5 1 3 403 0.63 [ 0.24, 0.91 ] 1.00 [ 0.99, 1.00 ]
Liu 2012 1 0 0 152 1.00 [ 0.03, 1.00 ] 1.00 [ 0.98, 1.00 ]
Mazloom 2013 20 1 1 389 0.95 [ 0.76, 1.00 ] 1.00 [ 0.99, 1.00 ]
Porreco 2014 9 11 0 3258 1.00 [ 0.66, 1.00 ] 1.00 [ 0.99, 1.00 ]
Sehnert 2011 3 1 0 43 1.00 [ 0.29, 1.00 ] 0.98 [ 0.88, 1.00 ]
Shaw 2014 3 0 1 196 0.75 [ 0.19, 0.99 ] 1.00 [ 0.98, 1.00 ]
Song 2015 0 1 1 202 0.0 [ 0.0, 0.97 ] 1.00 [ 0.97, 1.00 ]
Sukhikh 2015 4 1 0 195 1.00 [ 0.40, 1.00 ] 0.99 [ 0.97, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 5. MPSS 47, XXX.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 5 MPSS 47, XXX
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lefkowitz 2016 1 0 0 1143 1.00 [ 0.03, 1.00 ] 1.00 [ 1.00, 1.00 ]
Liang 2013 1 0 0 411 1.00 [ 0.03, 1.00 ] 1.00 [ 0.99, 1.00 ]
Mazloom 2013 1 0 0 410 1.00 [ 0.03, 1.00 ] 1.00 [ 0.99, 1.00 ]
Porreco 2014 4 3 0 3271 1.00 [ 0.40, 1.00 ] 1.00 [ 1.00, 1.00 ]
Song 2015 0 0 1 203 0.0 [ 0.0, 0.97 ] 1.00 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 6. MPSS 47,XXY.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 6 MPSS 47,XXY
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hou 2012 0 0 1 204 0.0 [ 0.0, 0.97 ] 1.00 [ 0.98, 1.00 ]
Jiang 2012 2 0 0 901 1.00 [ 0.16, 1.00 ] 1.00 [ 1.00, 1.00 ]
Lau 2012 1 0 0 107 1.00 [ 0.03, 1.00 ] 1.00 [ 0.97, 1.00 ]
Lefkowitz 2016 3 0 0 1141 1.00 [ 0.29, 1.00 ] 1.00 [ 1.00, 1.00 ]
Liang 2013 1 0 0 411 1.00 [ 0.03, 1.00 ] 1.00 [ 0.99, 1.00 ]
Mazloom 2013 5 0 0 406 1.00 [ 0.48, 1.00 ] 1.00 [ 0.99, 1.00 ]
Porreco 2014 1 2 0 3198 1.00 [ 0.03, 1.00 ] 1.00 [ 1.00, 1.00 ]
Song 2015 0 0 1 203 0.0 [ 0.0, 0.97 ] 1.00 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 7. MPSS 47,XYY.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 7 MPSS 47,XYY
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hou 2012 0 0 1 204 0.0 [ 0.0, 0.97 ] 1.00 [ 0.98, 1.00 ]
Jiang 2012 1 0 0 902 1.00 [ 0.03, 1.00 ] 1.00 [ 1.00, 1.00 ]
Lefkowitz 2016 3 0 0 1141 1.00 [ 0.29, 1.00 ] 1.00 [ 1.00, 1.00 ]
Liang 2013 1 0 0 411 1.00 [ 0.03, 1.00 ] 1.00 [ 0.99, 1.00 ]
Liu 2012 1 0 0 152 1.00 [ 0.03, 1.00 ] 1.00 [ 0.98, 1.00 ]
Mazloom 2013 3 0 0 408 1.00 [ 0.29, 1.00 ] 1.00 [ 0.99, 1.00 ]
Porreco 2014 1 0 0 3200 1.00 [ 0.03, 1.00 ] 1.00 [ 1.00, 1.00 ]
Shaw 2014 1 0 0 199 1.00 [ 0.03, 1.00 ] 1.00 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 8. MPSS all 7 aneuploidies.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 8 MPSS all 7 aneuploidies
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Alberti 2015 47 0 0 136 1.00 [ 0.92, 1.00 ] 1.00 [ 0.97, 1.00 ]
Benachi 2015 110 1 3 744 0.97 [ 0.92, 0.99 ] 1.00 [ 0.99, 1.00 ]
Bianchi 2012 165 55 10 273 0.94 [ 0.90, 0.97 ] 0.83 [ 0.79, 0.87 ]
Bianchi 2013 63 1 2 47 0.97 [ 0.89, 1.00 ] 0.98 [ 0.89, 1.00 ]
Bianchi 2014a 8 12 0 1932 1.00 [ 0.63, 1.00 ] 0.99 [ 0.99, 1.00 ]
Bijok 2014 1 0 0 8 1.00 [ 0.03, 1.00 ] 1.00 [ 0.63, 1.00 ]
Canick 2012 8 0 0 19 1.00 [ 0.63, 1.00 ] 1.00 [ 0.82, 1.00 ]
Chen 2011 59 8 3 219 0.95 [ 0.87, 0.99 ] 0.96 [ 0.93, 0.98 ]
Chiu 2011 68 6 18 565 0.79 [ 0.69, 0.87 ] 0.99 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ehrich 2011 39 1 0 409 1.00 [ 0.91, 1.00 ] 1.00 [ 0.99, 1.00 ]
Fiorentino 2016 105 2 0 6975 1.00 [ 0.97, 1.00 ] 1.00 [ 1.00, 1.00 ]
Hou 2012 6 1 2 196 0.75 [ 0.35, 0.97 ] 0.99 [ 0.97, 1.00 ]
Huang 2014 10 0 1 178 0.91 [ 0.59, 1.00 ] 1.00 [ 0.98, 1.00 ]
Jeon 2014 16 0 0 139 1.00 [ 0.79, 1.00 ] 1.00 [ 0.97, 1.00 ]
Jiang 2012 36 2 1 864 0.97 [ 0.86, 1.00 ] 1.00 [ 0.99, 1.00 ]
Johansen 2016 34 1 1 137 0.97 [ 0.85, 1.00 ] 0.99 [ 0.96, 1.00 ]
Ke 2015 24 0 0 2316 1.00 [ 0.86, 1.00 ] 1.00 [ 1.00, 1.00 ]
Kim 2016 5 0 0 96 1.00 [ 0.48, 1.00 ] 1.00 [ 0.96, 1.00 ]
Lau 2012 32 0 0 76 1.00 [ 0.89, 1.00 ] 1.00 [ 0.95, 1.00 ]
Lee 2015 8 0 0 84 1.00 [ 0.63, 1.00 ] 1.00 [ 0.96, 1.00 ]
Lefkowitz 2016 152 8 0 1006 1.00 [ 0.98, 1.00 ] 0.99 [ 0.98, 1.00 ]
Liang 2013 66 2 3 341 0.96 [ 0.88, 0.99 ] 0.99 [ 0.98, 1.00 ]
Liu 2012 5 1 0 147 1.00 [ 0.48, 1.00 ] 0.99 [ 0.96, 1.00 ]
Ma 2016 211 4 0 10364 1.00 [ 0.98, 1.00 ] 1.00 [ 1.00, 1.00 ]
Mazloom 2013 29 1 1 380 0.97 [ 0.83, 1.00 ] 1.00 [ 0.99, 1.00 ]
Palomaki 2012 280 22 3 1716 0.99 [ 0.97, 1.00 ] 0.99 [ 0.98, 0.99 ]
Papageorghiou 2016a 56 0 0 370 1.00 [ 0.94, 1.00 ] 1.00 [ 0.99, 1.00 ]
Papageorghiou 2016b 2 0 0 9 1.00 [ 0.16, 1.00 ] 1.00 [ 0.66, 1.00 ]
Poon 2016 41 0 0 200 1.00 [ 0.91, 1.00 ] 1.00 [ 0.98, 1.00 ]
Porreco 2014 202 19 5 3096 0.98 [ 0.94, 0.99 ] 0.99 [ 0.99, 1.00 ]
Sehnert 2011 25 1 0 21 1.00 [ 0.86, 1.00 ] 0.95 [ 0.77, 1.00 ]
Shaw 2014 26 0 1 173 0.96 [ 0.81, 1.00 ] 1.00 [ 0.98, 1.00 ]
Song 2013 11 1 0 1729 1.00 [ 0.72, 1.00 ] 1.00 [ 1.00, 1.00 ]
Song 2015 4 1 2 197 0.67 [ 0.22, 0.96 ] 0.99 [ 0.97, 1.00 ]
Stumm 2014 53 1 2 416 0.96 [ 0.87, 1.00 ] 1.00 [ 0.99, 1.00 ]
Sukhikh 2015 30 2 2 166 0.94 [ 0.79, 0.99 ] 0.99 [ 0.96, 1.00 ]
Sung-Hee 2015 6 0 0 895 1.00 [ 0.54, 1.00 ] 1.00 [ 1.00, 1.00 ]
Tynan 2016 37 0 0 1011 1.00 [ 0.91, 1.00 ] 1.00 [ 1.00, 1.00 ]
Wang 2014 4 0 0 132 1.00 [ 0.40, 1.00 ] 1.00 [ 0.97, 1.00 ]
Wang 2015a 28 1 0 888 1.00 [ 0.88, 1.00 ] 1.00 [ 0.99, 1.00 ]
Yao 2014 38 2 0 5490 1.00 [ 0.91, 1.00 ] 1.00 [ 1.00, 1.00 ]
Zhang 2016 5 0 1 81 0.83 [ 0.36, 1.00 ] 1.00 [ 0.96, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
(Continued . . . )
267Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Zhou 2014a 5 0 0 296 1.00 [ 0.48, 1.00 ] 1.00 [ 0.99, 1.00 ]
Zhou 2014b 50 6 0 3894 1.00 [ 0.93, 1.00 ] 1.00 [ 1.00, 1.00 ]
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Test 9. MPSS, autosomes.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 9 MPSS, autosomes
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Alberti 2015 47 0 0 136 1.00 [ 0.92, 1.00 ] 1.00 [ 0.97, 1.00 ]
Benachi 2015 110 1 3 744 0.97 [ 0.92, 0.99 ] 1.00 [ 0.99, 1.00 ]
Bianchi 2012 144 9 4 346 0.97 [ 0.93, 0.99 ] 0.97 [ 0.95, 0.99 ]
Bianchi 2013 43 1 1 68 0.98 [ 0.88, 1.00 ] 0.99 [ 0.92, 1.00 ]
Bianchi 2014a 8 12 0 1932 1.00 [ 0.63, 1.00 ] 0.99 [ 0.99, 1.00 ]
Bijok 2014 1 0 0 8 1.00 [ 0.03, 1.00 ] 1.00 [ 0.63, 1.00 ]
Canick 2012 8 0 0 19 1.00 [ 0.63, 1.00 ] 1.00 [ 0.82, 1.00 ]
Chen 2011 59 8 3 219 0.95 [ 0.87, 0.99 ] 0.96 [ 0.93, 0.98 ]
Chiu 2011 68 6 18 565 0.79 [ 0.69, 0.87 ] 0.99 [ 0.98, 1.00 ]
Ehrich 2011 39 1 0 409 1.00 [ 0.91, 1.00 ] 1.00 [ 0.99, 1.00 ]
Fiorentino 2016 105 2 0 6975 1.00 [ 0.97, 1.00 ] 1.00 [ 1.00, 1.00 ]
Hou 2012 5 0 0 200 1.00 [ 0.48, 1.00 ] 1.00 [ 0.98, 1.00 ]
Huang 2014 10 0 1 178 0.91 [ 0.59, 1.00 ] 1.00 [ 0.98, 1.00 ]
Jeon 2014 16 0 0 139 1.00 [ 0.79, 1.00 ] 1.00 [ 0.97, 1.00 ]
Jiang 2012 30 1 0 872 1.00 [ 0.88, 1.00 ] 1.00 [ 0.99, 1.00 ]
Johansen 2016 34 1 1 137 0.97 [ 0.85, 1.00 ] 0.99 [ 0.96, 1.00 ]
Ke 2015 24 0 0 2316 1.00 [ 0.86, 1.00 ] 1.00 [ 1.00, 1.00 ]
Kim 2016 5 0 0 96 1.00 [ 0.48, 1.00 ] 1.00 [ 0.96, 1.00 ]
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Lau 2012 23 0 0 85 1.00 [ 0.85, 1.00 ] 1.00 [ 0.96, 1.00 ]
Lee 2015 8 0 0 84 1.00 [ 0.63, 1.00 ] 1.00 [ 0.96, 1.00 ]
Lefkowitz 2016 126 1 0 1039 1.00 [ 0.97, 1.00 ] 1.00 [ 0.99, 1.00 ]
Liang 2013 58 1 0 353 1.00 [ 0.94, 1.00 ] 1.00 [ 0.98, 1.00 ]
Liu 2012 3 1 0 149 1.00 [ 0.29, 1.00 ] 0.99 [ 0.96, 1.00 ]
Ma 2016 211 4 0 10364 1.00 [ 0.98, 1.00 ] 1.00 [ 1.00, 1.00 ]
Palomaki 2012 280 22 3 1716 0.99 [ 0.97, 1.00 ] 0.99 [ 0.98, 0.99 ]
Papageorghiou 2016a 56 0 0 370 1.00 [ 0.94, 1.00 ] 1.00 [ 0.99, 1.00 ]
Papageorghiou 2016b 2 0 0 9 1.00 [ 0.16, 1.00 ] 1.00 [ 0.66, 1.00 ]
Poon 2016 41 0 0 200 1.00 [ 0.91, 1.00 ] 1.00 [ 0.98, 1.00 ]
Porreco 2014 187 3 5 3127 0.97 [ 0.94, 0.99 ] 1.00 [ 1.00, 1.00 ]
Sehnert 2011 22 0 0 25 1.00 [ 0.85, 1.00 ] 1.00 [ 0.86, 1.00 ]
Shaw 2014 22 0 0 178 1.00 [ 0.85, 1.00 ] 1.00 [ 0.98, 1.00 ]
Song 2013 11 1 0 1729 1.00 [ 0.72, 1.00 ] 1.00 [ 1.00, 1.00 ]
Song 2015 4 0 0 200 1.00 [ 0.40, 1.00 ] 1.00 [ 0.98, 1.00 ]
Stumm 2014 53 1 2 416 0.96 [ 0.87, 1.00 ] 1.00 [ 0.99, 1.00 ]
Sukhikh 2015 26 1 2 171 0.93 [ 0.76, 0.99 ] 0.99 [ 0.97, 1.00 ]
Sung-Hee 2015 6 0 0 895 1.00 [ 0.54, 1.00 ] 1.00 [ 1.00, 1.00 ]
Tynan 2016 37 0 0 1011 1.00 [ 0.91, 1.00 ] 1.00 [ 1.00, 1.00 ]
Wang 2014 4 0 0 132 1.00 [ 0.40, 1.00 ] 1.00 [ 0.97, 1.00 ]
Wang 2015a 28 1 0 888 1.00 [ 0.88, 1.00 ] 1.00 [ 0.99, 1.00 ]
Yao 2014 38 2 0 5490 1.00 [ 0.91, 1.00 ] 1.00 [ 1.00, 1.00 ]
Zhang 2016 4 0 0 83 1.00 [ 0.40, 1.00 ] 1.00 [ 0.96, 1.00 ]
Zhou 2014a 5 0 0 296 1.00 [ 0.48, 1.00 ] 1.00 [ 0.99, 1.00 ]
Zhou 2014b 50 6 0 3894 1.00 [ 0.93, 1.00 ] 1.00 [ 1.00, 1.00 ]
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Test 10. MPSS, SCA.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 10 MPSS, SCA
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bianchi 2012 21 46 6 416 0.78 [ 0.58, 0.91 ] 0.90 [ 0.87, 0.93 ]
Bianchi 2013 20 0 1 92 0.95 [ 0.76, 1.00 ] 1.00 [ 0.96, 1.00 ]
Hou 2012 1 1 2 201 0.33 [ 0.01, 0.91 ] 1.00 [ 0.97, 1.00 ]
Jiang 2012 6 1 1 895 0.86 [ 0.42, 1.00 ] 1.00 [ 0.99, 1.00 ]
Lau 2012 9 0 0 99 1.00 [ 0.66, 1.00 ] 1.00 [ 0.96, 1.00 ]
Lefkowitz 2016 26 7 0 1111 1.00 [ 0.87, 1.00 ] 0.99 [ 0.99, 1.00 ]
Liang 2013 8 1 3 400 0.73 [ 0.39, 0.94 ] 1.00 [ 0.99, 1.00 ]
Liu 2012 2 0 0 151 1.00 [ 0.16, 1.00 ] 1.00 [ 0.98, 1.00 ]
Mazloom 2013 29 1 1 380 0.97 [ 0.83, 1.00 ] 1.00 [ 0.99, 1.00 ]
Porreco 2014 15 16 0 3291 1.00 [ 0.78, 1.00 ] 1.00 [ 0.99, 1.00 ]
Sehnert 2011 3 1 0 43 1.00 [ 0.29, 1.00 ] 0.98 [ 0.88, 1.00 ]
Shaw 2014 4 0 1 195 0.80 [ 0.28, 0.99 ] 1.00 [ 0.98, 1.00 ]
Song 2015 0 1 2 201 0.0 [ 0.0, 0.84 ] 1.00 [ 0.97, 1.00 ]
Sukhikh 2015 4 1 0 195 1.00 [ 0.40, 1.00 ] 0.99 [ 0.97, 1.00 ]
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Test 11. TMPS T21.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 11 TMPS T21
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ashoor 2012 50 0 0 347 1.00 [ 0.93, 1.00 ] 1.00 [ 0.99, 1.00 ]
Bevilacqua 2015 11 0 1 328 0.92 [ 0.62, 1.00 ] 1.00 [ 0.99, 1.00 ]
Comas 2015 4 0 0 308 1.00 [ 0.40, 1.00 ] 1.00 [ 0.99, 1.00 ]
del Mar Gil 2014 9 0 1 182 0.90 [ 0.55, 1.00 ] 1.00 [ 0.98, 1.00 ]
Gil 2016 43 1 1 3588 0.98 [ 0.88, 1.00 ] 1.00 [ 1.00, 1.00 ]
Jackson 2014 3 0 1 1157 0.75 [ 0.19, 0.99 ] 1.00 [ 1.00, 1.00 ]
Korostelev 2014 47 0 0 638 1.00 [ 0.92, 1.00 ] 1.00 [ 0.99, 1.00 ]
Nicolaides 2012 8 0 0 1941 1.00 [ 0.63, 1.00 ] 1.00 [ 1.00, 1.00 ]
Nicolaides 2013 25 0 0 204 1.00 [ 0.86, 1.00 ] 1.00 [ 0.98, 1.00 ]
Norton 2012 81 1 0 2998 1.00 [ 0.96, 1.00 ] 1.00 [ 1.00, 1.00 ]
Norton 2015 38 9 0 15794 1.00 [ 0.91, 1.00 ] 1.00 [ 1.00, 1.00 ]
Pergament 2014 58 0 0 905 1.00 [ 0.94, 1.00 ] 1.00 [ 1.00, 1.00 ]
Persico 2016 35 0 1 213 0.97 [ 0.85, 1.00 ] 1.00 [ 0.98, 1.00 ]
Quezada 2015 32 1 0 2752 1.00 [ 0.89, 1.00 ] 1.00 [ 1.00, 1.00 ]
Sparks 2012a 36 0 0 131 1.00 [ 0.90, 1.00 ] 1.00 [ 0.97, 1.00 ]
Verweij 2013 17 0 1 486 0.94 [ 0.73, 1.00 ] 1.00 [ 0.99, 1.00 ]
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Test 12. TMPS T18.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 12 TMPS T18
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ashoor 2012 49 0 1 347 0.98 [ 0.89, 1.00 ] 1.00 [ 0.99, 1.00 ]
Bevilacqua 2015 5 0 0 335 1.00 [ 0.48, 1.00 ] 1.00 [ 0.99, 1.00 ]
Gil 2016 21 4 0 3608 1.00 [ 0.84, 1.00 ] 1.00 [ 1.00, 1.00 ]
Korostelev 2014 2 0 0 683 1.00 [ 0.16, 1.00 ] 1.00 [ 0.99, 1.00 ]
Nicolaides 2012 2 2 0 1945 1.00 [ 0.16, 1.00 ] 1.00 [ 1.00, 1.00 ]
Nicolaides 2013 3 0 0 226 1.00 [ 0.29, 1.00 ] 1.00 [ 0.98, 1.00 ]
Norton 2012 37 2 1 3040 0.97 [ 0.86, 1.00 ] 1.00 [ 1.00, 1.00 ]
Norton 2015 9 1 1 15830 0.90 [ 0.55, 1.00 ] 1.00 [ 1.00, 1.00 ]
Pergament 2014 24 1 1 938 0.96 [ 0.80, 1.00 ] 1.00 [ 0.99, 1.00 ]
Persico 2016 13 0 0 236 1.00 [ 0.75, 1.00 ] 1.00 [ 0.98, 1.00 ]
Quezada 2015 9 5 1 2770 0.90 [ 0.55, 1.00 ] 1.00 [ 1.00, 1.00 ]
Sparks 2012a 8 0 0 159 1.00 [ 0.63, 1.00 ] 1.00 [ 0.98, 1.00 ]
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Test 13. TMPS T13.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 13 TMPS T13
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ashoor 2013 8 1 2 1938 0.80 [ 0.44, 0.97 ] 1.00 [ 1.00, 1.00 ]
del Mar Gil 2014 1 0 0 191 1.00 [ 0.03, 1.00 ] 1.00 [ 0.98, 1.00 ]
Gil 2016 2 4 2 3625 0.50 [ 0.07, 0.93 ] 1.00 [ 1.00, 1.00 ]
Hall 2014 15 0 0 49 1.00 [ 0.78, 1.00 ] 1.00 [ 0.93, 1.00 ]
Jackson 2014 0 1 1 1159 0.0 [ 0.0, 0.97 ] 1.00 [ 1.00, 1.00 ]
Korostelev 2014 3 0 1 681 0.75 [ 0.19, 0.99 ] 1.00 [ 0.99, 1.00 ]
Norton 2015 2 2 0 11181 1.00 [ 0.16, 1.00 ] 1.00 [ 1.00, 1.00 ]
Pergament 2014 12 0 0 953 1.00 [ 0.74, 1.00 ] 1.00 [ 1.00, 1.00 ]
Persico 2016 5 0 0 244 1.00 [ 0.48, 1.00 ] 1.00 [ 0.98, 1.00 ]
Quezada 2015 2 2 3 2778 0.40 [ 0.05, 0.85 ] 1.00 [ 1.00, 1.00 ]
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Test 14. TMPS 45,X.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 14 TMPS 45,X
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hooks 2014 26 2 1 385 0.96 [ 0.81, 1.00 ] 0.99 [ 0.98, 1.00 ]
Nicolaides 2013 2 0 0 227 1.00 [ 0.16, 1.00 ] 1.00 [ 0.98, 1.00 ]
Nicolaides 2014a 43 0 4 125 0.91 [ 0.80, 0.98 ] 1.00 [ 0.97, 1.00 ]
Pergament 2014 9 1 1 953 0.90 [ 0.55, 1.00 ] 1.00 [ 0.99, 1.00 ]
Persico 2016 2 0 1 246 0.67 [ 0.09, 0.99 ] 1.00 [ 0.99, 1.00 ]
Samango-Sprouse 2013 11 0 1 174 0.92 [ 0.62, 1.00 ] 1.00 [ 0.98, 1.00 ]
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Test 15. TMPS 47,XXX.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 15 TMPS 47,XXX
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hooks 2014 1 2 0 411 1.00 [ 0.03, 1.00 ] 1.00 [ 0.98, 1.00 ]
Nicolaides 2014a 5 1 0 166 1.00 [ 0.48, 1.00 ] 0.99 [ 0.97, 1.00 ]
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Test 16. TMPS 47,XXY.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 16 TMPS 47,XXY
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hooks 2014 6 0 0 408 1.00 [ 0.54, 1.00 ] 1.00 [ 0.99, 1.00 ]
Nicolaides 2014a 1 0 0 171 1.00 [ 0.03, 1.00 ] 1.00 [ 0.98, 1.00 ]
Persico 2016 1 0 0 248 1.00 [ 0.03, 1.00 ] 1.00 [ 0.99, 1.00 ]
Samango-Sprouse 2013 2 0 0 184 1.00 [ 0.16, 1.00 ] 1.00 [ 0.98, 1.00 ]
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Test 17. TMPS 47,XYY.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 17 TMPS 47,XYY
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Nicolaides 2014a 3 0 0 169 1.00 [ 0.29, 1.00 ] 1.00 [ 0.98, 1.00 ]
Samango-Sprouse 2013 1 0 0 185 1.00 [ 0.03, 1.00 ] 1.00 [ 0.98, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 18. TMPS all 7 aneuploidies.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 18 TMPS all 7 aneuploidies
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ashoor 2012 99 0 1 297 0.99 [ 0.95, 1.00 ] 1.00 [ 0.99, 1.00 ]
Ashoor 2013 8 1 2 1938 0.80 [ 0.44, 0.97 ] 1.00 [ 1.00, 1.00 ]
Bevilacqua 2015 16 0 1 323 0.94 [ 0.71, 1.00 ] 1.00 [ 0.99, 1.00 ]
Comas 2015 4 0 0 308 1.00 [ 0.40, 1.00 ] 1.00 [ 0.99, 1.00 ]
del Mar Gil 2014 10 0 1 181 0.91 [ 0.59, 1.00 ] 1.00 [ 0.98, 1.00 ]
Gil 2016 66 9 3 3555 0.96 [ 0.88, 0.99 ] 1.00 [ 1.00, 1.00 ]
Hall 2014 15 0 0 49 1.00 [ 0.78, 1.00 ] 1.00 [ 0.93, 1.00 ]
Hooks 2014 33 4 1 376 0.97 [ 0.85, 1.00 ] 0.99 [ 0.97, 1.00 ]
Jackson 2014 3 4 2 1152 0.60 [ 0.15, 0.95 ] 1.00 [ 0.99, 1.00 ]
Korostelev 2014 52 0 1 632 0.98 [ 0.90, 1.00 ] 1.00 [ 0.99, 1.00 ]
Nicolaides 2012 10 2 0 1937 1.00 [ 0.69, 1.00 ] 1.00 [ 1.00, 1.00 ]
Nicolaides 2013 30 0 0 199 1.00 [ 0.88, 1.00 ] 1.00 [ 0.98, 1.00 ]
Nicolaides 2014a 52 1 4 115 0.93 [ 0.83, 0.98 ] 0.99 [ 0.95, 1.00 ]
Norton 2012 118 3 1 2958 0.99 [ 0.95, 1.00 ] 1.00 [ 1.00, 1.00 ]
Norton 2015 49 12 1 15779 0.98 [ 0.89, 1.00 ] 1.00 [ 1.00, 1.00 ]
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(. . . Continued)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Pergament 2014 103 2 2 859 0.98 [ 0.93, 1.00 ] 1.00 [ 0.99, 1.00 ]
Persico 2016 56 0 2 191 0.97 [ 0.88, 1.00 ] 1.00 [ 0.98, 1.00 ]
Quezada 2015 43 8 4 2730 0.91 [ 0.80, 0.98 ] 1.00 [ 0.99, 1.00 ]
Samango-Sprouse 2013 14 0 1 171 0.93 [ 0.68, 1.00 ] 1.00 [ 0.98, 1.00 ]
Sparks 2012a 44 0 0 123 1.00 [ 0.92, 1.00 ] 1.00 [ 0.97, 1.00 ]
Verweij 2013 17 0 1 486 0.94 [ 0.73, 1.00 ] 1.00 [ 0.99, 1.00 ]
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Test 19. TMPS, autosomes.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 19 TMPS, autosomes
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Ashoor 2012 99 0 1 297 0.99 [ 0.95, 1.00 ] 1.00 [ 0.99, 1.00 ]
Ashoor 2013 8 1 2 1938 0.80 [ 0.44, 0.97 ] 1.00 [ 1.00, 1.00 ]
Bevilacqua 2015 16 0 1 323 0.94 [ 0.71, 1.00 ] 1.00 [ 0.99, 1.00 ]
Comas 2015 4 0 0 308 1.00 [ 0.40, 1.00 ] 1.00 [ 0.99, 1.00 ]
del Mar Gil 2014 10 0 1 181 0.91 [ 0.59, 1.00 ] 1.00 [ 0.98, 1.00 ]
Gil 2016 66 9 3 3555 0.96 [ 0.88, 0.99 ] 1.00 [ 1.00, 1.00 ]
Hall 2014 15 0 0 49 1.00 [ 0.78, 1.00 ] 1.00 [ 0.93, 1.00 ]
Jackson 2014 3 4 2 1152 0.60 [ 0.15, 0.95 ] 1.00 [ 0.99, 1.00 ]
Korostelev 2014 52 0 1 632 0.98 [ 0.90, 1.00 ] 1.00 [ 0.99, 1.00 ]
Nicolaides 2012 10 2 0 1937 1.00 [ 0.69, 1.00 ] 1.00 [ 1.00, 1.00 ]
Nicolaides 2013 28 0 0 201 1.00 [ 0.88, 1.00 ] 1.00 [ 0.98, 1.00 ]
Norton 2012 118 3 1 2958 0.99 [ 0.95, 1.00 ] 1.00 [ 1.00, 1.00 ]
Norton 2015 49 12 1 15779 0.98 [ 0.89, 1.00 ] 1.00 [ 1.00, 1.00 ]
Pergament 2014 94 1 1 870 0.99 [ 0.94, 1.00 ] 1.00 [ 0.99, 1.00 ]
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Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Persico 2016 53 0 1 165 0.98 [ 0.90, 1.00 ] 1.00 [ 0.98, 1.00 ]
Quezada 2015 43 8 4 2730 0.91 [ 0.80, 0.98 ] 1.00 [ 0.99, 1.00 ]
Sparks 2012a 44 0 0 123 1.00 [ 0.92, 1.00 ] 1.00 [ 0.97, 1.00 ]
Verweij 2013 17 0 1 486 0.94 [ 0.73, 1.00 ] 1.00 [ 0.99, 1.00 ]
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Test 20. TMPS, SCA.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 20 TMPS, SCA
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Hooks 2014 33 4 1 376 0.97 [ 0.85, 1.00 ] 0.99 [ 0.97, 1.00 ]
Nicolaides 2013 2 0 0 227 1.00 [ 0.16, 1.00 ] 1.00 [ 0.98, 1.00 ]
Nicolaides 2014a 52 1 4 115 0.93 [ 0.83, 0.98 ] 0.99 [ 0.95, 1.00 ]
Pergament 2014 9 1 1 953 0.90 [ 0.55, 1.00 ] 1.00 [ 0.99, 1.00 ]
Persico 2016 3 0 1 245 0.75 [ 0.19, 0.99 ] 1.00 [ 0.99, 1.00 ]
Samango-Sprouse 2013 14 0 1 171 0.93 [ 0.68, 1.00 ] 1.00 [ 0.98, 1.00 ]
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Test 21. Traditional screening tests, autosomes.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 21 Traditional screening tests, autosomes
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bianchi 2014a 4 80 0 1828 1.00 [ 0.40, 1.00 ] 0.96 [ 0.95, 0.97 ]
Nicolaides 2012 10 87 0 1852 1.00 [ 0.69, 1.00 ] 0.96 [ 0.94, 0.96 ]
Norton 2015 39 931 11 14860 0.78 [ 0.64, 0.88 ] 0.94 [ 0.94, 0.94 ]
Quezada 2015 49 124 0 2663 1.00 [ 0.93, 1.00 ] 0.96 [ 0.95, 0.96 ]
Song 2013 6 243 5 1487 0.55 [ 0.23, 0.83 ] 0.86 [ 0.84, 0.88 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 22. Traditional screening tests T21.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 22 Traditional screening tests T21
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bianchi 2014a 3 69 0 1840 1.00 [ 0.29, 1.00 ] 0.96 [ 0.95, 0.97 ]
Norton 2015 30 854 8 14949 0.79 [ 0.63, 0.90 ] 0.95 [ 0.94, 0.95 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 23. Traditional screening tests T18.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 23 Traditional screening tests T18
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Bianchi 2014a 1 11 0 1894 1.00 [ 0.03, 1.00 ] 0.99 [ 0.99, 1.00 ]
Norton 2015 8 49 2 15782 0.80 [ 0.44, 0.97 ] 1.00 [ 1.00, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 24. Traditional screening tests T13.
Review: Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women
Test: 24 Traditional screening tests T13
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Norton 2015 1 28 1 11155 0.50 [ 0.01, 0.99 ] 1.00 [ 1.00, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
A D D I T I O N A L T A B L E S
Table 1. Characteristics of target conditions
Target
condition
Affected birthsa
/100,000
Clinical features Prognosis
T21 140 to 230b,c In-
tellectual disability (mild to moderate)
, neurodevelopmental problems, char-
acteristic dysmorphic features, congen-
ital defects (cardiac (44% to 58%) and
gastrointestinal system (4% to 10%)),
vision or hearing impairment (38% to
Mean and median life expectancies are
estimated to be 51 and 58 years oldf
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Table 1. Characteristics of target conditions (Continued)
80%) and obstructive sleep apnoea syn-
drome (57%)d,e
T18 59c Severe intellectual disability and a wide
range of significantmalformations (car-
diac defects, gastrointestinal system de-
fects, renal anomalies, central nervous
system defects (apnoea and seizures))
d,g
Most affected fetuses die in utero. Me-
dian survival has been estimated at 14
days (95% confidence interval (CI) 10
to 20) and 8% (95% CI 4 to 14) reach
1 year of ageh
T13 23c Severe intellectual disability, seizures
and several dysmorphic features, mal-
formations of the extremities, cardiac
defects, renal anomalies, and abdomi-
nal wall defectsd,i
Most affected fetuses die in utero. Me-
dian survival time has been estimated
at 10 days (95% CI 7 to 19) and 8%
(95% CI 4 to 14) reach 1 year of ageh
45,X 30 to
50c,j
Learning disabilities (70%), short
stature, congenital heart diseases (30%)
and gonadal dysgenesis (90% with
amenorrhoea and infertility due to early
ovarian failure)k,l
Mortality in 45,X women is 3-fold
higher than in the general population
with an average life span of 69 yearsm
47,XXY 12c Learning disabilities (> 75%), small
testes (> 95%), azoospermia (> 95%)
, male infertility (91% to 99%), de-
creased testosterone level (63%to85%)
and gynaecomastia (38% to 75%)l,n
Life expectancy is slightly shorter (ap-
proximately 2 years) than euploid men
n
47,XXX 6c Developmental delays (motor and
speech), learning or intellectual disabil-
ity, attention deficits (25% to 35%)
, mood disorders (anxiety and depres-
sion), tall stature (80% to 89%), clin-
odactyly (42% to 65%), hypotonia in
infancy (55% to 71%), genitourinary
malformations and congenital heart de-
fectso
Mortality significantly increased with a
median survival age of 70.9 years com-
pare to 81.7 years for euploid femalesp
47,XYY 3c Developmental delays (speech, lan-
guage and motor), attention deficit dis-
order (52%), tall stature (78%), central
adiposity, macrocephaly (33%), hypo-
tonia (63%), clinodactyly (52%), hy-
pertelorism (59%) and testicular en-
largement for age (50%)but no increase
in genital anomaliesq
Mortality increased with a reduction of
life span of 10.3 years compared to eu-
ploid menr
45,X: Turner syndrome, 47,XXX: triple X syndrome, 47,XXY: Klinefelter syndrome, T21: trisomy 21, T18: trisomy 18, T13: trisomy
13.
aIncluding live births, fetal deaths and terminations of pregnancy.
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b(Christianson 2006; Parker 2010)
c(Wellesley 2012)
d (Driscoll 2009)
e(Irving 2012; Weijerman 2010)
f (Wu 2013b)
g(Cereda 2012)
h(Wu 2013a)
i (Chen 2009)
j (Stochholm 2006)
k(Karnis 2012; Mazzanti 1998; Sybert 2004)
l(Tyler 2004)
m(Saenger 1996; Schoemaker 2008)
n(Groth 2013)
o(Tartaglia 2010)
p(Stochholm 2010b)
q (Bardsley 2013; Leggett 2010)
r (Stochholm 2010a).
Table 2. Reported accuracy of commercially available genomics-based non-invasive prenatal testsa
Test name
(Company,
country)
Method Aneuploidy Reported
sensitivity
% (95% CI)
Reported
specificity
% (95% CI)
Reported
false positive
rate %
Bambni™
Test
(Berry Genomics
Co. Ltd, China)
MPSS T21 100.0 (ND) > 99.9 (ND) < 0.1
T18 100.0 (ND) > 99.9 (ND) < 0.1
T13 100.0 (ND) > 99.9 (ND) < 0.1
45,X 100.0 (ND) 99.8 (ND) 0.0
47,XXX 100.0 (ND) 100.0 (ND) 0.1
47,XXY 100.0 (ND) 100.0 (ND) 0.0
47,XYY 100.0 (ND) 100.0 (ND) 0.0
GENOMOM
(Genome Care,
Korea)
MPSS T21, T18
and T13
99.0 (ND) ND ND
SCA 95.0 (ND) ND ND
Harmony™
prenatal test
(Ariosa Diagnostics,
Inc., USA)
Oligo TMPS T21 > 99.0 (ND) > 99.9 (ND) < 0.1
T18 97.4 (ND) > 99.9 (ND) < 0.1
T13 93.8 (ND) > 99.9 (ND) < 0.1
45,Xb 96.3 (81.7 to 99.8) 99.5 (98.1 to 99.9) 0.5
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Table 2. Reported accuracy of commercially available genomics-based non-invasive prenatal testsa (Continued)
47,XXXb 100.0 (ND) 99.5 (98.1 to 99.9) 0.5
47,XXYb 100.0 (61.0 to 100.0) 100.0 (99.0 to 100.0) 0.0
IONA® test
(Premaitha Health
plc, UK)
MPSS T21 > 99.0 (ND) > 99.0 (ND) < 1.0
T18 > 99.0 (ND) > 99.0 (ND) < 1.0
T13 > 99.0 (ND) > 99.0 (ND) < 1.0
(Laboratoire
CERBA, France)
MPSS T21, T18
and T13
> 99.8 (ND) > 99.8 (ND) < 0.2
MaterniT21™
Plus test
(Sequenom Inc.,
USA)
MPSS T21 99.1 (96.6 to 99.9) 99.9 (99.7 to 99.9) 0.1
T18 > 99.9 (93.9 to 100.
0)
99.6 (99.3 to 99.7) 0.4
T13 91.7 (61.0 to 99.0) 99.7 (98.5 to 99.5) 0.3
combined sex
aneuploidies
96.2 (ND) 99.7 (ND) 0.3
MomGuard™
(LabGenomics,
Korea)
MPSS T21, T18, T13,
45,X, 47,XXX,
47,XXY, 47,XYY
> 99.0 (ND) ND ND
NIFTY™ test
(Bejing Genomics
Institute (BGI),
China)
MPSS T21 99.2 (ND) 100 (ND) 0
T18 98.2 (ND) 100 (ND) 0
T13 100 (ND) 100 (ND) 0
45,X > 99.9 (ND) > 99.9 (ND) < 0.1
Panorama™
prenatal testc
(Natera, Inc., USA)
SNP TMPS T21 > 99.9 (ND) 100 (ND) 0
T18 > 96.4 (ND) > 99.9 (ND) < 0.1
T13 > 99.9 (ND) 100 (ND) 0
45,X > 92.9 (ND) > 99.9 (ND) < 0.1
PrenaTest®
(LifeCodexx AG,
Germany)
MPSS T21 98.7 (ND) 99.9 (ND) 0.1
T18 100 (ND)
T13 100 (ND)
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Table 2. Reported accuracy of commercially available genomics-based non-invasive prenatal testsa (Continued)
45,X 90.9 (ND) 98.8 (ND) 1.2
47,XYY 100 (ND)
Prendia
(Genesupport,
Switzerland)
MPSS T21 100.0 (88.8 to 100.0) 100.0 (98.0 to 100.0) 0.0
T18 95.8 (76.8 to 99.7) 100.0 (97.0 to 100.0) 0.0
T13 100.0 (74.6 to 100.0) 100.0 (98.1 to 100.0) 0.0
45,X 100.0 (74.6 to 100.0) 100.0 (98.1 to 100.0) 0.0
47,XXX 100.0 (46.2 to 100.0) 100.0 (98.2 to 100.0) 0.0
Tranquility
(Genoma,
Switzerland)
MPSS T21 99.9 (ND) 99.8 (ND) 0.2
T18 99.9 (ND) 99.9 (ND) 0.1
T13 99.9 (ND) 99.7 (ND) 0.3
verifi® prenatal
test
(Illumina, Inc.,
USA)
MPSS T21 99.5 (98.7 to 99.5) 99.8 (98.9 to 99.9) 0.2
T18 97.3 (94.2 to 98.2) 99.7 (99.5 to 99.9) 0.3
T13 98.0 (95.6 to 98.9) 99.8 (99.8 to 99.9) 0.2
45,X 95.0 (75.1 to 99.9) 99.0 (97.6 to 99.7) 1.0
VisibiliT™
(Sequenom Inc.,
USA)
MPSS T21 > 99.0 (80.8 to 100) > 99.9 (99.5 to 100) < 0.1
T18 > 99.0 (65.5 to 100) > 99.9 (99.5 to 100) < 0.1
45,X: Turner syndrome, 47,XXX: triple X syndrome, 47,XXY: Klinefelter syndrome, T21: trisomy 21, T18: trisomy 18, T13: trisomy
13 CI: confidence interval, MPSS: massively parallel shotgun sequencing, ND: no data available, TMPS: targeted massively parallel
sequencing and SNP: single nucleotide polymorphism.
a(Ariosa Diagnostics 2016; BGI 2014; BGI 2016; Berry Genomics 2016; Genoma 2016; Genome Care 2016; Illumina 2014; Illumina
2016; LabGenomics 2016; LifeCodexx 2016; Natera 2016; Genesupport 2016; Premaitha Health plc 2016; Sequenom 2016).
b(Hooks 2014).
cDNA of maternal and paternal origin are needed.
Table 3. Traditional screening tests (mostly for T21)a
Screening tests First trimester
(before 14 weeks’ gestation)
Second trimester
(14 to 20 weeks’ gestation)
Ultrasonography • NT measurement • Various morphologic measurements that modify the
prior risk established
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Table 3. Traditional screening tests (mostly for T21)a (Continued)
Combined test • hCG (free β or total)
• PAPP-A
• NT measurement
NA
Triple test NA • hCG (free β or total)
• uE3
• AFP
Quadruple test NA • hCG (free β or total)
• uE3
• AFP
• inhibin A
Sequential testb • free β hCG
• PAPP-A
• NT measurement
• Invasive test is offered if 1st trimester result is
positive
• Quadruple test is offered if 1st trimester result is
negative
Contingent testb • free β hCG
• PAPP-A
• NT measurement
• Invasive test is offered if 1st trimester result is
positive
• Quadruple test is offered after an intermediate 1st
trimester result
• No test is offered after a low-risk result
Serum integrated testc • PAPP-A • Triple or Quadruple test
Integrated testc • PAPP-A
• NT measurement
• Quadruple test
Maternal age is often included in the algorithm for prenatal screening tests. AFP: alpha-fetoprotein, hCG: human chorionic go-
nadotropin, NA: not applicable, NT: nuchal translucency, PAPP-A: pregnancy associated plasma protein A and uE3: unconjugated
estriol.
a(Gekas 2009; Okun 2008; Wald 2005).
bA test result was available after first-trimester screening test.
cSingle test result available after second-trimester screening test.
Table 4. Characteristics of included studies by type of gNIPT
Study ID Target condi-
tion(s)
Study design
and
participants
Prior risk Index test de-
tails
Cutpoint Reference
standard
Comparator
MPSS
Alberti 2015 T21 • Case-
control study
(1:2) from a
prospective
High risk • Illumina
HiSeq 2000
sequencer
Z score of 3 Fetal
karyotypea
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Table 4. Characteristics of included studies by type of gNIPT (Continued)
cohort
• 976
singleton
pregnancies
enrolled, 183
were analysed
without
multiplexing
• In-house
test
• FF
measured
Benachi 2015 T21, T18,
T13
• Blinded
retrospective
study
• 900
singleton or
twin
pregnancies
enrolled, 886
were analysed
High risk • Illumina
v3 flow-cell
on a HiSeq
1500
sequencer in
12-plex
• Commercial -
Laboratoire
CERBA
• FF
measured
Z score of 3 for
T21; 3.95 for
T18 and T13
Fetal
karyotype or
neonatal clin-
ical examina-
tion
Bianchi 2012 T21, T18,
T13,
45,X,
47,XXX, 47,
XXY, 47,XYY
• Nested
case-control
study (1:4)
from a
prospective
cohort
(MELISSA)
• 2882
singleton
pregnancies
enrolled, 503
for T21, 502
for T18, 501
for T13 and
489 for 45,X
were analysed
High risk • Illumina
HiSeq 2000
sequencer in
6-plex
• Commercial
test - Verinata
• FF
measured
Different
cutpoints used
for autosomes
and SCAb
Fetal
karyotype
Bianchi 2013 T21, T18,
T13,
45,X
• Retrospective
study from
stored plasma
• 2882
singleton
pregnancies
enrolled, 113
were analysed
High risk • Illumina
TrueSeq 3.0
sequencing
chemistry
• Commercial
test - Verinata
Different
cutpoints used
for autosomes
and SCAb
Fetal
karyotype
Bianchi 2014a T21, T18,
T13
• Blinded
prospective
High, low
and without
• Illumina
HiSeq 2000
NCV of 4;
resequenced if
Fe-
tal or postna-
Stan-
dard screening
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Table 4. Characteristics of included studies by type of gNIPT (Continued)
cohort study
• 2052
singleton
pregnancies
enrolled,
1952 for T21
and T18, and
1914 for T13
were analysed
prior risk in 8-plex
• Commercial -
verifi®
prenatal test
• FF
measured
NCV is be-
tween 3 and 4
tal karyotype,
neonatal clin-
ical examina-
tion or medi-
cal record
from birth
(T21 only
with mixed
cutpoints)
which include
first-trimester
combined test
or a second-
trimester re-
sult (quadru-
ple, serum in-
tegrated, fully
integrated, or
sequential)
Bijok 2014 T21, T18,
T13 • Prospective
cohort study
• 10
singleton
pregnancies
enrolled, 9
were analysed
High risk • IIIumina
Genome
Analyzer IIx
or HiSeq
2000
sequencer in
multiplex
• Commercial -
NIFTY™
test, BGI-
Shenzhen
• FF
measured
NR Fetal
karyotype
Canick 2012 T21, T18,
T13
• Case-
control study
• 4664
pregnant
women
enrolled, 27
multifetal
pregnancies
were analysed
High risk • Illumina
HiSeq 2000
sequencer in
4-plex
• Commercial
test -
Sequenom,
Inc.
• FF
measured
Z score of 3 Fetal
karyotype
Chen 2011 T18, T13 • Nested
case-control
study from
prospective
and
retrospective
cohorts
• 392
High risk • Illumina
Genome
Analyzer IIx
in 2-plex
• Commercial
test -
Sequenom,
Z score of 3 Fetal
karyotype
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Table 4. Characteristics of included studies by type of gNIPT (Continued)
singleton
pregnancies
enrolled, 289
were analysed
Inc.
Chiu 2011 T21 • Blinded
case-control
study (1:5)
from
prospective
and
retrospective
cohorts
• 824
singleton
pregnancies
enrolled, 753
were analysed
by 8-plex
method and
314 by 2-plex
method
Mostly high
(> 1/300)
and some in-
termediate
risk (between
1/300 and 1/
1000)
• Illumina
Genome
Analyzer II in
8-plex and 2-
plex
• Commercial
test -
Sequenom,
Inc.
• FF
measured
Z score of 3 Fetal
karyotype
Ehrich 2011 T21 • Blinded
case-control
study (1:11)
from
prospective
cohort
• 480
pregnant
women
enrolled, 449
were analysed
High risk • Illumina
Genome
Analyzer IIx
sequencer in
4-plex
• Commercial
test -
Sequenom,
Inc.
• FF
measured
Z score of 2.5 Fetal
karyotype
Fiorentino
2016
T21, T18,
T13
• Blinded
prospective
cohort study
• 7103
singleton
pregnancies
enrolled,
7082 were
analysed
Mostly high
risk
and without
prior risk
• Illumina
HiSeq 2500
sequencer in
15-plex,
SAFeR™
algorithm.
• Commercial -
Genoma’s
prenatal test
• FF
measured
NCV of
4; aneuploidy
suspected
if NCV is be-
tween 3 and 4
Fetal
karyotype or
neonatal clin-
ical examina-
tion
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Table 4. Characteristics of included studies by type of gNIPT (Continued)
Hou 2012 T21, T18,
T13,
45,X,
47,XXX, 47,
XXY, 47,XYY
• Prospective
cohort study
• 308
singleton
pregnancies
enrolled, 205
were analysed
High risk • IIIumina
HiSeq 2000
sequencer
• Commercial
test - BGI-
Shenzhen
NR Fetal
karyotype
Huang 2014 T21, T18 • Blinded
prospective
cohort study
• 189 twin
pregnancies
enrolled, 189
were analysed
High risk • IIIumina
Genome
Analyzer IIx
or HiSeq
2000
sequencer
• Commercial
test - BGI-
Shenzhen
L score of 1
and t score of
2.5 including
warning zone
Fetal
karyotype
Jeon 2014 T21, T18
• Prospective
cohort study
• 155
singleton
pregnancies
enrolled, 155
were analysed
High risk • Ion
Torrent PGM
or HiSeq
2000
sequencers,
10 samples
per Chip
• Commercial
test - Genome
Care
Z score of 2.
566 for T21;
2.459 forT18.
Fetal
karyotype
Jiang 2012 T21, T18,
T13,
45,X, 47,
XXY,
47, XYY
• Prospective
cohort study
• 903
pregnant
women
enrolled, 903
were analysed
High risk • IIIumina
Genome
Analyzer IIx
or HiSeq
2000
sequencer in
multiplex
• Commercial -
NIFTY™
test, BGI-
Shenzhen
• FF
measured
Different
cutpoints used
for autosomes
and SCAb
Fetal
karyotype
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Table 4. Characteristics of included studies by type of gNIPT (Continued)
Johansen
2016
T21, T18,
T13 • Prospective
cohort study
• 375
singleton
pregnancies
enrolled, 173
were analysed
High risk • Ion
Proton™
sequencer in
5-plex
• In-house
test
• FF
measured
Z score of 4
(unclassified if
Z score is be-
tween 3 and 4)
and WISEC-
ONDOR of
1%
Fetal
karyotype
Ke 2015 T21, T18,
T13 • Prospective
cohort study
• 2340
singleton
pregnancies
enrolled,
2340 were
analysed
High risk • High
throughput
sequencing
platform
• Commercial
test - BGI-
Shenzhen
T score of 3 Fetal kary-
otype or new-
born outcome
Kim 2016 T21 • Blinded
prospective
cohort study
• 101
pregnant
women
enrolled, 101
were analysed
High risk • Ion
Proton™
sequencer in
multiplex
• Commercial
test - Genome
Care
Z score of 2.
10 for Ion Pro-
ton™
Fetal
karyotype
Lau 2012 T21, T18,
T13,
45,X,
47,XXX, 47,
XXY, 47,XYY
• Blinded
prospective
cohort study
• 108
singleton
pregnancies
enrolled, 108
were analysed
Mostly
high risk
• IIIumina
HiSeq 2000
sequencers in
12-plex
• Commercial -
NIFTY™
test, BGI-
Shenzhen
Different
cutpoints used
for autosomes
and SCAb
Fetal
karyotype
Lee 2015 T21, T18,
T13
and SCA (no
case found)
• Blinded
prospective
cohort study
• 93
singleton and
multifetal
pregnancies
enrolled, 92
were analysed
High risk • Illumina
MiSeq
sequencer in
12-plex or
NextSeq
sequencer in
96-plex
• Commercial
test - Mom-
Z score of 4
(intermediate
risk if Z score
is between 2.5
and 4) for T21
and T18; 2.8
for T13 (inter-
mediate risk if
Z score is be-
tween 1.9 and
Fe-
tal or neonatal
karyotype
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Table 4. Characteristics of included studies by type of gNIPT (Continued)
Guard™,
LabGenomics
• FF
measured
2.8)
Lefkowitz
2016
T21, T18,
T13,
45,X,
47,XXX, 47,
XXY, 47,XYY
• Retrospective
cohort,
blinded case-
control study
• 5321
pregnant
women
enrolled but
1222 were
selected and
1166 were
analysed
High risk • IIIumina
HiSeq 2000
sequencer in
6-plex or
uniplex
• Commercial
test -
Sequenom,
Inc.
• FF
measured
Different
cutpoints used
for autosomes
and SCAb
Fetal
karyotype
Liang 2013 T21, T18,
T13,
45,X,
47,XXX, 47,
XXY, 47,XYY
• Blinded
prospective
cohort study
• 435
singleton and
twin
pregnancies
enrolled, 412
were analysed
High risk • Illumina
HiSeq 2000
sequencer in
8-plex or 12-
plex
• Commercial
test - Berry
Genomics
Co. Ltd.
• FF
measured
Different
cutpoints used
for autosomes
and SCAb
Fetal
karyotype
Liu 2012 T21, T18,
T13,
45,X,
47,XXX, 47,
XXY, 47,XYY
• Prospective
cohort study
• 153
pregnant
women
enrolled, 153
were analysed
High risk • Illumina
HiSeq
sequencer in
multiplex.
Z score of 3 Fetal
karyotype
Ma 2016 T21, T18,
T13
• Blinded
retrospective
(archived
samples) and
prospective
cohorts study
• 10,598
singleton
High and
low risk • Sequencing
on BGISEQ-
1000 in 16 or
24-plex
• Commercial
test - BGI-
Z score of 3 Fetal
karyotype or
postnatal fol-
low-up
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Table 4. Characteristics of included studies by type of gNIPT (Continued)
pregnancies
enrolled, 10,
579 were
analysed
Shenzhen
Mazloom
2013
45,X,
47,XXX, 47,
XXY, 47,XYY
• Blinded
prospective
cohort study
• 1975
singleton
pregnancies
enrolled, 411
samples from
the validation
set were
analysed
High risk • Illumina
v3 flow-cell
on a HiSeq
2000
sequencer in
12-plex
• Laboratory
test
development
by Sequenom,
Inc.
• FF
measured
Different cut-
points used for
the four SCAb
Fetal
karyotype
Palomaki
2012
T21, T18,
T13
• Nested
case-control
study (1:3)
• 4664
pregnant
women
enrolled but
1988
singleton
pregnancies
were selected
and 1971
were analysed
High risk • Illumina
HiSeq 2000
sequencer in
4-plex
• Commercial
test -
Sequenom,
Inc.
• FF
measured
Z score of 3 for
T21; 3.88 for
T18; 7.17 for
T13
Fetal
karyotype
Papa-
georghiou
2016a
T21, T18,
T13 • Retrospective
cohort, case-
control study
(1:9)
• 442
singleton and
twin
pregnancies
enrolled, 426
singleton
pregnancies
were analysed
High risk • Ion
Proton™
sequencer in
8-plex
• Commercial -
IONA® test,
Premaitha
Health
(public
limited
company in
UK)
• FF
measured
Likelihood ra-
tio of 1 and
maternal age-
adjusted prob-
ability risk
score
Fetal kary-
otype or med-
ical record
from birth
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Table 4. Characteristics of included studies by type of gNIPT (Continued)
Papa-
georghiou
2016b
T21, T18,
T13 • Retrospective
cohort, case-
control study
(1:9)
• 442
singleton and
twin
pregnancies
enrolled, 11
twin
pregnancies
were analysed
High risk • Ion
Proton™
sequencer in
8-plex
• Commercial -
IONA® test,
Premaitha
Health
(public
limited
company in
UK)
• FF
measured
Likelihood ra-
tio of 1 and
maternal age-
adjusted prob-
ability risk
score
Fetal kary-
otype or med-
ical record
from birth
Poon 2016 T21, T18,
T13 • Retrospective
cohort,
blinded
nested case-
control study
• 242
singleton
pregnancies
enrolled, 241
were analysed
High risk • Ion
Proton™
sequencer,
IONA®
software
algorithm
• Commercial -
IONA® test,
Premaitha
Health
(public
limited
company in
UK)
• FF
measured
NR (authors
used the same
gNIPT than
Papa-
georghiou
2016a)
Fetal
karyotype
Porreco 2014 T21, T18,
T13,
45,X,
47,XXX, 47,
XXY, 47,XYY
• Blinded
prospective
cohort study
• 4170
singleton
pregnancies
enrolled,
3322 for
autosomes,
3278 for 45,X
and 47,XXX
and 3201 for
47,XXY and
47,XYY were
analysed
High risk • Illumina
HiSeq 2000
sequencer in
12-plex
• Commercial
test -
Sequenom,
Inc.
• FF
measured
Different
cutpoints used
for autosomes
and SCAb
Fetal kary-
otype or med-
ical record
from birth
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Table 4. Characteristics of included studies by type of gNIPT (Continued)
Sehnert 2011 T21, T18,
T13,
45,X
• Retrospective
(archived
samples)
cohort study
• 1014
singleton and
multifetal
pregnancies
enrolled but
only 47
singleton
pregnancies in
the test set
were analysed
in this review.
High risk • IIIumina
Genome
Analyzer IIx
sequencer in
uniplex
• Commercial
test - Verinata
Different
cutpoints used
for autosomes
and SCAb
Fetal
karyotype
Shaw 2014 T21, T18,
T13,
45,X,
47, XXX, 47,
XXY, 47,XYY
• Prospective
cohort study
• 201
singleton and
multifetal
pregnancies
enrolled, 200
were analysed
High and
low risk
• Illumina
v2 HiSeq
2000
sequencer in
12-plex
• Commercial
test - Berry
Genomics
Co. Ltd.
Different
cutpoints used
for autosomes
and SCAb
Fetal kary-
otype or med-
ical record
from birth
Song 2013 T21, T18,
T13,
45,X,
47,XXX, 47,
XXY, 47,XYY
(SCA data not
shown in this
review)
• Blinded
prospective
cohort study
• 1916
singleton
pregnancies
enrolled,
1741 were
analysed
Without prior
risk
• Illumina
v2 HiSeq2000
in 12-plex
• Commercial
test- Berry
Genomics
Co. Ltd.
Z score of 3 Fetal or post-
natal kary-
otype or med-
ical record
from birth
Triple test for
T21 and T18
(cutpoint of 1
in 270).
Song 2015 T21, T18,
T13,
45,X, 47,
XXX,
47,XYY
• Blinded
prospective
cohort study
• 213
singleton
pregnancies
enrolled, 204
were analysed
High risk • Illumina
v2 HiSeq
2000
sequencer in
12-plex
• Commercial
test - Berry
Genomics
Co. Ltd.
Z score of 3 Fetal
karyotype or
neonatal clin-
ical examina-
tion or both
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Table 4. Characteristics of included studies by type of gNIPT (Continued)
• FF
measured
Stumm 2014 T21, T18,
T13 • Prospective
cohort,
blinded study
for T21 and
unblinded for
T18 and T13
• 522
singleton
pregnancies
enrolled, 472
were analysed
High risk • Illumina
HiSeq 2000
sequencer in
12-plex (DAP.
21 algorithm
without CG
correction)
• Commercial
test -
LifeCodexx
AG
• FF
measured
MAD-basedZ
score of 3 for
T21; 3.2 for
T18; 3.9 for
T13
Fetal
karyotype
Sukhikh 2015 T21, T18,
T13,
45,X
• Prospective
cohort study
• 200
pregnant
women
enrolled, 200
were analysed
High risk • Ion
Proton™
sequencer
• In-house
test
T score of 5 for
T21 and T18;
4 for T13; 0.
04 Chrom. X
and 0.04
Chrom. Y for
45,X
Fetal
karyotype
Sung-Hee
2015
T21, T18,
T13,
45,X,
47,XXX, 47,
XXY, 47,XYY
• Retrospective
study
• 918
singleton
pregnancies
enrolled, 901
were analysed
High risk • IIIumina
Genome
Analyzer IIx
or HiSeq
2000
sequencer in
12-plex
• Commercial -
NIFTY™
test, BGI-
Shenzhen
• FF
measured
L score of 1
and t score of
2.5
Fetal kary-
otype or med-
ical record
from birth
Tynan 2016 T21, T18,
T13
• Blinded
retrospective
cohort study
• 1100
singleton
pregnancies
enrolled,
1048 were
High and
without prior
risk
• Illumina
HiSeq 2000
or HiSeq
2500
sequencers in
multiplex
risk score of
1%
Fetal kary-
otype or med-
ical record
from birth
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Table 4. Characteristics of included studies by type of gNIPT (Continued)
analysed • Commercial -
VisibiliT™
test,
Sequenom,
Inc.
• FF
measured
Wang 2014 T21, T18,
T13,
45,X
• Prospective
cohort study
• 136
singleton
pregnancies
enrolled, 136
were analysed
High risk • Illumina
HiSeq 2000
sequencer
• Commercial -
NIFTY™
test, BGI-
Shenzhen
NR Fetal or
neonatal kary-
otype or clin-
ical examina-
tion at 42 days
after birth or
both
Wang 2015a T21, T18,
T13, 45,X,
47,XXX, 47,
XXY, 47,XYY
• Prospective
cohort study
• 917
pregnant
women
enrolled, 917
were analysed
High risk • Illumina
v2 HiSeq
2000 flow cell
on a HiSeq
sequencer
• Commercial
test - Berry
Genomics
Co. Ltd
Z score of 3 for
T21, T18 and
T13; -3 for
Chrom. X and
3 for Chrom.
Y for sex
Chrom. classi-
fication
Fetal kary-
otype or clin-
ical follow-up
to 6 months
from birth
Yao 2014 T21, T18,
T13 and SCA
(SCA data not
shown in this
review)
• Retrospective
study
• 5950
singleton
pregnancies
enrolled,
5530 were
analysed
High, low
and without
prior risk
• IIIumina
Genome
Analyzer IIx
or HiSeq
2000
sequencer in
12-plex
• Commercial -
NIFTY™
test, BGI-
Shenzhen
• FF
measured
Different
cutpoints used
for autosomes
and SCAb
Fetal kary-
otype or clini-
cal follow-up
Zhang 2016 T21, T18,
45,X, 47,XXX
(SCA data not
shown in this
review)
• Blinded
prospective
cohort study
• 87
singleton
pregnancies
enrolled, 87
High risk • Illumina
HiSeq 2000
sequencer in
12-plex
• Commercial
Z score of 3
for T21 (no
other cutpoint
reported)
Fe-
tal or neonatal
karyotype or
neonatal clin-
ical examina-
tion
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Table 4. Characteristics of included studies by type of gNIPT (Continued)
were analysed test - Berry
Genomics
Co. Ltd.
Zhou 2014a T21, T18,
T13
• Blinded
prospective
cohort study
• 306
singleton
pregnancies
enrolled, 301
were analysed
High, low
and without
prior risk
• IIIumina
Genome
Analyzer IIx
or HiSeq
2000
sequencer in
12-plex
• Commercial -
NIFTY™
test, BGI-
Shenzhen
• FF
measured
L score of 1
and t score of
2.5
Fetal or
neonatal kary-
otype or birth
outcome
Zhou 2014b T21, T18,
T13
• Blinded
prospective
cohort study
• 7705
singleton
pregnancies
enrolled,
3950 were
analysed
High, low
and without
prior risk
• IIIumina
Genome
Analyzer IIx
or HiSeq
2000
sequencer in
12-plex
• Commercial -
NIFTY™
test, BGI-
Shenzhen
• FF
measured
L score of 1
and t score of
2.5
Fetal or
neonatal kary-
otype or birth
outcome
TMPS
Ashoor 2012 T21, T18 • Nested
case-control
study (1:3)
from a
prospective
cohort
• 400
singleton
pregnancies
enrolled, 397
were analysed
High risk • DANSR
assay
(FORTE
algorithm),
Illumina
HiSeq 2000
in 96-plex
• Commercial -
Harmony™
prenatal test,
Ariosa
Diagnostics,
Inc.
NR
(usually Har-
mony™ pre-
natal test uses
FORTE risk
score of 1%)
Fetal
karyotype
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Table 4. Characteristics of included studies by type of gNIPT (Continued)
Ashoor 2013 T13 • Blinded
prospective
cohort study
• 2167
singleton
pregnancies
enrolled,
1949 were
analysed
High and
low risk
• DANSR
assay
(FORTE
algorithm),
Illumina
HiSeq 2000
in 96-plex
• Commercial -
Harmony™
prenatal test,
Ariosa
Diagnostics,
Inc.
• FF
measured
FORTE risk
score of 1%
Fetal
karyotype or
neonatal clin-
ical examina-
tion
Bevilacqua
2015
T21, T18,
T13 • Prospective
cohort study
• 515
multifetal
pregnancies
enrolled, 340
were analysed
• Women
with singleton
pregnancies
were excluded
(incomplete 2
x 2 table).
High and
without
prior risk
• DANSR
assay
(FORTE
algorithm),
Illumina
HiSeq 2000
in 96-plex
• Commercial -
Harmony™
prenatal test,
Ariosa
Diagnostics,
Inc.
• FF
measured
NR
(usually Har-
mony™ pre-
natal test uses
FORTE risk
score of 1%)
Fe-
tal or neonatal
karyotype
Comas 2015 T21, T18,
T13, 45,X,
47,XXX, 47,
XXY, 47,XYY
(SCA data not
shown in this
review)
• Blinded
prospective
cohort study
• 333
singleton
pregnancies
enrolled, 312
were analysed
High and
without
prior risk
• DANSR
assay
(FORTE
algorithm) or
SNP-based
method
• Commercial -
Panorama™
test, Natera,
Inc. or
Harmony™
prenatal test,
Ariosa
Har-
mony™ pre-
natal test: NR
(usually Har-
mony™ pre-
natal test uses
FORTE risk
score of 1%)
Panorama™
test: NR
Fetal
karyotype or
neonatal clin-
ical examina-
tion
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Table 4. Characteristics of included studies by type of gNIPT (Continued)
Diagnostics,
Inc.
• FF
measured
del Mar Gil
2014
T21, T18,
T13 • Retrospective
cohort study
• 207
multifetal
pregnancies
enrolled, 192
twin
pregnancies
were analysed
Without prior
risk
• DANSR
assay
(FORTE
algorithm),
Illumina
HiSeq 2000
in 96-plex
• Commercial -
Harmony™
prenatal test,
Ariosa
Diagnostics,
Inc.
• FF
measured
NR
(usually Har-
mony™ pre-
natal test uses
FORTE risk
score of 1%)
Fetal
karyotype
Gil 2016 T21, T18,
T13 • Prospective
cohort study
• 11,692
singleton
pregnancies
enrolled,
3633 were
analysed
High
and interme-
diate
riskc
• DANSR
assay (usually
with FORTE
algorithm)
• Commercial -
Harmony™
prenatal test,
Ariosa
Diagnostics,
Inc.
NR
(usually Har-
mony™ pre-
natal test uses
FORTE risk
score of 1%)
Fetal or post-
natal
karyotype or
neonatal clin-
ical examina-
tion
Hall 2014 T13 • Case-
control study
(1:3)/1000
singleton
pregnancies
enrolled, 64
were analysed.
High risk • SNP-
based method
(NATUS
algorithm),
IIIumina
Genome
Analyzer IIx
or HiSeq
sequencer, 11,
000 or 19,
488-plex
targeted PCR
• Commercial -
Natera’s
NR Fetal
karyotype or
genetic testing
of cord blood,
buccal, saliva
or products of
conception
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Table 4. Characteristics of included studies by type of gNIPT (Continued)
prenatal test
• FF
measured
Hooks 2014 45,X,
47,XXX, 47,
XXY, 47,XYY
• Case-
control study
from archived
samples
• 432
singleton
pregnancies
enrolled, 414
were analysed
High risk • DANSR
assay
(FORTE
algorithm),
Illumina
HiSeq 2000
in 96-plex
• Commercial -
Harmony™
prenatal test,
Ariosa
Diagnostics,
Inc.
• FF
measured
NR
(usually Har-
mony™ pre-
natal test uses
FORTE risk
score of 1%)
Fetal
karyotype
Jackson 2014 T21, T18,
T13 • Prospective
cohort study
• 1228
pregnant
women
enrolled,
1161 were
analysed
High and
low risk
• DANSR
assay
(FORTE
algorithm)
• Commercial -
Harmony™
prenatal test,
Ariosa
Diagnostics,
Inc.
NR
(usually Har-
mony™ pre-
natal test uses
FORTE risk
score of 1%)
Fetal kary-
otype or med-
ical record
from birth
Korostelev
2014
T21,
T18, T13, 45,
X, 47,XXX,
47, XXY, 47,
XYY
• Prospective
cohort study
• 1968
singleton
pregnancies
enrolled, 685
were analysed
High and
without prior
risk
• SNP-
based method
(NATUS
algorithm),
IIIumina
Genome
Analyzer IIx
or HiSeq
sequencer, >
19,000-plex
targeted PCR
• Commercial -
Natera’s
prenatal test
• FF
measured
NR Fetal kary-
otype or med-
ical record
from birth
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Table 4. Characteristics of included studies by type of gNIPT (Continued)
Nicolaides
2012
T21, T18
• Retrospective
study from
archived
plasma
• 2230
singleton
pregnancies
enrolled,
1949 were
analysed
Without prior
risk
• DANSR
assay (usually
with FORTE
algorithm)
• Commercial -
Harmony™
prenatal test,
Ariosa
Diagnostics,
Inc.
• FF
measured
Risk score of
1%
Fetal
karyotype or
neonatal clin-
ical examina-
tion
First-trimester
combined test
(cutpoint of 1
in 150).
Nicolaides
2013
T21, T18,
T13, 45,X,
47,XXX, 47,
XXY, 47,XYY
• Blinded
prospective
cohort study
• 242
singleton
pregnancies
enrolled, 229
were analysed
High risk • SNP-
based method
(NATUS
algorithm),
IIIumina
Genome
Analyzer IIx
or HiSeq
sequencer, 19,
488-plex
targeted PCR
• Commercial -
Natera’s
prenatal test
• FF
measured
NR Fetal
karyotype
Nicolaides
2014a
45,X,
47,XXX, 47,
XXY, 47,XYY
• Case-
control study
(archived
samples)
• 177
singleton
pregnancies
enrolled, 172
were analysed
High risk • DANSR
assay
(FORTE
algorithm),
Illumina
HiSeq 2000
in 96-plex
• Commercial -
Harmony™
prenatal test
• FF
measured
FORTE risk
score of 1%
Fetal
karyotype
Norton 2012 T21, T18 • Blinded
prospective
cohort study
High risk • DANSR
assay
(FORTE
FORTE risk
score of 1%
Fetal
karyotype
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Table 4. Characteristics of included studies by type of gNIPT (Continued)
• 4002
singleton
pregnancies
enrolled,
3080 were
analysed
algorithm),
Illumina
HiSeq 2000
in 96-plex
• Commercial
test- Ariosa
Diagnostics,
Inc.
• FF
measured
Norton 2015 T21, T18,
T13
• Blinded
prospective
cohort study
• 18,955
singleton
pregnancies
enrolled, 15,
841 were
analysed
Without prior
risk
• DANSR
assay
(FORTE
algorithm)
• Commercial -
Harmony™
prenatal test,
Ariosa
Diagnostics,
Inc.
• FF
measured
NR
(usually Har-
mony™ pre-
natal test uses
FORTE risk
score of 1%)
Fe-
tal or postna-
tal karyotype,
neonatal clin-
ical examina-
tion or medi-
cal record
from birth
First-trimester
combined test
(cutpoint of 1
in 270 for T21
and 1 in 150
for T18 and
T13)
Pergament
2014
T21, T18,
T13, 45,X
• Blinded
prospective
cohort study
• 1064
singleton
pregnancies
enrolled, 963
were analysed
High and
low risk
• SNP-
based method
(NATUS
algorithm),
IIIumina
Genome
Analyzer IIx
or HiSeq
sequencer, 19,
488-plex
targeted PCR
• Commercial -
Natera’s
prenatal test
• FF
measured
NR Fetal
karyotype or
genetic testing
of cord blood,
buccal, saliva
or products of
conception or
birth outcome
Persico 2016 T21, T18, 45,
X,
47,XXX, 47,
XXY, 47,XYY
• Blinded
prospective
cohort study
• 259
singleton
pregnancies
High risk • SNP-
based method
(NATUS
algorithm),
IIIumina
Genome
Risk score of
1%
Fetal
karyotype
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Table 4. Characteristics of included studies by type of gNIPT (Continued)
enrolled, 249
were analysed
Analyzer IIx
or HiSeq
sequencer, 19,
488-plex
targeted PCR
• Commercial -
Natera’s
prenatal test
• FF
measured
Quezada 2015 T21, T18,
T13 • Prospective
cohort study
• 2905
singleton
pregnancies
enrolled,
2785 were
analysed
Without prior
risk
• DANSR
assay
(FORTE
algorithm)
• Commercial -
Harmony™
prenatal test
• FF
measured
NR
(usually Har-
mony™ pre-
natal test uses
FORTE risk
score of 1%)
Fe-
tal or postna-
tal karyotype,
neonatal clin-
ical examina-
tion or medi-
cal record
from birth
First-trimester
combined test
(cutpoint
of 1 in 100 for
T21)
Samango-
Sprouse 2013
45,X,
47,XXX, 47,
XXY, 47,XYY
• Blinded
prospective
cohort study
• 201
singleton
pregnancies
(with known
SCA and
euploid
pregnancies)
enrolled, 186
were analysed
High and
low risk
• SNP-
based method
(NATUS
algorithm),
IIIumina
HiSeq
sequencer, 19,
488-plex
targeted PCR
• Commercial -
Natera’s
prenatal test
• FF
measured
NR Fetal
karyotype or
genetic testing
of cord blood,
buccal, saliva
or products of
conception
Sparks 2012a T21, T18 • Case-
control study
from a
prospective
cohort
• 338
singleton
pregnancies
enrolled, 167
were analysed
High risk • DANSR
assay
(FORTE
algorithm),
Illumina
HiSeq 2000
in 96-plex
• Commercial
test- Ariosa
NR Fetal
karyotype
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Table 4. Characteristics of included studies by type of gNIPT (Continued)
Diagnostics,
Inc.
• FF
measured
Verweij 2013 T21 • Blinded
prospective
cohort study
• 595
singleton
pregnancies
enrolled, 504
were analysed
High risk • DANSR
assay
(FORTE
algorithm),
Illumina
HiSeq 2000
in 96-plex
• Commercial
test- Ariosa
Diagnostics,
Inc.
• FF
measured
FORTE risk
score of 1%
Fetal
karyotype
45,X: Turner syndrome, 47,XXX: triple X syndrome, 47,XXY: Klinefelter syndrome, DANSR: digital analysis of selected regions, FF:
fetal fractionDNA, FORTE: fetal-fraction optimised risk of trisomy evaluation, MAD:Median absolute deviation, MPSS: massively
parallel shotgun sequencing, NATUS: Next-generation Aneuploidy Test Using SNPs, NCV: normalised chromosome value, SCA:
sex chromosome aneuploidy, SNP: single-nucleotide polymorphism,TMPS: targeted massively parallel sequencing, T21: trisomy
21, T18: trisomy 18 and T13: trisomy 13.
aFetal karyotype include traditional banding techniques, spectral karyotype, fluorescence in situ hybridisation, array comparative
genomic hybridisation or quantitative fluorescence polymerase chain reaction.
bDifferent cutpoints used for autosomes or SCA as follows:
Bianchi 2012: NCV of 4 (aneuploidy suspected if NCV is between 2.5 and 4) for T21, T18, and T13; NCV for Chrom. X of -4 and
NCV for Chrom. Y of 2.5 for 45,X; NCV for Chrom. X of 4 and NCV for Chrom. Y of 2.5 for 47,XXX; NCV for Chrom. X between
-2.5 and 2.5 and NCV for Chrom. Y > 33 for 47,XXY; NCV for Chrom. X of -4 and NCV for Chrom. Y of 4 for 47,XYY with NCV
for Chrom. Y is two times greater than expected NCV Chrom. X.
Bianchi 2013: NCV of 4 (aneuploidy suspected if NCV is between 3 and 4) for T21, T18, and T13; NCV for Chrom. X of -3 and
NCV for Chrom. Y of 3 for 45,X.
Jiang 2012: t score of 3 and logarithmic LR of 1 for T21, T18 and T13; if female fetus, t score of -2.5 for 45,X and 47,XXX; t score
of 2.5 combined with estimation of fetal ccfDNA concentration by Chrom. X and Y independently for 47,XXY and 47,XYY.
Lau 2012: Z score of 3 for T21, T18 and T13; if female fetus, Z score for Chrom. X of -3 for 45,X; if female fetus, Z score for Chrom.
X of 3 for 47,XXX; if male fetus, Z score for Chrom. Y of 3 for 47,XXY.
Lefkowitz 2016: Z score of 3 for T21; Z score of 3.95 for T18 and T13; Z scores for SCA see Mazloom 2013.
Liang 2013: Z score of 3 for T21; 5.91 for T18; 5.72 for T13; ± 2.91 for Chrom. X and ± 3 for Chrom. Y for sex chromosome
classification.
Mazloom 2013: Z score of 3.5 for 47,XXX (non-reportable regions between 2.5 and 3.5); Z score of -3.5 for 45,X (non-reportable
regions between -2.5 and -3.5); Z score of -3.5 for 47,XYY with Chrom. Y representation; between -3.5 and 3.5 for 47,XXY with
Chrom. Y representation.
Porreco 2014: Z score of 3 for T21; Z score of 3,95 for T18 and T13; Z score of 3.5 for 47,XXX (non-reportable regions between
2.5 and 3.5); Z score of -3.5 for 45,X (non-reportable regions between -2.5 and -3.5); Z score of -3.5 for 47,XYY with Chrom. Y
representation; Z score between -3.5 and 3.5 for 47,XXY with Chrom. Y representation.
Sehnert 2011: NCV of 4 (unclassified if NCV is between 2.5 and 4) for T21, T18, and T13; NCV for Chrom. Y of -2.0 SDs from
the mean of male samples and NCV for Chrom. X of -3.0 SDs from the mean of female samples for sex chromosome classification.
Shaw 2014: Z score of 3 for T21, T18, and T13; Z score of -3 for Chrom. X and 3 for Chrom. Y for sex chromosome classification.
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Yao 2014: T score of 2.5 for T21, T18 and T13; if female fetus, T score for Chrom. X of -2.5 for 45,X and 2.5 for 47,XXX; if male
fetus, T score for Chrom. X of 2.5 combined with estimation of fetal ccfDNA concentration by Chrom. X (expected value of zero) for
47,XXY; if male fetus, T score for Chrom. X of 2.5 and R-value (the ratio of the fetal DNA fraction estimated by chromosome Y to
that estimated by chromosome X) between 1.8 and 2.2 for 47,XYY.
cPregnant women with a first-trimester combined test selected for their risk of fetal aneuploidy (cutpoint of 1 in 100 for high risk and
1 in 101 to 1 in 2500 for intermediate risk).
Table 5. Manufacturers of gNIPT used in the included studies by prior risk of fetal aneuploidy
Company Number of
studies
Number of
affected/
unaffected
pregnanciesa
Number of studies
with pregnant
women without
prior risk of
fetal aneuploidy
Number of studies
with high-risk
pregnant women
Number of studies
with
mixed riskb cohort
Ariosa
Diagnostics, Inc.
15 594/32,302 4 6 5
Bejing Genomics
Institute (BGI)
12 427/24,724 0 7 5
Sequenom, Inc. 9 904/8486 0 7 2
Berry Genomics
Co. Ltd
6 147/3414 1 4 1
Natera, Inc. 6 276/2103 0 3 3
Illumina, Inc. 4 273/2342 0 3 1
In-house 3 114/442 0 3 0
Premaitha
Health plc
3 99/579 0 3 0
Genome Care 2 21/235 0 2 0
CERBA 1 113/745 0 1 0
Genoma 1 105/6977 0 0 1
LabGenomics 1 8/84 0 1 0
LifeCodexx AG 1 55/417 0 1 0
Not reported 1 5/148 0 1 0
Total 65 3141/82,998 5 42 18
aWe included pregnancies with any other aneuploidy than the one under analysis with all euploid cases as “unaffected” pregnancies.
bMixed-risk cohort included a mix of pregnant women without prior risk, low risk or high risk of fetal aneuploidy.
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Table 6. Reasons for patient exclusion
Study ID Number of pregnant women en-
rolled
Reasons for exclusion Number of women with results
for 2 x 2 table analysis
Alberti 2015 976 • 701 not selected for the
case-control study
• 23 selected for reference set
• 8 selected for pretesting
phase
• 47 low amount of DNA
• 11 low fetal fraction DNA
or assay failure
• 3 haemolysed samples
Total: 793
183
Ashoor 2012 400 • 3 samples failed
amplification and sequencing
397
Ashoor 2013 2167 • 165 selected for first phase
(case-control study not included
in this review)
• 53 failed amplification or
sequencing
Total: 218
1949
Benachi 2015 900 • 8 without reference
standard result
• 6 low fetal fraction DNA or
result appeared atypical
Total: 14
886
Bevilacqua 2015 2362 • 1847 not selected
• 159 without follow-up
• 11 failed samples
• 5 failed samples and were
without follow-up
Total: 2022
340
Bianchi 2012 2882 • 127 ineligible
• 45 without karyotype
• 85 multifetal pregnancies
• 2091 not selected for this
case-control study
• 2 for tracking issue
• 16 without fetal DNA
detected
Total: 2366
In addition, other samples ex-
cluded from 2 x 2 tables for cen-
sored complex karyotype:
503 (T21)
502 (T18)
501 (T13)
489 (45,X)
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Table 6. Reasons for patient exclusion (Continued)
• 13 for T21
• 14 for T18
• 15 for T13
• 27 for 45,X
Bianchi 2013 2882 • 2769 not selected for the
study
113
Bianchi 2014a 2052 • 10 failed blood quality
control
• 72 without clinical outcome
• 17 without gNIPT result
• 28 without standard
screening result
• 1 without gNIPT result and
without standard screening result
Total for T21 and T18: 100
Total for T13: 128
1952 (T21 and T18)
1914 (T13)
Bijok 2014 10 • 1 low fetal fraction DNA 9
Canick 2012 4664 • 4637 not selected for the
case-control study
27
Chen 2011 392 • 103 selected for reference
control
289
Chiu 2011 824 • 46 failed quality control for
blood sampling
• 12 without karyotype
• 2 twin pregnancies
• 11 failed quality control for
sequencing
Total: 71 (8-plex)
753 (8-plex)
Comas 2015 333 • 17 without follow-up
• 3 unrepeated tests
• 1 failed test second timea
and without follow-up
Total: 21
312
del Mar Gil 2014 207 • 11 low fetal fraction DNA
• 4 laboratory processing
failures
Total: 15
192
Ehrich 2011 480 • 13 preanalytic failure
(including 9 for low plasma
volume and 4 processing errors)
449
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Table 6. Reasons for patient exclusion (Continued)
• 18 failed quality control at
second time (including 7 for low
fetal fraction DNA)
Total: 31
Fiorentino 2016 7103 • 21 failed quality control
(unrepeated tests)
7082
Gil 2016 11,692 • 7994 patients did not
undergo a gNIPT
• 45 failed tests first timeb
• 20 failed tests second time
Total: 8059
3633
Hall 2014 > 1000 • About 932 samples not
selected for the case-control study
• 4 failed quality control
Total: 936
64
Hooks 2014 432 • 18 low fetal fraction DNA,
unusually high variation in
ccfDNA counts or failed QC
414
Hou 2012 308 • 103 patients did not
undergo a gNIPT
205
Huang 2014 189 NR 189
Jackson 2014 1228 • 7 with other abnormal
ultrasound
• 14 opted for CVS without
gNIPT
• 32 declined all testing
• 14 failed tests twice
Total: 67
1161
Jeon 2014 155 NR 155
Jiang 2012 903 NR 903
Johansen 2016 375 • 191 not selected for
validation set
• 11 low fetal fraction DNA
Total: 202
173
Ke 2015 2340 NR 2340
Kim 2016 101 NR 101
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Table 6. Reasons for patient exclusion (Continued)
Korostelev 2014 1968 • 1043 without follow-up
• 240 samples did not
undergo a gNIPT
Total: 1283
685
Lau 2012 108 NR 108
Lee 2015 93 • 1 low fetal fraction DNA 92
Lefkowitz 2016 5321 • 4099 not selected for the
study
• 11 for incomplete follow-up
• 3 with confirmed mosaicism
• 11 low fetal fraction DNA
• 29 for technical reasons
• 2 for maternal event
Total: 4155 (autosomes)
In addition:
• 22 sequencing failures for
SCA
Total: 4177 (SCA)
1166 (autosomes)
1144 (SCA)
Liang 2013 435 • 11 without karyotype
• 12 failed quality control
Total: 23
412
Liu 2012 153 NR 153
Ma 2016 10,598 • 14 with incomplete follow-
up
• 5 failed quality control
Total: 19
10,579
Mazloom 2013 1975 • 1564 selected for the
training set
411
Nicolaides 2012 2230 • 181 ineligible
• 46 low fetal fraction DNA
• 54 assay failures
Total: 281
1949
Nicolaides 2013 242 • 13 failed quality control 229
Nicolaides 2014a 177 • 1 failed quality control
• 4 low fetal fraction DNA
Total: 5
172
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Table 6. Reasons for patient exclusion (Continued)
Norton 2012 4002 • 774 ineligible
• 57 low fetal fraction DNA
• 91 assay failures
Total: 922
3080
Norton 2015 18,955 • 381 ineligible
• 64 withdrawn
• 384 handling errors
• 308 without standard
screening test result
• 1489 without follow-up
• 192 low fetal fraction DNA
• 83 no fetal fraction DNA
• 213 high assay variance or
assay failures
Total: 3114
15,841
Palomaki 2012 4876 • 2888 not selected for this
study
• 17 failed tests second time
(mostly for low fetal fraction
DNA)
Total: 2905
1971
Papageorghiou 2016a 442 • 11 twin not selected
• 3 low fetal fraction DNA
• 2 failed quality control
Total: 16
426
Papageorghiou 2016b 442 • 426 singleton not selected
• 3 low fetal fraction
• 2 failed quality control
Total: 431
11
Pergament 2014 1064 • 13 not selected (other
aneuploidies)
• 85 samples failed quality
control for all five chromosomes
(including 65 for low fetal
fraction DNA)
Total: 98
In addition,
• 3 samples failed only for
T21 (total for T21: 101)
• 2 samples failed only for
T18 and 45,X (total for T18 and
45,X: 100)
• 1 sample failed only for T13
(total for T13: 99)
963 (T21)
964 (T18 and 45,X)
965 (T13)
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Table 6. Reasons for patient exclusion (Continued)
Persico 2016 259 • 8 low fetal fraction DNA
• 2 failed internal quality
control
Total: 10
249
Poon 2016 242 • 1 low fetal fraction DNA 241
Porreco 2014 4170 • 320 for insufficient sample
volume
• 390 failed quality control
• 24 with incomplete follow-
up
• 6 without invasive
procedure
In addition,
• 54 failed quality control
and 54 for complex autosome
karyotypesc (total: 108 for
autosomes)
• 102 failed quality control or
otherd and 50 for complex SCA
karyotype (total: 152 for 45,X
and 47,XXX)
• 182 low fetal fraction DNA
or otherd and 47 for complex
SCA karyotype (total: 229 for
47,XXY and 47,XYY)
3322 (T21, T18, T13)
3278 (45,X, 47,XXX)
3201 (47,XXY, 47,XYY)
Quezada 2015 2905 • 66 without follow-up
• 1 lost in mail
• 38 low fetal fraction DNA
• 15 assay failures
Total: 120
2785
Samango-Sprouse 2013 201 • 12 low fetal fraction DNA
or poor DNA quality
• 2 without gNIPT result
• 1 with conflicting algorithm
metrics
Total: 15
186
Sehnert 2011 1014 • 895 not selected for
sequencing
• 71 selected for training set
• 1 twin pregnancy
Total: 967
47
Shaw 2014 201 • 1 for early GA 200
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Table 6. Reasons for patient exclusion (Continued)
Song 2013 1916 • 102 without follow-up
• 64 failed quality control
• 9 failed quality control and
without follow-up
Total: 175
1741
Song 2015 213 • 8 without follow-up
• 1 failed quality control
Total: 9
204
Sparks 2012a 338 • 171 selected for training set 167
Stumm 2014 522 • 8 without reference
standard
• 9 without consent
• 1 previously analysed
• 14 failed sequencing quality
control
• 18 failed libraries
Total: 50
472
Sukhikh 2015 200 NR 200
Sung-Hee 2015 918 • 8 ineligible
• 9 without follow-up
Total: 17
901
Tynan 2016 1100 • 28 library preparation
failures or failed quality control
• 24 for discretionary non
reporting
Total: 52
1048
Verweij 2013 595 • 75 ineligible
• 7 low fetal fraction DNA
• 9 laboratory processing
failures or specimen issues
Total: 91
504
Wang 2014 136 NR 136
Wang 2015a 917 NR 917
Yao 2014 5950 • 420 without follow-up 5530
Zhang 2016 87 NR 87
Zhou 2014a 306 • 5 without follow-up 301
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Table 6. Reasons for patient exclusion (Continued)
Zhou 2014b 7705 • 4 low fetal fraction DNA
• 3751 without follow-up
Total: 3755
3950
ccfDNA: circulating cell-free DNA, CVS: chorionic villi sampling, GA: gestational age, gNIPT: genomics-based non-invasive prenatal
testing, NR: not reported by authors.
aSecond time: sample failed the second gNIPT assay.
bFirst time: sample failed the initial gNIPT assay.
cComplex autosome karyotypes are mosaic, triploidies, unbalanced rearrangements with missing or duplicated genetic material.
dOther are copy number variation of the X chromosome is confounded by maternal component and cannot be determined.
Table 7. Proportion of pregnant women with a reference standard and assay failure during gNIPT process
Study ID Failure rate at
first attempt
(%)
Repeated testsa
(%)
Failure rate of
repeated tests
(%)
Final failure
rate
total (%)
Aneuploidb
samples
(%)
Euploidb
samples
(%)
MPSS
Alberti 2015 61/244 (25%) 0 NA 61/244 (25%) NR NR
Benachi 2015 42/892 (4.7%) 42 (100%) with
second
aliquot
6/42 (14.3%) 6/892 (0.7%) 2.7% 0.4%
Bianchi 2012 16/519 (3.1%) 0 NA 16/356 (3.1%) NR NR
Bianchi 2014a 18/1970 (0.9%) 0c NA T21 and T18:
18/1970 (0.9%)
T13: 18/1932
(0.9%)
NR NR
Bijok 2014 1/10 (10.0%) 0 NA 1/10 (10.0%) 50% 0%
Chiu 2011 11/764 (1.4%) 0 NA 11/764 (1.4%) NR NR
Ehrich 2011 20/467 (4.3%) 20 (100%) rese-
quenced
18/20 (90%) 18/467 (3.9%) NR NR
Fiorentino 2016 100/7103 (1.
4%)
79 (79%) with
new
sampling
0 (0%) 21/7103 (0.3%) 0% 0.3%
Johansen 2016 NR 2 with second
aliquot or
resequenced
were in the
NR 11/184 (6%)d 5.8% 6.1%
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Table 7. Proportion of pregnant women with a reference standard and assay failure during gNIPT process (Continued)
grey zone (be-
tween
affected and un-
affected)
Lee 2015 1/93 (1.1%) 0 NA 1/93 (1.1%) NR NR
Lefkowitz 2016 Autosomes: 42/
1208 (3.5%)
SCA: 64/1208
(5.3%)
0 NA Autosomes: 42/
1208 (3.5%)
SCA: 64/1208
(5.3%)
Autosomes: 3.
8%
SCA: 29.7%
Autosomes: 3.
4%
SCA: 4.5%
Liang 2013 12/424 (2.8%) 0 NA 12/424 (2.8%) NR NR
Ma 2016 5/10,584 (0.
05%)
0 NA 5/10,584 (0.
05%)
NR NR
Mazloom 2013 21/432 (4.9%) 0 NA 21/432 (4.9%) 11.8% 4.3%
Palomaki 2012 110/1988 (5.
5%)
105 (95.5%)
with second
aliquot and 5 (4.
5%)
resequenced
17/110 (15.5%) 17/1988 (0.9%) 1.0% 0.8%
Papageorghiou
2016a
Papageorghiou
2016b
5/431 (1.2%) 0 NA 5/431 (1.2%) NR NR
Poon 2016 1/242 (0.4%) 0 NA 1/242 (0.4%) 0% 0.5%
Porreco 2014 Autosomes:
108/3430 (3.
1%)
45,X and 47,
XXX:
152/3430 (4.
4%)
47,XXY and 47,
XYY:
229/3430 (6.
7%)
0 NA Autosomes: 108/
3430 (3.1%)
45,X and 47,
XXX: 152/3430
(4.4%)
47,XXY and 47,
XYY: 229/3430
(6.7%)
NR NR
Song 2013 73/1814 (4.0%) 0 NA 73/1814 (4.0%) 0% 4.0%
Song 2015 1/205 (0.5%) 0 NA 1/205 (0.5%) NR NR
Stumm 2014 32/504 (6.3%) 0 NA 32/504 (6.3%) 3.5% 6.7%
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Table 7. Proportion of pregnant women with a reference standard and assay failure during gNIPT process (Continued)
Sung-Hee 2015 21/908 (2.3%) 16 (76.2%) with
new
sampling
2/16 (12.5%) 7/908 (0.8%) NR NR
Tynan 2016 52/1100 (4.7%) 0 NA 52/1100 (4.7%) 0% 4.9%
Yao 2014 0 0 NA 0 NA NA
Zhou 2014a 0 0 NA 0 NA NA
Zhou 2014b 141/3954 (3.
6%)
141 (100%)
with new
sampling
4/141 (2.8%) 4/3954 (0.1%) NR NR
Overall range of final assay failure for MPSS 0% to 25% 0% to 50% 0% to 6.7%
TMPS
Ashoor 2012 3/400 (0.8%) 0 NA 3/400 (0.8%) 0% 1%
Ashoor 2013 53/2002 (2.6%) 0 NA 53/2002 (2.6%) 0% 2.7%
Bevilacqua 2015 29/356 (8.1%) 26 (90%) with 2
nd
aliquot
13/26 (50%) 16/356 (4.5%) NR NR
Comas 2015 9/316 (2.8%) 6 (67%) with
new
sampling
1/6 (16.7%) 4/316 (1.3%) NR NR
delMarGil 2014 15/207 (7.2%) 0 NA 15/207 (7.2%) 23% 6%
Gil 2016 99/3698 (2.8%) 54 (54,5%) with
new
sampling
20/54 (37%) 65/3698 (1.8%) NR NR
Hall 2014 4/68 (5.9%) 0 NA 4/68 (5.9%) 11.8% 3.9%
Hooks 2014 18/432 (4.2%) 0 NA 18/432 (4.2%) NR NR
Jackson 2014 NR NR 14 (NR) 14/1175 (1.2%) NR NR
Nicolaides 2012 100/2049 (4.
9%)
0 NA 100/2049 (4.
9%)
9.1% 4.9%
Nicolaides 2013 13/242 (5.4%) 0 NA 13/242 (5.4%) 6.3% 5.2%
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Table 7. Proportion of pregnant women with a reference standard and assay failure during gNIPT process (Continued)
Nicolaides
2014a
5/177 (2.8%) 0 NA 5/177 (2.8%) 5.1% 1.7%
Norton 2012 148/3228 (4.
6%)
0 NA 148/3228 (4.
6%)
NR NR
Norton 2015 488/16,329 (3.
0%)
0 NA 488/16,329 (3.
0%)
20.6% 2.9%
Pergament 2014 T21: 88/1051
(8.4%)
T18, 45,X: 87/
1052 (8.3%)
T13: 86/1053
(8.2%)
0 NA T21: 88/1051
(8.4%)
T18, 45,X: 87/
1052 (8.3%)
T13: 86/1053
(8.2%)
All five chromo-
somes
(n = 85): 15.2%
All five chromo-
somes
(n = 85): 7.1%
Persico 2016 10/259 (3.9%) 0 NA 10/259 (3.9%) 8.4% 2.1%
Quezada 2015 122e/2838 (4.
2%)
110 (90.1%)
with new
sampling
41/110 (37.3%) 53/2838 (1.9%) 4.1% 1.8%
Samango-
Sprouse 2013
15/201 (7.5%) 0 NA 15/201 (7.5%) 6.3% 7.6%
Verweij 2013 51/520 (9.8%) 51 (100%) with
2nd
aliquot
16/51 (31.4%) 16/520 (3.1%)
NR
NR NR
Overall range of final assay failure for TMPS 0.8% to 7.5% 0% to 23% 1% to 7.63%
CVS: chorionic villi sampling, FF: fetal fraction DNA, GA: gestational age, NA: not applicable, NR: not reported by authors, QC:
quality control.
aRepeated tests included second aliquot (aliquot from first sampling), resequenced (same library) or new sampling.
baneuploid: proportion of failed samples of aneuploid cases out of all aneuploid tested with reference standard and gNIPT result.
euploid: proportion of failed samples of euploid cases out of all euploid tested with reference standard and gNIPT result.
cAuthors decided to resequence 12 samples with gNIPT results. They were in the grey zone (between affected and unaffected) and
were resequenced in uniplex. All repeated tests were in affected or unaffected zone.
dOnly the final failure rate was reported.The failure rate at first attempt was not reported nor the failure rate of repeated tests.
eAuthor reported 123 failed tests but this number included one sample lost in the mail and so did not undergo the sequencing process.
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Table 8. Data for 47,XXX, 47,XXY and 47,XYY according to the prior risk of fetal aneuploidy and gNIPT approach
Test Number of
studies
Number of
affected pregnancies
Number of
unaffected pregnanciesa
47,XXX
Selected high risk
pregnant women
MPSS 5 8 5441
TMPS 2 6 580
47,XXY
Selected high risk
pregnant women
MPSS 7 14 6466
TMPS 3 8 827
47,XYY
Selected high risk
pregnant women
MPSS 7 11 6418
TMPS 1 3 169
aUnaffected pregnancies: we included pregnancies with any other aneuploidy than the one under analysis with all euploid cases as
“unnon affected”.
Table 9. Subgroup analyses of MPSS and TMPS (type of pregnancy and gestational age)
Test subgroups Number of
studies
Number of
affected
pregnancies
Number of unaf-
fected
pregnanciesa
Sensitivityb
% (95% CI)
Specificityb
% (95% CI)
Pregnancy type
Autosomes (T21, T18 and T13 combined), unselected population
MPSS singleton 1 11 1730 100 (74.1 to 100) 99.9 (99.7 to 100)
TMPS singleton 3 107 20,468 95.5 (87.4 to 98.
4)
99.9 (99.8 to 100)
multifetal 1 11 181 90.9 (62.3 to 98.
4)
100 (97.9 to 100)
Autosomes (T21, T18 and T13 combined), selected high-risk population
MPSS singleton 19 1087 11,180 98.3 (97.3 to 98.
9)
99.6 (99.5 to 99.
7)
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Table 9. Subgroup analyses of MPSS and TMPS (type of pregnancy and gestational age) (Continued)
multifetal 3 21 206 95.2 (72.9 to 99.
3)
100 (98.2 to 100)
c
TMPS singleton 7 378 4282 98.9 (97.2 to 99.
6)
99.9 (99.8 to 100)
SCA (45,X, 47,XXX, 47,XXY and 47,XYY combined), selected high-risk population
MPSS singleton 7 101 4690 88.3 (52.9 to 98.
1)
99.3 (97.5 to 99.
8)
TMPS 4 96 968 93.8 (86.8 to 97.
2)
99.6 (98.1 to 99.
9)
Gestational age
Autosomes (T21, T18 and T13 combined), unselected population
MPSS ≤29 weeks 1 11 1730 100 (74.1 to 100) 99.9 (99.7 to 100)
TMPS ≤15 weeks 4 118 20,649 94.9 (89.1 to 97.
7)
99.9 (99.8 to 99.
9)
Autosomes (T21, T18 and T13 combined), selected high-risk population
MPSS ≤15 weeks 3 49 532 100 (92.7 to 100)
c
100 (99.3 to 100)
c
≤29 weeks 12 594 4605 98.3 (96.9 to 99.
1)
99.3 (99.0 to 99.
5)
≤42 weeks 13 729 7831 98.9 (95.0 to 99.
8)
99.9 (99.8 to 99.
9)
TMPS ≤15 weeks 2 128 498 99.2 (95.7 to 99.
9)c
100 (99.2 to 100)
c
≤29 weeks 2 33 535 97.0 (84.7 to 99.
5)c
100 (99.3 to 100)
c
≤42 weeks 2 163 3084 99.4 (95.8 to 99.
9)
99.9 (99.7 to 100)
SCA (45,X, 47,XXX, 47,XXY and 47,XYY combined), selected high-risk population
MPSS ≤15 weeks 1 2 202 0.00 (0.00 to 65.
8)
99.5 (97.2 to 99.
9)
317Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 9. Subgroup analyses of MPSS and TMPS (type of pregnancy and gestational age) (Continued)
≤29 weeks 5 58 996 86.5 (63.1 to 96.
0)
95.1 (93.5 to 96.
3)
≤42 weeks 5 89 6103 95.8 (80.3 to 99.
2)
99.6 (99.4 to 99.
7)
TMPS ≤15 weeks 2 58 343 93.1 (83.0 to 97.
4)
99.7 (98.0 to 100)
≤42 weeks 1 34 380 97.1 (85.1 to 99.
5)
98.9 (97.3 to 99.
6)
45,X: Turner syndrome, 47,XXX: triple X syndrome, 47,XXY: Klinefelter syndrome, T21: trisomy 21, T18: trisomy 18, T13: trisomy
13 CI: confidence interval, MPSS: massively parallel shotgun sequencing, SCA: sex chromosome aneuploidies, TMPS: targeted
massively parallel sequencing.
aWe included pregnancies with any other aneuploidy than the one under analysis with all euploid cases as “unaffected” pregnancies.
bFor two or more studies, the sensitivities and specificities are the summary estimates obtained from meta-analysis.
cSimple pooling used to obtain summary estimates of sensitivity, specificity or both.
Table 10. Direct comparisons of gNIPT and traditional screening tests for autosomes (T21, T18 and T13 combined) in
unselected population of pregnant women undergoing aneuploidy screening
Study Sensitivity (true positives/cases)
%
Difference
% (95% CI)
Specificity (true negatives/unaf-
fecteda )
%
Difference
% (95% CI)
MPSS Traditional
screening tests
MPSS Traditional
screening tests
Song 2013 100 (11/11) 54.6 (6/11) 45.5 (10.0 to 72.
0)
99.9 (1729/
1730)
86.0 (1487/
1730)
14.0 (12.4 to 15.
7)
TMPS Traditional
screening tests
TMPS Traditional
screening tests
Nicolaides 2012 100 (10/10) 100 (10/10) 0.00 (-27.8 to
27.8)
99.9 (1937/
1939)
95.5 (1852/
1939)
4.38 (3.51 to 5.
40)
Norton 2015 98.0 (49/50) 78.0 (39/50) 20.0 (7.44 to 33.
3)
99.9 (15,779/
15,791)
94.1 (14,860/
15,791)
5.82 (5.46 to 6.
20)
Quezada 2015 91.5 (43/47) 100 (49/49) -8.51 (-19.9 to 0.
40)
99.7 (2730/
2738)
95.6 (2663/
2787)
4.16 (3.40 to 5.
00)
CI: confidence interval, MPSS: massively parallel shotgun sequencing, TMPS: targeted massively parallel sequencing.
aWe included pregnancies with any other aneuploidy than the one under analysis with all euploid cases as “unaffected” pregnancies.
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Table 11. Sensitivity analyses
Test Number of
studies
Number of
affected
pregnancies
Number of unaf-
fected
pregnanciesa
Summary sensi-
tivity
% (95% CI)
Summary speci-
ficity
% (95% CI)
P valueb
Case-control studies excluded
Autosomes (T21, T18 and T13 combined), selected high-risk population
MPSS 22 696 11,293 98.3 (95.1 to 99.
4)
99.9 (99.8 to 100) 0.72
TMPS 4 219 3,813 98.6 (95.8 to 99.
6)
99.9 (99.8 to 100)
SCA (45,X, 47,XXX, 47,XXY and 47,XYY combined), selected high-risk population
MPSS 10 98 5,872 91.9 (73.8 to 97.
9)
99.5 (98.8 to 99.
8)
0.41
TMPS 2 6 472 93.8 (86.8 to 97.
2)
99.6 (98.1 to 99.
9)
Exclusion of studies with less than 10 pregnancies with aneuploidy
Autosomes (T21, T18 and T13 combined), selected high-risk population
MPSS 21 1458 13,921 98.7 (96.8 to 99.
4)
99.8 (99.5 to 100) 0.07
TMPS 7 378 4,282 98.9 (97.2 to 99.
6)
99.9 (99.8 to 100)
SCA (45,X, 47,XXX, 47,XXY and 47,XYY combined), selected high-risk population
MPSS 6 130 5,761 94.5 (80.6 to 98.
6)
99.4 (97.6 to 99.
8)
0.28
TMPS 2 90 496 94.4 (87.3 to 97.
7)
99.0 (97.6 to 99.
6)
45,X: Turner syndrome, 47,XXX: triple X syndrome, 47,XXY: Klinefelter syndrome, T21: trisomy 21, T18: trisomy 18, T13: trisomy
13 CI: confidence interval, MPSS: massively parallel shotgun sequencing, SCA: sex chromosome aneuploidies, TMPS: targeted
massively parallel sequencing.
aWe included pregnancies with any other aneuploidy than the one under analysis with all euploid cases as “unaffected” pregnancies.
bThe P value indicates the statistical significance of the difference in model fit and was obtained from likelihood ratio tests comparing
models with and without a covariate for test type.
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A P P E N D I C E S
Appendix 1. Screening tests and medical terms glossarya
Terms Definitions
Amniocentesis Invasive procedure under continuous ultrasound guidance (performed
between 15 to 19 weeks of gestational age). A sterile needle is passed
through the mother’s abdomen, uterus and amniotic sac. A sample
of fetal cells present in the amniotic fluid surrounding the fetus is
aspirated with a syringe and sent for analysis to test for a range of
chromosomal and inherited disorders
Aneuploidy The state of having a different (additional or missing) number of chro-
mosomes than the 23 pairs normally present in humans
Attention deficit disorder (ADD) ADD is a neurodevelopmental disorder defined by impairing levels of
inattention and disorganisation. Inattention manifests behaviourally
in ADD as wandering off task, lacking persistence, having difficulty
sustaining focus and being disorganised
Case-control study In the context of diagnostic accuracy, existing records are used to iden-
tify a group of people known to have the target condition (cases) and
another group (controls) without the target condition. The control
groupmay consist of healthy individuals or those with other conditions
similar to the target condition Cases and controls are then compared
with respect to certain variables hypothesised to increase the risk of
having the disease
Chorionic villus sampling (CVS) An abdominal or cervical procedure performed under continuous ul-
trasound guidance to obtain a sample of placental tissue for chromo-
somal or genetic analysis (between 12 to 19 weeks of gestational age).
The range of chromosomal and genetic conditions that can be detected
is similar to those for amniocentesis
Clinodactyly Permanent deflection of one or more fingers.
Cut-off Synonyms: cutpoint or threshold.
Cutpoint A value for a test result measured on an ordinal or continuous scale
which divides the group of people tested into a group at lower risk of
the condition being screened for and a group at higher risk (for whom
further investigations may be offered). Synonyms: cut-off or threshold
Detection rate The proportion of affected individuals with a positive screening result.
The detection rate is the same as the sensitivity of a test
Developmental delay An individual with this neurodevelopmental disorder fails to meet ex-
pected developmental milestones in several areas of intellectual func-
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tioning
Diagnostic accuracy The ratio of true positive and true negative results to the total number
of test results (true positives, true negatives, false positives and false
negatives). Represents the level of agreement between the information
from the index test and the reference standard
Diagnostic test A test recognised as having best performances to provide sufficient
information allowing a definite diagnosis (as opposed to screening
test results that need to be confirmed before a final diagnosis can be
reached)
Dysgenesis Defective or abnormal formation of an organ or part, primarily during
embryonic development. Gonodal dysgenesis is a defective develop-
ment of the gonads, which may be accompanied by abnormalities of
the sex chromosomes
False negative A negative test result in someone with the target condition.
False positive A positive test result in someone without the target condition
Fluorescence in situ
Hybridisation
Describes a type of DNA analysis by the hybridisation of fluorescently-
labelled probes complementary to certain genomic regions. In the con-
text of fetal aneuploidy detection, describes a diagnostic test in which
chromosome-specific fluorescently-labelled DNA probes are used on
uncultured cells from chorionic villi or amniotic fluid to assess the
number of homologous chromosome copies present
High risk of fetal aneuploidy A pregnancy is considered at high risk of fetal aneuploidy if the result of
the prenatal screening test puts the fetus at increased risk for aneuploidy
Hypertelorism Abnormal distance between two paired organs.
Intellectual disability
or intellectual developmental
disorder
This neurodevelopmental disorder is characterised by deficits in general
mental abilities, such as reasoning, problem solving, planning, abstract
thinking, judgment, academic learning and learning from experience.
It is a condition diagnosed before age 18. In the past, the term mental
retardation was used to describe this condition but this term is no
longer used
Invasive procedure A method used to obtain a biological sample that involves significant
disruption of the physical integrity of a patient. Examples include
amniocentesis and chorionic villi sampling
Karyotype A photomicrograph of an individual’s chromosomes arranged in a stan-
dard format and visualised by various staining methods, showing the
number, size, and shape of each chromosome; used to correlate chro-
mosomal anomalies with specific diseases (karyotyping). In humans,
there are a total of 23 pairs of homologous chromosomes (total of 46
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chromosomes)
Learning disability Learning disability refers to inadequate development of specific aca-
demic, language and speech skills such as reading disability, mathe-
matics disability and writing disability
Low risk of fetal aneuploidy A pregnancy is considered at low risk of fetal aneuploidy if the result of
the prenatal screening test puts the fetus at decreased risk for aneuploidy
Meta-analysis The use of statistical techniques in a systematic review to integrate
the results of included studies. Sometimes misused as a synonym for
systematic reviews which may or may not include a meta-analysis
Mosaic An individual who has some cells with an unusual genetic or chromo-
somal make-up while the rest of the cells in the body have the typical
genetic or chromosomal constitution
Mixed risk population Mixed risk population included a mixture of selected pregnant women
with low, high or no prior risk of fetal aneuploidy
Negative predictive value A measure of test performance. Defined as the proportion of people
with a negative test result who do not have the target condition
Nuchal translucency scan The thickness of fluid in the tissue space within the nape of the fetal
neck typically measured by ultrasonography. An increased amount of
fluid is associated with Down syndrome and other structural or genetic
anomalies
Positive predictive value A measure of test performance. Defined as the proportion of people
with a positive test result who do have the target condition
Probability The chance or risk of an event happening.
Prospective study A study in which a group of individuals is followed through time
in order to detect the occurrence of a disease or another outcome of
interest
Reference standard The best available test to detect the presence or absence of the target
condition
Retrospective study A study in which all or part of the data collection occurred before
initiation of the study
Screening Testing asymptomatic people for the likelihood of the presence of a
disease, either with the aim of reducing risk of an adverse outcome, or
with the aim of giving information about risk
Seizure A sudden attack, spasm, or convulsion caused by abnormal electrical
conduction in the brain
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Sensitivity A measure of test performance. Defined as the proportion of individ-
uals with the target condition who have a positive test result. Higher
sensitivity values means that a higher proportion of affected individ-
uals will be detected by the test (few false negatives).Sensitivity is the
same as the detection rate
Single nucleotide
polymorphism
Single nucleotide polymorphisms are themost common type of genetic
variation among people. A difference in a single DNA nucleotide (A,
T, C or G) in a DNA sequence
Specificity A measure of test performance. Defined as the proportion of individu-
als without the target condition who have a negative test result. Higher
specificity values means that a smaller proportion of unaffected indi-
viduals will be wrongly classified as having the target condition (few
false positives)
Threshold Synonyms: cutpoint or cut-off.
True negative An individual with a negative test result who does not have the target
condition
True positive An individual with a positive test result who has the target condition
Trisomy Three copies of a particular chromosome rather than the usual pair
Unselected pregnant women A pregnant women who did not undergo any prenatal screening test
at the time of enrolment
aAdapted in part from the United Kingdom National Screening Committee Glossary, MedlinePlus Medical Encyclopedia, American
Psychiatric Association and The Cochrane Collaboration’s Glossary of terms (APA 2013; Cochrane Glossary 2014; MedlinePlus 2014;
UK Screening Glossary 2012).
Appendix 2. List of acronyms and abbreviations
Acronyms or abbreviations Terms
45,X monosomy X or Turner syndrome
47,XXX trisomy X or triple X syndrome
47,XXY Klinefelter syndrome
aCGH array comparative genomic hybridisation
AFP alpha-fetoprotein
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Bioch/US biochemical or ultrasound or both screening test
ccfDNA circulating cell-free DNA
Chrom. 21 chromosome 21
CVS chorionic villi sampling
FISH fluorescence in situ hybridisation
gNIPT genomics-based non-invasive prenatal testing
hCG human chorionic gonadotropin
HSROC hierarchical summary receiver operating characteristic
MPSS massively parallel shotgun sequencing
NA not applicable
ND no data available
NGS next generation sequencing
NR not reported
NT nuchal translucency
PAPP-A pregnancy associated plasma protein A
QF-PCR quantitative fluorescent polymerase chain reaction
QUADAS-2 QUality Assessment of Diagnostic Accuracy Studies
Ref. Chrom reference chromosome
RS reference standard
SCA sex chromosome aneuploidy
SNP single nucleotide polymorphism
T13 trisomy 13 or Patau syndrome
T18 trisomy 18 or Edward syndrome
T21 trisomy 21 or Down syndrome
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TMPS targeted massively parallel sequencing
uE3 unconjugated estriol
Appendix 3. Index test technical details
Typically, blood samples from pregnant women are obtained by venous puncture in the first or second trimester. After two centrifugation
steps, plasma is separated from maternal whole blood and ccfDNA is extracted from plasma with commercial kits. DNA is converted
into a genomic library where each of the DNA fragments are ligated with platform specific adapters. For TMPS only, libraries are
clonally amplified before being sequenced. Then the libraries of several pregnant women are loaded on a next generation sequencer.
The produced sequencing reads are aligned on a reference human genome to their respective chromosomal location and the number
of sequence reads from each chromosome is computed (Rothberg 2011). MPSS randomly sequences DNA fragments from across the
whole genome while TMPS sequences DNA fragments from selected regions (Figure 1). Ultimately, all gNIPT for aneuploidies rely
on assigning sequence reads of DNA fragments to their chromosome of origin and comparing total number or proportions of reads or
single nucleotide polymorphisms (SNP) genotype between each chromosome of interest (e.g. 13, 18, 21, X and Y) and a reference set of
chromosomes. A Z score (or other statistics) are computed and a patient-specific risk can be assessed based on a risk threshold determined
from read counts from a series of known euploid and aneuploid pregnancies. For MPSS, the counts from chromosomes of interest
are normalised using the counts from all other chromosome sequences, while, for TMPS, the counts are normalised against a subset
of selected sequences. Bioinformatic approaches vary according to the testing approach (MPSS or TMPS) and research team. Besides
the use of normalised chromosome read counts, TMPS also allows for the use of additional allelic information when polymorphic loci
such as SNP are targeted, such as an estimate of fetal DNA concentration (fetal DNA proportion) (Liao 2012). Thus, while MPSS
produces a larger number of total sequence reads, TMPS will generates a larger number of reads from each targeted chromosomes.
Appendix 4. Search strategy
MEDLINE (Ovid)
Steps Text words and subject headings Sets of search
1 ’cell-free dna’.mp Index test
2 ’cell free dna’.mp
3 cfdna.mp
4 ffdna.mp
5 cffdna.mp
6 ’free foetal dna’.mp
7 ’free fetal dna’.mp
8 nipd.mp
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9 nipt.mp
10 (non invasive or noninvasive or non-invasive).mp
11 (genetic adj2 (diagnos* or detect* or test* or screen*))
.mp
12 exp Genetic Testing/
13 exp Sequence Analysis, DNA/
14 ((antenatal or ante natal) adj2 (diagnos* or detect* or
test* or screen*)).mp
15 ((prenatal or pre natal) adj2 (diagnos* or detect* or
test* or screen*)).mp
16 exp Prenatal Diagnosis/
17 or/1-16
18 maternal.mp Patient description
19 exp Pregnancy/
20 exp Pregnancy Complications/
21 pregnant.mp
22 pregnanc*.mp
23 exp Fetus/
24 fetus.mp
25 foetus.mp
26 fetal.mp
27 foetal.mp
28 or/18-27
29 trisom*.mp Target condition
30 aneuploid*.mp
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31 (down* adj syndrome*).mp
32 exp Aneuploidy/
33 exp Trisomy/
34 exp Down Syndrome/
35 chromosome disorders.mp
36 or/29-35
37 or/1-5,11-13 Combined sets
38 6 or 7 or 8 or 9 or 14 or 15 or 16
39 36 and 37 and 28 and 10
40 38 and 37 and 36
41 39 or 40 Final combined set
Embase (Embase.com)
Steps Text words and subject headings Sets of search
1 ’cell-free dna’ Index test
2 ’cell free dna’
3 cfdna
4 ffdna
5 cffdna
6 ’free foetal dna’
7 ’free fetal dna’
8 nipd
9 nipt
10 ’non invasive’
11 noninvasive
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12 ’non-invasive’
13 genetic NEXT/1 (diagnos* or screen* or test* or de-
tect*)
14 ’genetic screening’/exp
15 ’genetic testing’/exp
16 ’sequence analysis dna’/exp
17 antenatal NEXT/1 (diagnos* or screen* or test* or
detect*)
18 prenatal NEXT/1 (diagnos* or screen* or test* or
detect*)
19 pre?natal NEXT/1 (diagnos* or screen* or test* or
detect*)
20 ’prenatal diagnosis’/exp
21 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9
OR 10 OR 11 OR 12
OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR
18 OR 19 OR 20
22 antenatal Patient description
23 prenatal
24 pre?natal
25 maternal
26 foetus
27 fetus
28 foetal
29 fetal
30 pregnanc*
31 pregnant
32 ’pregnancy’/exp
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33 ’pregnancy complications’/exp
34 ’pregnant woman’/exp
35 ’pregnant women’/exp
36 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR
29
OR 30 OR 31 OR 32 OR 33 OR 34 OR 35
37 trisom* Target condition
38 aneuploid*
39 down* NEXT/1 syndrome
40 ’aneuploid’/exp
41 ’aneuploidy’/exp
42 ’trisomy’/exp
43 ’downs syndrome’/exp
44 ’down syndrome’/exp
45 ’chromosome disorders’
46 37 OR 38 OR 39 OR 40 OR 41 OR 42 OR 43 OR
44 OR 45
47 21 and 36 and 46 Final combined set
Web of Science (ISI)
Steps Text words and subject headings Sets of search
1 TOPIC: (down* syndrome) OR TOPIC: (trisom*)
OR TOPIC: (aneuploid*)
Target condition
2 TOPIC: (pregnan*) Patient description
3 TOPIC: (dna) OR TOPIC: (blood) Index test
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4 TOPIC: (pre?natal screen*) OR TOPIC: (prenatal
screen*) OR TOPIC: (pre?natal test*)
OR TOPIC: (prenatal test*) OR TOPIC: (genetic
test*) OR TOPIC: (genetic screen*)
OR TOPIC: (prenatal diagnos*) OR TOPIC: (pre?
natal diagnos*) OR TOPIC: (detection)
OR TOPIC: (genetic diagnos*) OR TOPIC: (non
invasive) OR TOPIC: (non-invasive)
OR TOPIC: (noninvasive)
Index test
5 #1 AND #2 AND #3 AND #4 Final combined set
Cochrane Register of Diagnostic Test Accuracy Studies
Hand search: in diagnostic test accuracy database, there are 18 publications from the Cochrane Pregnancy and Childbirth group
Clinicaltrials.gov
Steps Text words and subject headings Sets of search
1 (down syndrome OR trisomy OR aneuploidy) Target condition
2 (testing OR screening OR diagnosis OR detection) Index test
3 #1 AND #2 Final combined set
European Clinical Trials Register
Steps Text words and subject headings Sets of search
1 pregnan* Population
2 trisom* OR aneuploid* Target condition
3 #1 OR #2 Final combined set
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Who ICTRP
Steps Text words and subject headings Sets of search
1 screen* OR detect* OR diagnos* OR test* OR pregnan* Index test and population
2 down syndrome » OR trisom* OR aneuploid* Target condition
3 #1 AND #2 Final combined set
NTIS.gov
Steps Text words and subject headings Sets of search
1 (down syndrome OR trisomy OR aneuploidy) Target condition
2 (testing OR screening OR diagnosis OR detection) Index test
3 #1 AND #2 Final combined set
OpenGrey
Steps Text words and subject headings Sets of search
1 “down syndrome” OR trisom* OR aneuploid* Target condition
2 screen* OR detect* OR diagnos* OR test* OR pregnan* Index test and population
3 #1 AND #2 Final combined set
National Guideline Clearing House (NGCH)
Steps Text words and subject headings Sets of search
1 diagnosis (guideline category) Index test
2 screening (guideline category) Index test
3 aneuploid OR trisomy OR down syn-
drome »
Target condition
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4 (#1 OR #2) AND #3 Final combined set
TheseNet
Steps Text words and subject headings Sets of search
1 trisomy Target condition
2 screening Index test
3 #1 AND #2 Final combined set
These Canada Portal
Steps Text words and subject headings Sets of search
1 trisomy OR (down AND syndrome) Target condition
2 screening Index test
3 #1 AND #2 Final combined set
Appendix 5. Data collection form for study classification during full-text assessment
Heading Detailed instructions Data
Study ID Last name of the first author and year of
publication
Name:
Year:
Reference details Details allowing identification of the pub-
lication
Journal:
Volume:
Issue:
Pages:
Accession number (e.g. PMIDa ):
Multiple reports
of this study
For example, duplicate publications or fol-
low-up studies.
Provide the study ID linked to this classi-
fied study
Study ID:
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Type of report Check the appropriate box Journal article
Conference/abstract
Ongoing trial
Others
Specify:
Language In which language was the study written Language:
Translation needed? Yes No
Eligibility Provide reason for exclusion or awaiting
classification
(e.g. why authors should be contacted and
what issues should be clarified)
Study excluded? Yes No
Reason:
Awaiting classification? Yes No
Reason:
Report author contact
details for further
information
Date when the authors were contacted (dd/
mm/yyyy)
No need for further contact
Authors have been contacted on:
Reply received on:
Review author ID Who completed the form Name:
Date of classification (dd/mm/yyyy) Date:
Notes, questions or
reminders
aPMID: PubMed identifier.
Appendix 6. QUADAS-2 tool for assessing methodological quality of included studies
Signalling
question
Signalling
question
Signalling
question
Risk of bias Concerns about
applicability
Domain 1: Patient selection
Patient
selection
Was a consecutive
or random sam-
ple of patients en-
rolled?
Was a case-control
design avoided?
Did
the study avoid in-
appropriate exclu-
sions?
Could
the selection of pa-
tients have intro-
duced bias?
Are there concerns
that the included
patients and set-
ting do not match
the review ques-
tion?
Yes:
if all consecutive or
random samples or
convenient samples
Yes: if a case-control
design was avoided.
No: If a case-con-
trol design was not
Yes: if the study
avoided inappropri-
ate exclusions.
No:
Low risk: if ‘yes’ for
all signalling ques-
tion.
High or unclear
Low concern: if the
selected preg-
nant women repre-
sent the women in-
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or all eligible preg-
nant women were
enrolled
No: if selected preg-
nant women were
enrolled.
Unclear: if this was
not clear from the
report.
avoided.
Unclear: if this was
not clear from the
report.
if pregnant woman
was excluded based
on family’s situa-
tion, maternal age,
ethnicity, maternal
cancer history, type
of pregnancy, gesta-
tional age, assisted
reproductive tech-
nology or any other
aneuploidies
Unclear: if this was
not clear from the
report.
risk: if ‘no’ or ‘un-
clear’ was reported
for at least one sig-
nalling question
dicated by the re-
view questiona .
High concern:
if selected pregnant
women differ from
those targeted by the
review questiona .
Unclear concern: if
insufficient in-
formation was avail-
able.
Domain 2: Index test
Index
testb
Were the index test
results interpreted
with-
out knowledge of
the results of the
reference standard?
If a threshold was
used, was it pre-
specified?
Could the conduct
or in-
terpretation of the
index test have in-
troduced bias?
Are there concerns
that the index test,
its conduct, or in-
terpretation differ
from the review
question?
Yes: if the
gNIPT results were
interpreted without
knowledge of the re-
sults of the reference
standardc .
No: if the gNIPT
results were inter-
preted with knowl-
edge of the results of
the reference stan-
dardc .
Unclear: if this was
not clear from the
report.
Yes: if criteria for
a positive test were
prespecified.
No: if the criteria for
a positive test were
not prespecified.
Unclear: if this was
not clear from the
report.
Low risk: if ‘yes’ for
all signalling ques-
tion.
High or unclear
risk: if ‘no’ or ‘un-
clear’ was reported
for at least one sig-
nalling question
Low concern: if the
gNIPT was per-
formed such as de-
scribed in the review
questiona .
High concern: if
gNIPT vary from
those specified in
the review question.
Unclear concern: if
insufficient in-
formation was avail-
able.
Domain 3: Reference standard
Reference
Standardc
Is the
reference standard
c likely to correctly
classify the target
conditiond ?
Were the reference
standard results in-
terpreted without
knowledge of the
results of the index
testb?
Could the
reference standard,
its conduct, or its
interpretation have
introduced bias?
Are there concerns
that the target con-
dition as defined
by the reference
standard does not
match the review
question?
334Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Yes: if one appropri-
ate reference stan-
dardc was used.
No:
if pregnant women
did not undergo ap-
propriate reference
standardc .
Unclear: if this was
not clear from the
report.
Yes: if karyotype re-
sults were
interpreted without
knowledge of results
of the index testb .
No: if karyotype re-
sults were
interpreted with the
knowledge of results
of the index testb .
Unclear: if this was
not clear from the
report.
Low risk: if ‘yes’ for
all signalling ques-
tions.
High or unclear
risk: if ‘no’ or ‘un-
clear’ was reported
for at least one sig-
nalling question
Low concern: if the
reference standards
c were used as de-
scribed in the review
questiona .
High con-
cern: if the refer-
ence standardc vary
from those specified
in the review ques-
tiona .
Unclear concern: if
insufficient in-
formation was avail-
able.
Domain 4: Flow and timing
Flow and
timing
Was there an ap-
propriate inter-
val between gNIPT
and reference stan-
dard?
Did all analysed
patients receive the
reference standard?
Were all pa-
tients included in
the analysis?
Could the patient
flow have intro-
duced bias?
Yes: if the interval
between blood col-
lection for gNIPT
and fluid collection
for reference stan-
dardc wasmore than
one day (only if
blood collection oc-
curred after fluid
collection). If blood
collection occurred
before fluid collec-
tion, there is no time
limite .
No: if the interval
between blood col-
lection for gNIPT
and the fluid col-
lection for reference
standardc was less
than one day if the
blood collection oc-
curred after the fluid
collection
Unclear: if this was
Yes: if all preg-
nant women anal-
ysed have appropri-
ate reference stan-
dardc .
No: if some preg-
nant women anal-
ysed do not have a
karyotype result
Unclear: if this was
not clear from the
report.
Yes: if all pregnant
women recruited
into the study were
included in the anal-
ysis or if failed sam-
ples occurred before
NGS process
No: if
all pregnant women
recruited into the
study were not in-
cluded in the analy-
sis or if failed sam-
ples occurred during
NGS process
Unclear: if this was
not clear from the
report.
Low risk: if ‘yes’ for
all signalling ques-
tions.
High or unclear
risk: if ‘no’ or ‘un-
clear’ was reported
for at least one sig-
nalling question
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not clear from the
report.
aReview question: what is the diagnostic accuracy of massively parallel shotgun sequencing (MPSS) and targeted massively parallel
sequencing (TMPS) using circulating cell-freeDNA (ccfDNA) in maternal blood for the detection of common fetal aneuploidies (T21,
T18, T13, 45,X, 47,XXY, 47,XXX and 47,XYY) in pregnant women according to their prior risk of fetal aneuploidy?
bIndex test refers to genomics-based non-invasive prenatal testing (gNIPT) methods such as MPSS or TMPS.
cThe appropriate reference standard is karyotyping (traditional banding techniques or spectral karyotyping from invasive methods like
chorionic villi sampling or amniocentesis), chromosome analysis (e.g. FISH, aCGH and QF-PCR), clinical examination or medical
record from birth (for T21, T18 or T13). For sex chromosome aneuploidies, only fetal karyotype was appropriate reference standard
because they usually have a normal phenotype.
dTarget conditions (aneuploidies) are T21, T18, T13, 45,X, 47,XXY, 47,XXX and 47,XYY.
eTarget conditions (aneuploidies) do not vary over time.
Appendix 7. gNIPT accuracy in mixed prior risk of fetal aneuploidy
Test Number of
studies
Number of
affected
pregnancies
Number of un-
affected
pregnanciesa
Sensitivityb
% (95% CI)
Specificityb
% (95% CI)
P valuec
T21, mixed risk
MPSS 10 445 30,962 96.0 (93.7 to 97.
4)
99.9 (99.9 to
100)
TMPS 6 169 6925 98.2 (94.6 to 99.
4)
100 (99.9 to
100)
Difference between MPSS and TMPS -2.27 (-4.97 to 0.
43)
-0.04 (-0.08 to -
0.002)
0.10
Traditional
screening testsd
1 3 1909 100 (43.9 to
100)
96.4 (95.5 to 97.
1)
T18, mixed risk
MPSS 9 113 30,637 100 (98.3 to
100)e
99.9 (99.8 to
100)
TMPS 4 53 5569 98.1 (87.8 to 99.
7)
99.9 (99.8 to
100)
Traditional
screening tests
1 1 1905 100 (20.7 to
100)
99.4 (99.0 to 99.
7)
T13, mixed riskf
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MPSS 8 27 30,384 100 (87.5 to
100)e
100 (> 99.9 to
100)e
TMPS 5 31 8362 78.6 (48.3 to 93.
5)
99.9 (99.8 to
100)
45X, mixed risk
MPSS 2 12 296 91.7 (58.7 to 98.
8)
100 (98.7 to
100)e
TMPS 2 22 1128 90.9 (70.0 to 97.
7)
99.9 (99.4 to
100)
47,XXY, mixed risk
MPSS 1 1 107 ND
TMPS 1 2 184 ND
47,XYY, mixed risk
MPSS 1 1 199 ND
TMPS 1 1 185 ND
Autosomes (T21, T18 and T13 combined), mixed risk
MPSS 10 585 30,822 96.9 (95.2 to 98.
1)
99.9 (99.9 to 99.
9)
TMPS 7 253 8793 96.0 (92.8 to 97.
9)
99.8 (99.7 to 99.
9)
Difference between MPSS and TMPS 0.88 (-1.90 to 3.
65)
0.07 (-0.02 to 0.
16)
0.25
Traditional
screening tests
1 4 1908 100 (51.0 to
100)
95.8 (94.8 to 96.
6)
SCA (45,X, 47,XXX, 47,XXY and 47,XYY combined), mixed risk
MPSS 2 14 294 92.9 (63.0 to 99.
0)
100 (98.7 to
100)e
TMPS 2 25 1125 92.0 (73.1 to 98.
0)
99.9 (99.4 to
100)
337Genomics-based non-invasive prenatal testing for detection of fetal chromosomal aneuploidy in pregnant women (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
45,X: Turner syndrome, 47,XXX: triple X syndrome, 47,XXY: Klinefelter syndrome, ND: no data available, T21: trisomy 21, T18:
trisomy 18, T13: trisomy 13, CI: confidence interval, MPSS: massively parallel shotgun sequencing, TMPS: targeted massively parallel
sequencing, SCA: sex chromosome aneuploidies.
aWe included pregnancies with any other aneuploidy than the one under analysis with all euploid cases as “unaffected” pregnancies.
bFor two or more studies, the sensitivities and specificities are the summary estimates obtained from meta-analysis. Sensitivity and
specificity, and their 95% CIs are reported as percentages.
cThe P value indicates the statistical significance of the difference in model fit and was obtained from likelihood ratio tests comparing
models with and without a covariate for test type.
dTraditional screening test are first trimester combined test, second trimester quadruple test, second trimester fully integrated test,
second trimester sequential test or second trimester triple test.
eSimple pooling used to obtain summary estimates of sensitivity and/or specificity.
fTest comparison analysis did not converge.
Appendix 8. Investigation of heterogeneity
Test subgroups Number of
studies
Number of
affected
pregnancies
Number of
unaffected
pregnanciesa
Reference standard
Autosomes, unselected population
MPSS mixed reference standardb 1 11 1730
TMPS karyotypingc 1 11 181
mixed reference standard 3 107 20,468
Autosomes, selected high-risk population
MPSS karyotyping 22 1075 7028
mixed reference standard 10 433 8769
TMPS karyotyping 7 378 4282
SCA, selected high-risk population
MPSS karyotyping 10 134 3943
mixed reference standard 2 17 3509
TMPS karyotyping 4 96 968
Ethnicity
Autosomes, unselected population
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(Continued)
MPSS more than 50% Asiand 1 11 1730
TMPS more than 50% Caucasian
e
3 107 20,468
not reported 1 11 181
Autosomes, selected high-risk population
MPSS more than 50% Asian 14 206 6589
more than 50% Caucasian 7 843 6262
not reported 11 459 2946
TMPS more than 50% Caucasian 3 237 3744
not reported 4 141 538
SCA, selected high-risk population
MPSS more than 50% Asian 5 25 1852
more than 50% Caucasian 5 96 4286
not reported 2 30 1314
TMPS more than 50% Caucasian 1 56 116
not reported 3 40 852
45,X: Turner syndrome, 47,XXX: triple X syndrome, 47,XXY: Klinefelter syndrome, T21: trisomy 21, T18: trisomy 18, T13: trisomy
13, MPSS: massively parallel shotgun sequencing, TMPS: targeted massively parallel sequencing, SCA: sex chromosome aneuploidies
aWe included pregnancies with any other aneuploidy than the one under analysis with all euploid cases as “unaffected” pregnancies.
bMixed RS: include karyotyping and neonatal clinical examination or medical records from birth.
cKaryotyping: include fetal karyotyping performed on cells obtained from chorionic villi sampling (CVS), amniotic fluid, placental
tissue, a fetus lost by miscarriage or other equivalent and recognised methods on the same materials.
dMore than 50% Asian: in the cohort, more than 50% of all pregnant women were Asian ethnicity.
eMore than 50% Caucasian: in the cohort, more than 50% of all pregnant women were Caucasian ethnicity.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the “reference standards” section in the methods, the protocol did not specify that neonatal clinical examination or medical records
from birth are not appropriate reference standards for SCA diagnosis. These aneuploidies (SCA) usually have a normal phenotype and
can not be detected with neonatal clinical examination or medical records from birth.
In the “sensitivity analyses” section, of the protocol, the authors stated they intended to investigate “studies where not all pregnant
women received neither reference standard (no karyotyping confirmation nor birth follow-up); authors who have taken for granted
that the baby is normal“. We decided to remove this analysis because this goes against one of our criteria for considering studies for this
review (pregnant women with MPSS or TMPS and a reference standard). These type of studies were excluded.
We decide to remove Google scholar from our electronic searches databases list. Google scholar found more than 100,000 publications
about our topic but only the first 1000 are retrievable. This database is not reproducible and search fields did not allow us to specify
the search strategy. All first most relevant publications were already found with other databases.
We changed OpenSIGLE to Opengrey because the first has been replaced by the second.
Although studies used different cutpoints, there was little or no variation in threshold and no requirement to estimate the correlation
between sensitivity and specificity across studies in a meta-analysis. Therefore, we did not estimate summary ROC curves using the
HSROCmodel. As the cutpoints were regarded as qualitative, we estimated summary sensitivities and specificities using random-effects
and fixed-effect logistic regression models, and simple pooling as appropriate. Further details are available in the statistical analysis and
data synthesis section. We used the Stata software package for the analyses instead of SAS.
We made changes in the QUADAS-2 tool. In domain 1, at third signalling question, we added ”maternal cancer history, type of
pregnancy, gestational age, assisted reproductive technology“ in ”No“ answer. In concerns of applicability in domain 3, concerns about
applicability, we modified conditions for low and high concern according to the review question. In domain 4, at second signalling
question, we added ”analysed“ for clarify and we changed ”yes“ answer by removing ”karyotype result“ for ”appropriate reference
standard“.
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